{
  "analysis_mode": "HISTORICAL_ONLY",
  "symbol": "VAL.L",
  "generated_at": "2026-02-11T17:21:17.000860Z",
  "top_card": {
    "ticker": "VAL.L",
    "company_name": "ValiRx plc",
    "sector": "Healthcare",
    "market_cap_gbp": 2488383,
    "days_active": 82,
    "apex_score_100": 40,
    "confidence_score_100": 40,
    "ai_final_score_25": 15,
    "ai_strength": "STRONG",
    "timing_regime": "CONFIRMED",
    "action": "HOLD/WATCH",
    "thesis_one_liner": "HOLD/WATCH - CONFIRMED timing with 40/100 opportunity score"
  },
  "enrichment": {
    "company_info": {
      "name": "ValiRx plc",
      "sector": "Healthcare",
      "industry": "Biotechnology",
      "exchange": "LSE",
      "market": "AIM",
      "currency": "GBP",
      "risk_tier": "High Risk",
      "current_market_cap": 2488383,
      "current_close_price": 0.335
    },
    "basics": {
      "ticker": "VAL.L",
      "current_price": 0.335,
      "ath": 73.0,
      "atl": 0.22,
      "ath_date": "2020-09-28",
      "atl_date": "2025-10-30",
      "week_52_high": 0.875,
      "week_52_low": 0.22,
      "week_52_high_date": "2025-06-20",
      "week_52_low_date": "2025-10-30",
      "drawdown_from_ath_pct": 99.54,
      "data_start": "2020-01-02",
      "data_end": "2026-02-11",
      "total_bars": 1544
    },
    "latest_signal": {
      "date": "2025-11-21",
      "scan_date": "2026-01-26",
      "signal_type": "DEEP CRASH BOTTOM",
      "signal_color": "GREEN",
      "price": 0.225,
      "drawdown_pct": 87.14,
      "ai_score": 12.0,
      "rsi": 0.0,
      "cycle_position": 0.0094,
      "holding_period_days": 82,
      "current_pnl_pct": 48.89,
      "rally_state": "rallying",
      "distance_from_high_pct": -10.71,
      "Rally_Count": 1,
      "days_since_last_high": 7,
      "last_high_date": "2026-01-19",
      "lock_in_reached": true,
      "lock_in_date": "2025-12-17",
      "best_rally_pct": 86.67
    },
    "best_historical_signal": {
      "signal_date": "2024-05-15",
      "signal_type": "DEEP CRASH BOTTOM",
      "signal_color": "GREEN",
      "entry_price": 1.9,
      "peak_price": 4.489,
      "peak_date": "2024-05-21",
      "rally_pct": 136.26,
      "days_to_peak": 6,
      "ai_score": 15.0
    },
    "all_historical_signals": [
      {
        "signal_id": "VAL.L_2022-06-30",
        "signal_date": "2022-06-30",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 10.75,
        "current_price": 0.375,
        "current_return_pct": -96.51,
        "best_rally_pct": 86.05,
        "best_rally_date": "2022-09-12",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -98.12,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1306,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2022-07-01",
        "signal_date": "2022-07-01",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 10.5,
        "current_price": 0.375,
        "current_return_pct": -96.43,
        "best_rally_pct": 90.48,
        "best_rally_date": "2022-09-12",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -98.12,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1305,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2022-07-04",
        "signal_date": "2022-07-04",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 10.75,
        "current_price": 0.375,
        "current_return_pct": -96.51,
        "best_rally_pct": 86.05,
        "best_rally_date": "2022-09-12",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -98.12,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1302,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2022-07-05",
        "signal_date": "2022-07-05",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 10.9,
        "current_price": 0.375,
        "current_return_pct": -96.56,
        "best_rally_pct": 83.49,
        "best_rally_date": "2022-09-12",
        "rally_state": "accumulating",
        "Rally_Count": 7,
        "distance_from_high_pct": -98.12,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1301,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2022-07-08",
        "signal_date": "2022-07-08",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 10.75,
        "current_price": 0.375,
        "current_return_pct": -96.51,
        "best_rally_pct": 86.05,
        "best_rally_date": "2022-09-12",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -98.12,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1298,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2024-05-15",
        "signal_date": "2024-05-15",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.9,
        "current_price": 0.375,
        "current_return_pct": -80.26,
        "best_rally_pct": 110.53,
        "best_rally_date": "2024-05-20",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -90.62,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 621,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2024-05-16",
        "signal_date": "2024-05-16",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.9,
        "current_price": 0.375,
        "current_return_pct": -80.26,
        "best_rally_pct": 110.53,
        "best_rally_date": "2024-05-20",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -90.62,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 620,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2024-08-23",
        "signal_date": "2024-08-23",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 2.25,
        "current_price": 0.375,
        "current_return_pct": -83.33,
        "best_rally_pct": 6.67,
        "best_rally_date": "2024-08-27",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -84.38,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 521,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2024-08-29",
        "signal_date": "2024-08-29",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 2.2,
        "current_price": 0.375,
        "current_return_pct": -82.95,
        "best_rally_pct": -2.27,
        "best_rally_date": "2024-10-21",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 515,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2024-08-30",
        "signal_date": "2024-08-30",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 2.05,
        "current_price": 0.375,
        "current_return_pct": -81.71,
        "best_rally_pct": 4.88,
        "best_rally_date": "2024-10-21",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -82.56,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 514,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2024-09-04",
        "signal_date": "2024-09-04",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 2.05,
        "current_price": 0.375,
        "current_return_pct": -81.71,
        "best_rally_pct": 4.88,
        "best_rally_date": "2024-10-21",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -82.56,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 509,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2024-09-17",
        "signal_date": "2024-09-17",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.825,
        "current_price": 0.375,
        "current_return_pct": -79.45,
        "best_rally_pct": 17.81,
        "best_rally_date": "2024-10-21",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -82.56,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 496,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2024-09-18",
        "signal_date": "2024-09-18",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.65,
        "current_price": 0.375,
        "current_return_pct": -77.27,
        "best_rally_pct": 30.3,
        "best_rally_date": "2024-10-21",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -82.56,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 495,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2024-09-26",
        "signal_date": "2024-09-26",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.7,
        "current_price": 0.375,
        "current_return_pct": -77.94,
        "best_rally_pct": 26.47,
        "best_rally_date": "2024-10-21",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -82.56,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 487,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2024-09-27",
        "signal_date": "2024-09-27",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 1.45,
        "current_price": 0.375,
        "current_return_pct": -74.14,
        "best_rally_pct": 48.28,
        "best_rally_date": "2024-10-21",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -82.56,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 486,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2024-10-03",
        "signal_date": "2024-10-03",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.35,
        "current_price": 0.375,
        "current_return_pct": -72.22,
        "best_rally_pct": 59.26,
        "best_rally_date": "2024-10-21",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -82.56,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 480,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2024-12-09",
        "signal_date": "2024-12-09",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.775,
        "current_price": 0.375,
        "current_return_pct": -51.61,
        "best_rally_pct": 12.9,
        "best_rally_date": "2025-01-16",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -57.14,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 413,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2024-12-10",
        "signal_date": "2024-12-10",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.775,
        "current_price": 0.375,
        "current_return_pct": -51.61,
        "best_rally_pct": 12.9,
        "best_rally_date": "2025-01-16",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -57.14,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 412,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2024-12-11",
        "signal_date": "2024-12-11",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.8,
        "current_price": 0.375,
        "current_return_pct": -53.12,
        "best_rally_pct": 9.37,
        "best_rally_date": "2025-01-16",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -57.14,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 411,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2024-12-13",
        "signal_date": "2024-12-13",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.775,
        "current_price": 0.375,
        "current_return_pct": -51.61,
        "best_rally_pct": 12.9,
        "best_rally_date": "2025-01-16",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -57.14,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 409,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2024-12-18",
        "signal_date": "2024-12-18",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.725,
        "current_price": 0.375,
        "current_return_pct": -48.28,
        "best_rally_pct": 20.69,
        "best_rally_date": "2025-01-16",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -57.14,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 404,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2024-12-27",
        "signal_date": "2024-12-27",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.675,
        "current_price": 0.375,
        "current_return_pct": -44.44,
        "best_rally_pct": 29.63,
        "best_rally_date": "2025-01-16",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -57.14,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 395,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2024-12-30",
        "signal_date": "2024-12-30",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.625,
        "current_price": 0.375,
        "current_return_pct": -40.0,
        "best_rally_pct": 40.0,
        "best_rally_date": "2025-01-16",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -57.14,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 392,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2025-01-03",
        "signal_date": "2025-01-03",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 0.7,
        "current_price": 0.375,
        "current_return_pct": -46.43,
        "best_rally_pct": 25.0,
        "best_rally_date": "2025-01-16",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -57.14,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 388,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2025-02-13",
        "signal_date": "2025-02-13",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.625,
        "current_price": 0.375,
        "current_return_pct": -40.0,
        "best_rally_pct": 20.0,
        "best_rally_date": "2025-09-08",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -50.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 347,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2025-02-24",
        "signal_date": "2025-02-24",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.575,
        "current_price": 0.375,
        "current_return_pct": -34.78,
        "best_rally_pct": 30.43,
        "best_rally_date": "2025-09-08",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -50.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 336,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2025-03-24",
        "signal_date": "2025-03-24",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.575,
        "current_price": 0.375,
        "current_return_pct": -34.78,
        "best_rally_pct": 30.43,
        "best_rally_date": "2025-09-08",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -50.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 308,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2025-03-27",
        "signal_date": "2025-03-27",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.525,
        "current_price": 0.375,
        "current_return_pct": -28.57,
        "best_rally_pct": 42.86,
        "best_rally_date": "2025-09-08",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -50.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 305,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2025-03-28",
        "signal_date": "2025-03-28",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.5,
        "current_price": 0.375,
        "current_return_pct": -25.0,
        "best_rally_pct": 50.0,
        "best_rally_date": "2025-09-08",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -50.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 304,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2025-04-03",
        "signal_date": "2025-04-03",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.45,
        "current_price": 0.375,
        "current_return_pct": -16.67,
        "best_rally_pct": 66.67,
        "best_rally_date": "2025-09-08",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -50.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 298,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2025-04-04",
        "signal_date": "2025-04-04",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.415,
        "current_price": 0.375,
        "current_return_pct": -9.64,
        "best_rally_pct": 80.72,
        "best_rally_date": "2025-09-08",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -50.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 297,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2025-04-07",
        "signal_date": "2025-04-07",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.425,
        "current_price": 0.375,
        "current_return_pct": -11.76,
        "best_rally_pct": 76.47,
        "best_rally_date": "2025-09-08",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -50.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 294,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2025-10-30",
        "signal_date": "2025-10-30",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.25,
        "current_price": 0.375,
        "current_return_pct": 50.0,
        "best_rally_pct": 68.0,
        "best_rally_date": "2025-12-17",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -10.71,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 88,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2025-10-31",
        "signal_date": "2025-10-31",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.25,
        "current_price": 0.375,
        "current_return_pct": 50.0,
        "best_rally_pct": 68.0,
        "best_rally_date": "2025-12-17",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -10.71,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 87,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2025-11-03",
        "signal_date": "2025-11-03",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.245,
        "current_price": 0.375,
        "current_return_pct": 53.06,
        "best_rally_pct": 71.43,
        "best_rally_date": "2025-12-17",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -10.71,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 84,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2025-11-04",
        "signal_date": "2025-11-04",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.24,
        "current_price": 0.375,
        "current_return_pct": 56.25,
        "best_rally_pct": 75.0,
        "best_rally_date": "2025-12-17",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -10.71,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 83,
        "status": "historical"
      },
      {
        "signal_id": "VAL.L_2025-11-21",
        "signal_date": "2025-11-21",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.225,
        "current_price": 0.375,
        "current_return_pct": 66.67,
        "best_rally_pct": 86.67,
        "best_rally_date": "2025-12-17",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -10.71,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 66,
        "status": "historical"
      }
    ],
    "stats": {
      "total_signals": 37,
      "win_rate_pct": 100.0,
      "avg_rally_pct": 65.16,
      "median_rally_pct": 63.24,
      "best_rally_pct": 136.26,
      "worst_rally_pct": 7.59
    },
    "splits": [
      {
        "date": "2020-02-18",
        "detected_at": "2026-01-26T17:45:59.996229",
        "market": "LSE_AIM",
        "ratio": 0.008,
        "ratio_display": "1/125",
        "source": "yahoo",
        "type": "stock_split"
      },
      {
        "date": "2020-03-26",
        "detected_at": "2026-01-26T17:45:59.996394",
        "market": "LSE_AIM",
        "ratio": 0.008,
        "ratio_display": "1/125",
        "source": "yahoo",
        "type": "stock_split"
      },
      {
        "date": "2020-04-06",
        "detected_at": "2026-01-26T17:45:59.996558",
        "market": "LSE_AIM",
        "ratio": 0.008,
        "ratio_display": "1/125",
        "source": "yahoo",
        "type": "stock_split"
      }
    ],
    "split_risk": {
      "split_detected": true,
      "risk_level": "HIGH",
      "confidence": "HIGH",
      "latest_split": {
        "date": "2020-04-06",
        "detected_at": "2026-01-26T17:45:59.996558",
        "market": "LSE_AIM",
        "ratio": 0.008,
        "ratio_display": "1/125",
        "source": "yahoo",
        "type": "stock_split"
      }
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "EXTREME_DRAWDOWN",
      "FREQUENT_CRASHES"
    ],
    "last_updated": "2026-02-11 17:06:21 UTC",
    "volatility": {
      "atr_normalized": 10.0,
      "stddev_20d": 0.0
    },
    "trends": {
      "intelligence_signal": "UPTREND"
    }
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 40/100 indicates moderate opportunity quality",
      "Timing regime: CONFIRMED",
      "Historical profile: 1 rallies, 87% best run"
    ],
    "main_risk": "Confidence 40/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "VAL.L",
      "latest": [
        {
          "title": "Exercise of Warrants",
          "announcement_date": "19th Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "19 Jan 2026 07:00\nRNS Number : 3318P\nValiRx PLC\n19 January 2026\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nExercise of Warrants\nValiRx plc (the \"Company\") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health announces it has received notification for the exercise of warrants over 80,000 ordinary shares in the Company at an exercise price of 0.5 pence per share providing the Company with gross proceeds of \u00a3400 (\"Warrant Exercise\").\nApplication will be made to the London Stock Exchange to admit the 80,000 new ordinary shares resulting from the Warrant Exercise to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 23 January 2026. The new ordinary shares will rank\npari passu\nwith the existing ordinary shares.\nFor the purposes of the Disclosure and Transparency Rules, following the issue of shares detailed above as a result of the Warrant Exercise, the enlarged issued share capital of the Company will comprise 742,801,072 ordinary shares of 0.1 pence each. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\"). The Directors of the Company take responsibility for this announcement.\n*** ENDS **\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investor\nhub here:\nhttps://valirx.com/s/cc8ef3\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nhttps://valirx.com/link/exkQJy\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0025\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d1\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.\nLead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.\nValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.\nFor further information, visit:\nwww.valirx.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nIOEBPMLTMTJBBTF",
          "rns_number": "RNS Number : 3318P"
        },
        {
          "title": "Replacement: Evaluation and Transfer Agreement",
          "announcement_date": "9th Jan 2026",
          "release_time": "3:45 pm",
          "source": "RNS",
          "content": "Today 15:45\nRNS Number : 3936O\nValiRx PLC\n09 January 2026\n9 January 2026\nThe following amendment has been made to the 'New Evaluation and Material Transfer Agreement' announcement released on 9 January 2026 at 7:00 a.m. under RNS No 2552O.\nThe announcement has been amended to 'the Company has an option to license the Evaluation Results into NewCo for a pre-agreed equity holding.' in the third paragraph of the announcement.\nAll other details remain unchanged.\nThe full amended text is shown below.\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nNew Evaluation and Material Transfer Agreement\nValiRx plc (the \"Company\") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health and The Royal Institute for the Advancement of Learning/McGill University (\"McGill\"), a Canadian based University, and The Institute for Research in Immunology, and Cancer - Commercialization of Research (\"IRICoR\"), a Canadian based non-profit organisation, have entered into a nine-month, Evaluation and Material transfer agreement (the \"Agreement\").\nUnder the new format Agreement with McGill and IRICoR (the \"Institutions\"),\ntarget engagement and potency of a second generation, orally available, RNA Helicase inhibitor will be established by the Company's wholly owned subsidiary, Inaphaea Biolabs Ltd (\"Inaphaea\").\nDuring the evaluation period, any results generated will be owned by ValiRx (the \"Evaluation Results\").\nIRICoR will establish a Canadian registered, wholly owned, subsidiary\n(\"NewCo\") for the purpose of commercialising the Evaluation Results and Background Intellectual Property and grant\nNewCo an\nexclusive, worldwide sub-licensable license to any Background Intellectual Property.\nOn completion of the Evaluation Results, the Company has an option to license the Evaluation Results into NewCo for a pre-agreed equity holding.\nNewCo will seek external non-dilutive and dilutive funding and ValiRx (and potentially other investors arranged by ValiRx) may, subject to availability of funds, provide up to \u00a32 million of seed funding (\"Seed Funding\"). Any such Seed Funding would be provided in tranches in line with the cash requirements, in exchange for further equity under a development plan provided by the Company. Funding other than the Seed Funding shall dilute all shares\npari passu\n.\nAlternatively, if within 30 days of the completion of the evaluation, ValiRx elects not to proceed with the license for equity, the rights to the Evaluation Results will be assigned to the Institutions and, if the Institutions then\nout-license, sell or otherwise commercialise the Technology\nat any time following the evaluation period, ValiRx will be entitled to a cash payment of 1.5x its total investment (estimated at no more than \u00a3150,000) from IRICoR.\nMark Eccleston, CEO of ValiRx commented\n\"I am excited to announce this Evaluation Agreement with McGill and IRICoR, who have already carried out extensive development work on this high quality, second-generation RNA Helicase Inhibitor making it one of the latest stage assets we've been able to access. We have performed extensive due diligence on the technical, clinical and commercial positioning of this asset and see significant opportunities in the human and veterinary health markets. The structure of the agreement reflects the quality and stage of the asset, the value Inaphaea can bring, and a desire from all parties to secure external funding to support rapid translation to a clinical candidate.\"\nMartin Gouldstone, Chairman of ValiRx\ncommented\n\"This is an important agreement with McGill and IRICoR as it\nreflects ValiRx's commitment to identifying, developing and partnering high quality, later stage assets that are closer to the clinic and therefore commercialisation.\nThis new style agreement envisages additional, external, investment into the NewCo set up to commercialise the results alongside future investments from ValiRx. This approach to diluting individual assets rather than ValiRx plc is designed to maximise the use and impact of our funding.\"\nClaude Larose, VP Business Development at IRICoR commented \"\nWe are delighted to be working with Inaphaea ValiRx and to commercialise our RNA Helicase asset\n.\nIn parallel, we will set up a commercial entity with a strategic objective to maximise the clinical and commercial value of the Evaluation Results and original data and look forward to working with ValiRx and their appointed directors to secure additional investment. For clinical development we envisage the NewCo may (1) out-license the Technology and Background Intellectual Property to a biopharmaceutical partner, (2) raise additional institutional capital to independently advance the program into clinical studies, or (3) pursue a strategic transaction, including a potential sale or merger. This structure provides multiple pathways to value creation while maintaining alignment between ValiRx, McGill and IRICoR\n.\"\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\"). The Directors of the Company take responsibility for this announcement.\n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investor\nhub here:\nhttps://valirx.com/s/cc8ef3\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nhttps://valirx.com/link/exkQJy\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0025\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d1\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.\nLead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.\nValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.\nFor further information, visit:\nwww.valirx.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAGRZZGGMKLVGVZM",
          "rns_number": "RNS Number : 3936O"
        },
        {
          "title": "New Evaluation and Material Transfer Agreement",
          "announcement_date": "9th Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "Today 07:00\nRNS Number : 2552O\nValiRx PLC\n09 January 2026\n9 January 2026\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nNew Evaluation and Material Transfer Agreement\nValiRx plc (the \"Company\") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health and The Royal Institute for the Advancement of Learning/McGill University (\"McGill\"), a Canadian based University, and The Institute for Research in Immunology, and Cancer - Commercialization of Research (\"IRICoR\"), a Canadian based non-profit organisation, have entered into a nine-month, Evaluation and Material transfer agreement (the \"Agreement\").\nUnder the new format Agreement with McGill and IRICoR (the \"Institutions\"),\ntarget engagement and potency of a second generation, orally available, RNA Helicase inhibitor will be established by the Company's wholly owned subsidiary, Inaphaea Biolabs Ltd (\"Inaphaea\").\nDuring the evaluation period, any results generated will be owned by ValiRx (the \"Evaluation Results\").\nIRICoR will establish a Canadian registered, wholly owned, subsidiary\n(\"NewCo\") for the purpose of commercialising the Evaluation Results and Background Intellectual Property and grant\nNewCo an\nexclusive, worldwide sub-licensable license to any Background Intellectual Property.\nOn completion of the Evaluation Results, the Company has an option to license the Evaluation Results into NewCo for a 15% equity holding under pre-agreed terms.\nNewCo will seek external non-dilutive and dilutive funding and ValiRx (and potentially other investors arranged by ValiRx) may, subject to availability of funds, provide up to \u00a32 million of seed funding (\"Seed Funding\"). Any such Seed Funding would be provided in tranches in line with the cash requirements, in exchange for further equity under a development plan provided by the Company. Funding other than the Seed Funding shall dilute all shares\npari passu\n.\nAlternatively, if within 30 days of the completion of the evaluation, ValiRx elects not to proceed with the license for equity, the rights to the Evaluation Results will be assigned to the Institutions and, if the Institutions then\nout-license, sell or otherwise commercialise the Technology\nat any time following the evaluation period, ValiRx will be entitled to a cash payment of 1.5x its total investment (estimated at no more than \u00a3150,000) from IRICoR.\nMark Eccleston, CEO of ValiRx commented\n\"I am excited to announce this Evaluation Agreement with McGill and IRICoR, who have already carried out extensive development work on this high quality, second-generation RNA Helicase Inhibitor making it one of the latest stage assets we've been able to access. We have performed extensive due diligence on the technical, clinical and commercial positioning of this asset and see significant opportunities in the human and veterinary health markets. The structure of the agreement reflects the quality and stage of the asset, the value Inaphaea can bring, and a desire from all parties to secure external funding to support rapid translation to a clinical candidate.\"\nMartin Gouldstone, Chairman of ValiRx\ncommented\n\"This is an important agreement with McGill and IRICoR as it\nreflects ValiRx's commitment to identifying, developing and partnering high quality, later stage assets that are closer to the clinic and therefore commercialisation.\nThis new style agreement envisages additional, external, investment into the NewCo set up to commercialise the results alongside future investments from ValiRx. This approach to diluting individual assets rather than ValiRx plc is designed to maximise the use and impact of our funding.\"\nClaude Larose, VP Business Development at IRICoR commented \"\nWe are delighted to be working with Inaphaea ValiRx and to commercialise our RNA Helicase asset\n.\nIn parallel, we will set up a commercial entity with a strategic objective to maximise the clinical and commercial value of the Evaluation Results and original data and look forward to working with ValiRx and their appointed directors to secure additional investment. For clinical development we envisage the NewCo may (1) out-license the Technology and Background Intellectual Property to a biopharmaceutical partner, (2) raise additional institutional capital to independently advance the program into clinical studies, or (3) pursue a strategic transaction, including a potential sale or merger. This structure provides multiple pathways to value creation while maintaining alignment between ValiRx, McGill and IRICoR\n.\"\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\"). The Directors of the Company take responsibility for this announcement.\n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investor\nhub here:\nhttps://valirx.com/s/cc8ef3\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nhttps://valirx.com/link/exkQJy\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0025\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d1\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.\nLead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.\nValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.\nFor further information, visit:\nwww.valirx.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAGRGGGDBLBGDGLC",
          "rns_number": "RNS Number : 2552O"
        },
        {
          "title": "Holding(s) in Company",
          "announcement_date": "8th Jan 2026",
          "release_time": "1:00 pm",
          "source": "RNS",
          "content": "8 Jan 2026 13:00\nRNS Number : 2091O\nValiRx PLC\n08 January 2026\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BLH13C52\nIssuer Name\nVALIRX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nJaspal Singh\nCity of registered office (if applicable)\nWolverhampton\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n05-Jan-2026\n6. Date on which Issuer notified\n08-Jan-2026\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n2.960000\n0.000000\n2.960000\n22000000\nPosition of previous notification (if applicable)\n4.510000\n0.000000\n4.510000\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BLH13C52\n22000000\n2.960000\nSub Total 8.A\n22000000\n2.960000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n08-Jan-2026\n13. Place Of Completion\nWOLVERHAMPTON\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUWUURNNUARAR",
          "rns_number": "RNS Number : 2091O"
        },
        {
          "title": "Holding(s) in Company",
          "announcement_date": "5th Dec 2025",
          "release_time": "10:56 am",
          "source": "RNS",
          "content": "5 Dec 2025 10:56\nRNS Number : 4689K\nValiRx PLC\n05 December 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nValiRx PLC\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nStephen Wolstenhulme\nCity and country of registered office (if applicable)\nUK\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n04/12/2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n05/12/2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\nBelow 3%\nBelow 3%\nPosition of previous notification (if\napplicable)\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BLH13C52\nSUBTOTAL 8. A\nBelow 3%\nBelow 3%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nStephen Wolstenhulme\nBelow 3%\nBelow 3%\nDaniele Wolstenhulme\nBelow 3%\nBelow 3%\nTotal\nBelow 3%\nBelow 3%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nUK\nDate of completion\n05/12/2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUVVRRVVUURAA",
          "rns_number": "RNS Number : 4689K"
        }
      ],
      "themes": [
        "funding",
        "drilling",
        "operations"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 863,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 0,
      "trend_direction": "flat",
      "intelligence_signal": "UPTREND"
    },
    "volatility": {
      "atr_normalized": 10.0,
      "stddev_20d": 0.0
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    },
    "all_events": [
      {
        "event_id": "RNS-9th Jan 2026-replacem",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.603200Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Replacement: Evaluation and Transfer Agreement",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/replacement-evaluation-and-transfer-agreement-4s4bfyqsqsbb8ao.html",
          "rns_number": "RNS Number : 3936O",
          "full_content": "Today 15:45\nRNS Number : 3936O\nValiRx PLC\n09 January 2026\n9 January 2026\nThe following amendment has been made to the 'New Evaluation and Material Transfer Agreement' announcement released on 9 January 2026 at 7:00 a.m. under RNS No 2552O.\nThe announcement has been amended to 'the Company has an option to license the Evaluation Results into NewCo for a pre-agreed equity holding.' in the third paragraph of the announcement.\nAll other details remain unchanged.\nThe full amended text is shown below.\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nNew Evaluation and Material Transfer Agreement\nValiRx plc (the \"Company\") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health and The Royal Institute for the Advancement of Learning/McGill University (\"McGill\"), a Canadian based University, and The Institute for Research in Immunology, and Cancer - Commercialization of Research (\"IRICoR\"), a Canadian based non-profit organisation, have entered into a nine-month, Evaluation and Material transfer agreement (the \"Agreement\").\nUnder the new format Agreement with McGill and IRICoR (the \"Institutions\"),\ntarget engagement and potency of a second generation, orally available, RNA Helicase inhibitor will be established by the Company's wholly owned subsidiary, Inaphaea Biolabs Ltd (\"Inaphaea\").\nDuring the evaluation period, any results generated will be owned by ValiRx (the \"Evaluation Results\").\nIRICoR will establish a Canadian registered, wholly owned, subsidiary\n(\"NewCo\") for the purpose of commercialising the Evaluation Results and Background Intellectual Property and grant\nNewCo an\nexclusive, worldwide sub-licensable license to any Background Intellectual Property.\nOn completion of the Evaluation Results, the Company has an option to license the Evaluation Results into NewCo for a pre-agreed equity holding.\nNewCo will seek external non-dilutive and dilutive funding and ValiRx (and potentially other investors arranged by ValiRx) may, subject to availability of funds, provide up to \u00a32 million of seed funding (\"Seed Funding\"). Any such Seed Funding would be provided in tranches in line with the cash requirements, in exchange for further equity under a development plan provided by the Company. Funding other than the Seed Funding shall dilute all shares\npari passu\n.\nAlternatively, if within 30 days of the completion of the evaluation, ValiRx elects not to proceed with the license for equity, the rights to the Evaluation Results will be assigned to the Institutions and, if the Institutions then\nout-license, sell or otherwise commercialise the Technology\nat any time following the evaluation period, ValiRx will be entitled to a cash payment of 1.5x its total investment (estimated at no more than \u00a3150,000) from IRICoR.\nMark Eccleston, CEO of ValiRx commented\n\"I am excited to announce this Evaluation Agreement with McGill and IRICoR, who have already carried out extensive development work on this high quality, second-generation RNA Helicase Inhibitor making it one of the latest stage assets we've been able to access. We have performed extensive due diligence on the technical, clinical and commercial positioning of this asset and see significant opportunities in the human and veterinary health markets. The structure of the agreement reflects the quality and stage of the asset, the value Inaphaea can bring, and a desire from all parties to secure external funding to support rapid translation to a clinical candidate.\"\nMartin Gouldstone, Chairman of ValiRx\ncommented\n\"This is an important agreement with McGill and IRICoR as it\nreflects ValiRx's commitment to identifying, developing and partnering high quality, later stage assets that are closer to the clinic and therefore commercialisation.\nThis new style agreement envisages additional, external, investment into the NewCo set up to commercialise the results alongside future investments from ValiRx. This approach to diluting individual assets rather than ValiRx plc is designed to maximise the use and impact of our funding.\"\nClaude Larose, VP Business Development at IRICoR commented \"\nWe are delighted to be working with Inaphaea ValiRx and to commercialise our RNA Helicase asset\n.\nIn parallel, we will set up a commercial entity with a strategic objective to maximise the clinical and commercial value of the Evaluation Results and original data and look forward to working with ValiRx and their appointed directors to secure additional investment. For clinical development we envisage the NewCo may (1) out-license the Technology and Background Intellectual Property to a biopharmaceutical partner, (2) raise additional institutional capital to independently advance the program into clinical studies, or (3) pursue a strategic transaction, including a potential sale or merger. This structure provides multiple pathways to value creation while maintaining alignment between ValiRx, McGill and IRICoR\n.\"\nThe information contained within this announcement is deemed b",
          "content_length": 8306
        },
        "ingested_at": "2026-01-12T22:04:49.603245Z"
      },
      {
        "event_id": "RNS-9th Jan 2026-newevalu",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.603275Z",
        "source": "LSE_RNS",
        "data": {
          "title": "New Evaluation and Material Transfer Agreement",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/new-evaluation-and-material-transfer-agreement-530d5jg41j4qfxf.html",
          "rns_number": "RNS Number : 2552O",
          "full_content": "Today 07:00\nRNS Number : 2552O\nValiRx PLC\n09 January 2026\n9 January 2026\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nNew Evaluation and Material Transfer Agreement\nValiRx plc (the \"Company\") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health and The Royal Institute for the Advancement of Learning/McGill University (\"McGill\"), a Canadian based University, and The Institute for Research in Immunology, and Cancer - Commercialization of Research (\"IRICoR\"), a Canadian based non-profit organisation, have entered into a nine-month, Evaluation and Material transfer agreement (the \"Agreement\").\nUnder the new format Agreement with McGill and IRICoR (the \"Institutions\"),\ntarget engagement and potency of a second generation, orally available, RNA Helicase inhibitor will be established by the Company's wholly owned subsidiary, Inaphaea Biolabs Ltd (\"Inaphaea\").\nDuring the evaluation period, any results generated will be owned by ValiRx (the \"Evaluation Results\").\nIRICoR will establish a Canadian registered, wholly owned, subsidiary\n(\"NewCo\") for the purpose of commercialising the Evaluation Results and Background Intellectual Property and grant\nNewCo an\nexclusive, worldwide sub-licensable license to any Background Intellectual Property.\nOn completion of the Evaluation Results, the Company has an option to license the Evaluation Results into NewCo for a 15% equity holding under pre-agreed terms.\nNewCo will seek external non-dilutive and dilutive funding and ValiRx (and potentially other investors arranged by ValiRx) may, subject to availability of funds, provide up to \u00a32 million of seed funding (\"Seed Funding\"). Any such Seed Funding would be provided in tranches in line with the cash requirements, in exchange for further equity under a development plan provided by the Company. Funding other than the Seed Funding shall dilute all shares\npari passu\n.\nAlternatively, if within 30 days of the completion of the evaluation, ValiRx elects not to proceed with the license for equity, the rights to the Evaluation Results will be assigned to the Institutions and, if the Institutions then\nout-license, sell or otherwise commercialise the Technology\nat any time following the evaluation period, ValiRx will be entitled to a cash payment of 1.5x its total investment (estimated at no more than \u00a3150,000) from IRICoR.\nMark Eccleston, CEO of ValiRx commented\n\"I am excited to announce this Evaluation Agreement with McGill and IRICoR, who have already carried out extensive development work on this high quality, second-generation RNA Helicase Inhibitor making it one of the latest stage assets we've been able to access. We have performed extensive due diligence on the technical, clinical and commercial positioning of this asset and see significant opportunities in the human and veterinary health markets. The structure of the agreement reflects the quality and stage of the asset, the value Inaphaea can bring, and a desire from all parties to secure external funding to support rapid translation to a clinical candidate.\"\nMartin Gouldstone, Chairman of ValiRx\ncommented\n\"This is an important agreement with McGill and IRICoR as it\nreflects ValiRx's commitment to identifying, developing and partnering high quality, later stage assets that are closer to the clinic and therefore commercialisation.\nThis new style agreement envisages additional, external, investment into the NewCo set up to commercialise the results alongside future investments from ValiRx. This approach to diluting individual assets rather than ValiRx plc is designed to maximise the use and impact of our funding.\"\nClaude Larose, VP Business Development at IRICoR commented \"\nWe are delighted to be working with Inaphaea ValiRx and to commercialise our RNA Helicase asset\n.\nIn parallel, we will set up a commercial entity with a strategic objective to maximise the clinical and commercial value of the Evaluation Results and original data and look forward to working with ValiRx and their appointed directors to secure additional investment. For clinical development we envisage the NewCo may (1) out-license the Technology and Background Intellectual Property to a biopharmaceutical partner, (2) raise additional institutional capital to independently advance the program into clinical studies, or (3) pursue a strategic transaction, including a potential sale or merger. This structure provides multiple pathways to value creation while maintaining alignment between ValiRx, McGill and IRICoR\n.\"\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\"). The Directors of the Company take responsibility for this announcement.\n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what o",
          "content_length": 7894
        },
        "ingested_at": "2026-01-12T22:04:49.603306Z"
      },
      {
        "event_id": "RNS-8th Jan 2026-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.603330Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/holdings-in-company-725hfk7hh4w5lbe.html",
          "rns_number": "RNS Number : 2091O",
          "full_content": "8 Jan 2026 13:00\nRNS Number : 2091O\nValiRx PLC\n08 January 2026\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BLH13C52\nIssuer Name\nVALIRX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nJaspal Singh\nCity of registered office (if applicable)\nWolverhampton\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n05-Jan-2026\n6. Date on which Issuer notified\n08-Jan-2026\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n2.960000\n0.000000\n2.960000\n22000000\nPosition of previous notification (if applicable)\n4.510000\n0.000000\n4.510000\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BLH13C52\n22000000\n2.960000\nSub Total 8.A\n22000000\n2.960000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n08-Jan-2026\n13. Place Of Completion\nWOLVERHAMPTON\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUWUURNNUARAR",
          "content_length": 3801
        },
        "ingested_at": "2026-01-12T22:04:49.603352Z"
      },
      {
        "event_id": "RNS-5th Dec 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.603377Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/holdings-in-company-orwge9g7wwjwlo2.html",
          "rns_number": "RNS Number : 4689K",
          "full_content": "5 Dec 2025 10:56\nRNS Number : 4689K\nValiRx PLC\n05 December 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nValiRx PLC\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nStephen Wolstenhulme\nCity and country of registered office (if applicable)\nUK\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n04/12/2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n05/12/2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\nBelow 3%\nBelow 3%\nPosition of previous notification (if\napplicable)\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BLH13C52\nSUBTOTAL 8. A\nBelow 3%\nBelow 3%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nStephen Wolstenhulme\nBelow 3%\nBelow 3%\nDaniele Wolstenhulme\nBelow 3%\nBelow 3%\nTotal\nBelow 3%\nBelow 3%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nUK\nDate of completion\n05/12/2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUVVRRVVUURAA",
          "content_length": 4390
        },
        "ingested_at": "2026-01-12T22:04:49.603402Z"
      },
      {
        "event_id": "RNS-24th Nov 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.603424Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/holdings-in-company-1ksuxg1zaz63h0o.html",
          "rns_number": "RNS Number : 7861I",
          "full_content": "24 Nov 2025 15:54\nRNS Number : 7861I\nValiRx PLC\n24 November 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nValiRx PLC\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nX\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nStephen Wolstenhulme\nCity and country of registered office (if applicable)\nUK\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n21/11/2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n24/11/2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n3.25%\n3.25%\n24,150,000\nPosition of previous notification (if\napplicable)\n5.84%\n5.84%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BLH13C52\n13,475,000\n10,675,000\n1.81%\n1.44%\nSUBTOTAL 8. A\n24,150,000\n3.25%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nStephen Wolstenhulme\n1.81%\n1.81%\nDaniele Wolstenhulme\n1.44%\n1.44%\nTotal\n3.25%\n3.25%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nUK\nDate of completion\n24/11/2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUSVVRVUUAUAA",
          "content_length": 4425
        },
        "ingested_at": "2026-01-12T22:04:49.603445Z"
      },
      {
        "event_id": "RNS-24th Nov 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.603470Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/holdings-in-company-kf9tafxier87v2o.html",
          "rns_number": "RNS Number : 7235I",
          "full_content": "24 Nov 2025 09:30\nRNS Number : 7235I\nValiRx PLC\n24 November 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BLH13C52\nIssuer Name\nVALIRX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nJaspal Singh\nCity of registered office (if applicable)\nWolverhampton\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n20-Nov-2025\n6. Date on which Issuer notified\n24-Nov-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n4.510000\n0.000000\n4.510000\n33500000\nPosition of previous notification (if applicable)\n8.010000\n0.000000\n8.010000\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BLH13C52\n33500000\n4.510000\nSub Total 8.A\n33500000\n4.510000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n24-Nov-2025\n13. Place Of Completion\nWolverhampton\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUSUKRVRUAURA",
          "content_length": 3803
        },
        "ingested_at": "2026-01-12T22:04:49.603492Z"
      },
      {
        "event_id": "RNS-20th Nov 2025-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.603514Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of GM & Issue of Equity",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/result-of-gm-issue-of-equity-pbs9a6mcewa0fhd.html",
          "rns_number": "RNS Number : 3996I",
          "full_content": "20 Nov 2025 12:11\nRNS Number : 3996I\nValiRx PLC\n20 November 2025\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF\nTHE MARKET ABUSE REGULATION (EU) 596/2014 AS AMENDED BY REGULATION 11 OF THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS 2019/310\n. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n20 November 2025\nVALIRX PLC\n(\"ValiRx\" or the \"Company\")\nResult of General Meeting\nIssue of Equity and Total Voting Rights\nDirector and PDMR Shareholding\nLondon, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces that, further to the announcement on 4 November 2025, at the Company's General Meeting held earlier today, all resolutions were duly passed. Details of the votes received in respect of the resolutions will be available shortly on the Company's website.\nIssue of Equity\nThe Tranche 2 Placing Shares, the Subscription Shares, the Fee Shares and the WRAP Retail Offer Shares have been allotted, conditional upon Admission, and application has been made to the London Stock Exchange for, in aggregate, 256,067,800 Shares to be admitted to trading on AIM. Admission is expected to occur at 8.00 a.m. on 21 November 2025, with dealings in the Tranche 2 Placing Shares, the Subscription Shares, the Fee Shares and the WRAP Retail Offer Shares commencing at the same time. The Tranche 2 Placing Shares, the Subscription Shares, the Fee Shares and the WRAP Retail Offer Shares will rank\npari passu\nwith all other issued Shares.\nIssue of Warrants\nPursuant to the Fundraising and in connection with the issuance of the Fee Shares the Company has issued 368,372,400 Fundraising Warrants. The Fundraising Warrants will be exercisable at a price of 0.5 pence per Ordinary Share and are exercisable at any time until the third anniversary of Tranche 2 Admission.\nIn addition, the Company has issued 16,036,120 Broker Warrants. The Broker Warrants will be exercisable at the Issue Price. The Broker Warrants are exercisable at any time until the third anniversary of Tranche 2 Admission.\nDirector and PDMR Shareholdings\nFollowing completion of the Fundraising, the shareholdings of the Directors who participated in the Fundraising are set out in the table below:\nName\nNumber of existing Ordinary Shares\nPercentage of existing issued share capital\nNumber of New Ordinary Shares\nNumber of Ordinary Shares on Tranche 2 Admission\nPercentage of enlarged share capital on Tranche 2 Admission\nMark Eccleston\n22,746,187\n6.08%\n36,000,000\n58,746,187\n7.91%\nCathy Tralau-Stewart\n835,897\n0.22%\n1,200,000\n2,035,897\n0.27%\nGerry Desler\n964,565\n0.26%\n1,200,000\n2,164,565\n0.29%\nMartin Gouldstone\n769,231\n0.21%\n1,200,000\n1,969,231\n0.27%\nTotal\n25,315,880\n6.76%\n39,600,000\n64,915,880\n8.74%\nTotal Voting Rights\nFor the purpose of the Disclosure Guidance and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 742,721,072 ordinary shares of 0.1 pence each. The Company does not hold any shares in the treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.\nCapitalised terms used in this announcement have the meaning given to them in the Circular dated 4 November 2025, unless otherwise defined in this announcement.\nThe Directors of the Company take responsibility for this announcement.\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\nhttps://valirx.com/link/yEMZvy\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0026\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Broker)\nDamon Heath\nAndrew Gutmann\nTel: +44 (0) 20 7186 9000\nSP Angel Corporate Finance LLP (Placing Agent)\nDavid Hignell\nVadim Alexandre\nTel: +44 (0) 20 3470 0470\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nNotification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014\n1\nDetails of the person discharging managerial responsibilities/person closely associated\na.\nName\nA) Mark Eccleston\nB) Cathy Tralau-Stewart\nC) Gerry Desler\nD) Martin Gouldstone\n2\nReason for notification\na.\nPosition/Status\nA) Director\nB) Director\nC) Director\nD) Director\nb.\nInitial notification/\nAmendment\nInitial notification\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na.\nName\nValiRx",
          "content_length": 10712
        },
        "ingested_at": "2026-01-12T22:04:49.603543Z"
      },
      {
        "event_id": "RNS-13th Nov 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.603565Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/holdings-in-company-5s63z047ev7tqvi.html",
          "rns_number": "RNS Number : 4759H",
          "full_content": "13 Nov 2025 14:16\nRNS Number : 4759H\nValiRx PLC\n13 November 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BLH13C52\nIssuer Name\nVALIRX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nPeel Hunt LLP\nCity of registered office (if applicable)\nLondon\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n10-Nov-2025\n6. Date on which Issuer notified\n13-Nov-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\nBelow 10%\n0.000000\nBelow 10%\nBelow 10% of shares in issue\nPosition of previous notification (if applicable)\n10.061786\n0.000000\n10.061786\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BLH13C52\nBelow 10% of shares in issue\nBelow 10%\nSub Total 8.A\nBelow 10% of shares in issue\nBelow 10%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n13-Nov-2025\n13. Place Of Completion\nLondon\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUOASRVUUAAAA",
          "content_length": 3855
        },
        "ingested_at": "2026-01-12T22:04:49.603589Z"
      },
      {
        "event_id": "RNS-10th Nov 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.603614Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/holdings-in-company-dyzf5j690gjvl7x.html",
          "rns_number": "RNS Number : 7770G",
          "full_content": "10 Nov 2025 07:00\nRNS Number : 7770G\nValiRx PLC\n10 November 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BLH13C52\nIssuer Name\nVALIRX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nPeel Hunt LLP\nCity of registered office (if applicable)\nLondon\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n06-Nov-2025\n6. Date on which Issuer notified\n07-Nov-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n10.061786\n0.000000\n10.061786\n48966010\nPosition of previous notification (if applicable)\n9.459765\n0.000000\n9.459765\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BLH13C52\n48966010\n10.061786\nSub Total 8.A\n48966010\n10.061786%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n07-Nov-2025\n13. Place Of Completion\nLondon\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUKVNRVUUARAA",
          "content_length": 3794
        },
        "ingested_at": "2026-01-12T22:04:49.603639Z"
      },
      {
        "event_id": "RNS-4th Nov 2025-postingo",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.603665Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Posting of Circular and Notice of General Meeting",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/posting-of-circular-and-notice-of-general-meeting-uiafraa5egept93.html",
          "rns_number": "RNS Number : 1835G",
          "full_content": "4 Nov 2025 17:15\nRNS Number : 1835G\nValiRx PLC\n04 November 2025\n4 November 2025\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nPosting of Circular and Notice of General Meeting\nLondon, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health,\u00a0announces that, further to the announcement made on 30 October 2025, a circular (the \"Circular\"), including the Notice of General Meeting and a Form of Proxy, has been posted to shareholders.\nThe General Meeting will be held at the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London, EC4R 3TT at 11 a.m. on 20 November 2025.\nA copy of the Circular will shortly be available on the Company's website at\nhttps://www.valirx.com/aim-rule-26\n.\nCapitalised terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Company's announcement of 30 October 2025.\nFUNDRAISING STATISTICS\nIssue Price\n0.25 pence\nNumber of Existing Shares\n374,348,672\nNumber of Tranche 1 Placing Shares\n112,304,600\nNumber of Tranche 2 Placing Shares\n183,695,400\nAggregate Number of Placing Shares\n296,000,000\nNumber of WRAP Retail Offer Shares\n60,722,400\nNumber of Subscription Shares\n4,000,000\nNumber of Fee Shares\n7,650,000\nAggregate Number of New Ordinary Shares to be issued in connection with the Fundraising\n368,372,400\nNumber of Shares in issue following Admission and issue of the New Ordinary Shares\n742,721,072\nPercentage of the Enlarged Share Capital represented by the New Ordinary Shares\n49.60%\nNumber of Fundraising Warrants to be issued following Admission\n368,372,400\nNumber of Broker Warrants to be issued following Admission\n16,036,120\nGross proceeds of the Placing\n\u00a3740,000\nGross proceeds of the WRAP Retail Offer\n\u00a3152,000\nGross proceeds of the Subscription\n\u00a310,000\nGross proceeds of the Fundraising\n\u00a3902,000\nOrdinary Share ISIN\nGB00BLH13C52\nEXPECTED TIMETABLE OF PRINCIPAL EVENTS\n2025\nAnnouncement of the Fundraising\n30 October\nLaunch of the WRAP Retail Offer\n30 October\nDate of publication and posting of this Circular & the Form of Proxy\n4 November\nAnnouncement of the results of the WRAP Retail Offer\n4 November\nAdmission and dealings in the Tranche 1 Placing Shares expected to commence on AIM\n8:00 a.m. on or around 6 November\nExpected date for CREST accounts to be credited for Tranche 1 Placing Shares to be held in uncertificated form\n6 November\nDespatch of definitive share certificates in respect of the Tranche 1 Placing Shares to be held in certificated form, if applicable\nby 20 November\nLatest time and date for receipt of CREST Proxy Votes or the completed Forms of Proxy\n11.00 a.m. on 18 November\nGeneral Meeting\n11.00 a.m. on 20 November\nAnnouncement of the results of the General Meeting\n20 November\nAdmission and dealings in the Tranche 2 Placing Shares, Subscription Shares, Fee Shares and WRAP Retail Offer Shares expected to commence on AIM\n8:00 a.m. on or around 21 November\nExpected date for CREST accounts to be credited for Tranche 2 Placing Shares, Subscription Shares, WRAP Retail Offer Shares, Fee Shares and Fundraising Warrants to be held in uncertificated form\n21 November\nDespatch of definitive share certificates in respect of the Tranche 2 Placing Shares, Subscription Shares, WRAP Retail Offer Shares, Fee Shares and Fundraising Warrants to be held in certificated form, if applicable\nby 5 December\nNotes:\n1. Each of the times and dates above are indicative only and if any of the details contained in the timetable above should change, the revised times and dates will be notified to Shareholders by means of an announcement through a Regulatory Information Service.\n2. All of the above times refer to London time unless otherwise stated.\n3. All events listed in the above timetable related to the granting of the Fundraising Warrants and the Broker Warrants and Admission of the Tranche 2 Placing Shares, the Subscription Shares, the WRAP Retail Offer Shares and the Fee Shares are conditional on the passing at the General Meeting of the Fundraising Resolutions to provide the relevant authorities.\nCautionary statement\nCertain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\nhttps://valirx.com/link/yVwkje\nVal",
          "content_length": 8316
        },
        "ingested_at": "2026-01-12T22:04:49.603692Z"
      },
      {
        "event_id": "RNS-4th Nov 2025-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.603714Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of WRAP Retail Offer",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/result-of-wrap-retail-offer-2beguhbjaljpk5m.html",
          "rns_number": "RNS Number : 0156G",
          "full_content": "4 Nov 2025 07:00\nRNS Number : 0156G\nValiRx PLC\n04 November 2025\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF THE LAWS OF ENGLAND AND WALES PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (\"\nUK MAR\n\"). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE WITHIN THE PUBLIC DOMAIN.\n4 November 2025\nValiRx PLC\n(\"\nValiRx\n\" or the \"\nCompany\n\")\nResult of WRAP Retail Offer\nValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to confirm, further to the announcements made on 30 October 2025, the result of WRAP Retail Offer at the Issue Price of 0.25 pence per share. The WRAP Retail Offer has raised gross proceeds of approximately \u00a3152,000, through the issue of 60,722,400 new ordinary shares of 0.1 pence each at a price of 0.25 pence per share (the \"\nWRAP Retail Offer Shares\n\"). With the gross proceeds of the Placing and Subscription of \u00a3750,000, in aggregate the Company has therefore raised gross proceeds of approximately \u00a3902,000 at a price of 0.25 pence per new Ordinary Share. In connection with the Fundraising the Company will grant 360,722,400 Fundraising Warrants and 16,036,120 Broker Warrants.\nThe issue of the Tranche 2 Placing Shares, Subscription Shares, WRAP Retail Offer Shares and the grant of the Fundraising Warrants and Broker Warrants are subject to the passing of the Fundraising Resolutions at the General Meeting.\nAdmission\nSubject to,\ninter alia\n, the passing of the Fundraising Resolutions, application will be made to the London Stock Exchange for the Tranche 2 Placing Shares, Subscription Shares, Fee Shares and WRAP Retail Offer Shares to be admitted to trading on AIM. It is anticipated that Tranche 2 Admission will become effective and that dealings in the Tranche 2 Placing Shares, Subscription Shares, WRAP Retail Offer Shares will commence on AIM at 8.00 a.m. on or around 21 November 2025.\nThe new Ordinary Shares to be issued pursuant to the WRAP Retail Offer will be issued free of all liens, charges and encumbrances and will, on Admission, rank\npari passu\nin all respects with the new Ordinary Shares to be issued pursuant to the Placing, the Subscription and the Company's existing Ordinary Shares.\nTerms used but not defined in this announcement have the same meaning as set out in the Company's announcement released at 7:17 a.m. on 30 October 2025.\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investor\nhub here:\nhttps://valirx.com/s/cc8ef3\nFor further information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nhttps://valirx.com/link/P76jor\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0026\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nWinterflood Retail Access Platform\nSophia Bechev / Kaitlan Billings\nWRAP@winterflood.com\n+44(0) 20 3100 0286\nFurther information on the Company can be found on its website at\nwww.valirx.com\nThe Company's LEI is 213800VQKB9SJCQDET40.\nThis announcement should be read in its entirety. In particular, the information in the \"\nImportant Notices\n\" section of the announcement should be read and understood.\nImportant Notices\nThe content of this announcement, which has been prepared by and is the sole responsibility of the Company.\nThis announcement and the information contained herein is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into or from the United States (including its territories and possessions, any state of the United States and the District of Columbia (the \"\nUnited States\n\" or \"\nUS\n\")), Australia, Canada, New Zealand, Japan, the Republic of South Africa, any member state of the EEA or any other jurisdiction where to do so might constitute a violation of the relevant laws or regulations of such jurisdiction.\nThe WRAP Retail Offer Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the ",
          "content_length": 15023
        },
        "ingested_at": "2026-01-12T22:04:49.603743Z"
      },
      {
        "event_id": "RNS-30th Oct 2025-wrapreta",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.603766Z",
        "source": "LSE_RNS",
        "data": {
          "title": "WRAP Retail Offer for up to \u00a3300,000",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/wrap-retail-offer-for-up-to-163300000-1uwianngwfopez7.html",
          "rns_number": "RNS Number : 4833F",
          "full_content": "30 Oct 2025 07:21\nRNS Number : 4833F\nValiRx PLC\n30 October 2025\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.\nTHIS ANNOUNCEMENT AMOUNTS TO A FINANCIAL PROMOTION FOR THE PURPOSES OF SECTION 21 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (\"FSMA\") AND HAS BEEN APPROVED BY WINTERFLOOD SECURITIES LIMITED WHICH IS AUTHORISED AND REGULATED BY THE FINANCIAL CONDUCT AUTHORITY (FRN 141455).\n30 October 2025\nValiRx PLC\n(\"\nValiRx\n\" or the \"\nCompany\n\")\nWRAP Retail Offer for up to \u00a3300,000\nValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to announce a retail offer via the Winterflood Retail Access Platform (\"\nWRAP\n\") to raise up to \u00a3300,000 (the \"\nWRAP Retail Offer\n\") through the issue of new ordinary shares of 0.1 pence each in the capital of the Company (\"\nOrdinary Shares\n\") and Warrants (as defined below). Under the WRAP Retail Offer up to 120,000,000 new Ordinary Shares (the \"\nWRAP Retail Offer Shares\n\") will be made available at a price of 0.25 pence per share (\"\nIssue Price\")\n. As part of the WRAP Retail Offer, the Company has agreed that\none\nwarrant for every\none\nWRAP Retail Offer Share will be granted (for no additional subscription cost), with each warrant entitling the holder to acquire one new Ordinary Share at a price of\n0.50\npence up to the third year anniversary from the date of admission of the Tranche 2 Placing Shares to trading on AIM (as set out in the Company's announcement of 30 October 2025 (the \"\nWarrants\n\").\nIn addition to the WRAP Retail Offer and as announced at 7.15 a.m. on 30 October 2025, the Company has conditionally raised \u00a3750,000 through the Placing and Subscription (together the \"\nFundraise\n\") of new Ordinary Shares at the Issue Price. The Issue Price represents a premium of approximately 45.7 per cent. to the mid-market closing price of 0.46 pence per Existing Share on 29 October 2025 (being the latest practicable date prior to this announcement). The issue price of the WRAP Retail Offer Shares is equal to the Issue Price.\nA separate announcement has been made regarding the Fundraise and its terms which sets out the reasons for the Fundraise and use of proceeds. The proceeds of the WRAP Retail Offer will be utilised in the same way as the proceeds of the Fundraise.\nFor the avoidance of doubt, the WRAP Retail Offer is not part of the Placing. Completion of the WRAP Retail Offer is conditional, inter alia, upon the completion of the Placing but completion of the Placing is not conditional on the completion of the WRAP Retail Offer.\nThe WRAP Retail Offer and issue of the Warrants are conditional on shareholder approval of allotment authorities in relation to the Fundraise at a forthcoming general meeting and on the WRAP Retail Offer Shares being admitted to trading on AIM (\"\nAdmission\n\"). It is anticipated that Admission will become effective and that dealings in the WRAP Retail Offer Shares will commence on or around 21 November 2025. A circular is expected to be posted shortly to convene a general meeting on or around 20 November 2025. A further announcement will be made in due course.\nWRAP Retail Offer\nThe Company values its retail shareholder base and believes that it is appropriate to provide both new and existing retail shareholders in the United Kingdom the opportunity to participate in the WRAP Retail Offer.\nTherefore, the Company is making the WRAP Retail Offer open to eligible investors in the United Kingdom, being new or existing shareholders of ValiRx, following release of this announcement and through certain financial intermediaries.\nA number of retail platforms are able to access the WRAP Retail Offer. Non-holders or existing shareholders wishing to subscribe for WRAP Retail Offer Shares should contact their broker or wealth manager who will confirm if they are participating in the WRAP Retail Offer.\nRetail brokers wishing to participate in the WRAP Retail Offer on behalf of eligible retail investors, should contact WRAP@winterflood.com.\nThe WRAP Retail Offer\nis expected to close at 4.30 p.m. (UK) on 3 November 2025. Eligible retail investors should note that financial intermediaries may have earlier closing times.\nThe result of the WRAP Retail Offer is expected to be announced by the Company on or around\n4 November\n2025.\nTo be eligible to participate in the WRAP Retail Offer, applicants must be a customer of a participating intermediary including individuals aged 18 years or over, companies and other bodies corporate, partnerships, trusts, associations and other unincorporated organisations.\nThere is a minimum subscription o",
          "content_length": 22271
        },
        "ingested_at": "2026-01-12T22:04:49.603795Z"
      },
      {
        "event_id": "RNS-30th Oct 2025-fundrais",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.603819Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Fundraising of up to \u00a31,050,000",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/fundraising-of-up-to-1631050000-e69fu7unybn3rhw.html",
          "rns_number": "RNS Number : 4831F",
          "full_content": "30 Oct 2025 07:17\nRNS Number : 4831F\nValiRx PLC\n30 October 2025\n30 October 2025\nTHIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (THE \"ANNOUNCEMENT\") IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.\nTHIS ANNOUNCEMENT DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE ANY SECURITIES OF THE COMPANY.\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF\nTHE MARKET ABUSE REGULATION (EU) 596/2014 AS AMENDED BY REGULATION 11 OF THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS 2019/310\n. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nFundraising of up to \u00a31,050,000 comprising:\nPlacing of 112,304,600 Tranche 1 Placing Shares\nConditional Placing of 183,695,400 Tranche 2 Placing Shares\nConditional WRAP Retail Offer for up to 120,000,000 new Shares\nConditional Director/PDMR Subscriptions for 4,000,000 Shares\nConditional Fee Shares of 7,650,000\nall at the Issue Price of 0.25 pence per share\nConditional Issue of up to 427,650,000 Fundraising Warrants\nConditional Issue of up to 19,000,000 Broker Warrants\nLondon, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health,\u00a0announces a fundraising to raise up to \u00a31,050,000 (before expenses) comprising a firm placing of the Tranche 1 Placing Shares, a conditional Placing of the Tranche 2 Placing Shares, a conditional WRAP Retail Offer and a conditional Subscription through the allotment and issue of, in aggregate, up to 420,000,000 new Shares at the Issue Price of 0.25 pence per Ordinary Share plus the conditional grant of (in aggregate) up to 427,650,000 Fundraising Warrants. The Placing was conducted by SP Angel Corporate Finance LLP and Shard as placing agents for the Company.\nThe WRAP Retail Offer will provide Retail Investors an opportunity to participate in the Fundraising at the same price as subscribers for Placing Units. For the avoidance of doubt, the WRAP Retail Offer is not part of the Placing.\nIn addition to the Placing and the WRAP Retail Offer, the Directors of the Company and persons closely associated with them have participated in the Fundraising by way of direct subscription with the Company and via the Placing for, in aggregate, 4,000,000 Subscription Shares at the Issue Price (the \"Subscription\") and 36,000,000 Placing Shares. The aggregate participation by the Directors pursuant to the Fundraising is \u00a3100,000.\nThe issue of the Tranche 2 Placing Shares, Subscription Shares, WRAP Retail Offer Shares and the grant of the Fundraising Warrants is subject to the passing of the Fundraising Resolutions at the General Meeting.\nThe Issue Price represents a discount of 45.7 per cent. to the closing mid-market price of 0.46 pence per Existing Share on 29 October 2025 (being the last practicable Business Day before announcement of the Fundraising).\nFundraising Warrants\nIn connection with the Fundraising, the Company has offered to all subscribers in the Placing, Subscription and WRAP Retail Offer, warrants to subscribe for one (1) Ordinary Share for every one (1) New Ordinary Share subscribed for. The Fundraising Warrants will be exercisable at a price of 0.5 pence per Ordinary Share, a premium of approximately 100 per cent. to the Issue Price. The Fundraising Warrants are exercisable at any time until the third anniversary of Tranche 2 Admission. The Fundraising Warrants will only be granted to subscribers of New Ordinary Shares on Tranche 2 Admission, conditional inter alia on the passing of the Fundraising Resolutions at the General Meeting.\nBroker Warrants\nPursuant to the Placing Agreement and the WRAP Agreement, the Company has agreed to grant warrants to subscribe for new Ordinary Shares to each of SP Angel, Shard and Winterflood respectively. The Company has agreed to grant SP Angel 2,500,000 Broker Warrants; to grant Shard 10,500,000 Broker Warrants and to grant Winterflood up to 6,000,000 Broker Warrants. The Broker Warrants will be exercisable at the Issue Price per Ordinary Share. The Broker Warrants are exercisable at any time until the third anniversary of Tranche 2 Admission. The Broker Warrants will be granted to each of SP Angel, Shard and Winterflood on Tranche 2 Admission, conditional inter alia on the passing of the Fundraising Resolutions at the General Meeting.\nIn addition, pursuant to the terms of the Placing Agreement, the Company has agreed to issue 2,400,000 Tranche 2 Placing Shares to Cairn in considera",
          "content_length": 27697
        },
        "ingested_at": "2026-01-12T22:04:49.603843Z"
      },
      {
        "event_id": "RNS-14th Oct 2025-inaphaea",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.603864Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Inaphaea Commercial update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/inaphaea-commercial-update-yqxzsrhg5kvv07x.html",
          "rns_number": "RNS Number : 1829D",
          "full_content": "14 Oct 2025 07:00\nRNS Number : 1829D\nValiRx PLC\n14 October 2025\nValiRx PLC\n(\"ValiRx\"\nor the\n\"Company\")\nInaphaea Commercial update\nLondon, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to provide the following updates on its wholly owned subsidiary Inaphaea Limited (\"Inaphaea\").\nInaphaea is delighted to confirm the completion of\nthe second phase of the Amply Discovery Limited's (\"Amply\") service contract, announced on 19 November 2024 and receipt of a balancing payment of approximately \u00a331,000.\nInaphaea is also pleased to announce that, following the award of a Knowledge Transfer Voucher with The Open University announced on 7 August 2025, the academic partner has been awarded a \u00a3250,000 UK Research and Innovation (\"UKRI\") grant to further develop its in-silico spheroid modelling platform. Inaphaea, as the commercial partner, will supply its Patient Derived Cells (\"PDC\") for production of spheroids and share data generated on the PDCs including drug response profiling. Inaphaea will also evaluate the in-silico, predictive models as part of its commitment to New Advanced Methodologies (\"NAMs\") for drug development.\nInaphaea is receiving weekly updates and access to PDC samples under its agreement with Nottingham Health Trust, announced on 18 September 2025, whilst the first four ovarian PDCs from the Biobank have been successfully digitised by its partner TwinEdge BioScience (\"TwinEdge\"). The digital avatars created from the four PDCs exceeded all quality controls and TwinEdge will now move to phase 2 of the agreement which involves creating digital avatars of the remaining 63 ovarian PDC models with available RNA-sequence data.\nValiRx is also pleased to announce it has signed an agreement with Apis Assay Technologies Ltd (\"APIS\") to evaluate APIS's HER2 targeting\u00a0Clickmer - based on APIS's novel modified aptamer\u00a0technology. Initially for use on characterising the expression of HER2 on Inaphaea's PDCs, the technology will also be applied to CytoLytix's oncolytic peptide platform in order to selectively target HER2 positive cancer cells, including breast and ovarian cancer.\nIn addition to the commercial update, Dr Amelia Hatfield, recently promoted to Lead Scientist - Translational Science and Academic Liaison at Inaphaea, has been granted Visiting Lecturer status at Kings College London which will facilitate the ongoing collaboration with CytoLytix. Dylon Jones, Inaphaea's technician, has commenced a Level 6 Degree Apprenticeship in Applied Biosciences (BSc Hons) through Middlesex University and delivered via Tiro Training Ltd. (\"Tiro\"). Cathy Tralau-Stewart, Executive Director of the Milner Institute and Non-Executive Director of ValiRx has been appointed as a Research Professor (Therapeutics) at the University of Cambridge.\nMark Eccleston, CEO of ValiRx commented\n\"We are very pleased to have successfully completed the first three phases of the contract with Amply and to have recognised the revenue as we continue to build the sales pipeline\n.\"\n\"Our partnership with The Open University is going from strength to strength with the latest pump priming award being rapidly followed by a significant grant award for our partner which will benefit Inaphaea through shared data generation and publications using our PDCs. We strongly believe that more realistic disease models provide better results and have been developing our biobank to offer a range of services based on 2D and 3D culture models under normoxia and hypoxia. These low passage, non-immortalised models, supported by extensive RNA-sequence data, are closer to, and therefore more representative of, the patient which should ultimately translate to improved understanding of the candidate drugs and reduced failures in the clinic.\"\n\"We're excited by the potential for these models to be digitised through TwinEdge Bioscience and this collaboration has the potential to transform the way we access indicative clinical performance rapidly and economically alongside biomarker identification for patient selection for both our in house and client programs. The relationship with TwinEdge continues to grow as we expand the range of PDCs, adding to their selection of over 10,000 patient avatars. The data generated from these models is helping build more sophisticated patient avatars as the collaboration builds momentum.\"\n\"We are also really pleased to be working with APIS and to have access to their proprietary aptamer-based Clickmer technology. This is another win-win collaboration where we can help validate their HER2 targeting Clickmer whilst generating data on our PDCs. Going forward we will explore a commercial partnership to develop targeted CLX-001 derivatives.\"\n\"I'd also like to offer my congratulations to Amelia and Cathy for their recent academic appointments and Dylan for starting his degree apprenticeship. It is an important part of the upskilling of our technical team.\"\nThe informa",
          "content_length": 9969
        },
        "ingested_at": "2026-01-12T22:04:49.603896Z"
      },
      {
        "event_id": "RNS-29th Sep 2025-half-yea",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.603922Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Half-year Report",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/half-year-report-z0mho2qnvv71s5q.html",
          "rns_number": "RNS Number : 1025B",
          "full_content": "29 Sep 2025 07:00\nRNS Number : 1025B\nValiRx PLC\n29 September 2025\nVALIRX PLC\n(\"ValiRx\", \"the Company\" or \"the Group\")\nHALF YEARLY REPORT FOR THE PERIOD ENDED 30 JUNE 2025\nLondon, UK., 2025\n: ValiRx Plc (AIM\n: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary and novel technology for precision medicines towards commercialisation and partnering,\ntoday announces its unaudited Half Yearly Report for the period ended 30 June 2025 and provides an update on significant post-period events.\nHIGHLIGHTS\nOperational Highlights\n\u00b7\nImplementation of a full strategic and operational review\n\u00b7\nNew evaluation agreement for a delivery platform and CB2 agonist signed\n\u00b7\nLetter of Intent for Val201 terminated with TheoremRx\n\u00b7\nLicense Agreement for Val 401 signed with Ambrose Healthcare\n\u00b7\nPartnered with US based Omios Biologics to evaluate Cytolytix peptide in viral delivery system\n\u00b7\nInaphaea Biobank Evaluation and Commercial use agreements signed with ScreenIn3D, Cellomatics and Dominion Biotech\n\u00b7\nPartnership signed with Dominion Biotech to develop Inaphaea 3k-screen drug repurposed assets\nFinancial Highlights\n\u00b7\nResearch and developments costs (excluding employee costs) \u00a3105,489 (2024: \u00a3121,490)\n\u00b7\nAdministrative expenses \u00a3828,444 (2024: \u00a3947,565)\n\u00b7\nShare-based payment charge \u00a3nil (2024: \u00a318,994)\n\u00b7\nLoss before income taxation of \u00a3931,135 (2024: \u00a31,052,006)\n\u00b7\nTotal comprehensive loss for the period of \u00a3838,434 (2024: \u00a3970,908)\n\u00b7\nLoss per share from continuing operations of 0.22p (2024: Loss - 0.74p)\n\u00b7\nCash and cash equivalents at 30 June 2025 of \u00a3518,794 (2024: \u00a3809,147)\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\"). The Directors of the Company take responsibility for this announcement.\n*** ENDS ***\nFor more information, please contact:\nValiRx plc\nTel: +44 (0) 115 784 0026\nwww.valirx.com\nDr Mark Eccleston, CEO\ninfo@valirx.com\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+ 44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vinformation.biz\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray /\nLudovico Lazzaretti / James Western\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP\n(Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.\nLead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.\nValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.\nFor further information, visit:\nwww.valirx.com\nCHAIRMAN AND CHIEF EXECUTIVE OFFICER'S STATEMENT FOR THE HALF YEAR ENDED 30 JUNE 2025\nThe first half of 2025 has seen significant progress on the evolution of ValiRx and its subsidiaries following the major strategic review, initiated in Q4 2024, designed to improve operational efficiency and enable us to generate near-term revenue, build long-term value, and ultimately improve patient outcomes. A key pillar of this has been the expansion of Inaphaea's network of capability partners. These partnerships deliver three fundamental benefits to the Group:\ni) access to a wider customer base through referrals;\nii) access to advanced testing capabilities for internal and client programs; and\niii) partnered development opportunities.\nIn addition, we are actively working to create value from Inaphaea's assets, including its properitary data sets. Finally, we have refined our engagement model for evaluation and development programs which incorporate pre-agreed, financial upside on evaluation work where we can add significant value to an asset, if that asset is not in-licensed by ValiRx but is ultimately licensed externally.\nThere have been further changes to the board as Adrian de Courcey steppe",
          "content_length": 29737
        },
        "ingested_at": "2026-01-12T22:04:49.603954Z"
      },
      {
        "event_id": "RNS-18th Sep 2025-inaphaea",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.603979Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Inaphaea Commercial Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/inaphaea-commercial-update-hu56oerbkc50n1d.html",
          "rns_number": "RNS Number : 7851Z",
          "full_content": "18 Sep 2025 07:00\nRNS Number : 7851Z\nValiRx PLC\n18 September 2025\nValiRx PLC\n(\"ValiRx\"\nor the\n\"Company\")\nInaphaea Commercial Update\nLondon, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to provide the following updates on its wholly owned subsidiary Inaphaea Limited (\"\nInaphaea\n\").\nInaphaea is pleased to announce that, as it continues to expand its capability partnerships, it has signed a Collaboration Agreement with Swiss techbio company, TwinEdge Bioscience (\"\nTwinEdge\n\"). TwinEdge combine cutting-edge computational biology, artificial intelligence, and personalized medicine to transform how new cancer therapies are developed. Under the agreement, TwinEdge will combine their proprietary methodology with drug response datasets obtained from Inaphaea's Patient derived Cells (PDCs) to create \"patient avatars\" which are digitally actionable representations of the patients' tumours, ready for testing with new drugs in \"in-avatar\" trials. This AI aided classification of responses in PDCs can be used to provide mechanistic insight, predict response of new, or repurposed, drugs and identify biomarkers for patient selection in-silico in what will be one of the world's largest population of digital twins created by TwinEdge.\nAs part of its continued service and product development, Inaphaea has also signed a Material Transfer Agreement with Nottingham University Hospitals NHS Trust to obtain new\nPDC\nmodels, prioritising ovarian, breast, lung and prostate cancer samples with matched blood plasma, white blood cells and ascites/pleural fluids with full ethics and commercial use consent. These prospectively collected samples, with associated clinical data, will be used in advanced 3D models to understand host immune engagement, for example with CytoLytix oncolytic peptide program, as well as external client projects.\nAdditionally, a series of 6 colorectal Cancer PDC models have also been transferred to Cellomatics Ltd under the Evaluation Use Agreement, announced on 30 April 2025, in parallel with characterisation by low pass sequencing underway at Inaphaea.\nInaphaea is also pleased to announce that its collaborative 3K Screen program with Dominion, announced on 12 May 2025, has identified around 250 hits from the initial screen against 5 different models. Around 50 of these molecules, included as controls to validate the approach, have known activity in cancer. Inaphaea and Dominion have reviewed the initial hits and prioritised them based on selection criteria including oral availability of the drugs, freedom to operate regarding current patent position and likely patient positioning for unmet clinical need. A top 10 set of molecules has been selected for inclusion in the next phase which included testing of full dose response curves in selected Patient Derived Models at Inaphaea and Dominion. The data generated will be processed in TwinEdge's digital twin AI platform to support new patent filings and initial commercial discussions with potential licensees as well as application for non-dilutive grant funding to support further development of these and other assets from the 3K screen. Sales and marketing for PredictRx personalised therapy selection has also been initiated by Dominion with initial sales anticipated in Q4.\nMark Eccleston, CEO of ValiRx commented\n\"\nOur new partnership with TwinEdge Bioscience is a huge step forward in both our service and in house development capabilities at Inaphaea and for the broader ValiRx group. Digitising our 2D and 3D PDC models further leverages the valuable RNA-seq and treatment response data sets we have and provides another New Approach Methodology (NAM) to accelerate our translational drug development programs. The Patient Avatar approach enables unprecedented large-scale clinical insight at translational and early clinical decision points allowing an in-silico screen of 10,000 digitised patents and counting. This approach will accelerate internal and customer drug development programs and provide clinical insight at a fraction of the cost of a real-world clinical trial. The predictive biomarker readouts will also streamline future in-human and in-canine clinical trials by matching the right patient with the right drug, increasing the chances of success and maximising asset value to prospective licensees through an expedited clinical trails pathway.\"\n\"\nWe are also pleased that the additional quality control work and data generation through low pass sequencing is being recognised with colorectal cancer PDCs now under evaluation with Cellomatics\n. The new prospective sample collection capability established with the local NHS trust will support ongoing PDC development and supply agreements whilst also expanding our capabilities in the immune oncology space through the ability to procure patient blood samples matched to the PDC models. This is a major advantage for both our internal programs such a",
          "content_length": 11401
        },
        "ingested_at": "2026-01-12T22:04:49.604008Z"
      },
      {
        "event_id": "RNS-1st Sep 2025-cytolyti",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604035Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Cytolytix Commercial update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/cytolytix-commercial-update-vwetn5326h7okz9.html",
          "rns_number": "RNS Number : 3435X",
          "full_content": "1 Sep 2025 07:00\nRNS Number : 3435X\nValiRx PLC\n01 September 2025\nValiRx PLC\n(\"ValiRx\"\nor the\n\"Company\")\nCytolytix Commercial update\nLondon, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to provide the following updates on its majority owned subsidiary Cytolytix Limited (\"\nCytolytix\n\").\nCytolytix has received a notice of allowance for the European Patent application \"Nanoparticle for Anti-Cancer Peptides and Uses Thereof\" (application No.\n21798092.9\n), a key patent in the Cytolytix portfolio. This follows an earlier notification that claims within the\nEuropean Patent Application \"Polyleucine-Based Peptides As Anti-Cancer Agents\" (application No. 20793085.0) are considered allowable and an accelerated examination has been requested, following filing of routine amendments to the patent description, to expedite notice of allowance. These two patent families represent the core IP for Cytolytix whilst additional protection is sought for new inventions currently under validation. Further details of these improvements will be released once the corresponding patents have been filed.\nCytolytix has completed development and evaluation of its second-generation delivery platform and scheduled materials for evaluation in\nScreenin3D's\nUpScale3Dlab-on-a-chip platform\nincluding Inaphaea's Triple Negative Breast Cancer Patient Derived Cell models provided under the Evaluation and Commercial Use agreement announced on 3 February 2025. The evaluation will include assessment of the potential to activate the host immune system through immunogenic cell death.\nCytolytix's peptides have also shown to be effective in prostate cancer with preliminary results developed through our collaboration with the Open University, funded through their knowledge transfer Voucher scheme, indicating potential elevated activity under hypoxia. This state low oxygenation is associated with certain cancers, including prostate cancer and Triple Negative Breast Cancer and usually drives resistance to chemotherapy. Both these cancers also display a high population of Cancer Associated Fibroblasts which is replicated in Inaphaea Biolab's Patient derived Cell models. Inaphaea is working with the Open University and ScreenIn3D to develop mixed CAF/Cancer cell models for more representative testing. This work, in part, is supported by pump priming funding from the Open University's Higher Education Innovation funding.\nValiRx CEO and Cytolytix Director, Mark Eccleston, will be presenting Cytolytix oncolytic peptide program at the Charles River Biotech Symposium in Carlsbad (7 - 10 September 2025) and at the Oxford Global Discovery & Development US 2025 in San Diego (2 - 3 October 2025) following a series of presentations earlier in the year. These meetings represent excellent partnering opportunities as exemplified by the deal with Omios Bio which followed IO 360 in Boston in January 2025. ValiRx is in discussions with several potential partners to progress Cytolytix, including a major pharmaceutical company and further non-dilutive funding options with our academic partners.\nMark Eccleston, CEO of ValiRx commented\n\"We are pleased to receive the European Patent Office's notice of allowance and acknowledgement of patentable claims for Cytolytix's core intellectual property as we build our proprietary position in the oncolytic peptide space. We are expanding these core patents with new IP developed using in house expertise at ValiRx and Inaphaea and we expect to strengthen our portfolio with new filings in the coming weeks.\n\"In addition, we are rapidly progressing with the in-vitro and ex-vivo validation of the platform by leveraging the combined experience and resources of our tCRO, Inaphaea Biolabs, with the advanced non animal 3D-culture testing capabilities we have brought in through our capability partners.\nDevelopment of triple negative breast cancer models on Screenin3D's\nUpScale3Dlab-on-a-chip platform was a key strategic objective for\nValiRx's cytolytic peptide program through our partially owned subsidiary, Cytolytix. We are further extending these capabilities to include VoxCell's\nproprietary fully perfusable vascularised 3D tissue culture models as we announced in July 2025.\n\"These advanced models are critical in assessing the cell killing efficacy of our oncolytic peptides as well as their potential to engage the host immune system. The potential immune boost feature of this class of therapeutics could significantly enhance both efficacy and durability of response.\"\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\"). The Directors of the Company take responsibility for this announcement.\n*** ENDS ***\nEngage with the ValiRx management team directly ",
          "content_length": 7957
        },
        "ingested_at": "2026-01-12T22:04:49.604062Z"
      },
      {
        "event_id": "RNS-26th Aug 2025-commerci",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604085Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Commercial update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/commercial-update-3dc3vrqgckpmllf.html",
          "rns_number": "RNS Number : 5461W",
          "full_content": "26 Aug 2025 07:00\nRNS Number : 5461W\nValiRx PLC\n26 August 2025\nValiRx PLC\n(\"ValiRx\"\nor the\n\"Company\")\nCommercial update\nLondon, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces that, further to the announcement on 3 April 2025, the Company has established a new wholly owned subsidiary Blue Ribbon Bio Limited (\"\nBlue Ribbon\n\").\nBlue Ribbon has been incorporated to house all Prostate Cancer associated assets from ValiRx Plc which will initially consist of existing Intellectual Property for Val201, exclusively licensed to ValiRx by\nCancer Research Horizons in 2010\n. The Company plans to file new application-based patents for Val201 which will be held by Blue Ribbon.\nA detailed technical and market assessment has been conducted for Val201 as part of a comprehensive review of ValiRx's current and potential assets and concluded that there is a still a strong rationale for Val201 within the treatment pathway for prostate cancer. A critical path plan to expedite validation of improvements to Val201 to create additional value, extend patent coverage and position for partnering is now in place.\nA notice of allowance has also been received for Canadian \"\nMedical Use\"\npatent (application No. 2,853,671)\nfor the treatment of non-cancerous conditions relating to the use of the Val201 peptide in endometriosis (Val301).\nMark Eccleston, CEO of ValiRx commented\n\"We have an opportunity to build a broader prostate cancer focussed portfolio based on current and future pan cancer assets that can be applied in this indication. Having worked on the original pre-clinical development of Val201, I am pleased that there is still a market opportunity for this asset, and we intend to rapidly complete the planned work required to get this back into the clinic in new and improved form. This will build on the initial data package and key opinion leader feedback developed in the earlier clinical trial and development will be applicable to all applications of the peptide, including in endometriosis, so I also pleased to announce notification that our Canadian patent will be granted. We will leverage the combined experience and resources of our tCRO, Inaphaea Biolabs, including the prostate cancer Patient Derived Models that we are developing in partnership with the Open University, with the advanced non animal 3D-culture testing capabilities we have brought in through our capability partners. Several of our current assets, those in our repurposing program with Dominion and other assets under consideration for evaluation and in-licensing can be applied across various stages of prostate cancer as well as our core focus in women's health. By ringfencing these assets in a portfolio approach we believe that we can create significant value and attract partners for clinical development.\"\nTony Hickson, Chief Business Officer of Cancer Research Horizons, commented:\n\"Cancer Research Horizons is committed to bringing new drugs to market and supports the development of drugs at all stages, especially in areas of high unmet clinical need. Hormone therapies such as Enzalutamide and Abiraterone have transformed prostate cancer treatment, but most patients eventually become resistant to this form of therapy and there remains an unmet need for new drugs to overcome drug resistance. Val201 has a unique mechanism of action and can be positioned to address these resistant forms of cancer, as well as potentially earlier stages of the disease to mitigate the side effects seen under hormone ablation. We are pleased that ValiRx and Blue Ribbon Bio will continue with the development of a version of the therapy optimised for clinical impact.\"\nThe Directors of the Company take responsibility for this announcement.\n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investor\nhub here:\nhttps://valirx.com/s/cc8ef3\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\nhttps://valirx.com/link/0y5LzP\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0026\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d1\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific,",
          "content_length": 6816
        },
        "ingested_at": "2026-01-12T22:04:49.604123Z"
      },
      {
        "event_id": "RNS-7th Aug 2025-valirxaw",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604147Z",
        "source": "LSE_RNS",
        "data": {
          "title": "ValiRx Awarded Grant from Open University",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/valirx-awarded-grant-from-open-university-9itxu3tunn2qdn6.html",
          "rns_number": "RNS Number : 4259U",
          "full_content": "7 Aug 2025 10:51\nRNS Number : 4259U\nValiRx PLC\n07 August 2025\n7 August 2025\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nValiRx Awarded Grant from Open University\nLondon, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update from its wholly owned subsidiary Inaphaea BioLabs Limited (\"Inaphaea\").\nInaphaea is pleased to confirm it\nhas been awarded a Knowledge Transfer Voucher (\"KTV\") to partner with The Open University (\"OU\"). This funding will be used to perform advanced imaging-based analysis of Inaphaea biolab's patient derived cell models. The project, which will run from 1st August 2025 to 30th September 2026, will utilise The Open University's expertise in biophysical and machine learning approaches for predicting self-organisation in tissues to build algorithms to assess drug responses in tumour spheroids. The three primary aims of the program are to carry out confocal microscopy of tumoroids provided by Inaphaea; to validate the use of the OU developed\ncontractile network dipole orientation\n(\"CONDOR\") simulations to model these tumoroids and to strengthen links with Inaphaea for future grant applications.\nMark Eccleston, CEO of ValiRx commented\n\"We are grateful to The Open University for its continued support across multiple ValiRx companies as we work with leading academic experts to advance our technical capabilities around advanced PDC models and cell-based testing. This is the third award we have received and is very timely given recent updates to the FDA Modernization Act 2.0, which expands regulatory safety and efficacy testing options to include 3D cell cultures as a viable alternative to animal testing. We have built multiple partnerships to expand and develop our capabilities in this area to deliver better products and services through Inaphaea and progress assets faster and further down the pipeline with in-house resources, ultimately leading to better therapeutic candidates from our various SPVs.\"\nJim Hague,\nSenior Lecturer at the Faculty of Science, Technology, Engineering & Mathematics, The\u00a0Open University commented\n\"In partnership with Inaphaea, we want to improve spheroid use as models for drug-development, with a focus on treatments for major cancers (an area of significant interest for our partner, especially triple-negative breast, colorectal and prostate cancers).\nOur biophysical and machine learning solutions allow us to obtain key additional information about spheroid structure and cell organisation, vital to assess the health of the spheroid tissue. Therefore, addressing an unmet need for analytic tools to understand how accurately spheroid responses to drug candidates represent real tissues.\"\nThe Directors of the Company take responsibility for this announcement.\n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investor\nhub here:\nhttps://valirx.com/s/cc8ef3\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\nhttps://valirx.com/link/PljYke\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0026\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d1\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.\nLead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.\nValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ti",
          "content_length": 5844
        },
        "ingested_at": "2026-01-12T22:04:49.604173Z"
      },
      {
        "event_id": "RNS-5th Aug 2025-updateon",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604199Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Update on Evaluation Agreement with Stingray Bio",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/update-on-evaluation-agreement-with-stingray-bio-x3m0oxdyimff6tm.html",
          "rns_number": "RNS Number : 0294U",
          "full_content": "5 Aug 2025 09:53\nRNS Number : 0294U\nValiRx PLC\n05 August 2025\n5 August 2025\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nUpdate on Evaluation Agreement with Stingray Bio\nLondon, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health provides the following update on the Evaluation Agreement with Stingray Bio Limited (\"Stingray\") announced on 10 November 2023.\nUnder the terms of the Evaluation Agreement entered into, a defined series of preclinical tests was performed on a lead series of molecules developed by Stingray using a target-based drug design approach, to create novel candidate drugs for kinases with well-validated links to cancer. Inaphaea Biolabs (\"Inaphaea\") investigated the action of the molecules against a range of cancer types using patient derived cell models whilst specificity and safety profiles of lead candidates nominated from within the series were assessed through collaborative partners. This twelve-month program was designed to validate the technology and determine suitability for commercialisation. At the conclusion of the evaluation period, the technology had not met the strict criteria for the Company to exercise its option to license the technology on pre-agreed terms.\nValiRx has entered into a new format, twelve-month, agreement with Stingray to\nperform\nin-silico\nlead optimization of potency and target selectivity, and\nin-vitro\nbased experiments on lead Stingray drug compounds identified during the first agreement.\nThe cost of the work will be borne by ValiRx and outsourced activities will be capped at \u00a356,000 over the period. During the evaluation period, any evaluation results generated will be jointly owned by ValiRx and Stingray. At the conclusion of the evaluation period, the Company has an option to license the technology, under pre-agreed terms, into a Special Purpose Vehicle jointly owned with Stingray. On completion of IND enabling studies, ValiRx's ownership will increase to 75%.\nIf ValiRx elects not to proceed with the license, rights will return to Stingray and, if Stingray secures alternative investment within 12 months of the evaluation's completion, ValiRx will be entitled to a cash payment of 1.5x its total investment (estimated at no more than \u00a3150,000, including outsourced work and internal resources) and all evaluation results generated during the programme will be assigned to and owned by Stingray.\nMark Eccleston, CEO of ValiRx commented\n\"\nWe are pleased to progressing the Stingray assets through our new hybrid approach to evaluation and development programmes. Whilst the intention is to develop assets which we can in-license, by retaining some upside in the asset if we elect not to proceed to license, we can consider shorter and a broader range of projects where we see an opportunity to add significant value. The contract is for 12 months but we envisage completing the work significantly faster than this. This approach leverages Inaphaea's expanding \"New Approach Methodology\" capabilities promoted by the FDA as an alternative to non-animal testing as well as our broad range of collaboration partners offering complementary services. Under this new approach, the partner retains the right to seek additional funding for the asset which can lead to earlier partnering opportunities in the SPV or transition from an evaluation to a revenue generating service contract. This structure is informing the design of future evaluation programmes within ValiRx.\"\nSunil Shah, director of Stingray commmented \"\nWe're\nexcited to see the progress of ValiRx's latest programme, which focus on advancing innovative oncology assets especially in women's health space - an area which remains significantly undeserved with medical needs. The collaborative, hybrid model adopted with Stingray Bio not only strengthens the pathway of these novel compounds but also reflects ValiRx's commitment to de-risking early-stage innovation and driving it forward. We strongly believe that ValiRx's efforts, combined with Stingray's foundational contributions, can help realise the commercial potential of new cancer therapeutics. We look forward to seeing this programme evolve as it moves closer to potential clinical development.\n\"\nTo hear more about this update on the Stingray Bio Evaluation Agreement, please visit our website where Mark Eccleston, CEO has prepared a short video:\nhttps://valirx.com/link/eolBYr\n. Feel free to submit your questions for the ValiRx management team here, and we will endeavour to get back to you in due course.\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\"). The Directors of the Company take responsibility for this announcement.\n*** ENDS ***\nEngage with the ValiRx management team directly by asking questio",
          "content_length": 7939
        },
        "ingested_at": "2026-01-12T22:04:49.604223Z"
      },
      {
        "event_id": "RNS-4th Aug 2025-licensin",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604246Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Licensing Agreement with Dominion Biotech Ltd",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/licensing-agreement-with-dominion-biotech-ltd-5ve6hpw6gxx1r9a.html",
          "rns_number": "RNS Number : 8017T",
          "full_content": "4 Aug 2025 07:00\nRNS Number : 8017T\nValiRx PLC\n04 August 2025\n4 August 2025\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nValiRx Licensing Agreement with Dominion Biotech Ltd\nLondon, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to provide the following update on the commercial activity of its solely owned subsidiary Inaphaea BioLabs (\"Inaphaea\").\nInaphaea is pleased to announce the execution of an exclusive licence agreement (the \"Agreement\") with UK based Dominion Biotech Ltd (\"Dominion\") for Inaphaea's PredictRx\u00ae platform. PredictRx is a personalised cancer screening service whereby a patient's tumour sample is processed into Patient Derived Cells (PDCs) and subjected to a comprehensive drug combination screening panel to determine optimal chemotherapy treatment protocols.\nUnder the terms of the Agreement, Inaphaea will receive a 50% share of global net revenues from the PredictRx service to be offered by Dominion. Dominion and Inaphaea will also share ownership of any new Patient Derived Cells (PDCs) developed. The Agreement is for a period of 2 years with annual renewal thereafter. Either party may initiate a buyout of the rights of the other party after an initial period of 18 months under pre-agreed terms based on a multiple of trailing net revenue. Although initial revenues under the Agreement are expected to be modest, the arrangement is strategically important in demonstrating the commercial application of ValiRx's platform and establishing future buyout value.\nMark Eccleston, CEO of ValiRx commented\n\"We have expanded our relationship with Dominion as we continue to develop and commercialise Inaphaea's asset base. PredictRx is a pioneering, in-vitro approach for predicting drug sensitivity for cancer therapies at the individual patient level based on analysis of the patient's own cancer cells. This can deliver significant benefit by identifying the most effective treatment options leading to a truly personalised approach to therapy which ultimately should deliver improved outcomes for patients. Inaphaea's focus is translational drug development services and monetising of its biobank through its PDC models and through this license to Dominion which will develop and commercialise the PredictRx clinical service globally.\"\nAnthony Holmes, CEO of Dominion commented\n\"\nWe're delighted to expand our successful partnership with Inaphaea by bringing the PredictRx platform to market globally. This innovative personalised cancer screening service represents a significant advancement in precision oncology - using a patient's own cancer cells to identify the most effective treatment options before therapy begins. By leveraging our established network of oncologists and patient-derived cell expertise, we can now offer clinicians and patients a powerful tool to optimise treatment decisions from day one. This licensing agreement demonstrates our commitment to translating cutting-edge science into real-world clinical benefits that can improve patient outcomes and potentially reduce the trial-and-error approach that too often characterises cancer treatment today.\"\nThe Directors of the Company take responsibility for this announcement.\n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investor\nhub here:\nhttps://valirx.com/s/cc8ef3\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\nhttps://valirx.com/link/yVwQZe\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0026\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d1\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, d",
          "content_length": 6276
        },
        "ingested_at": "2026-01-12T22:04:49.604271Z"
      },
      {
        "event_id": "RNS-29th Jul 2025-collabor",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604297Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Collaboration Agreement with Voxcell BioInnovation",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/collaboration-agreement-with-voxcell-bioinnovation-aanerj7dj5ul1tl.html",
          "rns_number": "RNS Number : 8879S",
          "full_content": "29 Jul 2025 07:00\nRNS Number : 8879S\nValiRx PLC\n29 July 2025\nValiRx PLC\n(\"ValiRx\"\nor the\n\"Company\")\nCollaboration Agreement with Voxcell BioInnovation\nLondon, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update from its wholly owned subsidiary Inaphaea BioLabs Limited (\"Inaphaea\").\nInaphaea is pleased to announce the execution of a collaboration agreement (the \"Agreement\") with Canada based VoxCell BioInnovation Inc. (\"VoxCell\") to provide Inaphaea's Patient Derived Cells (\"PDC\") for evaluation and use in VoxCell's proprietary fully perfusable vascularised 3D tissue culture models. The Agreement initially focusses on establishment of three Triple Negative Breast Cancer (\"TNBC\")\nin-vitro\n3D tumour models which can then be offered for commercial sale and/or services by VoxCell and/or Inaphaea.\nAs part of the Agreement, three TNBC PDC models will be expanded and tested/optimised for growth on VoxCell's Bioink matrix at Inaphaea's facility. PDCs will then be transferred to VoxCell to generate vascularised 3D cell culture models and further evaluated. Both parties plan to jointly publish the results.\nMark Eccleston, CEO of ValiRx commented\n\"We continue to build partnerships that expand the markets for our PDC models and testing services, particularly in the ex-vivo space considering the FDA's decision to phase out animal-based testing requirements for new drug filings. This Agreement with VoxCell exemplifies our approach to leverage commercial access to our biobank with services and technologies that complement our internal pipeline development and is a real opportunity to develop valuable data to progress our Clx001 oncolytic peptide asset whilst exemplifying the utility of our PDC models in combination with a next generation, non-animal-based testing platform. VoxCell's perfused 3D culture platform is well positioned for testing aspects of nano-formulated drug delivery such as targeting, tumour accumulation from the vasculature and penetration into solid tumours.\"\nKarolina Valente, CEO of VoxCell commented\n\"\nWe are proud to partner with ValiRx to accelerate the development of physiologically relevant TNBC models. By combining their PDC models with our vascularized 3D bioprinting technology, we will create more predictive, human-like tumour tissues for drug screening. Integrating clinically relevant cells from ValiRx into our high-resolution vascular networks will allow us to support the assessment of ValiRx's Clx001 oncolytic peptide asset in a highly translational environment. This collaboration not only aims to generate valuable efficacy and tumor penetration data for Clx001, but also sets the foundation for expanding our partnership to other cancer indications, leveraging the breadth of ValiRx's PDC model biorepository and VoxCell's advanced, perfused tissue models. Together, we are helping shape a future where complex cancers like TNBC are studied and treated with greater precision and confidence\n.\"\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\"). The Directors of the Company take responsibility for this announcement.\n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investor\nhub here:\nhttps://valirx.com/s/cc8ef3\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\nhttps://valirx.com/link/aP3wwP\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0026\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d1\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx conn",
          "content_length": 6415
        },
        "ingested_at": "2026-01-12T22:04:49.604323Z"
      },
      {
        "event_id": "RNS-30th Jun 2025-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604350Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of AGM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/result-of-agm-n2hy7ikv38mjglc.html",
          "rns_number": "RNS Number : 0408P",
          "full_content": "30 Jun 2025 15:48\nRNS Number : 0408P\nValiRx PLC\n30 June 2025\n30 June 2025\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nResult of AGM\nLondon, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces that at its Annual General Meeting (\"AGM\") held earlier today, all resolutions were duly passed.\nDetails of the votes received will be available shortly on the Company's website.\nThe Directors of the Company take responsibility for this announcement.\n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investor\nhub here:\nhttps://valirx.com/s/cc8ef3\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\nhttps://valirx.com/link/peg6vy\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0026\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d1\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.\nLead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.\nValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.\nFor further information, visit:\nwww.valirx.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nRAGSDWFLSEISELM",
          "content_length": 3529
        },
        "ingested_at": "2026-01-12T22:04:49.604375Z"
      },
      {
        "event_id": "RNS-20th Jun 2025-ambrosee",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604402Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Ambrose Exercise Option on VAL401",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/ambrose-exercise-option-on-val401-06raqk7wgknfmni.html",
          "rns_number": "RNS Number : 6174N",
          "full_content": "20 Jun 2025 07:00\nRNS Number : 6174N\nValiRx PLC\n20 June 2025\n20 June 2025\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nAmbrose Healthcare Exercise Option on VAL 401 Out License Agreement for \u00a316 Million plus Royalties\nLondon, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health is pleased to announce that, further to the extension to the Letter of Intent (\"LOI\") with Ambrose Healthcare Ltd (\"Ambrose\") announced on 20 November 2024, Ambrose has now served notice to ValiSeek Limited (\"Valiseek\") to exercise their option (\"Option\") to licence Valiseek's VAL401 asset under the pre-agreed terms of the Option Agreement announced on 5 December 2023.\nUnder the terms of the Option Agreement and following exercise of the Option, ValiRx and Ambrose have entered into an Intellectual Property Licence Agreement for VAL401 under which ValiRx will receive 576,000 ordinary shares in Ambrose with clinical and commercial milestone payments to be made to Valiseek totalling a value of up to \u00a316 million plus royalties.\nAmbrose is a private UK specialist pharmaceutical company, incorporated in October 2022 and focussed on developing new treatments for rare diseases and patients managed in hospitals and specialist care. The initial \u00a36 million milestones are payable in cash or the equivalent value in new ordinary shares in Ambrose with the issue price determined by the latest issue of shares in Ambrose, at the discretion of Ambrose. Payment of milestones in cash is subject to Ambrose raising capital in due course.\nValiSeek is a 54.14% subsidiary joint venture of ValiRx alongside Tangent Reprofiling (a member of the SEEK Group), its sole asset is VAL 401 which is the repurposed Risperidone asset which in a novel lipid formulation is seen to have anticancer effect across a number of indications.\nUnder the License Agreement, Ambrose Healthcare will meet all future patent costs and commits to completing development and commercialisation of VAL401 at Ambrose's cost.\nMark Eccleston, CEO of ValiRx commented\n\"\nWe are pleased to be able to complete this technology license for VAL401 with Ambrose and we have been working to identify multiple funding partners to progress VAL401 through the various clinical stages with several options under discussion. In addition, we are also exploring short term opportunities to support a funded preclinical validation for VAL401 through our wholly owned subsidiary, Inaphaea Biolabs Limited, which has 19 pancreatic Patient Derived Cell models. These models can be applied in 3D systems as New Approach Methods which are receiving growing support from the FDA in support for IND submissions.\"\nToby Wilson Waterworth, CEO of Ambrose Healthcare commented \"\nAmbrose Healthcare is excited to announce the exercise of the option and enter a licensing agreement to develop and commercialise for VAL401 globally. This strategic partnership underscores Ambrose Healthcare's commitment to pioneering innovative rare disease therapies that enhance patient outcomes. This licensing deal marks an important step in our mission to accelerate safe and effective treatment to rare disease populations, including Oncology. For example, pancreatic cancer, one of the deadliest is considered a rare disease.\nVAL401 has demonstrated potential therapeutic benefits in a late-stage non-small cell lung cancer clinical trial. Broadening the potential for VAL401, Ambrose intends to work with ValiRx's Inaphaea to generate pre-clinical evidence in multiple other cancer indications, starting with pancreatic models. We are eager to accelerate its development, with expanded clinical trials and expedited regulatory submissions, to broaden the impact of this innovative therapy to patients worldwide.\n\"\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\"). The Directors of the Company take responsibility for this announcement.\n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investor\nhub here:\nhttps://valirx.com/s/cc8ef3\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\nhttps://valirx.com/link/peg6vy\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0026\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.bi",
          "content_length": 7143
        },
        "ingested_at": "2026-01-12T22:04:49.604430Z"
      },
      {
        "event_id": "RNS-9th Jun 2025-valirxin",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604453Z",
        "source": "LSE_RNS",
        "data": {
          "title": "ValiRx Investor Webinar",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/valirx-investor-webinar-6tid0ut6p4c8pp6.html",
          "rns_number": "RNS Number : 0200M",
          "full_content": "9 Jun 2025 10:57\nRNS Number : 0200M\nValiRx PLC\n09 June 2025\n9 June 2025\nValiRx\n(\"VAL\" or the \"Company\")\nValiRx Investor Webinar\nLondon, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, is pleased to announce a post-Results webinar with CEO Mark Eccleston.\nThe webinar will be hosted live via our website on\nThursday, 12 June 2025 at 10am BST\n, and we invite both existing and prospective investors to submit their questions in advance. You can do so from here:\nhttps://valirx.com/webinars/XyO1Xr-annual-results-fy2024\nFor further information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\nhttps://valirx.com/link/lyapKP\nValiRx plc\nDr Mark Eccleston, CEO\nTel:\n+44 115 784 0025\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d1\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.\nLead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.\nValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.\nFor further information, visit:\nwww.valirx.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCSSLSUUEISEIM",
          "content_length": 3375
        },
        "ingested_at": "2026-01-12T22:04:49.604474Z"
      },
      {
        "event_id": "RNS-6th Jun 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604496Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/holdings-in-company-gvum18wbuyp4anw.html",
          "rns_number": "RNS Number : 8222L",
          "full_content": "6 Jun 2025 10:54\nRNS Number : 8222L\nValiRx PLC\n06 June 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nValiRx PLC\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nStephen Wolstenhulme\nCity and country of registered office (if applicable)\nUK\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n05/06/2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n06/06/2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n6.17%\n6.17%\n23,125,000\nPosition of previous notification (if\napplicable)\n5.84%\n5.84%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BLH13C52\n12,450,000\n10,675,000\n3.32%\n2.85%\nSUBTOTAL 8. A\n23,125,000\n6.17%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nStephen Wolstenhulme\n3.32%\n3.32%\nDaniele Wolstenhulme\n2.85%\n2.85%\nTotal\n6.17%\n6.17%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nUK\nDate of completion\n06/06/2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUNVKRVOUNRRR",
          "content_length": 4418
        },
        "ingested_at": "2026-01-12T22:04:49.604518Z"
      },
      {
        "event_id": "RNS-6th Jun 2025-finalres",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604544Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Final Results & Notice of AGM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/final-results-notice-of-agm-nog57u343cqh8pc.html",
          "rns_number": "RNS Number : 7093L",
          "full_content": "6 Jun 2025 07:00\nRNS Number : 7093L\nValiRx PLC\n06 June 2025\nValiRx PLC\n(\"ValiRx\"\nor the\n\"Company\")\nFinal Results & Notice of AGM\nLondon, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces its audited results for the year ended 31 December 2024.\nHighlights\nOperational Highlights:\n\u00b7\nExtension of Dundee evaluation agreement with\n\u00a350,000 grant from the Queen Mary University London Impact Fund.\n\u00b7\nGrant funding secured to progress Cytolytix and Inaphaea programmes through Open University Knowledge transfer and Higher Education Innovation Fund schemes.\n\u00b7\nCompletion of Stingray evaluation agreement with negotiations underway for follow up underway post period.\n\u00b7\nTermination of Barcelona and evaluation agreement.\n\u00b7\nInitiation of strategic review to identify operational efficiencies and cost savings culminating in post period reductions of approximately \u00a3200, 000 in staffing costs.\n\u00b7\n\u00a349, 775 revenue from Inaphaea reflecting first payment of a multiphase contract and first sale of Assay ready reagents from Biobank bank.\nFinancial Highlights:\nResearch and developments costs of \u00a3\n245,163\u00a0for the year ended 31 December 2024 as compared to \u00a3383,362 in 2023,\u00a0a reduction of \u00a3138,199 with cost savings due to reduced outsourced activities.\nAdministrative expenses of \u00a3\n1,976,283\u00a0for the year ended 31 December 2024 as compared to \u00a31,886,401 in 2023,\u00a0an increase of \u00a389,882\u00a0reflecting increase staff costs and compensation paid and intellectual property costs.\nTotal comprehensive loss for the year ended 31 December 2024 of \u00a3\n1,915,693\u00a0as compared to \u00a32,037,701 in 2023,\u00a0and a loss per share of 1.45p as compared to 2.01p in 2023.\nCash\nbalance at 31 December 2024 of \u00a3\n1,555,986\u00a0as compared to \u00a3174,684 in 2023.\nMaterial uncertainty relating to going concern\nThe Auditors have drawn attention to the policy on Going Concern within note 2 to the financial statements, which indicates that the accounts have been prepared on the going concern basis. The Board has referred to the fact that the Group and Parent Company are reliant on future fund raisings to continue their activities as budgeted. Should future fund raisings be unsuccessful, this may cast significant doubt on the Group and parent Company's ability to continue as a going concern. The Auditors opinion is not modified in respect of this matter. The full Auditor's report is contained in the Company's Annual Report.\nNotice of AGM\nThe Company's Annual General Meeting (\"AGM\") will be held at 11:00 am on 30 June 2025 at the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London EC4R 3TT. A copy of the Company's annual report and accounts, together with the Notice of AGM, have been posted to all shareholders and will shortly be available on the Company's website\nwww.valirx.com\n.\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\"). The Directors of the Company take responsibility for this announcement.\n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investor\nhub here:\nhttps://valirx.com/s/cc8ef3\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\nhttps://valirx.com/link/MrDAkP\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0025\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d1\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected co",
          "content_length": 35262
        },
        "ingested_at": "2026-01-12T22:04:49.604570Z"
      },
      {
        "event_id": "RNS-3rd Jun 2025-newevalu",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604593Z",
        "source": "LSE_RNS",
        "data": {
          "title": "New Evaluation and Material Transfer Agreement",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/new-evaluation-and-material-transfer-agreement-37t2oo5wcbx9kye.html",
          "rns_number": "RNS Number : 1164L",
          "full_content": "3 Jun 2025 07:00\nRNS Number : 1164L\nValiRx PLC\n03 June 2025\n3 June 2025\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nNew Evaluation and Material Transfer Agreement\nValiRx plc (the \"Company\") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to announce that its majority owned subsidiary, Cytolytix Ltd. (\"Cytolytix\") and Omios Biologics (\"Omios\"), a California based corporation, have entered into an Evaluation and Material Transfer agreement to evaluate the ability of Cytolytix's CLX001 oncolytic peptide technology to enhance activity of Omios's next-generation oncolytic virus immunotherapies (the \"Agreement\").\nThe Agreement focuses on incorporating Cytolytix's Oncolytic Peptide technology into the Omios next-generation Oncolytic Virus platform and is expected to take up to 12 months, for a nominal upfront payment. On conclusion of the evaluation, Omios has an option to enter into an\nOncolytic Peptide License Agreement to continue using Cytolytix technology\n. This signifies an exciting new opportunity for ValiRx and Cytolytix to further expand its portfolio and commercialise its portfolio of innovative cancer therapeutics.\nMark Eccleston, CEO of ValiRx commented\n\"We are pleased to announce this first Cytolytix commercial evaluation with Omios Bio and we see great synergy with their virus platform with a built-in biomarker for tumour targeting. We are very excited to work with Omios on the next generation of oncolytic virus leveraging Cytolytix's oncolytic peptide technology to enhance activity. Omios's innovative approach to enhancing their viruses' ability to selectively target and destroy cancer cells offers great synergy with our oncolytic peptide technology.\"\nAldo Pourceht, CEO of Omios Biologics commented\n\"Our agreement with Cytolytix marks a significant strategic advancement for Omios. We look forward to evaluating how Cytolytix's oncolytic peptides can maximize the therapeutic impact of our next-generation VACV therapies. This collaboration is perfectly aligned with our core strategy: to build a leading oncolytic immunotherapy and tumor-targeted gene delivery platform, and most importantly, to rapidly advance our transformative cancer treatments into the clinic, for patients with challenging solid tumors.\"\n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investor\nhub here:\nhttps://valirx.com/s/cc8ef3\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\nhttps://valirx.com/link/Ve9mNe\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0026\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d1\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.\nLead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.\nValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.\nFor further information, visit:\nwww.valirx.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse",
          "content_length": 5325
        },
        "ingested_at": "2026-01-12T22:04:49.604617Z"
      },
      {
        "event_id": "RNS-20th May 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604639Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/holdings-in-company-5bf3mpqberaxleh.html",
          "rns_number": "RNS Number : 4494J",
          "full_content": "20 May 2025 13:25\nRNS Number : 4494J\nValiRx PLC\n20 May 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BLH13C52\nIssuer Name\nVALIRX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nJaspal Singh\nCity of registered office (if applicable)\nWolverhampton\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n15-May-2025\n6. Date on which Issuer notified\n16-May-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n8.010000\n0.000000\n8.010000\n30000000\nPosition of previous notification (if applicable)\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BLH13C52\n30000000\n8.010000\nSub Total 8.A\n30000000\n8.010000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n13. Place Of Completion\nWolverhampton\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLURUURVUUVUAR",
          "content_length": 3759
        },
        "ingested_at": "2026-01-12T22:04:49.604665Z"
      },
      {
        "event_id": "RNS-12th May 2025-inaphaea",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604692Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Inaphaea Deal Extension With Dominion",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/inaphaea-deal-extension-with-dominion-fxwnb2xpj5835hs.html",
          "rns_number": "RNS Number : 2312I",
          "full_content": "12 May 2025 07:00\nRNS Number : 2312I\nValiRx PLC\n12 May 2025\nValiRx PLC\n(\"ValiRx\"\nor the\n\"Company\")\nInaphaea Deal Extension With Dominion\nLondon, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to provide the following update on the commercial activity of its wholly owned subsidiary Inaphaea BioLabs (\"Inaphaea\").\nInaphaea is pleased to announce that it has signed an extension to the evaluation and commercial use agreement with UK based Dominion Biotech Ltd (\"Dominion\") announced on 30 April 2025. Under the extension, Inaphaea will share access to results from a proprietary screen of approximately 3000 FDA approved drugs (\"3k Screen\") generated in a panel of Patient Derived Cells. The drugs are approved for non-cancer applications and Dominion will mine the data for potential cancer applications, carrying out routine analysis to validate the most promising candidates at its own expense; the parties will agree and share any additional in-depth studies if required. The results of the analysis will be jointly owned and both parties will share equally all costs associated with filing, prosecution and maintenance of any arising patents for any repurposed drugs.\nThe parties will work together to commercialise any new assets either to the owner of the original drug compounds or alternative companies interested in the repurposed assets. Both companies will be free to pursue further research and development projects based on the findings. All revenues generated from this arrangement shall be equally shared after directly attributable costs.\nMark Eccleston, CEO of ValiRx commented\n\"This is an excellent opportunity to unlock additional value from existing data sets acquired with our biobank. We believe there could be significant untapped potential for drug repurposing within this data set which can be realised at a minimal cost by working with our new partner, Dominion. Whilst ValiRx remains committed to its model of evaluation and in-licensing of novel assets, we will leverage all potential value from our assets, including our extensive data sets, particularly where we can achieve some quick wins from established drugs with validated safety profiles. We are pleased to be able to extend our initial agreement with Dominion and look forward to further opportunities to build value through our collaboration.\"\nAnthony Holmes, CEO of Dominion commented\n\"\nThis collaboration with Inaphaea represents an exciting opportunity to unlock hidden value in existing approved drugs. By analysing Inaphaea's extensive drug screening database against patient-derived cancer models, we aim to identify novel cancer applications for established compounds. This approach could significantly accelerate the development timeline for new cancer treatments, as these drugs have already cleared important safety hurdles. Dominion is committed to applying our analytical expertise to this valuable dataset, potentially creating win-win opportunities for pharmaceutical companies while ultimately providing cancer patients with entirely new treatment options that would otherwise not exist.\"\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\"). The Directors of the Company take responsibility for this announcement.\n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investor\nhub here:\nhttps://valirx.com/s/cc8ef3\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\nhttps://valirx.com/link/VyEObr\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0025\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d1\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guide",
          "content_length": 6541
        },
        "ingested_at": "2026-01-12T22:04:49.604720Z"
      },
      {
        "event_id": "RNS-30th Apr 2025-commerci",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604746Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Commercial Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/commercial-update-ddi7ym8fnwyucx1.html",
          "rns_number": "RNS Number : 7152G",
          "full_content": "30 Apr 2025 07:00\nRNS Number : 7152G\nValiRx PLC\n30 April 2025\nValiRx PLC\n(\"ValiRx\"\nor the\n\"Company\")\nCommercial Update\nLondon, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to provide the following update on the commercial activity of its wholly owned subsidiary Inaphaea BioLabs (\"Inaphaea\").\nInaphaea is a pleased to announce the execution of an evaluation and commercial use agreement (\"Evaluation and Commercial Agreement\") with UK based Dominion Biotech Ltd (\"Dominion\") to co-market services based on a client ownership model, where each company operates independently whilst marketing and delivering services using their combined PDC biobanks. The Evaluation and Commercial Agreement provides mutual access to Inaphaea's range of 66 cancer types alongside Dominion's collected tumour samples with comprehensive genetic profiling (NGS based mutation profiling and RNA-Seq expression analysis). Access to PDCs and services by each company will be agreed on a case-by-case basis subject to a minimum fee. The Evaluation and Commercial Agreement is for a period of 12 months initially and may be extended in writing by mutual agreement.\nAn evaluation use agreement (\"Evaluation Agreement\") has also been executed with UK based Cellomatics Biosciences Ltd (\"Cellomatics\"). The Evaluation Agreement initially focusses on in house evaluation of Inaphaea's Colorectal Cancer PDCs by Cellomatics which, if successful, will be offered for commercial services by Cellomatics and Inaphaea on terms to be agreed. Both companies have also agreed to co-market their respective services. The Evaluation Agreement is for a period of 12 months initially and may be extended in writing by mutual agreement.\nMark Eccleston, CEO of ValiRx commented\n\"We're pleased to announce two further deals for Inaphaea's PDC biobank. Both deals demonstrate the commercial potential and interest in the biobank and support our approach to cross marketing to achieve better market awareness and penetration of this resource. The Dominion deal brings a new angle whereby we can access additional, prospectively collected models for clients whilst dominion benefits from our established biobank. Cellomatics are a Nottingham based Contract Research Organisation with an established client base and complementary pre-clinical testing capabilities.\"\nAnthony Holmes, CEO of Dominion commented\n\"\nWe're excited to partner with Inaphaea to expand access to patient-derived cancer models for drug discovery and development. This collaboration combines Dominion's expertise in collecting and characterizing fresh tumour samples with Inaphaea's established biobank of diverse cancer types, creating a powerful resource for pharmaceutical companies seeking to improve clinical trial success rates. By joining forces under this innovative client ownership model, we can offer clients an even more comprehensive service while maintaining our independent operations. We look forward to working with the Inaphaea team to accelerate the development of more effective cancer therapies\n.\n\"\nShailendra Singh, CEO of Cellomatics commented \"\nWe are excited to announce the execution of an Evaluation Agreement with Inaphaea BioLabs. This collaboration marks an important step forward in expanding our oncology service offerings, starting with the in-house evaluation of Inaphaea's Colorectal Cancer PDCs. If successful, we look forward to jointly offering these cutting-edge models as part of our commercial service portfolio. This partnership reflects Cellomatics' commitment to innovation, collaboration, and delivering meaningful value to our clients in the oncology space.\n\"\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\"). The Directors of the Company take responsibility for this announcement.\n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investor\nhub here:\nhttps://valirx.com/s/cc8ef3\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\nhttps://valirx.com/link/lyapKP\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0025\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d",
          "content_length": 7078
        },
        "ingested_at": "2026-01-12T22:04:49.604774Z"
      },
      {
        "event_id": "RNS-3rd Apr 2025-terminat",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604801Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Termination of Letter of Intent with TheoremRx",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/termination-of-letter-of-intent-with-theoremrx-pkjedn1a0uppsak.html",
          "rns_number": "RNS Number : 4376D",
          "full_content": "3 Apr 2025 07:00\nRNS Number : 4376D\nValiRx PLC\n03 April 2025\n3 April 2025\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nTermination of Letter of Intent with TheoremRx Inc\nLondon, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health announces that, further to the announcement on 31 December 2024 to grant a final extension of exclusivity to TheoremRx Inc (\"TheoremRx\") under the letter of intent (\"LOI\") until 31 May 2025, the Company has terminated the LOI with TheoremRx with immediate effect by mutual agreement.\nThe termination of the LOI follows notification by TheoremRx of a decision not to proceed with an amendment to the LOI to return the territory of Taiwan and maintain exclusivity in exchange for a non-refundable payment of $200,000 by 31 March 2025.\nVAL201 will be moved to a prostate cancer focussed special purpose vehicle within ValiRx and plans to file IP to extend the patent life. The Company has recieved interest from a new consortium regarding the asset and is in early stage discussions with charities regarding possible support for clinical development.\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\"). The Directors of the Company take responsibility for this announcement.\nMark Eccleston, CEO of ValiRx commented\n\"\nWhilst the decision to terminate the LOI is obviously disappointing, we have contingencies for this eventuality. Moving VAL201 into a prostate cancer focussed SPV will give us the opportunity to file and develop new, ValiRx owned, IP based on in house technical knowhow to reset the patent coverage back to 20 years with proof of concept data for Val201 2.0 and to seek new partnerships from a position of strength. We will apply the same level of technical and comercial assessment applied to all new evaluation programs\n.\"\n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investor\nhub here:\nhttps://valirx.com/s/cc8ef3\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\nhttps://valirx.com/link/4PK9Je\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0026\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d1\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.\nLead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.\nValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.\nFor further information, visit:\nwww.valirx.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal dat",
          "content_length": 5069
        },
        "ingested_at": "2026-01-12T22:04:49.604823Z"
      },
      {
        "event_id": "RNS-27th Mar 2025-director",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604838Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Directorate Changes and new Advisory Board",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/directorate-changes-and-new-advisory-board-w0uwjoizrxykp6c.html",
          "rns_number": "RNS Number : 3974C",
          "full_content": "27 Mar 2025 07:00\nRNS Number : 3974C\nValiRx PLC\n27 March 2025\nValiRx PLC\n(\"ValiRx\"\nor the\n\"Company\")\nDirectorate Changes and Formation of new Advisory Board\nLondon, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces the resignation of Adrian de Courcey from its Board of Directors and that Cathy Tralau-Stewart has agreed with the Board to transition to a role as Non-Executive Director of the Company. The Company also announces the formation of its new Advisory Board which will replace its current Scientific Advisory Board.\nDirectorate Changes\nCathy Tralau-Stewart, Chief Scientific Officer and Director of the Company, has agreed with the Board to transition to a role as Non-Executive Director of the Company with immediate effect. Cathy will be appointed as Chair of the new Advisory Board set up to deliver Scientific, Commercial and Strategic Advice to the Company. Adrian de Courcey has informed the Board that he has resigned as Non-Executive Director of the Company with immediate effect, to focus on other opportunities.\nDuring her tenure as our fractional CSO, Cathy has been instrumental in developing ValiRx's pipeline strategy, identifying, reviewing and advising on a series of Evaluation and In-licensing options. Cathy brings a wealth of experience in drug development as well as industry contacts and recognition which ValiRx wishes to retain.\nDuring Adrian's tenure as a ValiRx Non-Executive Director, he has helped the Company navigate a major strategic and organisational overhaul with the new management team to achieve significant operational efficiencies and reduce cash burn.\nThese changes at the Board level form part of implementing a significant restructure and reduction in headcount across the Company As part of the restructure, the Company has hired a new, full time, Director of Research (non-board role), Michelle Barnard, who brings over 10 years' experience as a Senior Scientist specialising in Oncology Biology at Cancer Research Horizons and in Drug Discovery at the University of Graz prior. The Inaphaea team will also be supported by a specialist technician. These changes are expected to reduce annual costs by approximately \u00a3200,000.\nNew Advisory Board\nValiRx has also assembled a range of experts to establish its new Advisory Board (\"AB\"). The initial members of the AB, in addition to Cathy Tralau-Stewart as chair, will comprise:\n\u00b7\nDr Heather Wilson Robles, a clinical oncologist and former President of the Veterinary Cancer Society, specialising in veterinary medicine is based at United Veterinary Care and Ethos Discovery based in Washington DC US.\n\u00b7\nDr Simon Wheeler, a former member of Novartis Ventures tasked with finding Veterinary medicine investments and now an Independent Animal Health and Veterinary Consultant.\nThe AB brings a combination of scientific and commercial expertise as well as contacts within the industry. The AB also brings a balance of human and veterinary medicine expertise as we explore opportunities to leverage our preclinical data for earlier access to the veterinary market in addition to our primary focus on the human market.\nMartin Gouldstone, Chairman of ValiRx commented\n\"\nI would very much like to extend my sincere appreciation to Cathy for her contributions whilst serving as CSO and Executive Director for ValiRx. I am delighted that Cathy will continue to work with ValiRx as a Non-Executive Director as well as supporting the scientific and commercial direction of the Company by chairing our new AB.\n\"Equally I would like to thank Adrian for his contribution, helping the Board implement significant strategic and operational changes following a difficult transitional period during the time that both Mark Eccleston and I have been in our respective roles.\n\"The operational efficiencies and cost reductions that ValiRx has now made will allow us to concentrate on the Company's longer term commercial and strategic objectives.\"\nMark Eccleston, CEO of ValiRx commented\n\"I too would like to thank Adrian for his invaluable guidance during the first half year of my tenure. The main objectives when I took over as CEO were to bring more commercial and clinical development experience, enhance operational efficiency and deliver substantial cost savings whilst the Company builds its therapeutic pipeline.\n\"I am also very happy that Cathy is going to continue her involvement with ValiRx by chairing our newly formed Advisory Board as well as acting as Non-Executive Director to the Company. To be able to continue to access her advice alongside her role as Executive Director of the Milner Institute in Cambridge is invaluable to ValiRx.\"\n\"In addition to measures to reduce costs across the Company from our external service providers, I have made some difficult choices to improve operational efficiency and reduce cash burn which inevitably meant fewer available positions within the Company. I would like to thank everyone a",
          "content_length": 8512
        },
        "ingested_at": "2026-01-12T22:04:49.604852Z"
      },
      {
        "event_id": "RNS-21st Mar 2025-director",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604865Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Director Disclosure Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/director-disclosure-update-uhwoikywcxw3gdl.html",
          "rns_number": "RNS Number : 6998B",
          "full_content": "21 Mar 2025 11:07\nRNS Number : 6998B\nValiRx PLC\n21 March 2025\nValiRx PLC\n(\"ValiRx\"\nor the\n\"Company\")\nDirector Disclosure Update\nLondon, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, issues the following disclosure in relation to Martin Gouldstone, Chairman of the Company pursuant to AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies.\nOncimmune Holdings PLC, a company which Martin Gouldstone is a Director, recently announced its intention to appoint administrators.\nThere is nothing further to disclose in respect of Schedule 2(g) of the AIM Rules for Companies.\nThe Directors of the Company take responsibility for this announcement.\n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investor\nhub here:\nhttps://valirx.com/s/cc8ef3\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\nhttps://valirx.com/link/oPB60P\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0025\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d1\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.\nLead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.\nValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.\nFor further information, visit:\nwww.valirx.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCBBGDXSGDDGUB",
          "content_length": 3736
        },
        "ingested_at": "2026-01-12T22:04:49.604878Z"
      },
      {
        "event_id": "RNS-24th Feb 2025-conclusi",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604891Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Conclusion of Evaluation Project",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/conclusion-of-evaluation-project-di19h2kb23zfqzk.html",
          "rns_number": "RNS Number : 0597Y",
          "full_content": "24 Feb 2025 07:00\nRNS Number : 0597Y\nValiRx PLC\n24 February 2025\n24 February 2025\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nConclusion of Evaluation Project\nLondon, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update at the conclusion of the Evaluation project from Imperial College London announced on 21 March 2024.\nOn entering the collaboration agreement with Imperial College London in March 2024, the Company synthesised, tested and profiled drug candidates from the Dual Kinase series in comparison with gold standard therapeutics in a range of tests.\nAlthough initial results showed promise, the development programme is at an early stage, and the Company has decided to return the project to the university researchers for further development, with no further financial commitment from the Company. The parties have agreed to terminate the current collaboration agreement and revert responsibility for maintaining the intellectual property to Imperial College London.\nMark Eccleston, CEO of ValiRx commented\n\"\nWorking alongside the Imperial College London team on this project has been an engaging experience, and although we are not in a position to progress with this lead series of molecules at this stage, we look forward to retaining close contact with the team at Imperial to hear further updates on these and other projects which could lead to future agreements.\"\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\"). The Directors of the Company take responsibility for this announcement.\n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investor\nhub here:\nhttps://valirx.com/s/cc8ef3\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\nhttps://valirx.com/link/Ve96or\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0025\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d1\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.\nLead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.\nValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.\nFor further information, visit:\nwww.valirx.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCPKDBKDBKDFBB",
          "content_length": 4837
        },
        "ingested_at": "2026-01-12T22:04:49.604903Z"
      },
      {
        "event_id": "RNS-3rd Feb 2025-inaphaea",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604916Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Inaphaea Evaluation and Commercial Use Agreement",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/inaphaea-evaluation-and-commercial-use-agreement-qpsvn1upthlfxpl.html",
          "rns_number": "RNS Number : 6237V",
          "full_content": "3 Feb 2025 07:00\nRNS Number : 6237V\nValiRx PLC\n03 February 2025\n3 February 2025\nValiRx plc\n(\"\nValiRx\n\" or the \"\nCompany\n\")\nInaphaea Evaluation and Commercial Use Agreement\nLondon, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update from its wholly owned subsidiary Inaphaea BioLabs Limited (\"Inaphaea\").\nInaphaea is pleased to confirm the execution of an Evaluation and Commercial Use agreement (\"Agreement\") with UK based Screenin3d Limited (\"Screenin3D\") to provide Inaphaea's Patient Derived Cells (\"PDC\") for evaluation and commercial use in Screenin3D's state-of-the-art UpScale3Dlab-on-a-chip technology with associated image analysis software. The Agreement initially focusses on establishment of three Triple Negative Breast Cancer\nin-vitro\n3D tumour model which will then be offered for commercial services by Screenin3D and Inaphaea. Additional PDCs across Inaphaea's range of 66 cancer types can be added at any time.\nInaphaea will be entitled to an upfront fee of \u00a310,000 per PDC cell line upon commercialisation of the models. Screenin3D have an option to buy the commercial rights in relation to the PDCs and support future drug development. Both companies have also agreed to co-market their respective services. The Agreement is for a period of 12 months initially and may be extended in writing by mutual agreement.\nMark Eccleston, CEO of ValiRx commented\n\"We are continuously looking for commercial partners to accelerate Inaphaea's capabilities and market access. Screenin3D's\nUpScale3Dlab-on-a-chip platform and established customer base is a perfect example of technology and commercial synergy for Inaphaea's biobank of Patient Derived Cells\n. We look forward to the development of the triple negative breast cancer models which will also be used to support ValiRx's cytolytic peptide program through our partially owned subsidiary, Cytolytix. The data sets generated, alongside standard of care drugs, will be used to support commercialisation of the new\nUpScale3D PDC models\nand we look forward to publishing the results with ScreenIn3D in due course.\"\nMichele Zagnoni, CEO of Screenin3d Limited, commented\n\"We are excited to collaborate with Inaphaea to expand commercial opportunities for accelerating drug discovery and translational research. Combining our patented UpScale3D lab-on-a-chip technology with Inaphaea's biobank of Patient Derived Cells, this partnership will offer novel and powerful preclinical services in oncology and women's health, enabling us to facilitate large numbers of drug tests on very small quantities of predictive human samples of disease.\"\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\"). The Directors of the Company take responsibility for this announcement.\n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investorhub here:\nhttps://valirx.com/s/cc8ef3\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nhttps://valirx.com/link/mPqJoy\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0025\nwww.valirx.com\nMark.Eccleston@valirx.com\nScreenIn3D\nDr Michele Zagnoni, CEO\nhttps://screenin3d.com/\nmichele.zagnoni@screenin3d.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d1\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise requ",
          "content_length": 6149
        },
        "ingested_at": "2026-01-12T22:04:49.604930Z"
      },
      {
        "event_id": "RNS-30th Jan 2025-extensio",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604943Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Extension of Evaluation Agreement",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/extension-of-evaluation-agreement-bqsp370h7nb4e74.html",
          "rns_number": "RNS Number : 1893V",
          "full_content": "30 Jan 2025 07:00\nRNS Number : 1893V\nValiRx PLC\n30 January 2025\n30 January 2025\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nExtension of Evaluation Agreement\nLondon, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update on the Evaluation Agreement with the University of Dundee and their Drug Discovery Unit announced on 12 February 2024.\nThe Evaluation Agreement under the Overarching agreement with Dundee University focuses on investigating a lead series of therapeutic candidates in the increasingly important research area of pro-senescence (selectively promoting ageing of cancer cells to cease growth in tumours).\nThe evaluation process for this project in the Inaphaea BioLabs facility continues to demonstrate activity but specialist techniques are required to complete the mechanism of action studies. ValiRx have agreed a one year extension with the University of Dundee until 9 February 2026 to continue the mechanism of action studies which will be provided by the research group of Professor Cleo Bishop (Professor of Senescence and Director of the Queen Mary University London Phenotypic Screening Facility), supported by a \u00a350,000 grant from the Queen Mary University London Impact Fund and \u00a39,000 from ValiRx.\nThe Directors of the Company take responsibility for this announcement.\nMark Eccleston, CEO of ValiRx commented\n\"We are pleased with the demonstration of activity for the compounds under evaluation in Inaphaea's lab. A key decision point for in-licensing the asset is determination of the precise mechanism of action of the asset which requires access to techniques and equipment that we do not currently possess. We are fortunate to be working with Professor Bishop and have worked with her to secure non-dilutive funding to undertake the required work.\"\n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investorhub here:\nhttps://valirx.com/s/cc8ef3\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nhttps://valirx.com/link/DP4BGe\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0025\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d1\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.\nLead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.\nValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.\nFor further information, visit:\nwww.valirx.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nUPDSEIFAUEISEFF",
          "content_length": 4886
        },
        "ingested_at": "2026-01-12T22:04:49.604955Z"
      },
      {
        "event_id": "RNS-29th Jan 2025-newevalu",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604968Z",
        "source": "LSE_RNS",
        "data": {
          "title": "New Evaluation and Option Agreement",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/new-evaluation-and-option-agreement-glpo3gfb89w88gu.html",
          "rns_number": "RNS Number : 0325V",
          "full_content": "29 Jan 2025 07:00\nRNS Number : 0325V\nValiRx PLC\n29 January 2025\n29 January 2025\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nNew Evaluation and Option Agreement\nValiRx plc (the \"Company\") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, and Altus Formulation Inc (\"Altus\") a Canada based drug development and delivery company, have entered into an evaluation and option agreement to determine the value of Altus' SmartCelle drug delivery technologies and novel anti-inflammatory compounds in the treatment of cancer (the \"Agreement\") for an initial twelve month period.\nUnder the Agreement, ValiRx will assess the SmartCelle platform's ability to enhance the solubility, potency and targeting of a series of drug candidates including ValiRx's CLX001 cytolytic peptide and Altus' novel CB2 agonist TA-A001. The evaluation will be performed on a range of Patient Derived Cells (PDCs) by ValiRx's subsidiary Inaphaea BioLabs, with lead candidates then being tested\nin vivo\nthrough collaborative partners to assess safety, biodistribution and efficacy. ValiRx has an option to license the technologies for the treatment of certain cancers.\nThe period during which the option must be exercised is three months after the date when a clinical development candidate is identified after which time no such option will exist unless mutually agreed. Any clinical development candidate would be subject to a separate license. The period for negotiation of the terms of the separate license is limited to a period of three months from the exercise of the option by ValiRx.\nMark Eccleston, CEO of ValiRx commented\n\"In a first for ValiRx, we are signing an evaluation agreement with a proprietary formulation technology provider to develop novel drug/delivery combinations for both our own assets as well as accessing preformulated assets from Altus. This builds on my personal technical background in drug delivery and opens up a range of possibilities to accelerate our development and evaluation programs.\"\nDamon Smith, CEO of Altus commented \"\nValiRx's track record of accelerated drug development makes them the ideal partner to validate SmartCelle and TA-A001 in the oncology space. We look forward to working with Mark and the team in this exciting new enterprise.\"\nThe Directors of the Company take responsibility for this announcement.\n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investor\nhub here:\nhttps://valirx.com/s/cc8ef3\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\nhttps://valirx.com/link/NPwQwe\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0025\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d1\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.\nLead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.\nValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.\nFor further information, visit:\nwww.valirx.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP add",
          "content_length": 5393
        },
        "ingested_at": "2026-01-12T22:04:49.604982Z"
      },
      {
        "event_id": "RNS-15th Jan 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.604995Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/holdings-in-company-esoz05bik30m63m.html",
          "rns_number": "RNS Number : 4630T",
          "full_content": "15 Jan 2025 12:47\nRNS Number : 4630T\nValiRx PLC\n15 January 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BLH13C52\nIssuer Name\nVALIRX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nPeel Hunt LLP\nCity of registered office (if applicable)\nLondon\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n14-Jan-2025\n6. Date on which Issuer notified\n15-Jan-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\nBelow 10%\n0.000000\nBelow 10%\nBelow 10% of shares in issue\nPosition of previous notification (if applicable)\n10.321361\n0.000000\n10.321361\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BLH13C52\nBelow 10% of shares in issue\n0\nBelow 10%\n0.000000\nSub Total 8.A\nBelow 10% of shares in issue\nBelow 10%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n15-Jan-2025\n13. Place Of Completion\nLondon\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUVSURVVUAAAR",
          "content_length": 3865
        },
        "ingested_at": "2026-01-12T22:04:49.605007Z"
      },
      {
        "event_id": "RNS-15th Jan 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.605019Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/holdings-in-company-19le90sopqw0r7d.html",
          "rns_number": "RNS Number : 4521T",
          "full_content": "15 Jan 2025 11:29\nRNS Number : 4521T\nValiRx PLC\n15 January 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nValiRx PLC\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nStephen Wolstenhulme\nCity and country of registered office (if applicable)\nUK\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n08/01/2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n14/01/2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n5.84%\n5.84%\n21,875,000\nPosition of previous notification (if\napplicable)\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BLH13C52\n11,200,000\n10,675,000\n2.99%\n2.85%\nSUBTOTAL 8. A\n21,875,000\n5.84%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nStephen Wolstenhulme\n2.99%\n2.99%\nDaniele Wolstenhulme\n2.85%\n2.85%\nTotal\n5.84%\n5.84%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nUK\nDate of completion\n14/01/2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUVUARVBUAAAR",
          "content_length": 4410
        },
        "ingested_at": "2026-01-12T22:04:49.605032Z"
      },
      {
        "event_id": "RNS-14th Jan 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.605044Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/holdings-in-company-az1a5wvmer7xuqw.html",
          "rns_number": "RNS Number : 1508T",
          "full_content": "14 Jan 2025 07:00\nRNS Number : 1508T\nValiRx PLC\n14 January 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BLH13C52\nIssuer Name\nVALIRX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nPeel Hunt LLP\nCity of registered office (if applicable)\nLondon\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n10-Jan-2025\n6. Date on which Issuer notified\n13-Jan-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n10.321361\n0.000000\n10.321361\n38637876\nPosition of previous notification (if applicable)\n9.611049\n0.000000\n9.611049\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BLH13C52\n38637876\n0\n10.321361\n0.000000\nSub Total 8.A\n38637876\n10.321361%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n13-Jan-2025\n13. Place Of Completion\nLondon\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUOUBRVBUAAAR",
          "content_length": 3804
        },
        "ingested_at": "2026-01-12T22:04:49.605056Z"
      },
      {
        "event_id": "RNS-9th Jan 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.605069Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/holdings-in-company-otnv2tfcuuy14qx.html",
          "rns_number": "RNS Number : 7801S",
          "full_content": "9 Jan 2025 11:37\nRNS Number : 7801S\nValiRx PLC\n09 January 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nValiRx PLC\n1b. Please indicate if the issuer is a non-UK issuer (\nplease mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nMark Eccleston\nCity and country of registered office (if applicable)\nUK\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n31/12/2024\n6.\nDate on which issuer notified (DD/MM/YYYY):\n08/01/2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n6.08%\n6.08%\n22,746,187\nPosition of previous notification (if\napplicable)\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BLH13C52\n15,592,341\n7,153,846\n4.17%\n1.91%\nSUBTOTAL 8. A\n22,746,187\n6.08%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nMark Eccleston\n4.17%\n4.17%\nOncoLytika Ltd\n1.03%\n1.03%\nAnnette Williams\n0.88%\n0.88%\nTotal\n6.08%\n6.08%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nFurther to the announcement on 30 December 2024, Mark Eccleston subscribed for 14,615,384 ordinary shares and OncoLytika Ltd subscribed for 3,846,154. Annette Williams's subscription remained unchanged. Mark Eccleston's aggregate subscription amount (including Annette Williams's) of \u00a3135k remains unchanged.\nPlace of completion\nUK\nDate of completion\n08/01/2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUKOARVNUARAR",
          "content_length": 4729
        },
        "ingested_at": "2026-01-12T22:04:49.605082Z"
      },
      {
        "event_id": "RNS-9th Jan 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.605095Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/holdings-in-company-qi03zvcjzxqff33.html",
          "rns_number": "RNS Number : 7766S",
          "full_content": "9 Jan 2025 11:14\nRNS Number : 7766S\nValiRx PLC\n09 January 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BLH13C52\nIssuer Name\nVALIRX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nPeel Hunt LLP\nCity of registered office (if applicable)\nLondon\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n07-Jan-2025\n6. Date on which Issuer notified\n08-Jan-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\nBelow 10%\n0.000000\nBelow 10%\nBelow 10% of shares in issue\nPosition of previous notification (if applicable)\n10.265939\n0.000000\n10.265939\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BLH13C52\nBelow 10% of shares in issue\n0\nBelow 10\n0.000000\nSub Total 8.A\nBelow 10% of shares in issue\nBelow 10%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n08-Jan-2025\n13. Place Of Completion\nLondon, United Kingdom\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUKAARVUUARAR",
          "content_length": 3879
        },
        "ingested_at": "2026-01-12T22:04:49.605134Z"
      },
      {
        "event_id": "RNS-8th Jan 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.605149Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/holdings-in-company-gx2h5vn5z7dp483.html",
          "rns_number": "RNS Number : 4855S",
          "full_content": "8 Jan 2025 07:00\nRNS Number : 4855S\nValiRx PLC\n08 January 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BLH13C52\nIssuer Name\nVALIRX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nPeel Hunt LLP\nCity of registered office (if applicable)\nLondon\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n06-Jan-2025\n6. Date on which Issuer notified\n07-Jan-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n10.265939\n0.000000\n10.265939\n38430406\nPosition of previous notification (if applicable)\n8.379788\n0.000000\n8.379788\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BLH13C52\n38430406\n0\n10.265939\n0.000000\nSub Total 8.A\n38430406\n10.265939%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n07-Jan-2025\n13. Place Of Completion\nLondon, United Kingdom\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUBUARVOUARUR",
          "content_length": 3819
        },
        "ingested_at": "2026-01-12T22:04:49.605162Z"
      },
      {
        "event_id": "RNS-2nd Jan 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.605175Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/holdings-in-company-hjt396yeujltemz.html",
          "rns_number": "RNS Number : 9458R",
          "full_content": "2 Jan 2025 11:45\nRNS Number : 9458R\nValiRx PLC\n02 January 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BLH13C52\nIssuer Name\nVALIRX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nPeel Hunt LLP\nCity of registered office (if applicable)\nLondon\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n31-Dec-2024\n6. Date on which Issuer notified\n02-Jan-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\nBelow 10%\n0.000000\nBelow 10%\nBelow 10%\nPosition of previous notification (if applicable)\n10.327209\n0.000000\n10.327209\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BLH13C52\nBelow 10%\n0\nBelow 10%\n0.000000\nSub Total 8.A\nBelow 10%\nBelow 10%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n13. Place Of Completion\nLondon\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUUSARVUUARAR",
          "content_length": 3795
        },
        "ingested_at": "2026-01-12T22:04:49.605187Z"
      },
      {
        "event_id": "RNS-31st Dec 2024-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.605199Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/holdings-in-company-pfosdc64dto1onw.html",
          "rns_number": "RNS Number : 8023R",
          "full_content": "31 Dec 2024 13:06\nRNS Number : 8023R\nValiRx PLC\n31 December 2024\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BLH13C52\nIssuer Name\nVALIRX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nPeel Hunt LLP\nCity of registered office (if applicable)\nLondon\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n30-Dec-2024\n6. Date on which Issuer notified\n31-Dec-2024\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n10.327209\n0.000000\n10.327209\n38659770\nPosition of previous notification (if applicable)\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BLH13C52\n38659770\n10.327209\nSub Total 8.A\n38659770\n10.327209%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n31-Dec-2024\n13. Place Of Completion\nLondon\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUARORSSUUOAA",
          "content_length": 3767
        },
        "ingested_at": "2026-01-12T22:04:49.605211Z"
      },
      {
        "event_id": "RNS-31st Dec 2024-updateon",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.605224Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Update on proposed sub-license of VAL201",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/update-on-proposed-sub-license-of-val201-rwwir11ltvikc97.html",
          "rns_number": "RNS Number : 7407R",
          "full_content": "31 Dec 2024 08:39\nRNS Number : 7407R\nValiRx PLC\n31 December 2024\n31 December 2024\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nUpdate on proposed sub-license of VAL201\nLondon, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health announces that, further to the amendment to the Letter of Intent (\"LOI\") with TheoremRx Inc (\"TheoremRx\") announced on 30 October 2024 granting an extension of exclusivity until 31 December 2024, the Company has signed a further amendment to the Letter of Intent (\"LOI\") with TheoremRx . The exclusivity provided has been extended for a final time period until 31 May 2025.\nThis final extension has been provided following developments announced by TheoremRx regarding a transaction with a NASDAQ listed company which the board at ValiRx believe may lead to a positive conclusion for the proposed sub-license of VAL201. The LOI and proposed Licence Agreement (as referred to in the announcement of 2 November 2021) remain non-binding and there is no guarantee that this Licence Agreement will be executed or that it will generate material revenues within the expected timeframe or at all.\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\"). The Directors of the Company take responsibility for this announcement.\nMark Eccleston, CEO of ValiRx commented\n\"\nThis final, time limited, extension has been granted to allow TheoremRx to complete their M&A transaction with a NASDAQ listed company, which is required to enable execution of the sub-license of VAL201 to TheoremRx. Further details on the transaction will be made public in due course and we remain supportive of the TheoremRx team and continue to closely monitor their progress.\n\"\n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investor\nhub here:\nhttps://valirx.com/s/cc8ef3\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\nhttps://valirx.com/link/lejvQe\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0026\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d1\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.\nLead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.\nValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.\nFor further information, visit:\nwww.valirx.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nUPDTBBPTMTJJMRI",
          "content_length": 4966
        },
        "ingested_at": "2026-01-12T22:04:49.605236Z"
      },
      {
        "event_id": "RNS-30th Dec 2024-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.605249Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of GM, Issue of Equity, Warrants and TVR",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/result-of-gm-issue-of-equity-warrants-and-tvr-25vc8n55pysf48f.html",
          "rns_number": "RNS Number : 6309R",
          "full_content": "30 Dec 2024 13:30\nRNS Number : 6309R\nValiRx PLC\n30 December 2024\nTHIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (THE \"ANNOUNCEMENT\") IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (\"\nMAR\n\"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n30 December 2024\nVALIRX PLC\n(\"ValiRx\" or the \"Company\")\nResult of General Meeting\nIssue of Equity, Warrants and Total Voting Rights\nDirector/PDMR Shareholding\nValiRx plc (the \"Company\") (AIM: VAL), announces that, further to the Conditional Fundraising & Notice of General Meeting announcements on 9 December 2024 and 10 December 2024, at its General Meeting held earlier today, all resolutions were duly passed. Details of the votes received in respect of the resolutions will be available shortly on the Company's website.\nIn aggregate the Company has issued 241,999,999 New Ordinary Shares and 241,999,999 Fundraise Warrants over new ordinary shares.\nThe Fundraise Warrants are exercisable for a period of three years from Admission and are exercisable at a price of 1.3 pence per new ordinary share.\nDirector/PDMR Shareholdings\nFollowing completion of the Fundraising, the shareholdings of the Directors and persons closely associated with them who have participated in the Fundraising are set out in the table below:\nName\nNumber of existing Ordinary Shares\nPercentage of existing issued share capital\nNumber of New Ordinary Shares\nNumber of Ordinary Shares on Admission\nPercentage of enlarged share capital on Admission\nNumber of Fundraise Warrants\nMark Eccleston\n1,976,957\n1.49%\n20,769,230\n1\n22,746,187\n6.08%\n20,769,230\nAdrian de Courcey\n871,036\n0.66%\n1,538,461\n2,409,497\n0.64%\n1,538,461\nCathy Tralau-Stewart\n66,666\n0.05%\n769,231\n835,897\n0.22%\n769,231\nGerry Desler\n195,334\n0.15%\n769,231\n964,565\n0.26%\n769,231\nMartin Gouldstone\n0\n0.00%\n769,231\n769,231\n0.21%\n769,231\nTotal\n3,109,993\n2.35%\n24,615,384\n27,725,377\n7.41%\n24,615,384\n1\nof which, 9,846,145 New Ordinary Shares have been subscribed for by Mark Eccleston directly, 5,538,470 New Ordinary Shares have been subscribed for by OncoLytika Ltd (a company in which Mr. Eccleston is interested) and 2,307,692 New Ordinary Shares have been subscribed for by Mark Eccleston's partner. In addition, Mr Eccleston subscribed for a further 3,076,923 New Ordinary Shares as part of the Broker Offer\nIssue of Equity\nThe Placing Shares, the Subscription Shares and the Broker Offer Shares have been allotted, conditional upon Admission, and application has been made to the London Stock Exchange for, in aggregate, 241,999,999 Placing Shares, Subscription Shares and Broker Offer Shares to be admitted to trading on AIM. Admission is expected to occur at 8.00 a.m. on or around 31 December 2024, with dealings in the Placing Shares, the Subscription Shares and the Broker Offer Shares commencing at the same time. The Placing Shares, the Subscription Shares and the Broker Offer Shares will rank\npari passu\nwith all other issued Shares.\nTotal Voting Rights\nFor the purpose of the Disclosure Guidance and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 374,348,672 ordinary shares of 0.1 pence each. The Company does not hold any shares in the treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.\nCapitalised terms used in this announcement have the meaning given to them in the Conditional Fundraising announcement dated 9 December 2024, unless otherwise defined in this announcement.\nThe Directors of the Company take responsibility for this announcement.\nFor further information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\nhttps://valirx.com/link/vPn48e\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 (0) 2476 796496\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vfo",
          "content_length": 10108
        },
        "ingested_at": "2026-01-12T22:04:49.605264Z"
      },
      {
        "event_id": "RNS-20th Dec 2024-valirxla",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.605277Z",
        "source": "LSE_RNS",
        "data": {
          "title": "ValiRx launches new interactive investor website",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/VAL/valirx-launches-new-interactive-investor-website-2cofj1o9ezhu47s.html",
          "rns_number": "RNS Number : 8515Q",
          "full_content": "20 Dec 2024 07:00\nRNS Number : 8515Q\nValiRx PLC\n20 December 2024\n20 December 2024\nVALIRX PLC\n(\"ValiRx\" or the \"Company\")\nValiRx launches new interactive investor website\nproviding shareholders with a more proactive way of communication and enquiry support\nValiRx, a life science company focusing on early-stage cancer therapeutics and women's health, is pleased to announce the launch of our interactive investor website.\nFor both existing and prospective shareholders, the new investor hub brings all ValiRx content into a single integrated platform to better inform and engage with investors and stakeholders, including:\n\u25cf Regulatory announcements\n\u25cf Reports\n\u25cf Presentations\n\u25cf Educational material\n\u25cf Interviews\n\u25cf Corporate research\nThe investor hub also provides an interactive online experience allowing ValiRx stakeholders to comment on and ask the ValiRx team questions via a portal which will be monitored and responded to in a timely manner.\nThe Company's AIM Rule 26 website address and all information required by AIM Rule 26 remains unchanged.\nHow to sign up for the ValiRx investor hub:\n1. Visit www.valirx.com\n2. Follow the prompts to sign up for an investor hub account\n3. Complete your account profile\nMark Eccleston, CEO, commented:\n\"As a life sciences company focused on advancing cutting-edge therapies, it is essential that we keep our shareholders informed and engaged throughout our journey. InvestorHub enables us to identify and understand our investor base more clearly, allowing us to tailor communications that highlight key milestones, clinical developments, and the value of our progress. This ensures our shareholders remain aligned with our mission to deliver innovative solutions in healthcare.\"\nEnds\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investor\nhub here:\nhttps://valirx.com/s/cc8ef3\nThe Directors are responsible for the release of this announcement.\nFor further information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\nhttps://valirx.com/link/vPn48e\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 (0) 2476 796496\nwww.valirx.com\nMark.Eccleston@valirx.com\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d1\nThis communication is a \"Reach\" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAGPGPWPUPCPWB",
          "content_length": 3748
        },
        "ingested_at": "2026-01-12T22:04:49.605289Z"
      },
      {
        "event_id": "RNS-10th Dec 2024-brokerof",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.605302Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Broker Offer Results & Director/PDMR Subscription",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/broker-offer-results-directorpdmr-subscription-e7f9eq7gom37xay.html",
          "rns_number": "RNS Number : 5679P",
          "full_content": "10 Dec 2024 16:45\nRNS Number : 5679P\nValiRx PLC\n10 December 2024\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (\"MAR\"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\nValiRx plc\n(\"\nValiRx\n\" or the \"\nCompany\n\")\nBroker Offer Results and Director/PDMR Subscription\nFurther to the announcement made at 7.00 a.m. on 9 December 2024 by the Company in connection with the Fundraising to raise up to \u00a31,573,000 (before expenses) (the \"Fundraise Announcement\"), ValiRx, a life science company focusing on early-stage cancer therapeutics and women's health, announces that a total of 38,461,538 Broker Offer Shares have been subscribed for at the Issue Price in connection with the conditional Broker Offer, raising \u00a3250,000.\nFollowing the closing of the Broker Offer, the total gross proceeds for the Company from the conditional Fundraising, comprising the Placing Shares, the Subscription Shares and the Broker Offer Shares (together the \"New Ordinary Shares\"), are \u00a31,573,000.\nDirector/PDMR Subscription\nAs set out in the announcement of 9 December 2024,\nMark Eccleston, CEO of the Company has informed the Company that, in addition to his participation in the Subscription, he has subscribed for a further 3,076,923 Broker Offer Shares under the Broker Offer. Details of his shareholdings following completion of the Fundraising and subject to shareholder approval at the General Meeting, are set out below:\nName\nNumber of existing Ordinary Shares and Subscription Shares\nNumber of Broker Offer Shares\nNumber of Ordinary Shares on Admission\nPercentage of enlarged share capital on Admission\nMark Eccleston\n19,669,2641\n3,076,923\n22,746,187\n6.08\n%\n1\nof which, 9,846,145 New Ordinary Shares have been subscribed for by Mark Eccleston directly, 5,538,470 New Ordinary Shares have been subscribed for by OncoLytika Ltd (a company in which Dr. Eccleston is interested) and 2,307,692 New Ordinary Shares have been subscribed for by Mark Eccleston's partner.\nAdmission\nSubject to shareholder approval at the General Meeting, the Company will make an application to the London Stock Exchange plc for th New Ordinary Shares to be admitted to trading on AIM (\"Admission\"). It is expected that Admission of the New Ordinary Shares will become effective and dealings will commence at 8.00 a.m. on or around 31 December 2024. The New Ordinary Shares will rank\npari passu\nwith the Existing Shares.\nTotal Voting Rights\nFor the purpose of the Disclosure Guidance and Transparency Rules, subject to shareholder approval at the General Meeting and following Admission, the enlarged issued share capital of the Company will comprise 374,348,672 ordinary shares of 0.1 pence each. The Company does not hold any shares in the treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.\nCapitalised terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Company's announcement of 9 December 2024.\n*** ENDS ***\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\").The Directors of the Company take responsibility for this announcement.\nFor more information, please contact:\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 (0) 2476 796496\nwww.valirx.com\nMark.Eccleston\n@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines acros",
          "content_length": 7104
        },
        "ingested_at": "2026-01-12T22:04:49.605316Z"
      },
      {
        "event_id": "RNS-10th Dec 2024-postingo",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.605329Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Posting of Circular and Notice of General Meeting",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/posting-of-circular-and-notice-of-general-meeting-bjbs5judk3bb6d1.html",
          "rns_number": "RNS Number : 5605P",
          "full_content": "10 Dec 2024 15:03\nRNS Number : 5605P\nValiRx PLC\n10 December 2024\nValiRx plc\n(\"\nValiRx\n\" or the \"\nCompany\n\")\nPosting of Circular and Notice of General Meeting\nLondon, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces that, further to the announcement made on 9 December 2024, a circular (the \"\nCircular\n\"), including the Notice of General Meeting and a Form of Proxy will be posted today.\nThe General Meeting will be held at the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London, EC4R 3TT at 11 a.m. on 30 December 2024.\nA copy of the Circular will shortly be available for the Company's website at\nhttps://www.valirx.com/aim-rule-26\n.\nCapitalised terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Company's announcement of 9 December 2024.\n2024\nAnnouncement of the Fundraising\n9 December\nDate of publication and posting of this Circular & the Form of Proxy\n10 December\nLatest time and date for receipt of proxy forms\n11.00 a.m. on 24 December\nGeneral Meeting\n30 December\nAnnouncement of the results of the General Meeting\n30 December\nAdmission and dealings in the New Ordinary Shares expected to commence on AIM\n8.00 a.m. on or around 31 December\nExpected date for CREST accounts to be credited for New Ordinary Shares to be held in uncertificated form\n31 December\nDespatch of definitive share certificates in respect of the New Ordinary Shares to be held in certificated form, if applicable\nby 14 January 2025\nNotes:\n1. Each of the times and dates above are indicative only and if any of the details contained in the timetable above should change, the revised times and dates will be notified to Shareholders by means of an announcement through a Regulatory Information Service.\n2. All of the above times refer to London time unless otherwise stated.\n3. All events listed in the above timetable related to the Admission, the Placing, the Broker Offer and the Subscription are conditional on the passing at the General Meeting of the Resolutions to provide the relevant authorities.\n*** ENDS ***\nFor more information, please contact:\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 (0) 2476 796496\nwww.valirx.com\nMark.Eccleston\n@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.\nLead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.\nValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.\nFor further information, visit:\nwww.valirx.com\nCautionary statement\nCertain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\n",
          "content_length": 5429
        },
        "ingested_at": "2026-01-12T22:04:49.605343Z"
      },
      {
        "event_id": "RNS-9th Dec 2024-conditio",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.605356Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Conditional Fundraising & Launch of Broker Offer",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/conditional-fundraising-launch-of-broker-offer-w0xd1omvyxn023t.html",
          "rns_number": "RNS Number : 2545P",
          "full_content": "9 Dec 2024 07:00\nRNS Number : 2545P\nValiRx PLC\n09 December 2024\nTHIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (THE \"ANNOUNCEMENT\") IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.\nTHIS ANNOUNCEMENT DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OR OTHERWISE ACQUIRE, ANY SECURITIES OF THE COMPANY.\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (\"\nMAR\n\"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION, AS PERMITTED BY MAR. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.\nValiRx plc\n(\"\nValiRx\n\" or the \"\nCompany\n\")\nConditional Fundraising, Conditional Director/PDMR Subscription & Launch of Broker Offer\nLondon, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces that it has conditionally raised up to \u00a31,573,000 through a Fundraising, comprising: (i) a conditional Placing to raise \u00a31,183,000 (before expenses), (ii) a conditional Broker Offer to be made to certain existing shareholders in the Company to raise up to \u00a3250,000 before expenses, (iii) a conditional Subscription by Directors and persons closely associated with them to raise \u00a3140,000, and (iv) conditional issue of Fundraise Warrants to all subscribers of New Ordinary Shares through, in aggregate, the allotment and issue of up to 241,999,999 New Ordinary Shares (assuming the Broker Offer is taken up in full) at the issue price of 0.65 pence per New Ordinary Share .\nThe Fundraising is conditional on and subject to the passing of the resolutions (\"\nResolutions\n\") at a general meeting of shareholders to be held at the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London, EC4R 3TT at 11 a.m. on 30 December 2024 (the \"\nGeneral Meeting\n\"). A further announcement will be made when the circular convening the general meeting has been posted to shareholders.\nCapitalised terms in this announcement have the meaning ascribed to them at the end of this announcement.\nFundraising highlights:\nConditional Fundraising to raise, in aggregate, up to \u00a31,573,000 (before expenses) comprising:\no\nconditional Placing and Subscription to raise gross proceeds of \u00a31,323,000;\no\nconditional Broker Offer through Shard to raise up to an additional \u00a3250,000, providing certain existing Shareholders who did not participate in the Placing an opportunity to participate in the Fundraising; and\no\nconditional grant of Fundraise Warrants for all subscribers of New Ordinary Shares in the Fundraising on a 1 for 1 basis (i.e. one warrant for every New Ordinary Share).\nPlacing\nThe Group has conditionally raised \u00a31,183,000 (before expenses) through the Placing.\nThe Placing Shares have been conditionally placed with new and existing investors. The Placing Shares are not being underwritten. The Placing Shares were not, and are not being, offered to the public and are not being offered or sold in any jurisdiction where it would be unlawful to do so.\nDirector/PDMR Subscription\nIn addition to the Placing, certain Directors of the Company and persons closely associated with them have conditionally subscribed directly with the Company for, in aggregate, 21,538,461 Subscription Shares at the Issue Price. The aggregate participation by all such persons pursuant to the Subscription is \u00a3140,000.\nName\nNumber of existing Ordinary Shares\nPercentage of existing issued share capital\nNumber of Subscription Shares\nNumber of Ordinary Shares on Admission\nPercentage of enlarged share capital on Admission2\nMark Eccleston\n1,976,957\n1.49%\n17,692,307\n1\n19,669,264\n5.25%\nAdrian de Courcey\n871,036\n0.66%\n1,538,461\n2,409,497\n0.64%\nCathy Tralau-Stewart\n66,666\n0.05%\n769,231\n835,897\n0.22%\nGerry Desler\n195,334\n0.15%\n769,231\n964,565\n0.26%\nMartin Gouldstone\n0\n0.00%\n769,231\n769,231\n0.21%\nTotal\n3,109,993\n2.35%\n21,538,461\n24,648,454\n6.58%\n1\nof which, 9,846,145 New Ordinary Shares have been subscribed for by Mark Eccleston directly, 5,538,470 New Ordinary Shares have been subscribed for by OncoLytika Ltd (a company in which Mr. Eccleston is interested) a",
          "content_length": 22910
        },
        "ingested_at": "2026-01-12T22:04:49.605371Z"
      },
      {
        "event_id": "RNS-22nd Nov 2024-inaphaea",
        "event_type": "rns_announcement",
        "date": "2026-01-12T22:04:49.605384Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Inaphaea award of HEIF Funding and PhD sponsorship",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/inaphaea-award-of-heif-funding-and-phd-sponsorship-e7n5wjz077x9axk.html",
          "rns_number": "RNS Number : 2398N",
          "full_content": "22 Nov 2024 07:00\nRNS Number : 2398N\nValiRx PLC\n22 November 2024\nValiRx plc\n(\"\nValiRx\n\" or the \"\nCompany\n\")\nInaphaea award of HEIF Funding and PhD sponsorship\nLondon, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update from its wholly owned subsidiary Inaphaea BioLabs Limited (\"Inaphaea\").\nInaphaea is pleased to confirm it\nhas agreed to collaborate on a project using funds from The Open University's Higher Education Innovation Fund (HEIF) to characterise the subtype and drug sensitivity of up to 12 Prostate Cancer lines from Inaphaea's Patient Derived Cell (\"PDC\") bank. The project will utilise The Open University's expertise in characterisation of Neuroendocrine Prostate Cancer (\"NEPC\"), an incurable subtype of prostate cancer, to look for characteristic markers of NEPC in Inaphaea's PDC models under normal and low oxygen conditions, known to promote an NEPC like state.\nIn addition ValiRx will be co-sponsoring a PhD Studentship over the course of four years at The Open University titled '\nDeciphering the epigenetic vulnerabilities of neuroendocrine prostate cancer through novel patient-derived models'.\nThe four-year programme includes further characterisation and drug responsiveness of up to 12 of Inaphaea's Patient Derived Prostate Cancer Cell systems as well as screening for novel epigenetic targets as potential novel treatment opportunities.\nMark Eccleston, CEO of ValiRx commented\n\"Inaphaea has over 30 Patient Derived Cell models from prostate cancer patients, several with RNA-Seq data available. These cells have been stabilised for in vitro passage, but they are not characterised in terms of cancer subtype and drug sensitivity. Collecting and publishing this information is essential to enable the use of these cell lines by the scientific community. Hence, characterisation of the Inaphaea prostate PDCs could add significant value to this collection and generate an invaluable research tool for the NEPC community. However, this type of work requires specialised expertise in preclinical cancer research that is beyond the capabilities of Inaphaea.\"\nFrancesco Crea,\nProfessor of Cancer Pharmacology at the Faculty of Science, Technology, Engineering & Mathematics, The\u00a0Open University commented\n\"Neuroendocrine prostate cancer is a newly recognised disease with no effective therapy and median survival time shorter than one year. It is estimated that a fifth of advanced prostate cancer patients will develop NEPC. Hence it is of paramount importance to study the biology of this aggressive disease and to identify viable therapeutic targets. This is hampered by the lack of preclinical NEPC models. In particular, only one patient derived NEPC cell line has been fully characterised and is available for experiments. Since NEPC is a highly heterogeneous disease, more cell lines are needed to recapitulate the full clinical spectrum of this deadly disease and to validate findings.\"\nThe Directors of the Company take responsibility for this announcement.\n*** ENDS ***\nFor more information, please contact:\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 (0) 2476 796496\nwww.valirx.com\nMark.Eccleston\n@valirx.com\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray/ Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.\nLead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.\nValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.\nFor further information, visit:\nwww.valirx.com\nCautionary statement\nCertain statements made in this announcement are forward-looking statements. Such statements ",
          "content_length": 6384
        },
        "ingested_at": "2026-01-12T22:04:49.605398Z"
      },
      {
        "event_id": "RNS-19th Jan 2026-exercise",
        "event_type": "rns_announcement",
        "date": "2026-01-21T00:53:34.624275Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Exercise of Warrants",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VAL/exercise-of-warrants-9fj6sqhvjx3pg1s.html",
          "rns_number": "RNS Number : 3318P",
          "full_content": "19 Jan 2026 07:00\nRNS Number : 3318P\nValiRx PLC\n19 January 2026\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nExercise of Warrants\nValiRx plc (the \"Company\") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health announces it has received notification for the exercise of warrants over 80,000 ordinary shares in the Company at an exercise price of 0.5 pence per share providing the Company with gross proceeds of \u00a3400 (\"Warrant Exercise\").\nApplication will be made to the London Stock Exchange to admit the 80,000 new ordinary shares resulting from the Warrant Exercise to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 23 January 2026. The new ordinary shares will rank\npari passu\nwith the existing ordinary shares.\nFor the purposes of the Disclosure and Transparency Rules, following the issue of shares detailed above as a result of the Warrant Exercise, the enlarged issued share capital of the Company will comprise 742,801,072 ordinary shares of 0.1 pence each. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\"). The Directors of the Company take responsibility for this announcement.\n*** ENDS **\nEngage with the ValiRx management team directly by asking questions, watching video\nsummaries and seeing what other shareholders have to say. Navigate to our Interactive Investor\nhub here:\nhttps://valirx.com/s/cc8ef3\nFor more information, please contact:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nhttps://valirx.com/link/exkQJy\nValiRx plc\nDr Mark Eccleston, CEO\nTel: +44 115 784 0025\nwww.valirx.com\nMark.Eccleston@valirx.com\nCairn Financial Advisers LLP (Nominated Adviser)\nLiam Murray / Ludovico Lazzaretti\nTel: +44 (0) 20 7213 0880\nShard Capital Partners LLP (Sole Broker)\nDamon Heath\nTel: +44 (0) 20 7186 9000\nV Formation (Public Relations)\nLucy Wharton - Senior PR Executive\nSue Carr - Director\n+44 (0) 115 787 0206\nwww.vformation.biz\nlucy@vformation.biz\nsue@vformation.biz\nSubscribe to our news alert service:\nhttps://valirx.com/s/f298d1\nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.\nLead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.\nValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.\nFor further information, visit:\nwww.valirx.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nIOEBPMLTMTJBBTF",
          "content_length": 4727
        },
        "ingested_at": "2026-01-21T00:53:34.624306Z"
      },
      {
        "event_id": "SOCIAL-6Jan20261829-RayPoint--5106514",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.820911",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "As I understand it, CLX is not even a product yet since a formulation has not been decided upon. As per ME's recent presentation, products are developed as IND-ready before a deal is sought. So the vital question is \"how long before CLX is IND-ready?\". That's what you guys should be asking ME.",
          "sentiment": 0.0,
          "engagement": "5,059",
          "price_at_post": "0.42",
          "thread_title": "RE: Ramping stops",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=CA1E32F4-46E6-483A-9517-06D899E7140D"
        },
        "ingested_at": "2026-01-22T21:09:47.832258+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261907-uxm484-72887005",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.820495",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "The assessment of formulation options for CLX001 has progressed during Q1 2024, with the lead formulation now demonstrated to have activity against cancer cells.",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.42",
          "thread_title": "RE: Ramping stops",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=CA1E32F4-46E6-483A-9517-06D899E7140D"
        },
        "ingested_at": "2026-01-22T21:09:47.832240+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261945-RayPoint--7991050",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.820079",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "I do wish they would publish pre-clinical results",
          "sentiment": 0.0,
          "engagement": "5,059",
          "price_at_post": "0.42",
          "thread_title": "RE: Ramping stops",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=CA1E32F4-46E6-483A-9517-06D899E7140D"
        },
        "ingested_at": "2026-01-22T21:09:47.832222+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20262106-Notpotal--7272234",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.819671",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Heartbreaking times for the perpetual doom merchants on here. Imagine spending the last 4 years posting day and night of Val\u2019s demise \u2026. only for the new CEO to stroll in, tidy up the mess, and transform the company in just 16 months. Val is now positioned to excel with a glut of news imminent over the coming months. Many LT holders have savoured the progress and taken advantage of rock-bottom SPs to bring averages back into kilter. Funny how today\u2019s reality keeps overruling the history lesson brigade. While some cut and paste merchants just recycle the same gloomy monologue, the company\u2019s CEO and main shareholder watches in amusement as he finalises the first of a stream of RNSs. It must be quite disconcerting. Imagine insisting the house is on fire and will need to be demolished, only for the fire brigade to show up, check the place over, and announce someone has simply burnt the toast. And now\u2014just as the smoke clears\u2014someone tidies a sofa cushion and finds yesterday\u2019s winning lottery ticket. A bit like how it feels being a Valirx holder under Mark\u2019s regime.",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.42",
          "thread_title": "RE: Microcap of the Year 2026?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=484234E8-7807-44F2-9DE0-24AD533B59EB"
        },
        "ingested_at": "2026-01-22T21:09:47.832204+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20262130-viera-48431654",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.819246",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "\u201c only for the new CEO to stroll in, tidy up the mess, and transform the company in just 16 months.\u201d Tidy up the mess by paying a non BOD non revenue producing BDM with 2 paid jobs \u00a3100,000!! Transform the company by diluting shareholders  at 0.6p and 0.25p having been made CEO at 1.3p !! And now he\u2019s dependent on twitter gang ramping Val to sell out whilst no revenue or decent RNS are generated !! It\u2019s a shambles Notgotalot.",
          "sentiment": 0.0,
          "engagement": "1,549",
          "price_at_post": "0.42",
          "thread_title": "RE: Microcap of the Year 2026?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=484234E8-7807-44F2-9DE0-24AD533B59EB"
        },
        "ingested_at": "2026-01-22T21:09:47.832186+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20262210-Notpotal--7365965",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.818809",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Nick , get over it \u2013 Mark Treharne is going nowhere. Mark E has spent 16 months assembling his Dream Team and I\u2019m fairly sure the rants of a bitter ex-holder won\u2019t cause either of them to lose any sleep whatsoever. Funny how you have the gall to knock Twitter ramping when not long ago you threw your dummy out of the pram because your \u2018followers\u2019 dropped below 600 or so. \ud83d\ude02",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.42",
          "thread_title": "RE: Microcap of the Year 2026?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=484234E8-7807-44F2-9DE0-24AD533B59EB"
        },
        "ingested_at": "2026-01-22T21:09:47.832168+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20262226-viera--3938210",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.818395",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Made me smile ! Only cos I\u2019m an attention seeker : ) Night night x",
          "sentiment": 0.0,
          "engagement": "1,549",
          "price_at_post": "0.42",
          "thread_title": "RE: Microcap of the Year 2026?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=484234E8-7807-44F2-9DE0-24AD533B59EB"
        },
        "ingested_at": "2026-01-22T21:09:47.832149+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20262227-viera-90748758",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.817970",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Btw my dream team is Adam and Adrian and Kevin A You backed the wrong team in 2 x Mark ! 1.3p to 0.4p! Good luck m8 ,be lucky xxx",
          "sentiment": 0.0,
          "engagement": "1,549",
          "price_at_post": "0.42",
          "thread_title": "RE: Microcap of the Year 2026?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=484234E8-7807-44F2-9DE0-24AD533B59EB"
        },
        "ingested_at": "2026-01-22T21:09:47.832129+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20260906-Uncanny-59670703",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.817557",
        "source": "LSE_CHAT",
        "data": {
          "author": "Uncanny",
          "content": "Bubbling up nicely \ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "3,307",
          "price_at_post": "0.445",
          "thread_title": "RE: Microcap of the Year 2026?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=484234E8-7807-44F2-9DE0-24AD533B59EB"
        },
        "ingested_at": "2026-01-22T21:09:47.832090+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20260914-paternos-54357296",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.817146",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Many of Mark\u2019s presentations have highlighted the potential of grant-funding, the 14/10/25 RNS confirming a \u00a3250k award a prime example. The Inaphaea RNS (18/9/25), re the Dominion repurposing top 10, confirmed \u201cinitial commercial discussions with potential licensees as well as application for non-dilutive grant funding to support further development of these and other assets\u201d. As MD of OncoLytika, Mark secured almost \u20ac3 million in Eureka Eurostar funding, so is acutely aware of the opportunities available. Recent changes to UK and international grant frameworks \u2014 including the UK\u2019s modernised Official Development Assistance (ODA) strategy, refreshed criteria, and new SME friendly collaboration rules \u2014 have opened funding routes that previously excluded early stage biopharma companies. These shifts prioritise oncology projects with demonstrable patient relevance, human relevant New Approach Methodologies (NAMs), and academia/SME partnerships, all of which are highly compatible with Val\u2019s revised model. With regulators actively encouraging NAM adoption and funders rewarding translational cancer research, Val\u2019s assets, its academic evaluation programmes, and Inaphaea\u2019s NAM enabled platforms now score higher on feasibility, ethics, and strategic alignment. As a result, the company is better positioned than ever to secure substantial grants. Cytolytix, in particular is a strong candidate, having already successfully secured funding via Open Univ Knowledge Transfer and HEIF schemes. It ticks all the appropriate boxes: oncology focus, targets difficult to treat indications, specifically TNBC and ovarian, has strong academic King\u2019s College lineage, and clear SME eligibility\u2014 a combination to make CLX one of Val\u2019s most grant ready assets. However, when these criteria are applied to Inaphaea NAM focused capabilities, additional opportunities emerge across the wider portfolio. Major SME eligible programmes from Innovate UK, CRUK, UKRI, NIHR and Cancer Research Horizons \u2014 all prioritising oncology, NAMs and academia/industry collaboration \u2014 now align directly with Val\u2019s model. Alongside CLX, additional assets such as VAL201 (prostate), VAL301 (endometriosis), StingRay/Sussex Univ and the Dundee/QMUL projects all fit the same criteria. Valirx is now primed for a level of acceleration and value creation unmatched in its history.",
          "sentiment": 0.5,
          "engagement": "357",
          "price_at_post": "0.445",
          "thread_title": "The new funding landscape",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=2B0FFF9D-2F0B-4673-9D78-E6883F472B31"
        },
        "ingested_at": "2026-01-22T21:09:47.832072+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261003-Porky9--1911324",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.816709",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "So you think grant money is going to stave off the placing? Really? If he is lucky enough to get \u00a3250k of free cash from a grant that covers what another month's admin costs. Ridiculous. Look, 1) you need to get costs under control, pie off non productive staff and get a focus, no multi job staff, proper dedicated individuals solely 100% focus on this business. 2) get the lab actually covering its ars@ so it doesnt have to rely on financial handouts, by that i mean paid invoiced revenue coming in covering the cost. That means sorting his sales and marketing out so he can get invoiced work in. 3) And then if he can get the balance so that 100% is covered by invoiced lab work but only uses 70% capacity of the lab resource he can then use the remaining 30% on own peptides and projects (in other words the paid work funds own work) - he has to stop this constant merry go round of raise, spend, raise, spend, raise, spend consolidate, raise again. 4) when he returns to the table in a few weeks time for the next raise, he raises enough cash for ideally a two year runway. A the very worst 18 mths so not focusing all his attention on constantly squeezing shareholders for more cash all the time. Its not rocket science is it, but they lack any commercial acumen, proven. it remains a lifestyle play it is not a business. Thats how it is, you know exactly what's coming I am just amazed the brokers allow it, money being raised constantly on a business that constantly fails to perform causing constant financial loss to small investors.",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.46",
          "thread_title": "RE: The new funding landscape",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=2B0FFF9D-2F0B-4673-9D78-E6883F472B31"
        },
        "ingested_at": "2026-01-22T21:09:47.832054+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261137-ratcliff--2123548",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.816273",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "It's a bit ambitious calling 201 an 'asset' isn't it? But assuming a new patent is granted on it, do you imagine it will be tried on more than 11 patients over five years or so? And will it be in an accredited west European establishment, or once more in some backwater ex-communist clinic? Really it might be better trying to rename it and pass it off as new stuff from the old bin-dipping exercise, because the ghost of 201 from before is going to be far more of a hinderance than an 'asset.'",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.465",
          "thread_title": "RE: The new funding landscape",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=2B0FFF9D-2F0B-4673-9D78-E6883F472B31"
        },
        "ingested_at": "2026-01-22T21:09:47.832036+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261233-Oxmil-88955935",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.815851",
        "source": "LSE_CHAT",
        "data": {
          "author": "Oxmil",
          "content": "Share price is getting pretty close to the exercise price for the first set of warrants. When are people planning to exercise? I assume most will just take a ten percent profit when the price gets high enough rather than waiting for more. Anyone prepared to share their plans on here?",
          "sentiment": 0.0,
          "engagement": "273",
          "price_at_post": "0.465",
          "thread_title": "Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A4E34791-A8AC-42AC-8262-681BE6BC6461"
        },
        "ingested_at": "2026-01-22T21:09:47.832018+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261344-uxm484--1246719",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.815439",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "The crowd is aware of the  tiny valuation, I would think this will be done over 2 or 3 steps for each holder depending on the amounts. Strong momentum is expected, with incremental cash likely removing the need for a placing in 2026 and potentially any future placings once Cytolytix deal is concluded. Medium upfront preclinical deals are anticipated to exceed $40m. Market starting to wake up to the potential Obvious rerate under way now. Just the start. Lots of other catalysts which other informed investors have mentioned like PP and Notpotalot.",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.465",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A4E34791-A8AC-42AC-8262-681BE6BC6461"
        },
        "ingested_at": "2026-01-22T21:09:47.832000+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261348-uxm484-23999527",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.815001",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Average preclinical biopharma deal upfronts surged dramatically in 2025, with figures showing averages around $110 million by Q3, more than doubling the 2024 rate, driven by Big Pharma.",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.465",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A4E34791-A8AC-42AC-8262-681BE6BC6461"
        },
        "ingested_at": "2026-01-22T21:09:47.831982+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261429-Porky9-16451687",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.814595",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "1) The current value is EXCESSIVE - i am amazed its at the premium its at had it not been for the recent Zac Mir pump - hello this is a business with about 11 weeks or so of cash left, its either going into administration or its going to raise (most likely) at a major discount.  You can pump all you like but thats the reality. 2) Why would anyone want to cash in warrants for more exposure and immediate dilution and at a bloated share price. Good grief the warrants are only any good if some miracle landed and a licensing deal resulted in it worth cashing the warrants in to sell at a decent profit. If you have warrants you would just sit on them frankly, no rush.  This talk here about some rush to buy more stock is just utter utter BS",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.44",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A4E34791-A8AC-42AC-8262-681BE6BC6461"
        },
        "ingested_at": "2026-01-22T21:09:47.831964+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261648-uxm484--9021731",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.814180",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.415",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A4E34791-A8AC-42AC-8262-681BE6BC6461"
        },
        "ingested_at": "2026-01-22T21:09:47.831947+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261946-viera-71594947",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.813757",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Shares reached my 0.45p target and then dumped . I\u2019ve no view now and wis shareholders the best of luck: you\u2019ve all been so patient and deserve rich rewards . Only word of advice ,if Val come back to market for funds please insist on further costs cuts as we aren\u2019t lean enough ! Hopefully there will be no more placings though . I\u2019m outta here now ,take care xxx",
          "sentiment": 0.0,
          "engagement": "1,549",
          "price_at_post": "0.415",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A4E34791-A8AC-42AC-8262-681BE6BC6461"
        },
        "ingested_at": "2026-01-22T21:09:47.831929+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261356-ratcliff-55273269",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.813332",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Looks like you're not the only one taking the profit while they can Viera.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.41",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A4E34791-A8AC-42AC-8262-681BE6BC6461"
        },
        "ingested_at": "2026-01-22T21:09:47.831911+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261422-TopTrade--4137921",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.812912",
        "source": "LSE_CHAT",
        "data": {
          "author": "TopTraderTR",
          "content": "Took a small trade here",
          "sentiment": 0.5,
          "engagement": "339",
          "price_at_post": "0.41",
          "thread_title": "Trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=ACE1E361-4AA7-4827-9910-BCDFF9CA42F6"
        },
        "ingested_at": "2026-01-22T21:09:47.831893+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260738-GoldieLo--5647606",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.812505",
        "source": "LSE_CHAT",
        "data": {
          "author": "GoldieLock",
          "content": "NewCo will seek external non-dilutive and dilutive funding and ValiRx (and potentially other investors arranged by ValiRx) may, subject to availability of funds, provide up to \u00a32 million of seed funding (\"Seed Funding\"). Any such Seed Funding would be provided in tranches in line with the cash requirements, in exchange for further equity under a development plan provided by the Company. Funding other than the Seed Funding shall dilute all shares pari passu.",
          "sentiment": 0.0,
          "engagement": "1,404",
          "price_at_post": "0.41",
          "thread_title": "Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-22T21:09:47.831875+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260745-Badsterm--4852545",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.812085",
        "source": "LSE_CHAT",
        "data": {
          "author": "Badsterman",
          "content": "You're an idiot. The shares in \"Newco\" would be diluted to provide funding, not Valirx. In any case the agreement is for nine months, by which time Val will have run out of cash anyway. \"IRICoR will establish a Canadian registered, wholly owned, subsidiary (\"NewCo\")\" READ THE RNS.",
          "sentiment": 0.0,
          "engagement": "927",
          "price_at_post": "0.41",
          "thread_title": "RE: Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-22T21:09:47.831857+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260757-GoldieLo--1402562",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.811664",
        "source": "LSE_CHAT",
        "data": {
          "author": "GoldieLock",
          "content": "No. You are the fool. The phrase \"subject to availability of funds\" is the most important part of that sentence. It is a classic \"legal out.\" It tells you that while ValiRx wants to put up \u00a32 million, they don't necessarily have that cash sitting in the bank ready to go right now. To get that \u00a32 million, ValiRx essentially has three options: 1. Use existing cash: If they have it (unlikely to be the full amount given their typical burn rate). 2. External partners: They mentioned \"other investors arranged by ValiRx\" might step in. 3. A Placing (Equity Raise): If they can't find the money elsewhere and decide this project is a priority, they would need to raise more capital by issuing new shares.",
          "sentiment": 0.0,
          "engagement": "1,404",
          "price_at_post": "0.425",
          "thread_title": "RE: Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-22T21:09:47.831839+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260812-ratcliff-80937645",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.811223",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Looks like the string of hope-raising RNSs ahead of the next placing is starting even earlier than anticipated. Stand by for more fluffy announcements that 'could generate up to x billion pounds in five years subject to funding, institutional investment etc etc.' This will run in tandem with lots of pumping posts with 'if', 'could', 'might' and 'maybe' as a framework.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.415",
          "thread_title": "RE: Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-22T21:09:47.831821+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260816-Badsterm--3619534",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:47.810784",
        "source": "LSE_CHAT",
        "data": {
          "author": "Badsterman",
          "content": "No, Your thread is clearly entitled \"Placing coming, what we thinking? 0.2\" Why would Valirx raise funds for an evaluation that has nine months before it's even completed and the results known? We all know Val probably have five months cash (debatable) at most. Your thread title is scaremongering nonsense.",
          "sentiment": 0.0,
          "engagement": "927",
          "price_at_post": "0.415",
          "thread_title": "RE: Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-22T21:09:47.831803+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260824-paternos-95103423",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.443929",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "This one of the most strategically important deals in Val\u2019s history \u2014 and it\u2019s a major step forward in the \u201casset level dilution, plc level protection\u201d model the company has been signalling for months: 1. VAL secures access to a later stage, second generation RNA helicase inhibitor. This isn\u2019t an early academic idea. McGill/IRICoR have already done extensive development. RNA helicase inhibitors are a hot area in oncology and antiviral research and a second generation, orally available inhibitor is commercially attractive. VAL steps in at the target engagement/potency stage \u2014 far more advanced than typical VAL assets. 2. McGill and IRICoR are serious players so this deal elevates VAL\u2019s profile and opens doors for future deals. 3. Inaphaea runs the evaluation, and any data generated becomes VAL\u2019s property. VAL has explicitly structured the evaluation so that the data itself can be monetised. 4. IRICoR, NOT Val, creates a NewCo to commercialise the asset - That alone, signals confidence from the IRICor. NewCo gets the background IP and will seek external funding to push the asset forward. 5. VAL gets a 15% equity option in NewCo. This is the venture studio model in action - dilute the asset, not the plc. Mark announced the same intention with Val 201 in the webinar. 6. VAL may invest up to \u00a32m \u2014 but only if it chooses to: Funding is optional, staged, and subject to availability. No obligation, no upfront burden. 7. If VAL walks away, it can still get paid  If VAL declines the equity option, and the Institutions later commercialise the asset, VAL receives 1.5\u00d7 its evaluation spend (capped at ~\u00a3150k), similar to the recent StingRay update. It\u2019s a win/win, no risk deal. 8. Multiple exit routes - NewCo may: out license, raise institutional capital, merge or be acquired. All routes generate value for VAL. 9. It conforms with Mark\u2019s commitment to early monetisation. Because the asset is later stage, timelines to IND enabling studies and clinical entry are shorter. Today\u2019s RNS comes from having a commercially-savvy CEO protecting both his shareholders and his own 7% ownership of the company. Exciting times! One bus has arrived \u2014 but engines are revving across the garage. GLA, DYOR",
          "sentiment": 0.5,
          "engagement": "357",
          "price_at_post": "0.415",
          "thread_title": "A Bold New Chapter",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=25F7D62E-D969-4181-A77B-FE67C25BCE2B"
        },
        "ingested_at": "2026-01-22T21:09:47.831785+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260829-nomlungu--4767212",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.443461",
        "source": "LSE_CHAT",
        "data": {
          "author": "nomlungu",
          "content": "\"evaluation spend (capped at ~\u00a3150k)\" So where does the \u00a3150k come from? Those who thought a placing will be coming in April may have to revise their opinion to late Feb.",
          "sentiment": 0.0,
          "engagement": "23,960",
          "price_at_post": "0.415",
          "thread_title": "RE: A Bold New Chapter",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=25F7D62E-D969-4181-A77B-FE67C25BCE2B"
        },
        "ingested_at": "2026-01-22T21:09:47.831767+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260847-Fredd1eb-72059156",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.443035",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fredd1eboy",
          "content": "Happy new year ob.....and good luck with Val. Sincerely Fred",
          "sentiment": 0.0,
          "engagement": "11,207",
          "price_at_post": "0.41",
          "thread_title": "RE: Gloves off\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=101654E0-A902-4633-8E17-2659C51B89C0"
        },
        "ingested_at": "2026-01-22T21:09:47.831749+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260910-Badsterm-19821895",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.442614",
        "source": "LSE_CHAT",
        "data": {
          "author": "Badsterman",
          "content": "The \u00a3150,000 is within the budgeted spend of the last fundraise. The RNS clearly stated part of the raise was for new evaluations, which ME has now delivered. Don't people read RNS's?",
          "sentiment": 0.0,
          "engagement": "927",
          "price_at_post": "0.41",
          "thread_title": "RE: A Bold New Chapter",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=25F7D62E-D969-4181-A77B-FE67C25BCE2B"
        },
        "ingested_at": "2026-01-22T21:09:47.831726+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261021-paternos--7579663",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.442200",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "McGill is one of Canada\u2019s top research universities. It is a major research institution with a global reputation and substantial research funding.  McGill is #29 in the QS World University Rankings 2025 and ranks #44 globally across 14,131 institutions in EduRank\u2019s 2025 analysis, attracting $749 million in sponsored research income in 2024. It has an endowment of CA$2.3 Bn and an annual budget of CA$1.5Bn. IRICoR is a non profit commercialisation centre. However, key financial indicators are available: 1. IRICoR has generated over $107M in revenue from collaborations focused on R&D of new therapies. It has also secured $40M in federal grants and $4.1M in provincial grants. This level of funding is only possible for an organisation with a strong track record of delivering commercially viable science. 2. IRICoR and Universit\u00e9 de Montr\u00e9al have an extended collaboration since 2020 with Ipsen \u2014 a \u20ac9.7 Bn mkt cap international pharma. Two new oncology programs were added under this partnership, focusing on novel MAP kinase pathway inhibition. This is exactly the kind of partner that only a credible translational engine can attract. 3. A small molecule therapy for solid tumours developed at IRIC/IRICoR and licensed to Ipsen has already reached Phase 1. This demonstrates that IRICoR can take a discovery stage program all the way to human trials. 4. IRICoR specialises in creating spin off companies. Their mission statement confirms: IRICoR \u201cplays an essential role in establishing strategic partnerships\u2026 or creating spin off companies\u201d to commercialise academic discoveries. This is directly relevant to the VAL deal, where IRICoR will create a NewCo to commercialise the helicase inhibitor. The above shows that IRICoR has already taken assets from discovery \u2192 licensing \u2192 Phase 1 and has deep relationships with global pharma, increasing the likelihood of future out licensing or co development. It also has the infrastructure and funding to build and support spin outs with a proven ability to attract major non dilutive funding.",
          "sentiment": 0.5,
          "engagement": "357",
          "price_at_post": "0.40",
          "thread_title": "McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-22T21:09:47.831708+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261353-Porky9--3254656",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.441751",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Yes, deal perfectly 100% proves my point about lack of  any commercial acumen in the business.  Just incredidble. Perhaps the perma bulls can try and spin this one, give it your best shot PP",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-22T21:09:47.831690+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261602-Kaeren-36125245",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.441343",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kaeren",
          "content": "Happy new year P9.",
          "sentiment": 0.0,
          "engagement": "10,937",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-22T21:09:47.831672+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261713-Porky9-18561859",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.440929",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Happy New Year to @kaeren you too. Trust you and family are all well. X",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-22T21:09:47.831655+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261905-Gilders0-38876053",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.440518",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gilders01",
          "content": "Lot should be questioned , lots should be said, but I'm not invested. Still want this company to make a difference.",
          "sentiment": 0.0,
          "engagement": "1,156",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-22T21:09:47.831637+00:00"
      },
      {
        "event_id": "SOCIAL-10Jan20261344-Notpotal-55455700",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.440095",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "The asset/players: RNA Helicase Inhibitor \u2014 blocks the enzymes cancer cells rely on to grow and divide. \u2022 McGill: global top 30 university, CA$750m research income, CA$2+Bn endowment, deep oncology infrastructure. \u2022 IRICoR: $100m+ R&D revenue, major grants, long term partner of \u20ac9Bn Ipsen. \u2022 ValiRx: \u2013 a \u00a33m microcap with access to cutting-edge tech via Inaphaea and capability partners. McGill provides the science, IRICoR drives commercialisation, external investors bring funding, and VAL simply leverages its existing assets. Why VAL? - Big pharma is slow, expensive, and bureaucratic. Inaphaea can evaluate quickly, cheaply, and decisively. McGill doesn\u2019t have a commercial lab, IRICoR doesn\u2019t run wet lab evaluations, and big pharma won\u2019t touch early stage assets. VAL is hungry, flexible, and built to operate exactly in this gap, without corporate drag. The total RNA targeting small molecule market is projected at $\u202f5.5Bn by 2030. 1% of that is $55m. A tiny slice of a very large pie still tastes pretty good.",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-22T21:09:47.831618+00:00"
      },
      {
        "event_id": "SOCIAL-10Jan20261920-Kaeren--5116027",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.439670",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kaeren",
          "content": "All great thx.",
          "sentiment": 0.0,
          "engagement": "10,937",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-22T21:09:47.831601+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261042-paternos-54305157",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.439260",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "As standard, when Mark did the Dec webinar he emphasised nothing new, \u201cjust meat on the bones\u201d. However, often that meat can be pretty tasty. Blue Ribbon/VAL201 \u2013 \u201csynthesis almost complete\u201d (10m.30s). Then, \u201ca small amount (only \u00a350k) set aside for pre-clinical development of 201, the balance WILL then come from external investment into the asset\u201d (11m.55s). No \u201cMIGHT\u201d in that statement. The minimal outlay confirms that the VAL201 drug package is essentially finalised, and the entire development programme (preclinical \u2192 IND \u2192 partnering) is about to move forward. Mark has already confirmed Val will be diluting the asset, not Val PLC. With patents imminent, it\u2019s a clear signal that Blue Ribbon is not just a corporate shell \u2014 it\u2019s actively progressing VAL201 toward monetisation. Given Val\u2019s recent multi facet RNS style, the imminent update could well bundle new patent status with partnership confirmation. The last significant VAL201 update in 2021 saw the Val SP exceed 50p.",
          "sentiment": 0.5,
          "engagement": "357",
          "price_at_post": "0.365",
          "thread_title": "Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-22T21:09:47.831582+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261539-Porky9-57929828",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.438822",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Err nope Only thing that will bring hard cash into the company of any meaningful amount in the next 8 weeks will be new placing money - sorry Regarding your continual pumps and fluffy updates, jam tommorrow dream fantasy posts, NONE of it can pay the bills now, end of. Anyone with any brains will be working the sells into any mupets trading this that are oblivious to the dire need for cash to keep the lights on and the pending essential discounted placing that has to happen to support the lifestyles here to keep the gravy train going. Tick Tock, Tick Tock",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.35",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-22T21:09:47.831565+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261804-uxm484-69506569",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.438397",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Plenty of news to come at a tiny valuation and likely this month. Cash until at least July that without warrants, revenue, deals, grants. Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-22T21:09:47.831547+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261952-Notpotal--8920350",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.437971",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Porky, unlike some holders, I still keep you around for the entertainment value.  Calling Nick and other traders \u2018muppets\u2019 is certainly \u2026.\u201dcreative\u201d. \ud83d\ude00 Jaspal S and Stephen W dipping just under the 3% is nothing more than freeing up a couple of million to trade. There\u2019s no great sell-off and no drama. Most of us aren\u2019t brave enough to risk missing an RNS for the sake of a few hundred quid. Get your 40 winks while you can. Many sleepless nights await over the next few months.   \ud83e\udd71 Pleasant dreams.",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-22T21:09:47.831529+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260919-Porky9-11812165",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.437540",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@Notpotalot Nick is a VERY experienced prolific investor. Frankly, i doff my cap to him as he called the trade perfectly in at .25 and out at .40. Beautiful. The Muppets are the traders in on the back of the Zac Mir pump without any research in blind on the dead cat bounce they will get burnt if still holding. As for Stephen and Jaspal at u3% they now dont have to declare BUT IMO they have about 8 weeks to slowly work the sells in to ensure they are out (just holding warrants options) before that next raise drops as they will be diluted to oblivion as sure as night is day. They can only drip sells in slowly to avoid the brokers hammering them at discount. You try selling big volumes of this close to the raise, or at anytime for that matter, you need to do it on a bounce really, sell whilst traders are buying. This is NOT an investment, its a short term punt. The reason its not an investment is because it can't generate revenue (well none in the last 15 yrs anyhow)  and is reliant on raise after raise after raise to maintain lifestyles. As I say, tick tock. Tick tock countdown already started imo.",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-22T21:09:47.831511+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260954-uxm484-69506569",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.437105",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Plenty of news to come at a tiny valuation and likely this month. Cash until at least July that without warrants, revenue, deals, grants. Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-22T21:09:47.831493+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261107-ratcliff--8246796",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.436674",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "UXM - cutting and pasting the same post repeatedly is not convincing, but to humour you I had a listen to the link you have monotonously posted. It's not persuasive or convincing - Starts off about the 'objectives we have set' and 'milestones we're looking to achieve.' Then there's a bit about the group structure - this is rearranging the deck chairs on the Titanic isn't it? They've had more rearrangements over the decades, it's just a distraction now - meetings are the practical alternative to work. The we hear 'The objective is...' and 'If suitable...'  So nothing at all certain. Then he says BC201 and Val301 have 'not been spun out yet, but would benefit from all of the development work undertaken on Val201.' So BC201 and Val301 still of no interest (except maybe on Antiques Roadshow) and if Val201 had even a glimmer of potential it would have done something since it was quietly shelved - was that 6 years ago or 8? It's been stagnant for so long, the rest of the industry has moved on. The he says 'There is strong interest in endometriosis treatments.' True. There's strong interest in a lot of things, but stating a fact doesn't tie it to VAL. 'We have two new evaluations under consideration.' And...? I\u2019ve got a lot of things under consideration, but whether they get any further is often very uncertain. 'The vision is...' - A lot of people have visions, but a vision isn't even a plan. It's a nice idea at best. 'Our strategy is to do this based on identifying the highest quality assets we can find and afford.' That's like saying 'come round to my place for a meal' and when you get there you say 'There\u2019s a tin of Pedigree Chum between the four of us - it was the highest quality I could find on the available budget.' The he's going to have a system which 'allows us to prioritise selection of assets.' How early stage is all this? And no money to do it with.. Next we see \u2018The Team\u2019 but no mention of their salaries. Then a review of last year - no mention of the placings. Talk of last year's cost savings and redundancies - but if you are cutting 200k a year and laying people off, what were you wasting the money on in the first place? Or have you sold your food to pay the heating bill? Then he says 'Our runway through 2026' - sorry - that 'runway' stops in a couple of months without a placing. The 2026 Xmas do is potentially in the Job Centre unless money comes in very soon. Time is money. They seem dangerously short of both. Again.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.355",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-22T21:09:47.831474+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261145-Marty130--3141167",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.436209",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Be good to see the directors buying some of the stock..",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "0.355",
          "thread_title": "Directors deals",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=DC2D2A2F-B451-4EEF-B7C8-9C80695D4033"
        },
        "ingested_at": "2026-01-22T21:09:47.831456+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261224-paternos--2698580",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.435789",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "A \u00a33m microcap with a cash runway till H2 even before factoring in R&D tax credits, potential grant funding, additional Inaphaea income or warrant cash now within reach. Outgoings reduced by \u00a3200k PA following a team restructuring last year. Val\u2019s expansion into NAMs and advanced AI tech, supported by strong academic partnerships, aligns directly with revised US & UK gov\u2019t guidelines to reduce animal testing. This positions Val as a front runner for non dilutive grants and innovation funding, with a CEO geared to capitalise on this opportunity. The 1/9/25 RNS confirmed ongoing discussions with several potential partners to progress Cytolytix, including a major pharma. Val owns 60% of CLX with 10% owned by co-inventor, Dr Charles Chen (Senior Scientist at Astrazeneca). Val also has a 54% share of an Ambrose deal potentially worth up to \u00a316m, and a Biobank of 476 PDCs valued at \u00a310k per PDC cell-line upon commercialisation, plus commercial rights entitlement. Valirx has assets in several key cancer indications, all with huge global markets: 201/prostate ($11.3Bn*), CLX (primarily TNBC ($1.5Bn*), ovarian ($2.5Bn*) but also prostate, 301/endometriosis ($1.9Bn**), and 401-Ambrose/pancreatic ($2.9Bn**). Sources: *webinar, **GMI. Several RNS updates are imminent: CLX patents \u201cin coming weeks.\u201d (RNS 1/9/25), Dundee/Queen Mary project (extended to 9/2/26), StingRay (approx Feb \u201926 per Aug video), Blue Ribbon SPV - \u201cSeveral patents envisaged for 201\u201d, and the next evaluation/SPV \u201cimminent with discussions already at a mature stage\u201d. The Omios RNS (3/6/25) stated \u201c\u2026 expected to take up to 12 months. On conclusion of the evaluation, Omios has an option to enter into an Oncolytic Peptide License Agreement to continue using Cytolytix technology.\u201d Yet another potential source of income. In addition, the Val/Dominion repurposing project (teaching an old drug new tricks) has identified 200 FDA approved non-oncology drugs which already have phase 1 clinical data and are showing activity against various cancer PDCs. 10 of these candidates are now being fast-tracked. The median upfront deal size for pre-clinical IND ready assets was $110m in 2025. For phase 2 this increased to $775m. (Dec webinar). For context, Val\u2019s SP exceeded 55p in 2021 with only one key asset (VAL201). Currently, including the repurposing project, Val now has 200+ potential assets plus a valuable Biobank. Also, Mark has restructured evaluation agreements whereby if Val chooses not to progress an asset (eg StingRay, McGill/IRICoR), Inaphaea retains the data and can still monetise should a 3rd party take the asset forward. Multiple monetisation routes now sit across the pipeline, supported by a commercially-savvy CEO who now owns 7% of the company. Valirx \u2013 a microcap with midcap potential.",
          "sentiment": 0.5,
          "engagement": "357",
          "price_at_post": "0.355",
          "thread_title": "Why invest? \u2013 FINANCIAL",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=8931CA86-EC8C-43F3-AA7F-54C7D7FD717E"
        },
        "ingested_at": "2026-01-22T21:09:47.831438+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261313-paternos-71732466",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.435334",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "When Mark became CEO, ValirRx was effectively dormant - few assets in play, minimal Board investment and limited vision. He set about a major restructuring: rebuilding the team, reshaping the asset base and above all, resetting the mindset. Fast forward 17 months and Val is reborn. A microcap expanding into developing fields of oncology, yet every action taken has a cost/benefit analysis and timescale consideration. If concluded that a project cannot be monetised early, it is shelved or paused. Commercial decisions overrule all others. Valirx is now plugged into some of the most advanced platforms in modern drug development: \u2022\tpatient avatars (TwinEdge) \u2022\tmicrofluidics/3D tissue culture models (Screenin3D, Ignota & VoxCell) \u2022\trepurposing (Ignota, Altus & Dominion) \u2022\tpersonalised immunotherapy (PredictRx / Dominion) \u2022\tpro-senescence drugs (Dundee / Queen Mary Uni) \u2022\tClickmer technology/HER2 protein (Apis Assay) \u2022\tLMTK3 kinase targeting (StingRay). The most recent evaluation, a 2nd-gen RNA helicase inhibitor (McGill/IRICoR), brings Val into collaboration with major international research organisations. Last year, Mark identified a shift away from animal-testing and moved early to establish capability partners supporting NAMs and cutting-edge AI. Recent US & UK Gov\u2019t regulatory changes now actively favour such platforms with Europe to follow this year. Once again, Val anticipated this trend before much of the market. Meanwhile, the Advisory Board has been upgraded from academics and towards industry experts who can provide insight into Big Pharma priorities and identify new commercial pathways such as in veterinary science - quicker to market while opening a parallel revenue path thru\u2019 comparative oncology, further de risking the route to human oncology. Mark has also added a clause into evaluation agreements whereby if Val decides not to progress an asset eg StingRay, McGill/IRICoR, then Inaphaea retains the data and can still monetise should a 3rd party take the asset forward. Val is no longer waiting for opportunity; it is engineering it.",
          "sentiment": 0.5,
          "engagement": "357",
          "price_at_post": "0.385",
          "thread_title": "Why invest? \u2013 THE SCIENCE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=058BF091-3235-424B-9C46-FA00ED6BC8D5"
        },
        "ingested_at": "2026-01-22T21:09:47.831420+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261430-nomlungu--3305860",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.434854",
        "source": "LSE_CHAT",
        "data": {
          "author": "nomlungu",
          "content": "People should just ignore Rat... he is just jealous that he does not have the losses to use to reduce his tax liabilities. That 80% drop in the last tax year will have been very valuable for some; I think him moaning around the time that taxes are due for the 2024/25 year is a dead give away. \ud83d\udcc9 \u2757",
          "sentiment": 0.0,
          "engagement": "23,960",
          "price_at_post": "0.395",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-22T21:09:47.831402+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261432-mikee_p-26138912",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.434430",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "1 HR. Channel is all ya need.",
          "sentiment": 0.0,
          "engagement": "1,889",
          "price_at_post": "0.395",
          "thread_title": "Easy trade this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=81274FD9-0226-45F3-8CEA-B1F91E33B4A2"
        },
        "ingested_at": "2026-01-22T21:09:47.831384+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261503-Mr0nions-89825139",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.433999",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mr0nions",
          "content": "Because of this  post, I'm holding position.  Good luck all.",
          "sentiment": 0.0,
          "engagement": "1,969",
          "price_at_post": "0.41",
          "thread_title": "RE: Why invest? \u2013 THE SCIENCE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=058BF091-3235-424B-9C46-FA00ED6BC8D5"
        },
        "ingested_at": "2026-01-22T21:09:47.831366+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261507-ratcliff-64597250",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:44.433567",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "You swine Nomlungu. You've rumbled me.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.41",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-22T21:09:47.831347+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261719-Porky9-94434820",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.653770",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "And just a few reasons why not to believe the BS from the resident rampers here and why you should avoid:- * Lifestyle Business * Ridiculous Admin costs * Continual Raises and continual dilution * More than 20 Raises, 3 lots of 125:1 Consolidation events * business concept never proven * Rented lab space and zero revenue in 15 years * About 8 weeks cash runway left with yet another raise due anytime soon to keep the gravy train going. * if new investors or brokers say enough is enough and call time due to clients continually losing money then its admin and you could lose your entire investment. * materially overpriced as absoluly nothing here to invest in, its the emperors new clothes you are buying. 201 is older than hens teeth, no interest in 15 years and CLX years off and more cash required. Labs meanwhile doesnt know what an invoice is. * Poor decision making, lack of any commercial acumen *No real focus, practically everyone is work from home with multiple jobs. * Short term punts only not a long hold due to above. * loads of stock held for broker fees that will need to be drip fed into anyone buying. In all avoid at all costs unless you like dilution",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.385",
          "thread_title": "Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-22T21:09:47.831329+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261733-uxm484--4097675",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.653310",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "All lies. Watch the video previously posted. Past management issues but new management outstanding.  Cash until H2 without the add ons. CEO heavily invested over 250k. Negotiating with a major biotech in regards to a deal for CLX001. Lab space is to help progress the assets to eventually get a deal not to make instant revenue. Any research on CLX001 done against a valuation of 2 million and cash burn just over a million would know this is a great opportunity. Brokers only had 20k stock. Hardly lots of stock. Great decision making. Derisking assets with partnership deals.  Which other biotech has so much spending less than 2 million. With warrants at a premium to the current price hopefully no more dilutions.",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.385",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-22T21:09:47.831310+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20262049-ratcliff--2923438",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.652866",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Whatever it is you're smoking UXM, it's powerful stuff.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.385",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-22T21:09:47.831292+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260857-Notpotal-52991667",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.652461",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "\u201cYou can't go back and change the beginning, but you can start where you are and change the ending.\" \u2013 C.S. Lewis Early in his tenure, Mark acknowledged mistakes had been made \u2014 and while he couldn\u2019t rewrite the past, he could reshape the future. 17 months later, Val is reborn, with money in the bank, a rebuilt team, high calibre assets and a SH base that deserves success after years of one-way support. A few resident historians cling to their preferred mythology, inventing a minimal cash runway because the real picture is too uncomfortable to accept: a cash runway to H2 even without R&D tax credits, additional Inaphaea income, grants or exercised warrants. This is also before the wave of RNS due over the coming weeks. Unlike those posting fiction, Mark has backed his conviction with his own money \u2014 now holding 7% of the company. \u201cWhat matters now is not where we\u2019ve been, but where we\u2019re going.\u201d",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.365",
          "thread_title": "Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-22T21:09:47.831274+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260920-RayPoint--2522866",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.652032",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Living in fantasy land",
          "sentiment": 0.0,
          "engagement": "5,059",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-22T21:09:47.831256+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261050-Rebster4-78111898",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.651626",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rebster408",
          "content": "Its groundhog day again This is a binary bet...and Poky has called it right in the past and I thinks he's spot on again... 201 is older than me!!! place your bets... the wheel is spinning and will stop within the next 8 weeks All will become clear within the next two months...",
          "sentiment": 0.0,
          "engagement": "1,173",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-22T21:09:47.831238+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261059-viera-22062616",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.651202",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Are you PM in disguise ? Who in  their right mind would buy any company on Aim with only 3 or 4 months cash runway? You sound so so desperate for a rally to sell out !",
          "sentiment": 0.0,
          "engagement": "1,549",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-22T21:09:47.831219+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261201-ratcliff-19415366",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.650775",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "UXM - differences of opinion are generally understandable, but to say in your post 'All lies' is blatantly true and misleading, and as usual does nothing to bolster your credibility. Two of the things you say in that post are particularly inaccurate - 'Great decision making. Derisking assets with partnership deals. Which other biotech has so much spending less than 2 million.' - They are looking for deals (or claim to be anyway) but nothing so far has contributed anything to even cover the outgoings, let alone provide money for further work or expansion (hence the redundancies etc) Secondly - 'With warrants at a premium to the current price hopefully no more dilutions' - warrants don't kick in and generate cash the moment the sp goes above them as you and the others in your group seem to imply. In the unlikely event of the sp rising above that point and remaining so, it just might be worth warrant holders exercising them so they could buy shares at below the then-current price, but to sell them they'd need to be able to be sure the sp was strong enough to withstand the effect of the sells. You know that, so stop trying to imply that the mere existence of warrants is a long-term fool proof source of near or long term capital. Then again, if this company was fool proof you wouldn't be here I imagine.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.365",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-22T21:09:47.831201+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261207-ratcliff--6114823",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.650342",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Slight typo there - should read blatantly UNTRUE and misleading!",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.365",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-22T21:09:47.831182+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261222-Notpotal--3646896",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.649916",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "\u201cYou sound so desperate\u201d says the man who\u2019s last 60 posts have been on a share he isn\u2019t invested in. \ud83d\ude02\ud83d\ude02\ud83d\ude02",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-22T21:09:47.831164+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261935-uxm484-46431695",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.649511",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "No, but the holders all want the warrants exercised so we can do a 10 bagger in 12 months without a fund raise. For me i am really happy here with  the progression. We are definitely early in a news rich periods where all the negative posters are posting overtime and are only posting as they missed out on the last fundraise hoping for an even lower price. We will likely get a few meaningful RNS very soon. Brakes are now off\u2026",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.36",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-22T21:09:47.831145+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261216-steve196-67335785",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.649086",
        "source": "LSE_CHAT",
        "data": {
          "author": "steve196",
          "content": "How much does it cost to release an RNS just for \u00a3400 of warrants?",
          "sentiment": 0.0,
          "engagement": "2,754",
          "price_at_post": "0.385",
          "thread_title": "Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-22T21:09:47.831127+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261311-ratcliff-28507269",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.648682",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Probably about 450 quid...",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-22T21:09:47.831095+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261357-spantrou-35855058",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.648272",
        "source": "LSE_CHAT",
        "data": {
          "author": "spantrout",
          "content": "\u00a39.99 for rns",
          "sentiment": 0.0,
          "engagement": "13,949",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-22T21:09:47.831077+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261412-RayPoint-49474289",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.647859",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "\"Probably about 450 quid...\" Rats, stop ramping! The gross proceeds were \u00a3400",
          "sentiment": 0.0,
          "engagement": "5,059",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-22T21:09:47.831059+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261413-RayPoint-59084889",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.647447",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Sorry Rats. I misinterpreted your post.",
          "sentiment": 0.0,
          "engagement": "5,059",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-22T21:09:47.831041+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261434-ratcliff-47770381",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.647024",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "No problem RP - I'm wondering who paid 0.50 for a few shares worth about 25 percent less from the start, but I suppose 400 quid pays for the week's teabags and digestives.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-22T21:09:47.831022+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261529-RayPoint-57486010",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.646621",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "I hear that green fees are pretty steep in California",
          "sentiment": 0.0,
          "engagement": "5,059",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-22T21:09:47.831004+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261534-Notpotal-15871888",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.646210",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Val is obliged to RNS as it a change to No. shares in issue. Hardly the company\u2019s fault if a holder sees such value that he wants to buy above the current SP. Mind you, I\u2019m expecting a TR1 tomorrow to confirm Mark\u2019s holding has increased by 80,000 shares. \ud83e\udd23 If this is the reaction to \u00a3400 of warrants, heaven help Porky\u2019s groupies when the next material RNS arrives.  \ud83e\udee8 \ud83d\ude28 \ud83d\ude22\ud83d\ude2d",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-22T21:09:47.830985+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261543-Notpotal-52422416",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.645784",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "I notice a 71430 buy at 15.14 and a similar sell 4 mins later for a \u00a321 loss. Great to see Porky has started trading again!  \ud83e\udd23\ud83e\udd23\ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.385",
          "thread_title": "Welcome back, Porky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=FE350133-0204-48E9-9785-7F80407B3421"
        },
        "ingested_at": "2026-01-22T21:09:47.830968+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260943-paternos-13287721",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.645367",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Mark re JPM in San Fran -  \u201cI have meetings lined up with our partner Omios Biologics so looking forward to catching up with Aldo Pourchet (CEO).\u201d In the Omios RNS (3/6/25), the evaluation was \u201cexpected to run up to 12 months, after which Omios can exercise its license option to continue using Cytolytix technology.\u201d Across both the June and Dec webinars, Mark emphasised CLX synergy with the Omios virus for potential to treat canine HSA, a clear signal that Omios sits firmly in the frame for a CLX licence. Valirx\u2019s revamped Advisory Board reinforces this direction, now with a notable weighting toward veterinary oncology and commercial expertise. The composition reflects a deliberate strategy to position CLX across both human and animal oncology. When your advisory structure is rebuilt around people who understand canine cancers, comparative oncology, and veterinary commercial pathways, it becomes clear Valirx is preparing for licensing routes across both human and veterinary markets. As a co-founder of VolitionRx, Mark transformed a human cancer test into a canine diagnostic test (Nu.Q) before negotiating a licencing deal with Heska for $26m. What price a cure? Human and veterinary oncology operate in separate regulatory and commercial channels. Most major pharmas, inc. AZN, Roche, GSK, AbbVie do NOT have any vet divisions. Even those historically involved have spun off their animal health units (Pfizer \u2192 Zoetis, Eli Lilly \u2192 Elanco). By envisaging veterinary opportunities for CLX, Mark is implicitly confirming the compound won\u2019t be a one partner asset; the split infrastructures required make multiple CytoLytix deals the only realistic outcome. GLA, DYOR, AIMO",
          "sentiment": 0.5,
          "engagement": "357",
          "price_at_post": "0.385",
          "thread_title": "Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-01-22T21:09:47.830950+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261329-Porky9--5445101",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.644922",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@PP Yes, and as long as the rain holds off should be able to get some golf in on expenses. Who needs Zoom and Teams when you can have a nice all expenses trip to the US. Lovely. Keep pumping it, only a few weeks now to go before next placing @notpotatlot Only Update you will get shortly that isn't fluff, will be the placing news or the next 125:1 consolidation event which has to be well over due now. Keep ramping it though, the gravy train needs to stay on the tracks, there are lifestyles here that need to be maintained.",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.385",
          "thread_title": "RE: Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-01-22T21:09:47.830931+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261459-Notpotal-74367845",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.644486",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Some clever trading going on here \u2013 those selling at 0.37p will soon be able to buy back at 0.39p. \ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "76",
          "price_at_post": "0.385",
          "thread_title": "RE: Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-01-22T21:09:47.830912+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261513-paternos-41129833",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.644061",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "\u201cValix is in discussions with several potential partners to progress CytoLytix, including a major pharma\u201d. So, why is Mark, currently in California, continuing to promote the compound so actively both in the UK and overseas? While it\u2019s plausible a major pharma might seek exclusivity, the most realistic outcome is exclusive rights carved by territory, formulation, indication, or even species (human/veterinary)\u2014leaving room for multiple, parallel deals outside that scope. Indication splits are historically used when partners specialise in different therapeutic areas (eg ovarian only). Geographic exclusivity is even more common. The TrX/201 deal eventually failed when Mark attempted to remove Taiwan from the original LOI. The veterinary angle highlighted in recent webinars reinforces that CLX spans markets no single pharma can cover, making a multi partner licensing model far more realistic than a single global licence. There are numerous real world examples of multi partner licensing structures in biopharma: TERRITORY - Immunex (Enbrel) / initially Amgen \u2192 US & Canada rights, then Wyeth (later Pfizer) \u2192 Europe + Rest of World rights FORMULATION - Gilead (Tamiflu) / initially Roche \u2192 Oral formulation rights, then Hetero & Teva, \u2192 sublicenses for additional formulations INDICATION - AstraZeneca (Lynparza) / Merck \u2192 initially Ovarian cancer rights, then subsequently obtained licenses for breast and pancreatic cancers. Each example above shows one originator, no single-party lock in and multiple partners or deals to acquire different rights. With so many variables in play, it is increasingly clear that Valirx is preserving the same optionality for CytoLytix. Mark is still promoting CytoLytix because he is targeting several partners \u2013 not just one. Everything suggests CLX is being shaped as a multi deal platform, with the first handshake simply opening the monetisation cycle -",
          "sentiment": 0.5,
          "engagement": "357",
          "price_at_post": "0.385",
          "thread_title": "CLX - multi deal structure",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D1488F3A-09F4-41C4-B45B-AF908B85E267"
        },
        "ingested_at": "2026-01-22T21:09:47.830893+00:00"
      },
      {
        "event_id": "SOCIAL-Today2019-paternos-61932206",
        "event_type": "social_post",
        "date": "2026-01-22T21:09:41.643595",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "A lucrative VAL401 licensing deal was announced on 20/6/25: \u201c ValiRx will receive 576,000 ordinary shares in Ambrose with clinical and commercial milestone payments to be made to Valiseek totalling a value of up to \u00a316 million plus royalties.\u201d Valirx owns 54% of Valiseek. Ambrose has a pipeline consisting of just TWO products: VAL401 (pancreatic cancer) and Renzapride (cystic fibrosis), both currently at phase 2 clinical. Today, Ambrose announced two further additions to their already impressive team: Dr. Janette Thomas joins as Director of Manufacturing Operations and Wendy Richings-Barrow as Director of Regulatory Affairs. \u201cThese appointments reflect our continued focus on building a world class team to deliver solutions for patients with rare conditions with no approved treatments.\u201d The Ambrose team already had a strong backbone: Chairman, Toby Waterworth has been part of leadership teams in multiple life science companies that have generated close to $1 billion in shareholder value. CEO Dr Hazel Jones was formerly Chief of Staff for AstraZeneca\u2019s Oncology R&D Leadership Team. Chief of Staff Virag Stephens an ex PMO Director at AZN and has strong fundraising expertise while Mike Webb led departments of up to 150 scientists in a 30-year career at GSK. Dr. Nick Meyers has 30 years\u2019 experience as a Program Director. In 2024, Ambrose was acknowledged by its peers when it won the Best Startup Biotech Company Award at the prestigious OBN Awards in London. Since then, it has grown significantly and confirmed it is exploring potential Middle-East listings. One of the partners on their webpage is SEHA (Abu Dhabi Health Services), a subsidiary of Pure-Health the largest integrated healthcare network in the UAE. (total assets $13B). Another partner is listed as Aparito, part of the Eli Lilly group. As Ambrose strengthens its leadership and global partnerships, Valirx is strategically placed to benefit from every milestone achieved on the VAL401 journey.",
          "sentiment": 0.5,
          "engagement": "357",
          "price_at_post": "0.375",
          "thread_title": "The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-22T21:09:47.830870+00:00"
      },
      {
        "event_id": "SOCIAL-21Dec20250730-paternos--8653761",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.774062",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "LOL. Oh dear Porky, you obviously couldn\u2019t take watching the webinar (7 mins in): \u201c.... the runway extends into the second half of 2026\u201d. This is a no assumptions scenario: it doesn\u2019t allow for 0.5p or 1,3p warrants being exercised, it doesn\u2019t allow for further pending but as yet unconfirmed Inaphaea PDC / PredictRx income, it excludes tax credits & grants (and Mark has history here),  and above all \u2013 it excludes early partnering income which is potentially on the cards from the moment the VAL201 and CytoLytix patents are extended over the coming weeks. Mark E, the Grinch that destroyed Porky\u2019s Christmas.",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.395",
          "thread_title": "RE: Jokers with an agenda",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=1144128C-B9B2-4905-A92B-06B8098BA739"
        },
        "ingested_at": "2026-01-21T21:15:23.790159+00:00"
      },
      {
        "event_id": "SOCIAL-21Dec20250845-viera-26983359",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.773638",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "I\u2019m not bearish Val ..yet ! But ME promised Thx deal ..never happened . ME promised lab work be breaking even ..never happened ! Did you notice how he put aside 150k for Salaries ? That\u2019s 6 weeks worth !! What CEO depends on grants to pay salaries ?!! Sorry but that podcast was full of BS . We will have another year of \u00a32m losses with zero revenue . Yes the shares can still rally as the premiere Twitter rampers bought at 0.25p and are believing ME will do a deal . Ambrose has zero chance of a deal. So make sure you sell out by April as money will run out by June . This is a great trading stock. That\u2019s it as dilution every year kills long term investing here . Porky has absolutely nailed it here . Pater you keep getting diluted to oblivion . Rinse and repeat .",
          "sentiment": 0.0,
          "engagement": "1,549",
          "price_at_post": "0.395",
          "thread_title": "RE: Jokers with an agenda",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=1144128C-B9B2-4905-A92B-06B8098BA739"
        },
        "ingested_at": "2026-01-21T21:15:23.790140+00:00"
      },
      {
        "event_id": "SOCIAL-21Dec20250909-Uncanny-34044623",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.773195",
        "source": "LSE_CHAT",
        "data": {
          "author": "Uncanny",
          "content": "TBH I thought the update was excellent and you can see all the areas where ME is pushing on to monetise the assets plus the fact that the cash burn has reduced so significantly and now there is a clear runway up to H2 2026 is excellent. It\u2019s also appears and obviously he couldn\u2019t say in the presentation, that there are probably quite a few surprises in the next six months to which will help in terms of inflection points that will probably push this price way beyond the 0.5p warrant exercise but probably up to the 1p mark or perhaps even further who knows! NAI DYOR GLA",
          "sentiment": 0.0,
          "engagement": "3,307",
          "price_at_post": "0.395",
          "thread_title": "RE: Jokers with an agenda",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=1144128C-B9B2-4905-A92B-06B8098BA739"
        },
        "ingested_at": "2026-01-21T21:15:23.790122+00:00"
      },
      {
        "event_id": "SOCIAL-21Dec20250939-uxm484--3795058",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.772762",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "I think he is pushing for \u00a330 million plus upfront payment for CLX001 plus more milestones rather than an early deal without any further dilutions other than the warrants which are unlikely to be exercised until share price doubles from here. Once further cash comes in then the share price should go past 1p with any decent positivity before a deal takes this to the pennies. Medium upfront payment $110 million for preclinical/Ind compounds. Happy with 25/30 million plus 200 million plus milestones. Valirx to head back to \u00a350 million market cap seems very possible. Lots of catalysts, cash burn is under 1.5 million. No wonder he has invested so much.",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.395",
          "thread_title": "RE: Jokers with an agenda",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=1144128C-B9B2-4905-A92B-06B8098BA739"
        },
        "ingested_at": "2026-01-21T21:15:23.790095+00:00"
      },
      {
        "event_id": "SOCIAL-21Dec20251044-Porky9-55121686",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.772338",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Oh come on Stephen, you can't seriously believe that utter baloney surely? He is going to make \u00a3902k cover all his admin costs, bonuses and jollys abroad including Nov Salary, Dec Salary Jan Salary.... to June Salary and raise in July? In H2? Jeeze, Stephen talk is cheap we know but I want some of what you are smoking if you think that's reality.",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.395",
          "thread_title": "RE: Jokers with an agenda",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=1144128C-B9B2-4905-A92B-06B8098BA739"
        },
        "ingested_at": "2026-01-21T21:15:23.790077+00:00"
      },
      {
        "event_id": "SOCIAL-21Dec20251545-ratcliff-50749583",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.771908",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Simple mathematics - divide the amount raised by the amount per month needed to run the company gives you the length of time the funds will last. Then taken off that the time necessary to organise a raise, and spring at best is the result. Any talk of deals is just hope, not fact. And if the best hope is that 201 getting a revised patent is going to have big pharma knocking at the door with open cheque books, then they might as well stay up on Christmas Eve and ask Santa to join the board because he really will turn up cos he's really real.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.395",
          "thread_title": "RE: Jokers with an agenda",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=1144128C-B9B2-4905-A92B-06B8098BA739"
        },
        "ingested_at": "2026-01-21T21:15:23.790060+00:00"
      },
      {
        "event_id": "SOCIAL-21Dec20251730-paternos--1717810",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.771505",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Porky and Nick both clearly in denial mode, However, reality doesn\u2019t bend to fit a narrative just because it ruins all their forecasts. Like a pair of parrots, they keep repeating the same BS even when the CEO confirms the true situation. Using past management failures to deny current progress is basically the biotech version of flat earth theory \u2014 acknowledging past mistakes is fine but pretending that CEO Mark hasn\u2019t rebuilt the entire operating model is like ignoring the modern map because you prefer the old one with sea monsters on it. The runway guidance is the floor, not the forecast. The CEO has given a runway into H2 based on a stripped back, bare-bones, pessimistic model but because it doesn\u2019t fit their agenda, they are both sulking. As the RNS\u2019s drop over the coming months it is likely to be a highly traumatic time for Porky. Not so much Nick, as he will certainly join the buyers - he won\u2019t let the opportunity pass by, even if he doesn\u2019t admit it. The company today is still being valued on what it used to be, not its true value. That will be recognised over the coming months as the SP continues to climb.",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.395",
          "thread_title": "RE: Jokers with an agenda",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=1144128C-B9B2-4905-A92B-06B8098BA739"
        },
        "ingested_at": "2026-01-21T21:15:23.790041+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250448-Porky9--3527791",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.771069",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@paternostpauper who said anything about \"Past\" management? To be clear im referring to \"Current\" managent. To clarify: Two raises back ME was adamant that to quote \"Labs would break even that year\" it didn't. Further, it wasn't like it was a small miss, it didn't invoice a bloody thing, it delivered zilch financial revenue. ME was adamant that THX was doing the 201 deal, it was plainly obvious it was never going to happen, but he still ran with it, still convincing investors to chuck more cash at this to give it more tine for THX to come through. Sorry but that was also really poor judgement imo. \"Runway guidance\" is \"the floor\" dont be ridiculous, its an overly optimistic fantasy view that's not remotely realistic. And as for valuation, I would say its materially overvalued, in fact its currently enjoying a dead cat bounce at 80% premium to the placing, yet only has a few weeks of cash runway left before an emergency further raise required to keep the lights on. Who are you kidding? Closer you get to the cash running out the more the SP will reduce in line with the raising requirement.",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.395",
          "thread_title": "RE: Jokers with an agenda",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=1144128C-B9B2-4905-A92B-06B8098BA739"
        },
        "ingested_at": "2026-01-21T21:15:23.790024+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250655-uxm484-75300559",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.770639",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Brilliant presentation. Nailed it. Deals in 2026.\ud83d\udc4c. At 3M will not take much to lift this. Plenty of news to come. Mark was just employed 1 year ago. Takes time to build contacts and get things moving. He is now doing that at pace. He was decisive with THX after giving them a chance. Expecting news with some key value inflection milestones in the coming weeks backed with a possible deal that should also get  some HNW clients in and into the pennies. 3 Million valuation when the medium upfront payment is $110 million for pre clinical assets. Numerous other catalysts. Nice cash runway with possible grant funding, revenues from other sources coming. Cash burn tiny for a biotech.",
          "sentiment": 0.5,
          "engagement": "1,007",
          "price_at_post": "0.395",
          "thread_title": "RE: Jokers with an agenda",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=1144128C-B9B2-4905-A92B-06B8098BA739"
        },
        "ingested_at": "2026-01-21T21:15:23.790006+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250947-VikR--7958469",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.770200",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "Having watched the update on Friday I am glad I re topped here again last week, I have taken bigger risks then this on AIM so a fairly comfortable hold for me now to see the milestones come to fruition. I hope for the benefit of the patient population we can get life changing treatments a step closer to production. Mr Eccleston certainly seems to be very active on many fronts so  ten out of ten for effort on his part. Hopefully alongside the money he has invested here our  mutual interests are well aligned.",
          "sentiment": 0.5,
          "engagement": "934",
          "price_at_post": "0.395",
          "thread_title": "ValiRx at a pivotal turning point",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=03601821-9A7C-4FC7-ACA1-AFC9175EBFE9"
        },
        "ingested_at": "2026-01-21T21:15:23.789989+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251016-Notpotal-41319946",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.769783",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "\u201cIntention is move top 10 forward rapidly in 2026 \u2026 milestone is to file key patents and partner the lead asset\u201d. Median upfront deal size for phase 2 assets up from $150m in 2024 to $775 in 2025. \u201c\u2026. our repurposing assets already have phase 1 clinical data\u201d. NB - This is a joint exercise with Dominion so on a $0.5 Bn deal, Valirx would only receive $250m. At least it would keep the wolves from the door. \ud83d\ude00",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.395",
          "thread_title": "Dominion 3k program",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=052CB782-615D-406A-90A4-6049666203B0"
        },
        "ingested_at": "2026-01-21T21:15:23.789971+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251021-Porky9--4578437",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.769360",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Some quality ramping to try and suck in new money for the brokers and traders to sell into but, whilst I posted last week that you can clearly fool some of the people, hence the dead cat bounce, I actually think that pool of newbies to suck in is fairly thin on the ground, I mean it must be hard to find anyone on AiM that hasn't already been either a) shown it multiple times by multiple brokers b) been shafted already and left holding a position they will never recover from or c) stupid enough to chuck cash at this without doing any basic DD.",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.395",
          "thread_title": "RE: ValiRx at a pivotal turning point",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=03601821-9A7C-4FC7-ACA1-AFC9175EBFE9"
        },
        "ingested_at": "2026-01-21T21:15:23.789954+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251338-uxm484--1758196",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.768947",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Easy to see why the CEO has invested over \u00a3250K and is confident of a deal in 2026. Medium upfront payments of over $110 million dollars for preclinical compounds. This could be up with the best with its pan cancer potential. A synthetic peptide drug formulated into nanoparticles. Designed to destroy cancer cells with high specificity and minimal side effects compared to standard chemotherapy. It targets the tumour microenvironment, not just a single genetic marker, meaning it could be effective across multiple cancer subtypes. Rather than relying on targeting a single gene mutation or receptor, CLX001: Uses a cytolytic peptide to destroy cancer cells directly. This mechanism could work across different cancer types (pan-cancer potential), making it a broader opportunity. Discovery & Development Some scientific commentary suggests its design also enhances immune activation by releasing tumour antigens, which could help stimulate longer-lasting anti-tumour responses \u2014 a major plus in oncology drug design.",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.39",
          "thread_title": "CLX001- A world class novel compound",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=720E21C9-3C3E-40D3-A8FE-87A5C7A2935A"
        },
        "ingested_at": "2026-01-21T21:15:23.789936+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251341-VikR--6395423",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.768502",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "Candid conversation with the CEO some very interesting points and insight https://www.youtube.com/watch?v=mNwn196rPAM&t=1s",
          "sentiment": 0.5,
          "engagement": "934",
          "price_at_post": "0.39",
          "thread_title": "RE: ValiRx at a pivotal turning point",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=03601821-9A7C-4FC7-ACA1-AFC9175EBFE9"
        },
        "ingested_at": "2026-01-21T21:15:23.789919+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251703-RayPoint--5574445",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.768077",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Uxm \"Medium upfront payments of over $110 million dollars for preclinical compounds.\" Just as a matter of interest, where did you get the figure of over $110 million?",
          "sentiment": 0.0,
          "engagement": "5,058",
          "price_at_post": "0.38",
          "thread_title": "RE: CLX001- A world class novel compound",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=720E21C9-3C3E-40D3-A8FE-87A5C7A2935A"
        },
        "ingested_at": "2026-01-21T21:15:23.789901+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251729-Porky9-55950083",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.767661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Where did he get the figure from @Ray ? Well its very top secret, so dont tell anyone else but, I have it on very good authority that that it was told to him by Mr Roarke. Not long after a little chap going by the name of Tattoo for some odd reason kept shouting \"de plane, de plane\" and well the rest was history. Pork's x",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.38",
          "thread_title": "RE: CLX001- A world class novel compound",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=720E21C9-3C3E-40D3-A8FE-87A5C7A2935A"
        },
        "ingested_at": "2026-01-21T21:15:23.789883+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251826-desamax--5400427",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.767238",
        "source": "LSE_CHAT",
        "data": {
          "author": "desamax",
          "content": "Anyone know who he was referring to who threw his toys out the pram thinking he could upset the whole apple cart, just to get his own way? What a W\u2693\ufe0f",
          "sentiment": 0.0,
          "engagement": "2,190",
          "price_at_post": "0.38",
          "thread_title": "RE: ValiRx at a pivotal turning point",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=03601821-9A7C-4FC7-ACA1-AFC9175EBFE9"
        },
        "ingested_at": "2026-01-21T21:15:23.789865+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251938-uxm484--5460915",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.766823",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Everything is in the presentation. 2025 figures. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.5,
          "engagement": "1,007",
          "price_at_post": "0.38",
          "thread_title": "RE: CLX001- A world class novel compound",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=720E21C9-3C3E-40D3-A8FE-87A5C7A2935A"
        },
        "ingested_at": "2026-01-21T21:15:23.789847+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250839-viera-12288451",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.766408",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Afzal ramping hourly on Twitter . Does he know cash runway to April and maybe May if they get a grant . Not normally an investable opportunity. A trade yes BUT where\u2019s the revenue coming from ? 20 years of \u00a32m losses I just can\u2019t see a rally above 0.5p and no way am i in whilst being diluted again. So trade or buy but don\u2019t hold unless you like dilution !!",
          "sentiment": 0.0,
          "engagement": "1,549",
          "price_at_post": "0.375",
          "thread_title": "RE: CLX001- A world class novel compound",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=720E21C9-3C3E-40D3-A8FE-87A5C7A2935A"
        },
        "ingested_at": "2026-01-21T21:15:23.789830+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251051-Minnissa-86228143",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.765971",
        "source": "LSE_CHAT",
        "data": {
          "author": "Minnissage",
          "content": "With respect Nic that\u2019s not strictly accurate . A successful grant application could see Val through the whole of 2026, depending on the size of the grant.",
          "sentiment": 0.0,
          "engagement": "553",
          "price_at_post": "0.36",
          "thread_title": "RE: CLX001- A world class novel compound",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=720E21C9-3C3E-40D3-A8FE-87A5C7A2935A"
        },
        "ingested_at": "2026-01-21T21:15:23.789812+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251100-paternos--8630246",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.765558",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Nick\u2019s rule: when the CEO confirms the minimum cash runway into H2 but it doesn\u2019t suit the agenda, Nick is allowed to shorten it as he sees fit. Mark E\u2019s reality: the runway guidance is the absolute floor, not the forecast and excludes grants, further Inaphaea income, early partnership up-front payments, tax credits and the 0.5p / 1.3p warrants being exercised. If you are going to tell fairy stories Nick, remember to include the ending: \u201cAnd they all lived happily ever after\u201d.",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.36",
          "thread_title": "RE: CLX001- A world class novel compound",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=720E21C9-3C3E-40D3-A8FE-87A5C7A2935A"
        },
        "ingested_at": "2026-01-21T21:15:23.789794+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251322-Porky9-92161924",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.765133",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@Paternostpauper I suspect you work there or are connected and hence why you have a vested interest in the gravy train continuing for evermore but for all other investors / punters the situation is very different. They don\u2019t want to put up their hard earned cash if short term heavy dilution is practically bolted on or worse lose the lot if the raise doesn't happen and its administration. So lets bury a few of your posting myths shall we:- 1.The runway guidance is NOT the \u201cabsolute floor\u201d it can't possibly be and that\u2019s simply because there is NOT enough cash to maintain the current excessive pay levels, admin costs and bonus payments beyond the end of March without other cash landing. It is that simple - it is NOT a given. This is assuming that cash burn does not get worse than it is already. It could and that is also a risk factor. 2. Grants - Yes he could try and apply for grants, no guarantees. In the last 20 years they have secured some grants, I think the largest was about \u00a3200k so it is possible to extend the runway by circa another month or so IF they get one. With the mass of biotechs all in need of free money, join the queue. You can\u2019t build a business model on hoping and praying that grant money will land to delay a placing, good grief. 3. Inalpha Income. Now you really are trying to make us laugh. They don\u2019t know what an invoice is. There is no demand. I think the best they did was \u00a310k once, we are talking beer money, They have no sales and marketing other than a BDM with multiple jobs that hasn't sold a thing in years - so where are the sales going to generate from exactly? 4. Licensing Partnership upfront money - Have you been with Mr Roarke again? The DD alone is well beyond the cash runway and the peptides a) have no interest from anyone of any substance and b) not even close to being positioned so you posting utter BS and c) the days of big upfronts are practically over, it has to be something really special for that to happen they are almost always milestone led and no upfront money. BUT as I say they have nothing here even close to being ready in that position and certainly not in the timeline before the cash runway is out. 5. Tax credits - possibly a small tax credit against last year's R&D spend however HMRC rules have significantly tightened in this area and i would say its touch and go but lets say they get one, whats that, another month's money at best, and again you are hoping it would land before the placing? Again no guarantees. 6. Exercising Warrants - Nobody in their right mind would want to buy more stock at inflated price knowing a) it will cause them immediate dilution b) stock will shortly come on the market in the placing at an even better price and c) unless they can buy to sell and flip it for profit. The warrants are only any good if you can keep them in the bottom draw and some miracle licensing deal of substance landed where it would be worth you cashing them in for a dec",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.36",
          "thread_title": "RE: CLX001- A world class novel compound",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=720E21C9-3C3E-40D3-A8FE-87A5C7A2935A"
        },
        "ingested_at": "2026-01-21T21:15:23.789777+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251323-Porky9-33988730",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.764663",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "7. The warrants are only any good if you can keep them in the bottom draw and some miracle licensing deal of substance landed where it would be worth you cashing them in for a decent multiple. If the SP rallied to .50 there is absolutely no guarantee anyone would buy more stock cashing in the warrant. It's a total fantasy to think that and shows how naive they are to think that is something to cling to. Sorry but the most likely way for ME to get more cash in to keep lifestyles going will be via the next placing circa end of the tax year - this is NOT an investment its a high risk punt at best with short term dilution highly likely - those are the risks. The question will be; can ME get yet another placing away? Probably, it's the one thing this company is absolutely brilliant at. Pork's",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.36",
          "thread_title": "RE: CLX001- A world class novel compound",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=720E21C9-3C3E-40D3-A8FE-87A5C7A2935A"
        },
        "ingested_at": "2026-01-21T21:15:23.789758+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251444-ratcliff--2505513",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.764234",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Good posts Porky - the warrant prices are being pushed as a sort of trigger which will automatically generate cash the moment the share price passes a set threshold, and nothing could be further from the truth. The cash burn and rate at which the last placing will be used up is being ignored - if it's in an RNS (like the cash burn and amount raised are) then it has to be taken at face value. Your prediction for the next raise holds water (as have all your previous forecasts!) and none of the fan club acknowledge the time it will take actually to make all the arrangements to get a placing under way. ME won't just ring up a broker on a Monday morning and say 'we need a placing tomorrow.' I imagine we can expect the fluff and bluster RNS trail to start in late February to push things up, but looking at today's price movement it'll need some effort.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.35",
          "thread_title": "RE: CLX001- A world class novel compound",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=720E21C9-3C3E-40D3-A8FE-87A5C7A2935A"
        },
        "ingested_at": "2026-01-21T21:15:23.789740+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251706-uxm484-50132451",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:23.763781",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Reviewing the posting history against RNS, it appears the pig has consistently gotten the timing of every raise wrong over the past five years, each time overstating it by roughly three to four months sometimes longer. So much for forecasts.",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.35",
          "thread_title": "RE: CLX001- A world class novel compound",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=720E21C9-3C3E-40D3-A8FE-87A5C7A2935A"
        },
        "ingested_at": "2026-01-21T21:15:23.789722+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251715-uxm484--7096770",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.617032",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Sorry, Understated not over.",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.35",
          "thread_title": "RE: CLX001- A world class novel compound",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=720E21C9-3C3E-40D3-A8FE-87A5C7A2935A"
        },
        "ingested_at": "2026-01-21T21:15:23.789704+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251720-Luckybob--1278362",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.616622",
        "source": "LSE_CHAT",
        "data": {
          "author": "Luckybob23",
          "content": "Even when he was Vals biggest ramper? That's weird.",
          "sentiment": 0.0,
          "engagement": "4,025",
          "price_at_post": "0.35",
          "thread_title": "RE: CLX001- A world class novel compound",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=720E21C9-3C3E-40D3-A8FE-87A5C7A2935A"
        },
        "ingested_at": "2026-01-21T21:15:23.789687+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251721-ratcliff-41059793",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.616212",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Maybe not date-perfect with the timing, but he's correctly predicted a raise will take place unlike some here who trumpet about multi million pound deals or funding being 'imminent', and then vanish for a few weeks after the raise, wait till the dust settles and then churn out the same stuff again and again. Surely some of the phrases trotted out must be near copyright expiry by now...",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.35",
          "thread_title": "RE: CLX001- A world class novel compound",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=720E21C9-3C3E-40D3-A8FE-87A5C7A2935A"
        },
        "ingested_at": "2026-01-21T21:15:23.789669+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251814-paternos--5105836",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.615793",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "I\u2019ve finally conceded defeat with Porky. His venom towards Val will not permit reasoning or commonsense. Back into the bin he goes. Time to wish everyone a merry Christmas. I\u2019ll be back when the RNS start to flow.",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.35",
          "thread_title": "Merry Xmas & a prosperous 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=E4280D37-33A8-46E0-832E-C3CF294D2A96"
        },
        "ingested_at": "2026-01-21T21:15:23.789651+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251105-Uncanny--8680749",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.615381",
        "source": "LSE_CHAT",
        "data": {
          "author": "Uncanny",
          "content": "Have a wonderful Xmas break everyone! Best wishes S.",
          "sentiment": 0.0,
          "engagement": "3,307",
          "price_at_post": "0.35",
          "thread_title": "RE: Merry Xmas & a prosperous 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=E4280D37-33A8-46E0-832E-C3CF294D2A96"
        },
        "ingested_at": "2026-01-21T21:15:23.789633+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20252037-oldbaldy-82954783",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.614955",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldbaldy",
          "content": "Happy Christmas all..",
          "sentiment": 0.0,
          "engagement": "3,704",
          "price_at_post": "0.35",
          "thread_title": "Gloves off\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=101654E0-A902-4633-8E17-2659C51B89C0"
        },
        "ingested_at": "2026-01-21T21:15:23.789615+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20252159-Luckybob-22842442",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.614553",
        "source": "LSE_CHAT",
        "data": {
          "author": "Luckybob23",
          "content": "Merry Christmas OB",
          "sentiment": 0.0,
          "engagement": "4,025",
          "price_at_post": "0.35",
          "thread_title": "RE: Gloves off\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=101654E0-A902-4633-8E17-2659C51B89C0"
        },
        "ingested_at": "2026-01-21T21:15:23.789597+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251207-viera--1395659",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.614140",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Merry Xmas all. Let\u2019s hope Mark can cut costs by another \u00a3200,000 and do some kind of deal pre April that brings in some revenue. Good luck to all shareholders . Happy new year x",
          "sentiment": 0.0,
          "engagement": "1,549",
          "price_at_post": "0.35",
          "thread_title": "RE: Gloves off\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=101654E0-A902-4633-8E17-2659C51B89C0"
        },
        "ingested_at": "2026-01-21T21:15:23.789579+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20251634-mikee_p--7605138",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.613706",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "Hence the fizzle in SP",
          "sentiment": 0.0,
          "engagement": "1,888",
          "price_at_post": "0.335",
          "thread_title": "Ramping stops",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=CA1E32F4-46E6-483A-9517-06D899E7140D"
        },
        "ingested_at": "2026-01-21T21:15:23.789561+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20252352-Uncanny--8334485",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.613299",
        "source": "LSE_CHAT",
        "data": {
          "author": "Uncanny",
          "content": "Are we heading sub .30 or just a blip?",
          "sentiment": 0.0,
          "engagement": "3,307",
          "price_at_post": "0.335",
          "thread_title": "RE: Ramping stops",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=CA1E32F4-46E6-483A-9517-06D899E7140D"
        },
        "ingested_at": "2026-01-21T21:15:23.789542+00:00"
      },
      {
        "event_id": "SOCIAL-30Dec20251751-desamax-16165425",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.612881",
        "source": "LSE_CHAT",
        "data": {
          "author": "desamax",
          "content": "\u201cSub 30\u201d it don\u2019t look like it, there appears to be a nice steady rise into the new year in anticipation of the promised news. GLA",
          "sentiment": 0.0,
          "engagement": "2,190",
          "price_at_post": "0.335",
          "thread_title": "RE: Ramping stops",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=CA1E32F4-46E6-483A-9517-06D899E7140D"
        },
        "ingested_at": "2026-01-21T21:15:23.789525+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20260925-paternos-71090535",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.612469",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "\u2022\tRecent rise from 0.23p\u21920.37p in 2 weeks on zero newsflow, ahead of many RNS updates now due \u2022\tHit 50p+ highs in 2021 when only ONE key asset in play and a largely uninvested Board. c14,000% above current SP \u2022\tSP sits near historic lows despite now holding the most extensive and marketable pipeline in Val\u2019s history \u2022\tCEO, Mark bought 7% of the company - a rare alignment of insider knowledge and shareholder commitment \u2022\tMark in webinar: \u201cBig pharma are facing a patent cliff by 2030 so seeking to refresh their pipelines\u201d \u2022\tMany credible reports highlight major 2025\u201330 loss of patent exclusivity forcing pharma to source new assets. \u2022\tVal focus on cancer indications with huge annual markets: triple neg breast ($1.5Bn), prostate ($11.3Bn) & ovarian ($2.5Bn) \u2022\tCLX, co-invented by a senior AZN scientist and a leading Kings College prof - serious scientific pedigree \u2022\tDiscussions with an unnamed major pharma re CLX partnering now ongoing 6+ months, suggests clear progress \u2022\tMultiple CLX partnership deals potential with licensing determined by formulation, indication & geographic area. \u2022\tAmbrose/401 licence- Val receive 5.7k Ambrose shares with clinical & milestone payments up to \u00a316m & 4 yr target \u2022\tInaphaea are paid upfront for preclinical validation re 401, plus will benefit from any Ambrose funding sourced by Val \u2022\tCash runway confirmed into H2 which excludes R&D tax credits, additional revenue and UK/ international grants \u2022\tRevised grant guidelines now prioritise oncology, NAMs & academic/SME collaborations \u2013 essentially, Val\u2019s DNA. \u2022\tTwinEdge patient avatars allow faster, human-relevant in-silico testing. Mark: \u201ca hot topic for grants\u201d. \u2022\tWarrants pending @ 0.50p and 1.30p, actioning of either would significantly boost Val\u2019s coffers. \u2022\tInaphaea revenues starting to flow with early income from the unique PredictRx platform expected to follow. \u2022\tPredictRx uses patient derived tumour cells to reveal the most effective chemotherapy options for that individual. \u2022\tBiobank of 476 PDCs /66 indications. Nott\u2019m NHS Trust contract so ongoing supply. \u00a310k per PDC upon commercialisation \u2022\tVAL201 \u2013 target is to dilute the asset, not Val PLC \u2013 a 3rd party takes to clinical for a % share. \u2022\tDominion 3k repurposing project \u2013 identified 200 FDA-approved non-oncology drugs, all showing anti-cancer activity \u2022\tMark \u201cparticularly excited\u201d about the top 10 \u201clow-hanging fruit\u201d being fast-tracked - all 3k have phase 1 clinical data \u2022\tMilestone is to partner primary repurposing candidate this year. Median upfront deal for phase 2 assets now \u00a3775m \u2022\tOther imminent RNS: new patents, CLX formulation, StingRay, Dundee (\u201cprogressing well\u201d), et al \u2022\tWebinar - 2 more evaluations & SPV \u201cwith very mature discussions\u201d. SPVs often ring fenced & funded independently \u2022\tAdvisory Board manned with industry experts focused solely on compounds/activities to be monetise",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.39",
          "thread_title": "Microcap of the Year 2026?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=484234E8-7807-44F2-9DE0-24AD533B59EB"
        },
        "ingested_at": "2026-01-21T21:15:23.789506+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20260927-paternos--3876479",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.611943",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "\u2022\tAdvisory Board manned with industry experts focused solely on compounds/activities to be monetised early \u2022\tAll the above achieved while reducing annual costs by \u00a3200k+ GLA, DYOR ^^^^^^^^^^^^^^ Still unsure whether the SP is likely to rise? Consider this - the infamous Nick Slater (Viera), despite many other holdings, has devoted every one of his last 54 LSE posts to warn just how bad Val is! \ud83e\udd23\ud83e\udd23\ud83e\udd23 Wot a guy! \ud83e\udd23\ud83e\udd23\ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.39",
          "thread_title": "RE: Microcap of the Year 2026?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=484234E8-7807-44F2-9DE0-24AD533B59EB"
        },
        "ingested_at": "2026-01-21T21:15:23.789489+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261402-Porky9-24385604",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.611507",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Would you like me to list 20 points why this dead cat bounce wont last and why the discounted placing will hit this and dilute any remaining holders to oblivion. I thought you were going to refrain from ramping this. Same old, same old.",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.40",
          "thread_title": "RE: Microcap of the Year 2026?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=484234E8-7807-44F2-9DE0-24AD533B59EB"
        },
        "ingested_at": "2026-01-21T21:15:23.789471+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261405-Porky9-40175503",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.611087",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "And as for rise @PP - as much as you desperately want one, the chance of the placing, thats if he can get it away yet again, landing at anything other than a 70% discount will be nothing short of a miricle.  i'm betting on .15 to .20 max.",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.40",
          "thread_title": "RE: Microcap of the Year 2026?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=484234E8-7807-44F2-9DE0-24AD533B59EB"
        },
        "ingested_at": "2026-01-21T21:15:23.789453+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261459-uxm484-56506316",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.610677",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "At least PP's posts are factual and based on the current situation not history of what other CEOs did. Expecting some decent news this month. 1.0- 1.2p short term target in the next 6 weeks. But, and as always has been, whether Val can deliver is a question of when not if. MCap just canNOT stay at \u00a32m especially with so much newsflow due in the coming weeks. As for placing we are happy to consider it in July 2026 onwards but I suspect it will not be needed. At the moment no risk of any placing.",
          "sentiment": 0.5,
          "engagement": "1,007",
          "price_at_post": "0.40",
          "thread_title": "RE: Microcap of the Year 2026?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=484234E8-7807-44F2-9DE0-24AD533B59EB"
        },
        "ingested_at": "2026-01-21T21:15:23.789436+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261512-ratcliff-67402627",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.610260",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "'At the moment no risk of any placing' - Well it is a whole 30 working days since the last one, so even in 'Val World' another one would be a little surprising at this point. But I imagine discussions for the next one will be starting around the end of February if not sooner.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.40",
          "thread_title": "RE: Microcap of the Year 2026?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=484234E8-7807-44F2-9DE0-24AD533B59EB"
        },
        "ingested_at": "2026-01-21T21:15:23.789418+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261537-uxm484-86331107",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.609836",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": ":yawn:",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.40",
          "thread_title": "RE: Microcap of the Year 2026?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=484234E8-7807-44F2-9DE0-24AD533B59EB"
        },
        "ingested_at": "2026-01-21T21:15:23.789400+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261555-viera--5629727",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.609427",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "I would suggest you never buy any company on Aim with less than 6 months cash runway unless it\u2019s a trade. Val have probably 4 months runway without a grant. Worrying to say the least. I\u2019m sure ME will be begging Paternoster to keep posting his BS . I\u2019ve always said this may rally to mid 0.4s but be so careful holding for long as more dilution is inevitable as it has been for over 20 years now. Good luck all ,hope you all make loads of money here x",
          "sentiment": 0.0,
          "engagement": "1,549",
          "price_at_post": "0.40",
          "thread_title": "RE: Microcap of the Year 2026?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=484234E8-7807-44F2-9DE0-24AD533B59EB"
        },
        "ingested_at": "2026-01-21T21:15:23.789382+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261833-VikR--8051485",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.608990",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "Can\u2019t knock the effort and enthusiasm of current CEO. Excellent risk to reward at this SP \u2018And so it begins - 2026 - a transformational year for VALIRX PLC. Looking forward to JPM as the schedule fills up. Those who know it will know it\u2019s a brutal meeting but a great opportunity to pitch our SPVs. Particularly excited about our 3k repurposing program given it can deliver \u201ccloser to clinic\u201d assets in a faster, ethical approach which really leverages Inaphaea BioLabs\u2019s New Approach Methadologies including our patient derived cell Models and our Digital Twin partnership with TwinEdge Bioscience. We\u2019ll also be pitching Val201 2.0 as work on the new formulation begins this month as we expect to receive the first new format peptides. Finally things another great opportunity to  showcase Cytolytix and have meetings lined up with our partner Omios Biologics so looking forward to catching up with Aldo Pourchet. We\u2019ll be at the partnering meetings (search a ValiRx on the partneringOne platform) and also can meet outside the Biotech showcase for anyone circling the event simple feel free to ping me directly.\u2019",
          "sentiment": 0.5,
          "engagement": "934",
          "price_at_post": "0.40",
          "thread_title": "LinkedIN from the CEO",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=CDFE68FB-A4E6-4475-B474-90701094B4DC"
        },
        "ingested_at": "2026-01-21T21:15:23.789364+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261103-believei-14127040",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.608541",
        "source": "LSE_CHAT",
        "data": {
          "author": "believeinit",
          "content": "Looking good for a nice rise here.",
          "sentiment": 0.0,
          "engagement": "149",
          "price_at_post": "0.41",
          "thread_title": "RE: LinkedIN from the CEO",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=CDFE68FB-A4E6-4475-B474-90701094B4DC"
        },
        "ingested_at": "2026-01-21T21:15:23.789347+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261228-Ironmigh-29220833",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.608132",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ironmighty",
          "content": "@Uncanny , pretty sure it was just a blip \ud83d\ude09",
          "sentiment": 0.0,
          "engagement": "553",
          "price_at_post": "0.435",
          "thread_title": "RE: Ramping stops",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=CA1E32F4-46E6-483A-9517-06D899E7140D"
        },
        "ingested_at": "2026-01-21T21:15:23.789328+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261515-Uncanny--8440061",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.607705",
        "source": "LSE_CHAT",
        "data": {
          "author": "Uncanny",
          "content": "Jury still out TBH Still have a nice chunky eight figure Holding so obviously happy, but not sure if this has been driven by traders in which case profit-taking will happen, or whether it is holders in which case the price will consolidate. GLA NAI DYOR",
          "sentiment": 0.0,
          "engagement": "3,307",
          "price_at_post": "0.42",
          "thread_title": "RE: Ramping stops",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=CA1E32F4-46E6-483A-9517-06D899E7140D"
        },
        "ingested_at": "2026-01-21T21:15:23.789311+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261659-Porky9-26122199",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.607281",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@Stephen If you are genuinely holding that and not derisked it you are a blithering idiot - you are about to be diluted to oblivion there is no alternative because its not possible with DD time alone to get a licensing deal that would result in cash upfront even it it were possible, so you are in effect a sitting duck. Why do it to yourself? you know exactly how this game is played by now, good grief you have seen it enough times now surely...????? Enjoy the dead cat bounce with trades but dont get taken in by the ramping. Cash is king.",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.42",
          "thread_title": "RE: Ramping stops",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=CA1E32F4-46E6-483A-9517-06D899E7140D"
        },
        "ingested_at": "2026-01-21T21:15:23.789293+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261739-uxm484--4075314",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:20.606825",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.42",
          "thread_title": "RE: Ramping stops",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=CA1E32F4-46E6-483A-9517-06D899E7140D"
        },
        "ingested_at": "2026-01-21T21:15:23.789275+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261751-Uncanny-16657435",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.355526",
        "source": "LSE_CHAT",
        "data": {
          "author": "Uncanny",
          "content": "\u2018Blithering idiot\u2019\u2026. thanks Porky \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "3,307",
          "price_at_post": "0.42",
          "thread_title": "RE: Ramping stops",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=CA1E32F4-46E6-483A-9517-06D899E7140D"
        },
        "ingested_at": "2026-01-21T21:15:23.789257+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261829-RayPoint-70364954",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.355091",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "As I understand it, CLX is not even a product yet since a formulation has not been decided upon. As per ME's recent presentation, products are developed as IND-ready before a deal is sought. So the vital question is \"how long before CLX is IND-ready?\". That's what you guys should be asking ME.",
          "sentiment": 0.0,
          "engagement": "5,058",
          "price_at_post": "0.42",
          "thread_title": "RE: Ramping stops",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=CA1E32F4-46E6-483A-9517-06D899E7140D"
        },
        "ingested_at": "2026-01-21T21:15:23.789239+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261907-uxm484--7884071",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.354681",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "The assessment of formulation options for CLX001 has progressed during Q1 2024, with the lead formulation now demonstrated to have activity against cancer cells.",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.42",
          "thread_title": "RE: Ramping stops",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=CA1E32F4-46E6-483A-9517-06D899E7140D"
        },
        "ingested_at": "2026-01-21T21:15:23.789221+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261945-RayPoint--3076833",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.354275",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "I do wish they would publish pre-clinical results",
          "sentiment": 0.0,
          "engagement": "5,058",
          "price_at_post": "0.42",
          "thread_title": "RE: Ramping stops",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=CA1E32F4-46E6-483A-9517-06D899E7140D"
        },
        "ingested_at": "2026-01-21T21:15:23.789203+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20262106-Notpotal-62092030",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.353857",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Heartbreaking times for the perpetual doom merchants on here. Imagine spending the last 4 years posting day and night of Val\u2019s demise \u2026. only for the new CEO to stroll in, tidy up the mess, and transform the company in just 16 months. Val is now positioned to excel with a glut of news imminent over the coming months. Many LT holders have savoured the progress and taken advantage of rock-bottom SPs to bring averages back into kilter. Funny how today\u2019s reality keeps overruling the history lesson brigade. While some cut and paste merchants just recycle the same gloomy monologue, the company\u2019s CEO and main shareholder watches in amusement as he finalises the first of a stream of RNSs. It must be quite disconcerting. Imagine insisting the house is on fire and will need to be demolished, only for the fire brigade to show up, check the place over, and announce someone has simply burnt the toast. And now\u2014just as the smoke clears\u2014someone tidies a sofa cushion and finds yesterday\u2019s winning lottery ticket. A bit like how it feels being a Valirx holder under Mark\u2019s regime.",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.42",
          "thread_title": "RE: Microcap of the Year 2026?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=484234E8-7807-44F2-9DE0-24AD533B59EB"
        },
        "ingested_at": "2026-01-21T21:15:23.789185+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20262130-viera--7284011",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.353433",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "\u201c only for the new CEO to stroll in, tidy up the mess, and transform the company in just 16 months.\u201d Tidy up the mess by paying a non BOD non revenue producing BDM with 2 paid jobs \u00a3100,000!! Transform the company by diluting shareholders  at 0.6p and 0.25p having been made CEO at 1.3p !! And now he\u2019s dependent on twitter gang ramping Val to sell out whilst no revenue or decent RNS are generated !! It\u2019s a shambles Notgotalot.",
          "sentiment": 0.0,
          "engagement": "1,549",
          "price_at_post": "0.42",
          "thread_title": "RE: Microcap of the Year 2026?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=484234E8-7807-44F2-9DE0-24AD533B59EB"
        },
        "ingested_at": "2026-01-21T21:15:23.789167+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20262210-Notpotal--9119131",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.352991",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Nick , get over it \u2013 Mark Treharne is going nowhere. Mark E has spent 16 months assembling his Dream Team and I\u2019m fairly sure the rants of a bitter ex-holder won\u2019t cause either of them to lose any sleep whatsoever. Funny how you have the gall to knock Twitter ramping when not long ago you threw your dummy out of the pram because your \u2018followers\u2019 dropped below 600 or so. \ud83d\ude02",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.42",
          "thread_title": "RE: Microcap of the Year 2026?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=484234E8-7807-44F2-9DE0-24AD533B59EB"
        },
        "ingested_at": "2026-01-21T21:15:23.789149+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20262226-viera--8126891",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.352581",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Made me smile ! Only cos I\u2019m an attention seeker : ) Night night x",
          "sentiment": 0.0,
          "engagement": "1,549",
          "price_at_post": "0.42",
          "thread_title": "RE: Microcap of the Year 2026?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=484234E8-7807-44F2-9DE0-24AD533B59EB"
        },
        "ingested_at": "2026-01-21T21:15:23.789131+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20262227-viera-85600625",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.352167",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Btw my dream team is Adam and Adrian and Kevin A You backed the wrong team in 2 x Mark ! 1.3p to 0.4p! Good luck m8 ,be lucky xxx",
          "sentiment": 0.0,
          "engagement": "1,549",
          "price_at_post": "0.42",
          "thread_title": "RE: Microcap of the Year 2026?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=484234E8-7807-44F2-9DE0-24AD533B59EB"
        },
        "ingested_at": "2026-01-21T21:15:23.789112+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20260906-Uncanny-53356437",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.351741",
        "source": "LSE_CHAT",
        "data": {
          "author": "Uncanny",
          "content": "Bubbling up nicely \ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "3,307",
          "price_at_post": "0.445",
          "thread_title": "RE: Microcap of the Year 2026?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=484234E8-7807-44F2-9DE0-24AD533B59EB"
        },
        "ingested_at": "2026-01-21T21:15:23.789085+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20260914-paternos--8871472",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.351328",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Many of Mark\u2019s presentations have highlighted the potential of grant-funding, the 14/10/25 RNS confirming a \u00a3250k award a prime example. The Inaphaea RNS (18/9/25), re the Dominion repurposing top 10, confirmed \u201cinitial commercial discussions with potential licensees as well as application for non-dilutive grant funding to support further development of these and other assets\u201d. As MD of OncoLytika, Mark secured almost \u20ac3 million in Eureka Eurostar funding, so is acutely aware of the opportunities available. Recent changes to UK and international grant frameworks \u2014 including the UK\u2019s modernised Official Development Assistance (ODA) strategy, refreshed criteria, and new SME friendly collaboration rules \u2014 have opened funding routes that previously excluded early stage biopharma companies. These shifts prioritise oncology projects with demonstrable patient relevance, human relevant New Approach Methodologies (NAMs), and academia/SME partnerships, all of which are highly compatible with Val\u2019s revised model. With regulators actively encouraging NAM adoption and funders rewarding translational cancer research, Val\u2019s assets, its academic evaluation programmes, and Inaphaea\u2019s NAM enabled platforms now score higher on feasibility, ethics, and strategic alignment. As a result, the company is better positioned than ever to secure substantial grants. Cytolytix, in particular is a strong candidate, having already successfully secured funding via Open Univ Knowledge Transfer and HEIF schemes. It ticks all the appropriate boxes: oncology focus, targets difficult to treat indications, specifically TNBC and ovarian, has strong academic King\u2019s College lineage, and clear SME eligibility\u2014 a combination to make CLX one of Val\u2019s most grant ready assets. However, when these criteria are applied to Inaphaea NAM focused capabilities, additional opportunities emerge across the wider portfolio. Major SME eligible programmes from Innovate UK, CRUK, UKRI, NIHR and Cancer Research Horizons \u2014 all prioritising oncology, NAMs and academia/industry collaboration \u2014 now align directly with Val\u2019s model. Alongside CLX, additional assets such as VAL201 (prostate), VAL301 (endometriosis), StingRay/Sussex Univ and the Dundee/QMUL projects all fit the same criteria. Valirx is now primed for a level of acceleration and value creation unmatched in its history.",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.445",
          "thread_title": "The new funding landscape",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=2B0FFF9D-2F0B-4673-9D78-E6883F472B31"
        },
        "ingested_at": "2026-01-21T21:15:23.789067+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261003-Porky9-18741200",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.350895",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "So you think grant money is going to stave off the placing? Really? If he is lucky enough to get \u00a3250k of free cash from a grant that covers what another month's admin costs. Ridiculous. Look, 1) you need to get costs under control, pie off non productive staff and get a focus, no multi job staff, proper dedicated individuals solely 100% focus on this business. 2) get the lab actually covering its ars@ so it doesnt have to rely on financial handouts, by that i mean paid invoiced revenue coming in covering the cost. That means sorting his sales and marketing out so he can get invoiced work in. 3) And then if he can get the balance so that 100% is covered by invoiced lab work but only uses 70% capacity of the lab resource he can then use the remaining 30% on own peptides and projects (in other words the paid work funds own work) - he has to stop this constant merry go round of raise, spend, raise, spend, raise, spend consolidate, raise again. 4) when he returns to the table in a few weeks time for the next raise, he raises enough cash for ideally a two year runway. A the very worst 18 mths so not focusing all his attention on constantly squeezing shareholders for more cash all the time. Its not rocket science is it, but they lack any commercial acumen, proven. it remains a lifestyle play it is not a business. Thats how it is, you know exactly what's coming I am just amazed the brokers allow it, money being raised constantly on a business that constantly fails to perform causing constant financial loss to small investors.",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.46",
          "thread_title": "RE: The new funding landscape",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=2B0FFF9D-2F0B-4673-9D78-E6883F472B31"
        },
        "ingested_at": "2026-01-21T21:15:23.789049+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261137-ratcliff--1029299",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.350463",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "It's a bit ambitious calling 201 an 'asset' isn't it? But assuming a new patent is granted on it, do you imagine it will be tried on more than 11 patients over five years or so? And will it be in an accredited west European establishment, or once more in some backwater ex-communist clinic? Really it might be better trying to rename it and pass it off as new stuff from the old bin-dipping exercise, because the ghost of 201 from before is going to be far more of a hinderance than an 'asset.'",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.465",
          "thread_title": "RE: The new funding landscape",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=2B0FFF9D-2F0B-4673-9D78-E6883F472B31"
        },
        "ingested_at": "2026-01-21T21:15:23.789031+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261233-Oxmil--4505909",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.350039",
        "source": "LSE_CHAT",
        "data": {
          "author": "Oxmil",
          "content": "Share price is getting pretty close to the exercise price for the first set of warrants. When are people planning to exercise? I assume most will just take a ten percent profit when the price gets high enough rather than waiting for more. Anyone prepared to share their plans on here?",
          "sentiment": 0.0,
          "engagement": "273",
          "price_at_post": "0.465",
          "thread_title": "Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A4E34791-A8AC-42AC-8262-681BE6BC6461"
        },
        "ingested_at": "2026-01-21T21:15:23.789013+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261344-uxm484--5335684",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.349627",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "The crowd is aware of the  tiny valuation, I would think this will be done over 2 or 3 steps for each holder depending on the amounts. Strong momentum is expected, with incremental cash likely removing the need for a placing in 2026 and potentially any future placings once Cytolytix deal is concluded. Medium upfront preclinical deals are anticipated to exceed $40m. Market starting to wake up to the potential Obvious rerate under way now. Just the start. Lots of other catalysts which other informed investors have mentioned like PP and Notpotalot.",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.465",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A4E34791-A8AC-42AC-8262-681BE6BC6461"
        },
        "ingested_at": "2026-01-21T21:15:23.788994+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261348-uxm484-33764695",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.349203",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Average preclinical biopharma deal upfronts surged dramatically in 2025, with figures showing averages around $110 million by Q3, more than doubling the 2024 rate, driven by Big Pharma.",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.465",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A4E34791-A8AC-42AC-8262-681BE6BC6461"
        },
        "ingested_at": "2026-01-21T21:15:23.788977+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261429-Porky9-79089380",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.348786",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "1) The current value is EXCESSIVE - i am amazed its at the premium its at had it not been for the recent Zac Mir pump - hello this is a business with about 11 weeks or so of cash left, its either going into administration or its going to raise (most likely) at a major discount.  You can pump all you like but thats the reality. 2) Why would anyone want to cash in warrants for more exposure and immediate dilution and at a bloated share price. Good grief the warrants are only any good if some miracle landed and a licensing deal resulted in it worth cashing the warrants in to sell at a decent profit. If you have warrants you would just sit on them frankly, no rush.  This talk here about some rush to buy more stock is just utter utter BS",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.44",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A4E34791-A8AC-42AC-8262-681BE6BC6461"
        },
        "ingested_at": "2026-01-21T21:15:23.788959+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261648-uxm484--4075314",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.348376",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.415",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A4E34791-A8AC-42AC-8262-681BE6BC6461"
        },
        "ingested_at": "2026-01-21T21:15:23.788942+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261946-viera-68291819",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.347946",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Shares reached my 0.45p target and then dumped . I\u2019ve no view now and wis shareholders the best of luck: you\u2019ve all been so patient and deserve rich rewards . Only word of advice ,if Val come back to market for funds please insist on further costs cuts as we aren\u2019t lean enough ! Hopefully there will be no more placings though . I\u2019m outta here now ,take care xxx",
          "sentiment": 0.0,
          "engagement": "1,549",
          "price_at_post": "0.415",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A4E34791-A8AC-42AC-8262-681BE6BC6461"
        },
        "ingested_at": "2026-01-21T21:15:23.788924+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261356-ratcliff-17667104",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.347522",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Looks like you're not the only one taking the profit while they can Viera.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.41",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A4E34791-A8AC-42AC-8262-681BE6BC6461"
        },
        "ingested_at": "2026-01-21T21:15:23.788906+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261422-TopTrade-47229829",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.347109",
        "source": "LSE_CHAT",
        "data": {
          "author": "TopTraderTR",
          "content": "Took a small trade here",
          "sentiment": 0.5,
          "engagement": "337",
          "price_at_post": "0.41",
          "thread_title": "Trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=ACE1E361-4AA7-4827-9910-BCDFF9CA42F6"
        },
        "ingested_at": "2026-01-21T21:15:23.788888+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260738-GoldieLo--4915152",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.346694",
        "source": "LSE_CHAT",
        "data": {
          "author": "GoldieLock",
          "content": "NewCo will seek external non-dilutive and dilutive funding and ValiRx (and potentially other investors arranged by ValiRx) may, subject to availability of funds, provide up to \u00a32 million of seed funding (\"Seed Funding\"). Any such Seed Funding would be provided in tranches in line with the cash requirements, in exchange for further equity under a development plan provided by the Company. Funding other than the Seed Funding shall dilute all shares pari passu.",
          "sentiment": 0.0,
          "engagement": "1,392",
          "price_at_post": "0.41",
          "thread_title": "Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-21T21:15:23.788870+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260745-Badsterm--7705052",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.346282",
        "source": "LSE_CHAT",
        "data": {
          "author": "Badsterman",
          "content": "You're an idiot. The shares in \"Newco\" would be diluted to provide funding, not Valirx. In any case the agreement is for nine months, by which time Val will have run out of cash anyway. \"IRICoR will establish a Canadian registered, wholly owned, subsidiary (\"NewCo\")\" READ THE RNS.",
          "sentiment": 0.0,
          "engagement": "927",
          "price_at_post": "0.41",
          "thread_title": "RE: Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-21T21:15:23.788852+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260757-GoldieLo-34705320",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.345843",
        "source": "LSE_CHAT",
        "data": {
          "author": "GoldieLock",
          "content": "No. You are the fool. The phrase \"subject to availability of funds\" is the most important part of that sentence. It is a classic \"legal out.\" It tells you that while ValiRx wants to put up \u00a32 million, they don't necessarily have that cash sitting in the bank ready to go right now. To get that \u00a32 million, ValiRx essentially has three options: 1. Use existing cash: If they have it (unlikely to be the full amount given their typical burn rate). 2. External partners: They mentioned \"other investors arranged by ValiRx\" might step in. 3. A Placing (Equity Raise): If they can't find the money elsewhere and decide this project is a priority, they would need to raise more capital by issuing new shares.",
          "sentiment": 0.0,
          "engagement": "1,392",
          "price_at_post": "0.425",
          "thread_title": "RE: Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-21T21:15:23.788833+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260812-ratcliff-28682813",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:17.345388",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Looks like the string of hope-raising RNSs ahead of the next placing is starting even earlier than anticipated. Stand by for more fluffy announcements that 'could generate up to x billion pounds in five years subject to funding, institutional investment etc etc.' This will run in tandem with lots of pumping posts with 'if', 'could', 'might' and 'maybe' as a framework.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.415",
          "thread_title": "RE: Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-21T21:15:23.788815+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260816-Badsterm--6979461",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.179291",
        "source": "LSE_CHAT",
        "data": {
          "author": "Badsterman",
          "content": "No, Your thread is clearly entitled \"Placing coming, what we thinking? 0.2\" Why would Valirx raise funds for an evaluation that has nine months before it's even completed and the results known? We all know Val probably have five months cash (debatable) at most. Your thread title is scaremongering nonsense.",
          "sentiment": 0.0,
          "engagement": "927",
          "price_at_post": "0.415",
          "thread_title": "RE: Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-21T21:15:23.788797+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260824-paternos-72681139",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.178863",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "This one of the most strategically important deals in Val\u2019s history \u2014 and it\u2019s a major step forward in the \u201casset level dilution, plc level protection\u201d model the company has been signalling for months: 1. VAL secures access to a later stage, second generation RNA helicase inhibitor. This isn\u2019t an early academic idea. McGill/IRICoR have already done extensive development. RNA helicase inhibitors are a hot area in oncology and antiviral research and a second generation, orally available inhibitor is commercially attractive. VAL steps in at the target engagement/potency stage \u2014 far more advanced than typical VAL assets. 2. McGill and IRICoR are serious players so this deal elevates VAL\u2019s profile and opens doors for future deals. 3. Inaphaea runs the evaluation, and any data generated becomes VAL\u2019s property. VAL has explicitly structured the evaluation so that the data itself can be monetised. 4. IRICoR, NOT Val, creates a NewCo to commercialise the asset - That alone, signals confidence from the IRICor. NewCo gets the background IP and will seek external funding to push the asset forward. 5. VAL gets a 15% equity option in NewCo. This is the venture studio model in action - dilute the asset, not the plc. Mark announced the same intention with Val 201 in the webinar. 6. VAL may invest up to \u00a32m \u2014 but only if it chooses to: Funding is optional, staged, and subject to availability. No obligation, no upfront burden. 7. If VAL walks away, it can still get paid  If VAL declines the equity option, and the Institutions later commercialise the asset, VAL receives 1.5\u00d7 its evaluation spend (capped at ~\u00a3150k), similar to the recent StingRay update. It\u2019s a win/win, no risk deal. 8. Multiple exit routes - NewCo may: out license, raise institutional capital, merge or be acquired. All routes generate value for VAL. 9. It conforms with Mark\u2019s commitment to early monetisation. Because the asset is later stage, timelines to IND enabling studies and clinical entry are shorter. Today\u2019s RNS comes from having a commercially-savvy CEO protecting both his shareholders and his own 7% ownership of the company. Exciting times! One bus has arrived \u2014 but engines are revving across the garage. GLA, DYOR",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.415",
          "thread_title": "A Bold New Chapter",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=25F7D62E-D969-4181-A77B-FE67C25BCE2B"
        },
        "ingested_at": "2026-01-21T21:15:23.788779+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260829-nomlungu--4290144",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.178398",
        "source": "LSE_CHAT",
        "data": {
          "author": "nomlungu",
          "content": "\"evaluation spend (capped at ~\u00a3150k)\" So where does the \u00a3150k come from? Those who thought a placing will be coming in April may have to revise their opinion to late Feb.",
          "sentiment": 0.0,
          "engagement": "23,955",
          "price_at_post": "0.415",
          "thread_title": "RE: A Bold New Chapter",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=25F7D62E-D969-4181-A77B-FE67C25BCE2B"
        },
        "ingested_at": "2026-01-21T21:15:23.788762+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260847-Fredd1eb--3835732",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.177963",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fredd1eboy",
          "content": "Happy new year ob.....and good luck with Val. Sincerely Fred",
          "sentiment": 0.0,
          "engagement": "11,206",
          "price_at_post": "0.41",
          "thread_title": "RE: Gloves off\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=101654E0-A902-4633-8E17-2659C51B89C0"
        },
        "ingested_at": "2026-01-21T21:15:23.788740+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260910-Badsterm-10580962",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.177542",
        "source": "LSE_CHAT",
        "data": {
          "author": "Badsterman",
          "content": "The \u00a3150,000 is within the budgeted spend of the last fundraise. The RNS clearly stated part of the raise was for new evaluations, which ME has now delivered. Don't people read RNS's?",
          "sentiment": 0.0,
          "engagement": "927",
          "price_at_post": "0.41",
          "thread_title": "RE: A Bold New Chapter",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=25F7D62E-D969-4181-A77B-FE67C25BCE2B"
        },
        "ingested_at": "2026-01-21T21:15:23.788722+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261021-paternos-70427396",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.177119",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "McGill is one of Canada\u2019s top research universities. It is a major research institution with a global reputation and substantial research funding.  McGill is #29 in the QS World University Rankings 2025 and ranks #44 globally across 14,131 institutions in EduRank\u2019s 2025 analysis, attracting $749 million in sponsored research income in 2024. It has an endowment of CA$2.3 Bn and an annual budget of CA$1.5Bn. IRICoR is a non profit commercialisation centre. However, key financial indicators are available: 1. IRICoR has generated over $107M in revenue from collaborations focused on R&D of new therapies. It has also secured $40M in federal grants and $4.1M in provincial grants. This level of funding is only possible for an organisation with a strong track record of delivering commercially viable science. 2. IRICoR and Universit\u00e9 de Montr\u00e9al have an extended collaboration since 2020 with Ipsen \u2014 a \u20ac9.7 Bn mkt cap international pharma. Two new oncology programs were added under this partnership, focusing on novel MAP kinase pathway inhibition. This is exactly the kind of partner that only a credible translational engine can attract. 3. A small molecule therapy for solid tumours developed at IRIC/IRICoR and licensed to Ipsen has already reached Phase 1. This demonstrates that IRICoR can take a discovery stage program all the way to human trials. 4. IRICoR specialises in creating spin off companies. Their mission statement confirms: IRICoR \u201cplays an essential role in establishing strategic partnerships\u2026 or creating spin off companies\u201d to commercialise academic discoveries. This is directly relevant to the VAL deal, where IRICoR will create a NewCo to commercialise the helicase inhibitor. The above shows that IRICoR has already taken assets from discovery \u2192 licensing \u2192 Phase 1 and has deep relationships with global pharma, increasing the likelihood of future out licensing or co development. It also has the infrastructure and funding to build and support spin outs with a proven ability to attract major non dilutive funding.",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.40",
          "thread_title": "McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-21T21:15:23.788704+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261353-Porky9-81119393",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.176672",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Yes, deal perfectly 100% proves my point about lack of  any commercial acumen in the business.  Just incredidble. Perhaps the perma bulls can try and spin this one, give it your best shot PP",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-21T21:15:23.788686+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261602-Kaeren-69543797",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.176259",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kaeren",
          "content": "Happy new year P9.",
          "sentiment": 0.0,
          "engagement": "10,937",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-21T21:15:23.788668+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261713-Porky9-19790895",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.175834",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Happy New Year to @kaeren you too. Trust you and family are all well. X",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-21T21:15:23.788650+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261905-Gilders0-91312077",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.175422",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gilders01",
          "content": "Lot should be questioned , lots should be said, but I'm not invested. Still want this company to make a difference.",
          "sentiment": 0.0,
          "engagement": "1,156",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-21T21:15:23.788632+00:00"
      },
      {
        "event_id": "SOCIAL-10Jan20261344-Notpotal--4602822",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.174998",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "The asset/players: RNA Helicase Inhibitor \u2014 blocks the enzymes cancer cells rely on to grow and divide. \u2022 McGill: global top 30 university, CA$750m research income, CA$2+Bn endowment, deep oncology infrastructure. \u2022 IRICoR: $100m+ R&D revenue, major grants, long term partner of \u20ac9Bn Ipsen. \u2022 ValiRx: \u2013 a \u00a33m microcap with access to cutting-edge tech via Inaphaea and capability partners. McGill provides the science, IRICoR drives commercialisation, external investors bring funding, and VAL simply leverages its existing assets. Why VAL? - Big pharma is slow, expensive, and bureaucratic. Inaphaea can evaluate quickly, cheaply, and decisively. McGill doesn\u2019t have a commercial lab, IRICoR doesn\u2019t run wet lab evaluations, and big pharma won\u2019t touch early stage assets. VAL is hungry, flexible, and built to operate exactly in this gap, without corporate drag. The total RNA targeting small molecule market is projected at $\u202f5.5Bn by 2030. 1% of that is $55m. A tiny slice of a very large pie still tastes pretty good.",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-21T21:15:23.788614+00:00"
      },
      {
        "event_id": "SOCIAL-10Jan20261920-Kaeren--7672344",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.174570",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kaeren",
          "content": "All great thx.",
          "sentiment": 0.0,
          "engagement": "10,937",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-21T21:15:23.788595+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261042-paternos-21324498",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.174161",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "As standard, when Mark did the Dec webinar he emphasised nothing new, \u201cjust meat on the bones\u201d. However, often that meat can be pretty tasty. Blue Ribbon/VAL201 \u2013 \u201csynthesis almost complete\u201d (10m.30s). Then, \u201ca small amount (only \u00a350k) set aside for pre-clinical development of 201, the balance WILL then come from external investment into the asset\u201d (11m.55s). No \u201cMIGHT\u201d in that statement. The minimal outlay confirms that the VAL201 drug package is essentially finalised, and the entire development programme (preclinical \u2192 IND \u2192 partnering) is about to move forward. Mark has already confirmed Val will be diluting the asset, not Val PLC. With patents imminent, it\u2019s a clear signal that Blue Ribbon is not just a corporate shell \u2014 it\u2019s actively progressing VAL201 toward monetisation. Given Val\u2019s recent multi facet RNS style, the imminent update could well bundle new patent status with partnership confirmation. The last significant VAL201 update in 2021 saw the Val SP exceed 50p.",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.365",
          "thread_title": "Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-21T21:15:23.788577+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261539-Porky9-21646122",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.173725",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Err nope Only thing that will bring hard cash into the company of any meaningful amount in the next 8 weeks will be new placing money - sorry Regarding your continual pumps and fluffy updates, jam tommorrow dream fantasy posts, NONE of it can pay the bills now, end of. Anyone with any brains will be working the sells into any mupets trading this that are oblivious to the dire need for cash to keep the lights on and the pending essential discounted placing that has to happen to support the lifestyles here to keep the gravy train going. Tick Tock, Tick Tock",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.35",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-21T21:15:23.788559+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261804-uxm484-11334426",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.173300",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Plenty of news to come at a tiny valuation and likely this month. Cash until at least July that without warrants, revenue, deals, grants. Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-21T21:15:23.788542+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261952-Notpotal-55075620",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.172868",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Porky, unlike some holders, I still keep you around for the entertainment value.  Calling Nick and other traders \u2018muppets\u2019 is certainly \u2026.\u201dcreative\u201d. \ud83d\ude00 Jaspal S and Stephen W dipping just under the 3% is nothing more than freeing up a couple of million to trade. There\u2019s no great sell-off and no drama. Most of us aren\u2019t brave enough to risk missing an RNS for the sake of a few hundred quid. Get your 40 winks while you can. Many sleepless nights await over the next few months.   \ud83e\udd71 Pleasant dreams.",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-21T21:15:23.788523+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260919-Porky9-74921610",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.172439",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@Notpotalot Nick is a VERY experienced prolific investor. Frankly, i doff my cap to him as he called the trade perfectly in at .25 and out at .40. Beautiful. The Muppets are the traders in on the back of the Zac Mir pump without any research in blind on the dead cat bounce they will get burnt if still holding. As for Stephen and Jaspal at u3% they now dont have to declare BUT IMO they have about 8 weeks to slowly work the sells in to ensure they are out (just holding warrants options) before that next raise drops as they will be diluted to oblivion as sure as night is day. They can only drip sells in slowly to avoid the brokers hammering them at discount. You try selling big volumes of this close to the raise, or at anytime for that matter, you need to do it on a bounce really, sell whilst traders are buying. This is NOT an investment, its a short term punt. The reason its not an investment is because it can't generate revenue (well none in the last 15 yrs anyhow)  and is reliant on raise after raise after raise to maintain lifestyles. As I say, tick tock. Tick tock countdown already started imo.",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-21T21:15:23.788505+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260954-uxm484-11334426",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.171987",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Plenty of news to come at a tiny valuation and likely this month. Cash until at least July that without warrants, revenue, deals, grants. Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-21T21:15:23.788487+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261107-ratcliff-80287033",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.171563",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "UXM - cutting and pasting the same post repeatedly is not convincing, but to humour you I had a listen to the link you have monotonously posted. It's not persuasive or convincing - Starts off about the 'objectives we have set' and 'milestones we're looking to achieve.' Then there's a bit about the group structure - this is rearranging the deck chairs on the Titanic isn't it? They've had more rearrangements over the decades, it's just a distraction now - meetings are the practical alternative to work. The we hear 'The objective is...' and 'If suitable...'  So nothing at all certain. Then he says BC201 and Val301 have 'not been spun out yet, but would benefit from all of the development work undertaken on Val201.' So BC201 and Val301 still of no interest (except maybe on Antiques Roadshow) and if Val201 had even a glimmer of potential it would have done something since it was quietly shelved - was that 6 years ago or 8? It's been stagnant for so long, the rest of the industry has moved on. The he says 'There is strong interest in endometriosis treatments.' True. There's strong interest in a lot of things, but stating a fact doesn't tie it to VAL. 'We have two new evaluations under consideration.' And...? I\u2019ve got a lot of things under consideration, but whether they get any further is often very uncertain. 'The vision is...' - A lot of people have visions, but a vision isn't even a plan. It's a nice idea at best. 'Our strategy is to do this based on identifying the highest quality assets we can find and afford.' That's like saying 'come round to my place for a meal' and when you get there you say 'There\u2019s a tin of Pedigree Chum between the four of us - it was the highest quality I could find on the available budget.' The he's going to have a system which 'allows us to prioritise selection of assets.' How early stage is all this? And no money to do it with.. Next we see \u2018The Team\u2019 but no mention of their salaries. Then a review of last year - no mention of the placings. Talk of last year's cost savings and redundancies - but if you are cutting 200k a year and laying people off, what were you wasting the money on in the first place? Or have you sold your food to pay the heating bill? Then he says 'Our runway through 2026' - sorry - that 'runway' stops in a couple of months without a placing. The 2026 Xmas do is potentially in the Job Centre unless money comes in very soon. Time is money. They seem dangerously short of both. Again.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.355",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-21T21:15:23.788469+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261145-Marty130-58514391",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.171088",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Be good to see the directors buying some of the stock..",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "0.355",
          "thread_title": "Directors deals",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=DC2D2A2F-B451-4EEF-B7C8-9C80695D4033"
        },
        "ingested_at": "2026-01-21T21:15:23.788451+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261224-paternos--6494352",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.170675",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "A \u00a33m microcap with a cash runway till H2 even before factoring in R&D tax credits, potential grant funding, additional Inaphaea income or warrant cash now within reach. Outgoings reduced by \u00a3200k PA following a team restructuring last year. Val\u2019s expansion into NAMs and advanced AI tech, supported by strong academic partnerships, aligns directly with revised US & UK gov\u2019t guidelines to reduce animal testing. This positions Val as a front runner for non dilutive grants and innovation funding, with a CEO geared to capitalise on this opportunity. The 1/9/25 RNS confirmed ongoing discussions with several potential partners to progress Cytolytix, including a major pharma. Val owns 60% of CLX with 10% owned by co-inventor, Dr Charles Chen (Senior Scientist at Astrazeneca). Val also has a 54% share of an Ambrose deal potentially worth up to \u00a316m, and a Biobank of 476 PDCs valued at \u00a310k per PDC cell-line upon commercialisation, plus commercial rights entitlement. Valirx has assets in several key cancer indications, all with huge global markets: 201/prostate ($11.3Bn*), CLX (primarily TNBC ($1.5Bn*), ovarian ($2.5Bn*) but also prostate, 301/endometriosis ($1.9Bn**), and 401-Ambrose/pancreatic ($2.9Bn**). Sources: *webinar, **GMI. Several RNS updates are imminent: CLX patents \u201cin coming weeks.\u201d (RNS 1/9/25), Dundee/Queen Mary project (extended to 9/2/26), StingRay (approx Feb \u201926 per Aug video), Blue Ribbon SPV - \u201cSeveral patents envisaged for 201\u201d, and the next evaluation/SPV \u201cimminent with discussions already at a mature stage\u201d. The Omios RNS (3/6/25) stated \u201c\u2026 expected to take up to 12 months. On conclusion of the evaluation, Omios has an option to enter into an Oncolytic Peptide License Agreement to continue using Cytolytix technology.\u201d Yet another potential source of income. In addition, the Val/Dominion repurposing project (teaching an old drug new tricks) has identified 200 FDA approved non-oncology drugs which already have phase 1 clinical data and are showing activity against various cancer PDCs. 10 of these candidates are now being fast-tracked. The median upfront deal size for pre-clinical IND ready assets was $110m in 2025. For phase 2 this increased to $775m. (Dec webinar). For context, Val\u2019s SP exceeded 55p in 2021 with only one key asset (VAL201). Currently, including the repurposing project, Val now has 200+ potential assets plus a valuable Biobank. Also, Mark has restructured evaluation agreements whereby if Val chooses not to progress an asset (eg StingRay, McGill/IRICoR), Inaphaea retains the data and can still monetise should a 3rd party take the asset forward. Multiple monetisation routes now sit across the pipeline, supported by a commercially-savvy CEO who now owns 7% of the company. Valirx \u2013 a microcap with midcap potential.",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.355",
          "thread_title": "Why invest? \u2013 FINANCIAL",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=8931CA86-EC8C-43F3-AA7F-54C7D7FD717E"
        },
        "ingested_at": "2026-01-21T21:15:23.788433+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261313-paternos--5720473",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.170218",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "When Mark became CEO, ValirRx was effectively dormant - few assets in play, minimal Board investment and limited vision. He set about a major restructuring: rebuilding the team, reshaping the asset base and above all, resetting the mindset. Fast forward 17 months and Val is reborn. A microcap expanding into developing fields of oncology, yet every action taken has a cost/benefit analysis and timescale consideration. If concluded that a project cannot be monetised early, it is shelved or paused. Commercial decisions overrule all others. Valirx is now plugged into some of the most advanced platforms in modern drug development: \u2022\tpatient avatars (TwinEdge) \u2022\tmicrofluidics/3D tissue culture models (Screenin3D, Ignota & VoxCell) \u2022\trepurposing (Ignota, Altus & Dominion) \u2022\tpersonalised immunotherapy (PredictRx / Dominion) \u2022\tpro-senescence drugs (Dundee / Queen Mary Uni) \u2022\tClickmer technology/HER2 protein (Apis Assay) \u2022\tLMTK3 kinase targeting (StingRay). The most recent evaluation, a 2nd-gen RNA helicase inhibitor (McGill/IRICoR), brings Val into collaboration with major international research organisations. Last year, Mark identified a shift away from animal-testing and moved early to establish capability partners supporting NAMs and cutting-edge AI. Recent US & UK Gov\u2019t regulatory changes now actively favour such platforms with Europe to follow this year. Once again, Val anticipated this trend before much of the market. Meanwhile, the Advisory Board has been upgraded from academics and towards industry experts who can provide insight into Big Pharma priorities and identify new commercial pathways such as in veterinary science - quicker to market while opening a parallel revenue path thru\u2019 comparative oncology, further de risking the route to human oncology. Mark has also added a clause into evaluation agreements whereby if Val decides not to progress an asset eg StingRay, McGill/IRICoR, then Inaphaea retains the data and can still monetise should a 3rd party take the asset forward. Val is no longer waiting for opportunity; it is engineering it.",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.385",
          "thread_title": "Why invest? \u2013 THE SCIENCE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=058BF091-3235-424B-9C46-FA00ED6BC8D5"
        },
        "ingested_at": "2026-01-21T21:15:23.788414+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261430-nomlungu-77071701",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.169732",
        "source": "LSE_CHAT",
        "data": {
          "author": "nomlungu",
          "content": "People should just ignore Rat... he is just jealous that he does not have the losses to use to reduce his tax liabilities. That 80% drop in the last tax year will have been very valuable for some; I think him moaning around the time that taxes are due for the 2024/25 year is a dead give away. \ud83d\udcc9 \u2757",
          "sentiment": 0.0,
          "engagement": "23,955",
          "price_at_post": "0.395",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-21T21:15:23.788396+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261432-mikee_p--2765831",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.169306",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "1 HR. Channel is all ya need.",
          "sentiment": 0.0,
          "engagement": "1,888",
          "price_at_post": "0.395",
          "thread_title": "Easy trade this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=81274FD9-0226-45F3-8CEA-B1F91E33B4A2"
        },
        "ingested_at": "2026-01-21T21:15:23.788378+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261503-Mr0nions-50495396",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:13.168858",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mr0nions",
          "content": "Because of this  post, I'm holding position.  Good luck all.",
          "sentiment": 0.0,
          "engagement": "1,966",
          "price_at_post": "0.41",
          "thread_title": "RE: Why invest? \u2013 THE SCIENCE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=058BF091-3235-424B-9C46-FA00ED6BC8D5"
        },
        "ingested_at": "2026-01-21T21:15:23.788360+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261507-ratcliff-81390473",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.933530",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "You swine Nomlungu. You've rumbled me.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.41",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-21T21:15:23.788342+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261719-Porky9-24949684",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.933127",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "And just a few reasons why not to believe the BS from the resident rampers here and why you should avoid:- * Lifestyle Business * Ridiculous Admin costs * Continual Raises and continual dilution * More than 20 Raises, 3 lots of 125:1 Consolidation events * business concept never proven * Rented lab space and zero revenue in 15 years * About 8 weeks cash runway left with yet another raise due anytime soon to keep the gravy train going. * if new investors or brokers say enough is enough and call time due to clients continually losing money then its admin and you could lose your entire investment. * materially overpriced as absoluly nothing here to invest in, its the emperors new clothes you are buying. 201 is older than hens teeth, no interest in 15 years and CLX years off and more cash required. Labs meanwhile doesnt know what an invoice is. * Poor decision making, lack of any commercial acumen *No real focus, practically everyone is work from home with multiple jobs. * Short term punts only not a long hold due to above. * loads of stock held for broker fees that will need to be drip fed into anyone buying. In all avoid at all costs unless you like dilution",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.385",
          "thread_title": "Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-21T21:15:23.788324+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261733-uxm484-22579478",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.932653",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "All lies. Watch the video previously posted. Past management issues but new management outstanding.  Cash until H2 without the add ons. CEO heavily invested over 250k. Negotiating with a major biotech in regards to a deal for CLX001. Lab space is to help progress the assets to eventually get a deal not to make instant revenue. Any research on CLX001 done against a valuation of 2 million and cash burn just over a million would know this is a great opportunity. Brokers only had 20k stock. Hardly lots of stock. Great decision making. Derisking assets with partnership deals.  Which other biotech has so much spending less than 2 million. With warrants at a premium to the current price hopefully no more dilutions.",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.385",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-21T21:15:23.788306+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20262049-ratcliff-76892553",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.932218",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Whatever it is you're smoking UXM, it's powerful stuff.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.385",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-21T21:15:23.788288+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260857-Notpotal--7572521",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.931805",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "\u201cYou can't go back and change the beginning, but you can start where you are and change the ending.\" \u2013 C.S. Lewis Early in his tenure, Mark acknowledged mistakes had been made \u2014 and while he couldn\u2019t rewrite the past, he could reshape the future. 17 months later, Val is reborn, with money in the bank, a rebuilt team, high calibre assets and a SH base that deserves success after years of one-way support. A few resident historians cling to their preferred mythology, inventing a minimal cash runway because the real picture is too uncomfortable to accept: a cash runway to H2 even without R&D tax credits, additional Inaphaea income, grants or exercised warrants. This is also before the wave of RNS due over the coming weeks. Unlike those posting fiction, Mark has backed his conviction with his own money \u2014 now holding 7% of the company. \u201cWhat matters now is not where we\u2019ve been, but where we\u2019re going.\u201d",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.365",
          "thread_title": "Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-21T21:15:23.788270+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260920-RayPoint--4080500",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.931380",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Living in fantasy land",
          "sentiment": 0.0,
          "engagement": "5,058",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-21T21:15:23.788251+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261050-Rebster4-79097647",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.930962",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rebster408",
          "content": "Its groundhog day again This is a binary bet...and Poky has called it right in the past and I thinks he's spot on again... 201 is older than me!!! place your bets... the wheel is spinning and will stop within the next 8 weeks All will become clear within the next two months...",
          "sentiment": 0.0,
          "engagement": "1,173",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-21T21:15:23.788233+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261059-viera--3001216",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.930536",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Are you PM in disguise ? Who in  their right mind would buy any company on Aim with only 3 or 4 months cash runway? You sound so so desperate for a rally to sell out !",
          "sentiment": 0.0,
          "engagement": "1,549",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-21T21:15:23.788214+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261201-ratcliff-66070046",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.930120",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "UXM - differences of opinion are generally understandable, but to say in your post 'All lies' is blatantly true and misleading, and as usual does nothing to bolster your credibility. Two of the things you say in that post are particularly inaccurate - 'Great decision making. Derisking assets with partnership deals. Which other biotech has so much spending less than 2 million.' - They are looking for deals (or claim to be anyway) but nothing so far has contributed anything to even cover the outgoings, let alone provide money for further work or expansion (hence the redundancies etc) Secondly - 'With warrants at a premium to the current price hopefully no more dilutions' - warrants don't kick in and generate cash the moment the sp goes above them as you and the others in your group seem to imply. In the unlikely event of the sp rising above that point and remaining so, it just might be worth warrant holders exercising them so they could buy shares at below the then-current price, but to sell them they'd need to be able to be sure the sp was strong enough to withstand the effect of the sells. You know that, so stop trying to imply that the mere existence of warrants is a long-term fool proof source of near or long term capital. Then again, if this company was fool proof you wouldn't be here I imagine.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.365",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-21T21:15:23.788194+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261207-ratcliff--7782726",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.929687",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Slight typo there - should read blatantly UNTRUE and misleading!",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.365",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-21T21:15:23.788177+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261222-Notpotal-19955045",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.929286",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "\u201cYou sound so desperate\u201d says the man who\u2019s last 60 posts have been on a share he isn\u2019t invested in. \ud83d\ude02\ud83d\ude02\ud83d\ude02",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-21T21:15:23.788158+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261935-uxm484--1611821",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.928866",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "No, but the holders all want the warrants exercised so we can do a 10 bagger in 12 months without a fund raise. For me i am really happy here with  the progression. We are definitely early in a news rich periods where all the negative posters are posting overtime and are only posting as they missed out on the last fundraise hoping for an even lower price. We will likely get a few meaningful RNS very soon. Brakes are now off\u2026",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.36",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-21T21:15:23.788124+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261216-steve196--9215411",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.928453",
        "source": "LSE_CHAT",
        "data": {
          "author": "steve196",
          "content": "How much does it cost to release an RNS just for \u00a3400 of warrants?",
          "sentiment": 0.0,
          "engagement": "2,754",
          "price_at_post": "0.385",
          "thread_title": "Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-21T21:15:23.788082+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261311-ratcliff-37181109",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.928034",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Probably about 450 quid...",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-21T21:15:23.788065+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261357-spantrou--1141070",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.927626",
        "source": "LSE_CHAT",
        "data": {
          "author": "spantrout",
          "content": "\u00a39.99 for rns",
          "sentiment": 0.0,
          "engagement": "13,941",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-21T21:15:23.788047+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261412-RayPoint-53933647",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.927222",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "\"Probably about 450 quid...\" Rats, stop ramping! The gross proceeds were \u00a3400",
          "sentiment": 0.0,
          "engagement": "5,058",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-21T21:15:23.788029+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261413-RayPoint--7093669",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.926800",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Sorry Rats. I misinterpreted your post.",
          "sentiment": 0.0,
          "engagement": "5,058",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-21T21:15:23.788012+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261434-ratcliff--4233665",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.926391",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "No problem RP - I'm wondering who paid 0.50 for a few shares worth about 25 percent less from the start, but I suppose 400 quid pays for the week's teabags and digestives.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-21T21:15:23.787994+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261529-RayPoint-59791623",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.925974",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "I hear that green fees are pretty steep in California",
          "sentiment": 0.0,
          "engagement": "5,058",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-21T21:15:23.787976+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261534-Notpotal-41934988",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.925569",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Val is obliged to RNS as it a change to No. shares in issue. Hardly the company\u2019s fault if a holder sees such value that he wants to buy above the current SP. Mind you, I\u2019m expecting a TR1 tomorrow to confirm Mark\u2019s holding has increased by 80,000 shares. \ud83e\udd23 If this is the reaction to \u00a3400 of warrants, heaven help Porky\u2019s groupies when the next material RNS arrives.  \ud83e\udee8 \ud83d\ude28 \ud83d\ude22\ud83d\ude2d",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-21T21:15:23.787958+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261543-Notpotal-61520438",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.925150",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "I notice a 71430 buy at 15.14 and a similar sell 4 mins later for a \u00a321 loss. Great to see Porky has started trading again!  \ud83e\udd23\ud83e\udd23\ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.385",
          "thread_title": "Welcome back, Porky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=FE350133-0204-48E9-9785-7F80407B3421"
        },
        "ingested_at": "2026-01-21T21:15:23.787935+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260943-paternos--3085770",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.924727",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Mark re JPM in San Fran -  \u201cI have meetings lined up with our partner Omios Biologics so looking forward to catching up with Aldo Pourchet (CEO).\u201d In the Omios RNS (3/6/25), the evaluation was \u201cexpected to run up to 12 months, after which Omios can exercise its license option to continue using Cytolytix technology.\u201d Across both the June and Dec webinars, Mark emphasised CLX synergy with the Omios virus for potential to treat canine HSA, a clear signal that Omios sits firmly in the frame for a CLX licence. Valirx\u2019s revamped Advisory Board reinforces this direction, now with a notable weighting toward veterinary oncology and commercial expertise. The composition reflects a deliberate strategy to position CLX across both human and animal oncology. When your advisory structure is rebuilt around people who understand canine cancers, comparative oncology, and veterinary commercial pathways, it becomes clear Valirx is preparing for licensing routes across both human and veterinary markets. As a co-founder of VolitionRx, Mark transformed a human cancer test into a canine diagnostic test (Nu.Q) before negotiating a licencing deal with Heska for $26m. What price a cure? Human and veterinary oncology operate in separate regulatory and commercial channels. Most major pharmas, inc. AZN, Roche, GSK, AbbVie do NOT have any vet divisions. Even those historically involved have spun off their animal health units (Pfizer \u2192 Zoetis, Eli Lilly \u2192 Elanco). By envisaging veterinary opportunities for CLX, Mark is implicitly confirming the compound won\u2019t be a one partner asset; the split infrastructures required make multiple CytoLytix deals the only realistic outcome. GLA, DYOR, AIMO",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.385",
          "thread_title": "Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-01-21T21:15:23.787903+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261329-Porky9-90232392",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.924291",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@PP Yes, and as long as the rain holds off should be able to get some golf in on expenses. Who needs Zoom and Teams when you can have a nice all expenses trip to the US. Lovely. Keep pumping it, only a few weeks now to go before next placing @notpotatlot Only Update you will get shortly that isn't fluff, will be the placing news or the next 125:1 consolidation event which has to be well over due now. Keep ramping it though, the gravy train needs to stay on the tracks, there are lifestyles here that need to be maintained.",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.385",
          "thread_title": "RE: Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-01-21T21:15:23.787867+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261459-Notpotal--4270427",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.923845",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Some clever trading going on here \u2013 those selling at 0.37p will soon be able to buy back at 0.39p. \ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "76",
          "price_at_post": "0.385",
          "thread_title": "RE: Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-01-21T21:15:23.787847+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261513-paternos-38210098",
        "event_type": "social_post",
        "date": "2026-01-21T21:15:09.923417",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "\u201cValix is in discussions with several potential partners to progress CytoLytix, including a major pharma\u201d. So, why is Mark, currently in California, continuing to promote the compound so actively both in the UK and overseas? While it\u2019s plausible a major pharma might seek exclusivity, the most realistic outcome is exclusive rights carved by territory, formulation, indication, or even species (human/veterinary)\u2014leaving room for multiple, parallel deals outside that scope. Indication splits are historically used when partners specialise in different therapeutic areas (eg ovarian only). Geographic exclusivity is even more common. The TrX/201 deal eventually failed when Mark attempted to remove Taiwan from the original LOI. The veterinary angle highlighted in recent webinars reinforces that CLX spans markets no single pharma can cover, making a multi partner licensing model far more realistic than a single global licence. There are numerous real world examples of multi partner licensing structures in biopharma: TERRITORY - Immunex (Enbrel) / initially Amgen \u2192 US & Canada rights, then Wyeth (later Pfizer) \u2192 Europe + Rest of World rights FORMULATION - Gilead (Tamiflu) / initially Roche \u2192 Oral formulation rights, then Hetero & Teva, \u2192 sublicenses for additional formulations INDICATION - AstraZeneca (Lynparza) / Merck \u2192 initially Ovarian cancer rights, then subsequently obtained licenses for breast and pancreatic cancers. Each example above shows one originator, no single-party lock in and multiple partners or deals to acquire different rights. With so many variables in play, it is increasingly clear that Valirx is preserving the same optionality for CytoLytix. Mark is still promoting CytoLytix because he is targeting several partners \u2013 not just one. Everything suggests CLX is being shaped as a multi deal platform, with the first handshake simply opening the monetisation cycle -",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.385",
          "thread_title": "CLX - multi deal structure",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D1488F3A-09F4-41C4-B45B-AF908B85E267"
        },
        "ingested_at": "2026-01-21T21:15:23.787824+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20260914-paternos--5239367",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:45.662352",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Many of Mark\u2019s presentations have highlighted the potential of grant-funding, the 14/10/25 RNS confirming a \u00a3250k award a prime example. The Inaphaea RNS (18/9/25), re the Dominion repurposing top 10, confirmed \u201cinitial commercial discussions with potential licensees as well as application for non-dilutive grant funding to support further development of these and other assets\u201d. As MD of OncoLytika, Mark secured almost \u20ac3 million in Eureka Eurostar funding, so is acutely aware of the opportunities available. Recent changes to UK and international grant frameworks \u2014 including the UK\u2019s modernised Official Development Assistance (ODA) strategy, refreshed criteria, and new SME friendly collaboration rules \u2014 have opened funding routes that previously excluded early stage biopharma companies. These shifts prioritise oncology projects with demonstrable patient relevance, human relevant New Approach Methodologies (NAMs), and academia/SME partnerships, all of which are highly compatible with Val\u2019s revised model. With regulators actively encouraging NAM adoption and funders rewarding translational cancer research, Val\u2019s assets, its academic evaluation programmes, and Inaphaea\u2019s NAM enabled platforms now score higher on feasibility, ethics, and strategic alignment. As a result, the company is better positioned than ever to secure substantial grants. Cytolytix, in particular is a strong candidate, having already successfully secured funding via Open Univ Knowledge Transfer and HEIF schemes. It ticks all the appropriate boxes: oncology focus, targets difficult to treat indications, specifically TNBC and ovarian, has strong academic King\u2019s College lineage, and clear SME eligibility\u2014 a combination to make CLX one of Val\u2019s most grant ready assets. However, when these criteria are applied to Inaphaea NAM focused capabilities, additional opportunities emerge across the wider portfolio. Major SME eligible programmes from Innovate UK, CRUK, UKRI, NIHR and Cancer Research Horizons \u2014 all prioritising oncology, NAMs and academia/industry collaboration \u2014 now align directly with Val\u2019s model. Alongside CLX, additional assets such as VAL201 (prostate), VAL301 (endometriosis), StingRay/Sussex Univ and the Dundee/QMUL projects all fit the same criteria. Valirx is now primed for a level of acceleration and value creation unmatched in its history.",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.445",
          "thread_title": "The new funding landscape",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=2B0FFF9D-2F0B-4673-9D78-E6883F472B31"
        },
        "ingested_at": "2026-01-21T00:53:53.251045Z"
      },
      {
        "event_id": "SOCIAL-7Jan20261003-Porky9--7929610",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:45.661908",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "So you think grant money is going to stave off the placing? Really? If he is lucky enough to get \u00a3250k of free cash from a grant that covers what another month's admin costs. Ridiculous. Look, 1) you need to get costs under control, pie off non productive staff and get a focus, no multi job staff, proper dedicated individuals solely 100% focus on this business. 2) get the lab actually covering its ars@ so it doesnt have to rely on financial handouts, by that i mean paid invoiced revenue coming in covering the cost. That means sorting his sales and marketing out so he can get invoiced work in. 3) And then if he can get the balance so that 100% is covered by invoiced lab work but only uses 70% capacity of the lab resource he can then use the remaining 30% on own peptides and projects (in other words the paid work funds own work) - he has to stop this constant merry go round of raise, spend, raise, spend, raise, spend consolidate, raise again. 4) when he returns to the table in a few weeks time for the next raise, he raises enough cash for ideally a two year runway. A the very worst 18 mths so not focusing all his attention on constantly squeezing shareholders for more cash all the time. Its not rocket science is it, but they lack any commercial acumen, proven. it remains a lifestyle play it is not a business. Thats how it is, you know exactly what's coming I am just amazed the brokers allow it, money being raised constantly on a business that constantly fails to perform causing constant financial loss to small investors.",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.46",
          "thread_title": "RE: The new funding landscape",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=2B0FFF9D-2F0B-4673-9D78-E6883F472B31"
        },
        "ingested_at": "2026-01-21T00:53:53.251018Z"
      },
      {
        "event_id": "SOCIAL-7Jan20261137-ratcliff-27416825",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:45.661473",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "It's a bit ambitious calling 201 an 'asset' isn't it? But assuming a new patent is granted on it, do you imagine it will be tried on more than 11 patients over five years or so? And will it be in an accredited west European establishment, or once more in some backwater ex-communist clinic? Really it might be better trying to rename it and pass it off as new stuff from the old bin-dipping exercise, because the ghost of 201 from before is going to be far more of a hinderance than an 'asset.'",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.465",
          "thread_title": "RE: The new funding landscape",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=2B0FFF9D-2F0B-4673-9D78-E6883F472B31"
        },
        "ingested_at": "2026-01-21T00:53:53.250991Z"
      },
      {
        "event_id": "SOCIAL-7Jan20261233-Oxmil-37072384",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:45.661049",
        "source": "LSE_CHAT",
        "data": {
          "author": "Oxmil",
          "content": "Share price is getting pretty close to the exercise price for the first set of warrants. When are people planning to exercise? I assume most will just take a ten percent profit when the price gets high enough rather than waiting for more. Anyone prepared to share their plans on here?",
          "sentiment": 0.0,
          "engagement": "273",
          "price_at_post": "0.465",
          "thread_title": "Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A4E34791-A8AC-42AC-8262-681BE6BC6461"
        },
        "ingested_at": "2026-01-21T00:53:53.250965Z"
      },
      {
        "event_id": "SOCIAL-7Jan20261344-uxm484--2209859",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:45.660633",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "The crowd is aware of the  tiny valuation, I would think this will be done over 2 or 3 steps for each holder depending on the amounts. Strong momentum is expected, with incremental cash likely removing the need for a placing in 2026 and potentially any future placings once Cytolytix deal is concluded. Medium upfront preclinical deals are anticipated to exceed $40m. Market starting to wake up to the potential Obvious rerate under way now. Just the start. Lots of other catalysts which other informed investors have mentioned like PP and Notpotalot.",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.465",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A4E34791-A8AC-42AC-8262-681BE6BC6461"
        },
        "ingested_at": "2026-01-21T00:53:53.250938Z"
      },
      {
        "event_id": "SOCIAL-7Jan20261348-uxm484-33060696",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:45.660206",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Average preclinical biopharma deal upfronts surged dramatically in 2025, with figures showing averages around $110 million by Q3, more than doubling the 2024 rate, driven by Big Pharma.",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.465",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A4E34791-A8AC-42AC-8262-681BE6BC6461"
        },
        "ingested_at": "2026-01-21T00:53:53.250911Z"
      },
      {
        "event_id": "SOCIAL-7Jan20261429-Porky9--1856153",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:45.659782",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "1) The current value is EXCESSIVE - i am amazed its at the premium its at had it not been for the recent Zac Mir pump - hello this is a business with about 11 weeks or so of cash left, its either going into administration or its going to raise (most likely) at a major discount.  You can pump all you like but thats the reality. 2) Why would anyone want to cash in warrants for more exposure and immediate dilution and at a bloated share price. Good grief the warrants are only any good if some miracle landed and a licensing deal resulted in it worth cashing the warrants in to sell at a decent profit. If you have warrants you would just sit on them frankly, no rush.  This talk here about some rush to buy more stock is just utter utter BS",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.44",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A4E34791-A8AC-42AC-8262-681BE6BC6461"
        },
        "ingested_at": "2026-01-21T00:53:53.250885Z"
      },
      {
        "event_id": "SOCIAL-7Jan20261648-uxm484--2173723",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:45.659371",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.415",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A4E34791-A8AC-42AC-8262-681BE6BC6461"
        },
        "ingested_at": "2026-01-21T00:53:53.250857Z"
      },
      {
        "event_id": "SOCIAL-7Jan20261946-viera--8983099",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:45.658940",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Shares reached my 0.45p target and then dumped . I\u2019ve no view now and wis shareholders the best of luck: you\u2019ve all been so patient and deserve rich rewards . Only word of advice ,if Val come back to market for funds please insist on further costs cuts as we aren\u2019t lean enough ! Hopefully there will be no more placings though . I\u2019m outta here now ,take care xxx",
          "sentiment": 0.0,
          "engagement": "1,549",
          "price_at_post": "0.415",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A4E34791-A8AC-42AC-8262-681BE6BC6461"
        },
        "ingested_at": "2026-01-21T00:53:53.250831Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261356-ratcliff--3323903",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:45.658507",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Looks like you're not the only one taking the profit while they can Viera.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.41",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A4E34791-A8AC-42AC-8262-681BE6BC6461"
        },
        "ingested_at": "2026-01-21T00:53:53.250804Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261422-TopTrade-44340180",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:45.658081",
        "source": "LSE_CHAT",
        "data": {
          "author": "TopTraderTR",
          "content": "Took a small trade here",
          "sentiment": 0.5,
          "engagement": "337",
          "price_at_post": "0.41",
          "thread_title": "Trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=ACE1E361-4AA7-4827-9910-BCDFF9CA42F6"
        },
        "ingested_at": "2026-01-21T00:53:53.250777Z"
      },
      {
        "event_id": "SOCIAL-9Jan20260738-GoldieLo-24547916",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:45.657668",
        "source": "LSE_CHAT",
        "data": {
          "author": "GoldieLock",
          "content": "NewCo will seek external non-dilutive and dilutive funding and ValiRx (and potentially other investors arranged by ValiRx) may, subject to availability of funds, provide up to \u00a32 million of seed funding (\"Seed Funding\"). Any such Seed Funding would be provided in tranches in line with the cash requirements, in exchange for further equity under a development plan provided by the Company. Funding other than the Seed Funding shall dilute all shares pari passu.",
          "sentiment": 0.0,
          "engagement": "1,390",
          "price_at_post": "0.41",
          "thread_title": "Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-21T00:53:53.250751Z"
      },
      {
        "event_id": "SOCIAL-9Jan20260745-Badsterm--8397530",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:45.657254",
        "source": "LSE_CHAT",
        "data": {
          "author": "Badsterman",
          "content": "You're an idiot. The shares in \"Newco\" would be diluted to provide funding, not Valirx. In any case the agreement is for nine months, by which time Val will have run out of cash anyway. \"IRICoR will establish a Canadian registered, wholly owned, subsidiary (\"NewCo\")\" READ THE RNS.",
          "sentiment": 0.0,
          "engagement": "927",
          "price_at_post": "0.41",
          "thread_title": "RE: Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-21T00:53:53.250724Z"
      },
      {
        "event_id": "SOCIAL-9Jan20260757-GoldieLo-47894338",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:45.656812",
        "source": "LSE_CHAT",
        "data": {
          "author": "GoldieLock",
          "content": "No. You are the fool. The phrase \"subject to availability of funds\" is the most important part of that sentence. It is a classic \"legal out.\" It tells you that while ValiRx wants to put up \u00a32 million, they don't necessarily have that cash sitting in the bank ready to go right now. To get that \u00a32 million, ValiRx essentially has three options: 1. Use existing cash: If they have it (unlikely to be the full amount given their typical burn rate). 2. External partners: They mentioned \"other investors arranged by ValiRx\" might step in. 3. A Placing (Equity Raise): If they can't find the money elsewhere and decide this project is a priority, they would need to raise more capital by issuing new shares.",
          "sentiment": 0.0,
          "engagement": "1,390",
          "price_at_post": "0.425",
          "thread_title": "RE: Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-21T00:53:53.250697Z"
      },
      {
        "event_id": "SOCIAL-9Jan20260812-ratcliff-76219345",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:45.656353",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Looks like the string of hope-raising RNSs ahead of the next placing is starting even earlier than anticipated. Stand by for more fluffy announcements that 'could generate up to x billion pounds in five years subject to funding, institutional investment etc etc.' This will run in tandem with lots of pumping posts with 'if', 'could', 'might' and 'maybe' as a framework.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.415",
          "thread_title": "RE: Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-21T00:53:53.250670Z"
      },
      {
        "event_id": "SOCIAL-9Jan20260816-Badsterm-25279121",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.459743",
        "source": "LSE_CHAT",
        "data": {
          "author": "Badsterman",
          "content": "No, Your thread is clearly entitled \"Placing coming, what we thinking? 0.2\" Why would Valirx raise funds for an evaluation that has nine months before it's even completed and the results known? We all know Val probably have five months cash (debatable) at most. Your thread title is scaremongering nonsense.",
          "sentiment": 0.0,
          "engagement": "927",
          "price_at_post": "0.415",
          "thread_title": "RE: Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-21T00:53:53.250643Z"
      },
      {
        "event_id": "SOCIAL-9Jan20260824-paternos-71461174",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.459322",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "This one of the most strategically important deals in Val\u2019s history \u2014 and it\u2019s a major step forward in the \u201casset level dilution, plc level protection\u201d model the company has been signalling for months: 1. VAL secures access to a later stage, second generation RNA helicase inhibitor. This isn\u2019t an early academic idea. McGill/IRICoR have already done extensive development. RNA helicase inhibitors are a hot area in oncology and antiviral research and a second generation, orally available inhibitor is commercially attractive. VAL steps in at the target engagement/potency stage \u2014 far more advanced than typical VAL assets. 2. McGill and IRICoR are serious players so this deal elevates VAL\u2019s profile and opens doors for future deals. 3. Inaphaea runs the evaluation, and any data generated becomes VAL\u2019s property. VAL has explicitly structured the evaluation so that the data itself can be monetised. 4. IRICoR, NOT Val, creates a NewCo to commercialise the asset - That alone, signals confidence from the IRICor. NewCo gets the background IP and will seek external funding to push the asset forward. 5. VAL gets a 15% equity option in NewCo. This is the venture studio model in action - dilute the asset, not the plc. Mark announced the same intention with Val 201 in the webinar. 6. VAL may invest up to \u00a32m \u2014 but only if it chooses to: Funding is optional, staged, and subject to availability. No obligation, no upfront burden. 7. If VAL walks away, it can still get paid  If VAL declines the equity option, and the Institutions later commercialise the asset, VAL receives 1.5\u00d7 its evaluation spend (capped at ~\u00a3150k), similar to the recent StingRay update. It\u2019s a win/win, no risk deal. 8. Multiple exit routes - NewCo may: out license, raise institutional capital, merge or be acquired. All routes generate value for VAL. 9. It conforms with Mark\u2019s commitment to early monetisation. Because the asset is later stage, timelines to IND enabling studies and clinical entry are shorter. Today\u2019s RNS comes from having a commercially-savvy CEO protecting both his shareholders and his own 7% ownership of the company. Exciting times! One bus has arrived \u2014 but engines are revving across the garage. GLA, DYOR",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.415",
          "thread_title": "A Bold New Chapter",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=25F7D62E-D969-4181-A77B-FE67C25BCE2B"
        },
        "ingested_at": "2026-01-21T00:53:53.250616Z"
      },
      {
        "event_id": "SOCIAL-9Jan20260829-nomlungu--2191461",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.458844",
        "source": "LSE_CHAT",
        "data": {
          "author": "nomlungu",
          "content": "\"evaluation spend (capped at ~\u00a3150k)\" So where does the \u00a3150k come from? Those who thought a placing will be coming in April may have to revise their opinion to late Feb.",
          "sentiment": 0.0,
          "engagement": "23,945",
          "price_at_post": "0.415",
          "thread_title": "RE: A Bold New Chapter",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=25F7D62E-D969-4181-A77B-FE67C25BCE2B"
        },
        "ingested_at": "2026-01-21T00:53:53.250589Z"
      },
      {
        "event_id": "SOCIAL-9Jan20260847-Fredd1eb--7010040",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.458431",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fredd1eboy",
          "content": "Happy new year ob.....and good luck with Val. Sincerely Fred",
          "sentiment": 0.0,
          "engagement": "11,204",
          "price_at_post": "0.41",
          "thread_title": "RE: Gloves off\u2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=101654E0-A902-4633-8E17-2659C51B89C0"
        },
        "ingested_at": "2026-01-21T00:53:53.250561Z"
      },
      {
        "event_id": "SOCIAL-9Jan20260910-Badsterm-39152430",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.458001",
        "source": "LSE_CHAT",
        "data": {
          "author": "Badsterman",
          "content": "The \u00a3150,000 is within the budgeted spend of the last fundraise. The RNS clearly stated part of the raise was for new evaluations, which ME has now delivered. Don't people read RNS's?",
          "sentiment": 0.0,
          "engagement": "927",
          "price_at_post": "0.41",
          "thread_title": "RE: A Bold New Chapter",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=25F7D62E-D969-4181-A77B-FE67C25BCE2B"
        },
        "ingested_at": "2026-01-21T00:53:53.250534Z"
      },
      {
        "event_id": "SOCIAL-9Jan20261021-paternos-44967331",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.457584",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "McGill is one of Canada\u2019s top research universities. It is a major research institution with a global reputation and substantial research funding.  McGill is #29 in the QS World University Rankings 2025 and ranks #44 globally across 14,131 institutions in EduRank\u2019s 2025 analysis, attracting $749 million in sponsored research income in 2024. It has an endowment of CA$2.3 Bn and an annual budget of CA$1.5Bn. IRICoR is a non profit commercialisation centre. However, key financial indicators are available: 1. IRICoR has generated over $107M in revenue from collaborations focused on R&D of new therapies. It has also secured $40M in federal grants and $4.1M in provincial grants. This level of funding is only possible for an organisation with a strong track record of delivering commercially viable science. 2. IRICoR and Universit\u00e9 de Montr\u00e9al have an extended collaboration since 2020 with Ipsen \u2014 a \u20ac9.7 Bn mkt cap international pharma. Two new oncology programs were added under this partnership, focusing on novel MAP kinase pathway inhibition. This is exactly the kind of partner that only a credible translational engine can attract. 3. A small molecule therapy for solid tumours developed at IRIC/IRICoR and licensed to Ipsen has already reached Phase 1. This demonstrates that IRICoR can take a discovery stage program all the way to human trials. 4. IRICoR specialises in creating spin off companies. Their mission statement confirms: IRICoR \u201cplays an essential role in establishing strategic partnerships\u2026 or creating spin off companies\u201d to commercialise academic discoveries. This is directly relevant to the VAL deal, where IRICoR will create a NewCo to commercialise the helicase inhibitor. The above shows that IRICoR has already taken assets from discovery \u2192 licensing \u2192 Phase 1 and has deep relationships with global pharma, increasing the likelihood of future out licensing or co development. It also has the infrastructure and funding to build and support spin outs with a proven ability to attract major non dilutive funding.",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.40",
          "thread_title": "McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-21T00:53:53.250507Z"
      },
      {
        "event_id": "SOCIAL-9Jan20261353-Porky9--8627580",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.457142",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Yes, deal perfectly 100% proves my point about lack of  any commercial acumen in the business.  Just incredidble. Perhaps the perma bulls can try and spin this one, give it your best shot PP",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-21T00:53:53.250480Z"
      },
      {
        "event_id": "SOCIAL-9Jan20261602-Kaeren--8312795",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.456722",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kaeren",
          "content": "Happy new year P9.",
          "sentiment": 0.0,
          "engagement": "10,937",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-21T00:53:53.250453Z"
      },
      {
        "event_id": "SOCIAL-9Jan20261713-Porky9-90877981",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.456310",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Happy New Year to @kaeren you too. Trust you and family are all well. X",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-21T00:53:53.250427Z"
      },
      {
        "event_id": "SOCIAL-9Jan20261905-Gilders0--1185568",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.455889",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gilders01",
          "content": "Lot should be questioned , lots should be said, but I'm not invested. Still want this company to make a difference.",
          "sentiment": 0.0,
          "engagement": "1,156",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-21T00:53:53.250400Z"
      },
      {
        "event_id": "SOCIAL-10Jan20261344-Notpotal-15490108",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.455478",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "The asset/players: RNA Helicase Inhibitor \u2014 blocks the enzymes cancer cells rely on to grow and divide. \u2022 McGill: global top 30 university, CA$750m research income, CA$2+Bn endowment, deep oncology infrastructure. \u2022 IRICoR: $100m+ R&D revenue, major grants, long term partner of \u20ac9Bn Ipsen. \u2022 ValiRx: \u2013 a \u00a33m microcap with access to cutting-edge tech via Inaphaea and capability partners. McGill provides the science, IRICoR drives commercialisation, external investors bring funding, and VAL simply leverages its existing assets. Why VAL? - Big pharma is slow, expensive, and bureaucratic. Inaphaea can evaluate quickly, cheaply, and decisively. McGill doesn\u2019t have a commercial lab, IRICoR doesn\u2019t run wet lab evaluations, and big pharma won\u2019t touch early stage assets. VAL is hungry, flexible, and built to operate exactly in this gap, without corporate drag. The total RNA targeting small molecule market is projected at $\u202f5.5Bn by 2030. 1% of that is $55m. A tiny slice of a very large pie still tastes pretty good.",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-21T00:53:53.250373Z"
      },
      {
        "event_id": "SOCIAL-10Jan20261920-Kaeren-45091997",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.455040",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kaeren",
          "content": "All great thx.",
          "sentiment": 0.0,
          "engagement": "10,937",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-21T00:53:53.250345Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261042-paternos-18890801",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.454636",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "As standard, when Mark did the Dec webinar he emphasised nothing new, \u201cjust meat on the bones\u201d. However, often that meat can be pretty tasty. Blue Ribbon/VAL201 \u2013 \u201csynthesis almost complete\u201d (10m.30s). Then, \u201ca small amount (only \u00a350k) set aside for pre-clinical development of 201, the balance WILL then come from external investment into the asset\u201d (11m.55s). No \u201cMIGHT\u201d in that statement. The minimal outlay confirms that the VAL201 drug package is essentially finalised, and the entire development programme (preclinical \u2192 IND \u2192 partnering) is about to move forward. Mark has already confirmed Val will be diluting the asset, not Val PLC. With patents imminent, it\u2019s a clear signal that Blue Ribbon is not just a corporate shell \u2014 it\u2019s actively progressing VAL201 toward monetisation. Given Val\u2019s recent multi facet RNS style, the imminent update could well bundle new patent status with partnership confirmation. The last significant VAL201 update in 2021 saw the Val SP exceed 50p.",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.365",
          "thread_title": "Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-21T00:53:53.250318Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261539-Porky9--3314119",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.454210",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Err nope Only thing that will bring hard cash into the company of any meaningful amount in the next 8 weeks will be new placing money - sorry Regarding your continual pumps and fluffy updates, jam tommorrow dream fantasy posts, NONE of it can pay the bills now, end of. Anyone with any brains will be working the sells into any mupets trading this that are oblivious to the dire need for cash to keep the lights on and the pending essential discounted placing that has to happen to support the lifestyles here to keep the gravy train going. Tick Tock, Tick Tock",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.35",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-21T00:53:53.250291Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261804-uxm484-27742704",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.453777",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Plenty of news to come at a tiny valuation and likely this month. Cash until at least July that without warrants, revenue, deals, grants. Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-21T00:53:53.250264Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261952-Notpotal-68803067",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.453357",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Porky, unlike some holders, I still keep you around for the entertainment value.  Calling Nick and other traders \u2018muppets\u2019 is certainly \u2026.\u201dcreative\u201d. \ud83d\ude00 Jaspal S and Stephen W dipping just under the 3% is nothing more than freeing up a couple of million to trade. There\u2019s no great sell-off and no drama. Most of us aren\u2019t brave enough to risk missing an RNS for the sake of a few hundred quid. Get your 40 winks while you can. Many sleepless nights await over the next few months.   \ud83e\udd71 Pleasant dreams.",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-21T00:53:53.250238Z"
      },
      {
        "event_id": "SOCIAL-14Jan20260919-Porky9-89458958",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.452920",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@Notpotalot Nick is a VERY experienced prolific investor. Frankly, i doff my cap to him as he called the trade perfectly in at .25 and out at .40. Beautiful. The Muppets are the traders in on the back of the Zac Mir pump without any research in blind on the dead cat bounce they will get burnt if still holding. As for Stephen and Jaspal at u3% they now dont have to declare BUT IMO they have about 8 weeks to slowly work the sells in to ensure they are out (just holding warrants options) before that next raise drops as they will be diluted to oblivion as sure as night is day. They can only drip sells in slowly to avoid the brokers hammering them at discount. You try selling big volumes of this close to the raise, or at anytime for that matter, you need to do it on a bounce really, sell whilst traders are buying. This is NOT an investment, its a short term punt. The reason its not an investment is because it can't generate revenue (well none in the last 15 yrs anyhow)  and is reliant on raise after raise after raise to maintain lifestyles. As I say, tick tock. Tick tock countdown already started imo.",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-21T00:53:53.250211Z"
      },
      {
        "event_id": "SOCIAL-14Jan20260954-uxm484-27742704",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.452484",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Plenty of news to come at a tiny valuation and likely this month. Cash until at least July that without warrants, revenue, deals, grants. Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-21T00:53:53.250184Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261107-ratcliff-74337020",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.452055",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "UXM - cutting and pasting the same post repeatedly is not convincing, but to humour you I had a listen to the link you have monotonously posted. It's not persuasive or convincing - Starts off about the 'objectives we have set' and 'milestones we're looking to achieve.' Then there's a bit about the group structure - this is rearranging the deck chairs on the Titanic isn't it? They've had more rearrangements over the decades, it's just a distraction now - meetings are the practical alternative to work. The we hear 'The objective is...' and 'If suitable...'  So nothing at all certain. Then he says BC201 and Val301 have 'not been spun out yet, but would benefit from all of the development work undertaken on Val201.' So BC201 and Val301 still of no interest (except maybe on Antiques Roadshow) and if Val201 had even a glimmer of potential it would have done something since it was quietly shelved - was that 6 years ago or 8? It's been stagnant for so long, the rest of the industry has moved on. The he says 'There is strong interest in endometriosis treatments.' True. There's strong interest in a lot of things, but stating a fact doesn't tie it to VAL. 'We have two new evaluations under consideration.' And...? I\u2019ve got a lot of things under consideration, but whether they get any further is often very uncertain. 'The vision is...' - A lot of people have visions, but a vision isn't even a plan. It's a nice idea at best. 'Our strategy is to do this based on identifying the highest quality assets we can find and afford.' That's like saying 'come round to my place for a meal' and when you get there you say 'There\u2019s a tin of Pedigree Chum between the four of us - it was the highest quality I could find on the available budget.' The he's going to have a system which 'allows us to prioritise selection of assets.' How early stage is all this? And no money to do it with.. Next we see \u2018The Team\u2019 but no mention of their salaries. Then a review of last year - no mention of the placings. Talk of last year's cost savings and redundancies - but if you are cutting 200k a year and laying people off, what were you wasting the money on in the first place? Or have you sold your food to pay the heating bill? Then he says 'Our runway through 2026' - sorry - that 'runway' stops in a couple of months without a placing. The 2026 Xmas do is potentially in the Job Centre unless money comes in very soon. Time is money. They seem dangerously short of both. Again.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.355",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-21T00:53:53.250158Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261145-Marty130--5883617",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.451594",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Be good to see the directors buying some of the stock..",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "0.355",
          "thread_title": "Directors deals",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=DC2D2A2F-B451-4EEF-B7C8-9C80695D4033"
        },
        "ingested_at": "2026-01-21T00:53:53.250130Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261224-paternos-12455426",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.451186",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "A \u00a33m microcap with a cash runway till H2 even before factoring in R&D tax credits, potential grant funding, additional Inaphaea income or warrant cash now within reach. Outgoings reduced by \u00a3200k PA following a team restructuring last year. Val\u2019s expansion into NAMs and advanced AI tech, supported by strong academic partnerships, aligns directly with revised US & UK gov\u2019t guidelines to reduce animal testing. This positions Val as a front runner for non dilutive grants and innovation funding, with a CEO geared to capitalise on this opportunity. The 1/9/25 RNS confirmed ongoing discussions with several potential partners to progress Cytolytix, including a major pharma. Val owns 60% of CLX with 10% owned by co-inventor, Dr Charles Chen (Senior Scientist at Astrazeneca). Val also has a 54% share of an Ambrose deal potentially worth up to \u00a316m, and a Biobank of 476 PDCs valued at \u00a310k per PDC cell-line upon commercialisation, plus commercial rights entitlement. Valirx has assets in several key cancer indications, all with huge global markets: 201/prostate ($11.3Bn*), CLX (primarily TNBC ($1.5Bn*), ovarian ($2.5Bn*) but also prostate, 301/endometriosis ($1.9Bn**), and 401-Ambrose/pancreatic ($2.9Bn**). Sources: *webinar, **GMI. Several RNS updates are imminent: CLX patents \u201cin coming weeks.\u201d (RNS 1/9/25), Dundee/Queen Mary project (extended to 9/2/26), StingRay (approx Feb \u201926 per Aug video), Blue Ribbon SPV - \u201cSeveral patents envisaged for 201\u201d, and the next evaluation/SPV \u201cimminent with discussions already at a mature stage\u201d. The Omios RNS (3/6/25) stated \u201c\u2026 expected to take up to 12 months. On conclusion of the evaluation, Omios has an option to enter into an Oncolytic Peptide License Agreement to continue using Cytolytix technology.\u201d Yet another potential source of income. In addition, the Val/Dominion repurposing project (teaching an old drug new tricks) has identified 200 FDA approved non-oncology drugs which already have phase 1 clinical data and are showing activity against various cancer PDCs. 10 of these candidates are now being fast-tracked. The median upfront deal size for pre-clinical IND ready assets was $110m in 2025. For phase 2 this increased to $775m. (Dec webinar). For context, Val\u2019s SP exceeded 55p in 2021 with only one key asset (VAL201). Currently, including the repurposing project, Val now has 200+ potential assets plus a valuable Biobank. Also, Mark has restructured evaluation agreements whereby if Val chooses not to progress an asset (eg StingRay, McGill/IRICoR), Inaphaea retains the data and can still monetise should a 3rd party take the asset forward. Multiple monetisation routes now sit across the pipeline, supported by a commercially-savvy CEO who now owns 7% of the company. Valirx \u2013 a microcap with midcap potential.",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.355",
          "thread_title": "Why invest? \u2013 FINANCIAL",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=8931CA86-EC8C-43F3-AA7F-54C7D7FD717E"
        },
        "ingested_at": "2026-01-21T00:53:53.250083Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261313-paternos-49926690",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.450725",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "When Mark became CEO, ValirRx was effectively dormant - few assets in play, minimal Board investment and limited vision. He set about a major restructuring: rebuilding the team, reshaping the asset base and above all, resetting the mindset. Fast forward 17 months and Val is reborn. A microcap expanding into developing fields of oncology, yet every action taken has a cost/benefit analysis and timescale consideration. If concluded that a project cannot be monetised early, it is shelved or paused. Commercial decisions overrule all others. Valirx is now plugged into some of the most advanced platforms in modern drug development: \u2022\tpatient avatars (TwinEdge) \u2022\tmicrofluidics/3D tissue culture models (Screenin3D, Ignota & VoxCell) \u2022\trepurposing (Ignota, Altus & Dominion) \u2022\tpersonalised immunotherapy (PredictRx / Dominion) \u2022\tpro-senescence drugs (Dundee / Queen Mary Uni) \u2022\tClickmer technology/HER2 protein (Apis Assay) \u2022\tLMTK3 kinase targeting (StingRay). The most recent evaluation, a 2nd-gen RNA helicase inhibitor (McGill/IRICoR), brings Val into collaboration with major international research organisations. Last year, Mark identified a shift away from animal-testing and moved early to establish capability partners supporting NAMs and cutting-edge AI. Recent US & UK Gov\u2019t regulatory changes now actively favour such platforms with Europe to follow this year. Once again, Val anticipated this trend before much of the market. Meanwhile, the Advisory Board has been upgraded from academics and towards industry experts who can provide insight into Big Pharma priorities and identify new commercial pathways such as in veterinary science - quicker to market while opening a parallel revenue path thru\u2019 comparative oncology, further de risking the route to human oncology. Mark has also added a clause into evaluation agreements whereby if Val decides not to progress an asset eg StingRay, McGill/IRICoR, then Inaphaea retains the data and can still monetise should a 3rd party take the asset forward. Val is no longer waiting for opportunity; it is engineering it.",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.385",
          "thread_title": "Why invest? \u2013 THE SCIENCE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=058BF091-3235-424B-9C46-FA00ED6BC8D5"
        },
        "ingested_at": "2026-01-21T00:53:53.250056Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261430-nomlungu-65019403",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.450256",
        "source": "LSE_CHAT",
        "data": {
          "author": "nomlungu",
          "content": "People should just ignore Rat... he is just jealous that he does not have the losses to use to reduce his tax liabilities. That 80% drop in the last tax year will have been very valuable for some; I think him moaning around the time that taxes are due for the 2024/25 year is a dead give away. \ud83d\udcc9 \u2757",
          "sentiment": 0.0,
          "engagement": "23,945",
          "price_at_post": "0.395",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-21T00:53:53.250030Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261432-mikee_p--9712878",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.449822",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "1 HR. Channel is all ya need.",
          "sentiment": 0.0,
          "engagement": "1,887",
          "price_at_post": "0.395",
          "thread_title": "Easy trade this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=81274FD9-0226-45F3-8CEA-B1F91E33B4A2"
        },
        "ingested_at": "2026-01-21T00:53:53.250003Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261503-Mr0nions-24537284",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:42.449390",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mr0nions",
          "content": "Because of this  post, I'm holding position.  Good luck all.",
          "sentiment": 0.0,
          "engagement": "1,965",
          "price_at_post": "0.41",
          "thread_title": "RE: Why invest? \u2013 THE SCIENCE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=058BF091-3235-424B-9C46-FA00ED6BC8D5"
        },
        "ingested_at": "2026-01-21T00:53:53.249976Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261507-ratcliff--7606657",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.630901",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "You swine Nomlungu. You've rumbled me.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.41",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-21T00:53:53.249949Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261719-Porky9--3892735",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.630496",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "And just a few reasons why not to believe the BS from the resident rampers here and why you should avoid:- * Lifestyle Business * Ridiculous Admin costs * Continual Raises and continual dilution * More than 20 Raises, 3 lots of 125:1 Consolidation events * business concept never proven * Rented lab space and zero revenue in 15 years * About 8 weeks cash runway left with yet another raise due anytime soon to keep the gravy train going. * if new investors or brokers say enough is enough and call time due to clients continually losing money then its admin and you could lose your entire investment. * materially overpriced as absoluly nothing here to invest in, its the emperors new clothes you are buying. 201 is older than hens teeth, no interest in 15 years and CLX years off and more cash required. Labs meanwhile doesnt know what an invoice is. * Poor decision making, lack of any commercial acumen *No real focus, practically everyone is work from home with multiple jobs. * Short term punts only not a long hold due to above. * loads of stock held for broker fees that will need to be drip fed into anyone buying. In all avoid at all costs unless you like dilution",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.385",
          "thread_title": "Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-21T00:53:53.249922Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261733-uxm484-53931531",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.630027",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "All lies. Watch the video previously posted. Past management issues but new management outstanding.  Cash until H2 without the add ons. CEO heavily invested over 250k. Negotiating with a major biotech in regards to a deal for CLX001. Lab space is to help progress the assets to eventually get a deal not to make instant revenue. Any research on CLX001 done against a valuation of 2 million and cash burn just over a million would know this is a great opportunity. Brokers only had 20k stock. Hardly lots of stock. Great decision making. Derisking assets with partnership deals.  Which other biotech has so much spending less than 2 million. With warrants at a premium to the current price hopefully no more dilutions.",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.385",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-21T00:53:53.249896Z"
      },
      {
        "event_id": "SOCIAL-14Jan20262049-ratcliff--7216636",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.629590",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Whatever it is you're smoking UXM, it's powerful stuff.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.385",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-21T00:53:53.249869Z"
      },
      {
        "event_id": "SOCIAL-15Jan20260857-Notpotal--6263717",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.629186",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "\u201cYou can't go back and change the beginning, but you can start where you are and change the ending.\" \u2013 C.S. Lewis Early in his tenure, Mark acknowledged mistakes had been made \u2014 and while he couldn\u2019t rewrite the past, he could reshape the future. 17 months later, Val is reborn, with money in the bank, a rebuilt team, high calibre assets and a SH base that deserves success after years of one-way support. A few resident historians cling to their preferred mythology, inventing a minimal cash runway because the real picture is too uncomfortable to accept: a cash runway to H2 even without R&D tax credits, additional Inaphaea income, grants or exercised warrants. This is also before the wave of RNS due over the coming weeks. Unlike those posting fiction, Mark has backed his conviction with his own money \u2014 now holding 7% of the company. \u201cWhat matters now is not where we\u2019ve been, but where we\u2019re going.\u201d",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.365",
          "thread_title": "Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-21T00:53:53.249842Z"
      },
      {
        "event_id": "SOCIAL-15Jan20260920-RayPoint--1099657",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.628750",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Living in fantasy land",
          "sentiment": 0.0,
          "engagement": "5,057",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-21T00:53:53.249815Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261050-Rebster4-45088296",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.628339",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rebster408",
          "content": "Its groundhog day again This is a binary bet...and Poky has called it right in the past and I thinks he's spot on again... 201 is older than me!!! place your bets... the wheel is spinning and will stop within the next 8 weeks All will become clear within the next two months...",
          "sentiment": 0.0,
          "engagement": "1,173",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-21T00:53:53.249789Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261059-viera-43956140",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.627900",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Are you PM in disguise ? Who in  their right mind would buy any company on Aim with only 3 or 4 months cash runway? You sound so so desperate for a rally to sell out !",
          "sentiment": 0.0,
          "engagement": "1,549",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-21T00:53:53.249762Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261201-ratcliff-10401959",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.627485",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "UXM - differences of opinion are generally understandable, but to say in your post 'All lies' is blatantly true and misleading, and as usual does nothing to bolster your credibility. Two of the things you say in that post are particularly inaccurate - 'Great decision making. Derisking assets with partnership deals. Which other biotech has so much spending less than 2 million.' - They are looking for deals (or claim to be anyway) but nothing so far has contributed anything to even cover the outgoings, let alone provide money for further work or expansion (hence the redundancies etc) Secondly - 'With warrants at a premium to the current price hopefully no more dilutions' - warrants don't kick in and generate cash the moment the sp goes above them as you and the others in your group seem to imply. In the unlikely event of the sp rising above that point and remaining so, it just might be worth warrant holders exercising them so they could buy shares at below the then-current price, but to sell them they'd need to be able to be sure the sp was strong enough to withstand the effect of the sells. You know that, so stop trying to imply that the mere existence of warrants is a long-term fool proof source of near or long term capital. Then again, if this company was fool proof you wouldn't be here I imagine.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.365",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-21T00:53:53.249735Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261207-ratcliff--7070626",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.627050",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Slight typo there - should read blatantly UNTRUE and misleading!",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.365",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-21T00:53:53.249708Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261222-Notpotal-18639818",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.626646",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "\u201cYou sound so desperate\u201d says the man who\u2019s last 60 posts have been on a share he isn\u2019t invested in. \ud83d\ude02\ud83d\ude02\ud83d\ude02",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-21T00:53:53.249681Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261935-uxm484-75511497",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.626237",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "No, but the holders all want the warrants exercised so we can do a 10 bagger in 12 months without a fund raise. For me i am really happy here with  the progression. We are definitely early in a news rich periods where all the negative posters are posting overtime and are only posting as they missed out on the last fundraise hoping for an even lower price. We will likely get a few meaningful RNS very soon. Brakes are now off\u2026",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.36",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-21T00:53:53.249654Z"
      },
      {
        "event_id": "SOCIAL-19Jan20261216-steve196-28428650",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.625812",
        "source": "LSE_CHAT",
        "data": {
          "author": "steve196",
          "content": "How much does it cost to release an RNS just for \u00a3400 of warrants?",
          "sentiment": 0.0,
          "engagement": "2,745",
          "price_at_post": "0.385",
          "thread_title": "Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-21T00:53:53.249628Z"
      },
      {
        "event_id": "SOCIAL-19Jan20261311-ratcliff-38431638",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.625400",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Probably about 450 quid...",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-21T00:53:53.249600Z"
      },
      {
        "event_id": "SOCIAL-19Jan20261357-spantrou--1224196",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.624977",
        "source": "LSE_CHAT",
        "data": {
          "author": "spantrout",
          "content": "\u00a39.99 for rns",
          "sentiment": 0.0,
          "engagement": "13,941",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-21T00:53:53.249574Z"
      },
      {
        "event_id": "SOCIAL-19Jan20261412-RayPoint-69344430",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.624573",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "\"Probably about 450 quid...\" Rats, stop ramping! The gross proceeds were \u00a3400",
          "sentiment": 0.0,
          "engagement": "5,057",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-21T00:53:53.249547Z"
      },
      {
        "event_id": "SOCIAL-19Jan20261413-RayPoint-59410047",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.624156",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Sorry Rats. I misinterpreted your post.",
          "sentiment": 0.0,
          "engagement": "5,057",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-21T00:53:53.249520Z"
      },
      {
        "event_id": "SOCIAL-19Jan20261434-ratcliff--6459760",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.623733",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "No problem RP - I'm wondering who paid 0.50 for a few shares worth about 25 percent less from the start, but I suppose 400 quid pays for the week's teabags and digestives.",
          "sentiment": 0.0,
          "engagement": "11,392",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-21T00:53:53.249492Z"
      },
      {
        "event_id": "SOCIAL-19Jan20261529-RayPoint--5039743",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.623326",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "I hear that green fees are pretty steep in California",
          "sentiment": 0.0,
          "engagement": "5,057",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-21T00:53:53.249465Z"
      },
      {
        "event_id": "SOCIAL-19Jan20261534-Notpotal--7270198",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.622907",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Val is obliged to RNS as it a change to No. shares in issue. Hardly the company\u2019s fault if a holder sees such value that he wants to buy above the current SP. Mind you, I\u2019m expecting a TR1 tomorrow to confirm Mark\u2019s holding has increased by 80,000 shares. \ud83e\udd23 If this is the reaction to \u00a3400 of warrants, heaven help Porky\u2019s groupies when the next material RNS arrives.  \ud83e\udee8 \ud83d\ude28 \ud83d\ude22\ud83d\ude2d",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-21T00:53:53.249438Z"
      },
      {
        "event_id": "SOCIAL-19Jan20261543-Notpotal-89904432",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.622489",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "I notice a 71430 buy at 15.14 and a similar sell 4 mins later for a \u00a321 loss. Great to see Porky has started trading again!  \ud83e\udd23\ud83e\udd23\ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "76",
          "price_at_post": "0.385",
          "thread_title": "Welcome back, Porky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=FE350133-0204-48E9-9785-7F80407B3421"
        },
        "ingested_at": "2026-01-21T00:53:53.249411Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260943-paternos--8749124",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.622061",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Mark re JPM in San Fran -  \u201cI have meetings lined up with our partner Omios Biologics so looking forward to catching up with Aldo Pourchet (CEO).\u201d In the Omios RNS (3/6/25), the evaluation was \u201cexpected to run up to 12 months, after which Omios can exercise its license option to continue using Cytolytix technology.\u201d Across both the June and Dec webinars, Mark emphasised CLX synergy with the Omios virus for potential to treat canine HSA, a clear signal that Omios sits firmly in the frame for a CLX licence. Valirx\u2019s revamped Advisory Board reinforces this direction, now with a notable weighting toward veterinary oncology and commercial expertise. The composition reflects a deliberate strategy to position CLX across both human and animal oncology. When your advisory structure is rebuilt around people who understand canine cancers, comparative oncology, and veterinary commercial pathways, it becomes clear Valirx is preparing for licensing routes across both human and veterinary markets. As a co-founder of VolitionRx, Mark transformed a human cancer test into a canine diagnostic test (Nu.Q) before negotiating a licencing deal with Heska for $26m. What price a cure? Human and veterinary oncology operate in separate regulatory and commercial channels. Most major pharmas, inc. AZN, Roche, GSK, AbbVie do NOT have any vet divisions. Even those historically involved have spun off their animal health units (Pfizer \u2192 Zoetis, Eli Lilly \u2192 Elanco). By envisaging veterinary opportunities for CLX, Mark is implicitly confirming the compound won\u2019t be a one partner asset; the split infrastructures required make multiple CytoLytix deals the only realistic outcome. GLA, DYOR, AIMO",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.385",
          "thread_title": "Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-01-21T00:53:53.249385Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261329-Porky9--6529739",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.621627",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@PP Yes, and as long as the rain holds off should be able to get some golf in on expenses. Who needs Zoom and Teams when you can have a nice all expenses trip to the US. Lovely. Keep pumping it, only a few weeks now to go before next placing @notpotatlot Only Update you will get shortly that isn't fluff, will be the placing news or the next 125:1 consolidation event which has to be well over due now. Keep ramping it though, the gravy train needs to stay on the tracks, there are lifestyles here that need to be maintained.",
          "sentiment": 0.0,
          "engagement": "7,464",
          "price_at_post": "0.385",
          "thread_title": "RE: Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-01-21T00:53:53.249357Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261459-Notpotal-59319848",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.621190",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Some clever trading going on here \u2013 those selling at 0.37p will soon be able to buy back at 0.39p. \ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "76",
          "price_at_post": "0.385",
          "thread_title": "RE: Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-01-21T00:53:53.249328Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261513-paternos-73909754",
        "event_type": "social_post",
        "date": "2026-01-21T00:53:37.620749",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "\u201cValix is in discussions with several potential partners to progress CytoLytix, including a major pharma\u201d. So, why is Mark, currently in California, continuing to promote the compound so actively both in the UK and overseas? While it\u2019s plausible a major pharma might seek exclusivity, the most realistic outcome is exclusive rights carved by territory, formulation, indication, or even species (human/veterinary)\u2014leaving room for multiple, parallel deals outside that scope. Indication splits are historically used when partners specialise in different therapeutic areas (eg ovarian only). Geographic exclusivity is even more common. The TrX/201 deal eventually failed when Mark attempted to remove Taiwan from the original LOI. The veterinary angle highlighted in recent webinars reinforces that CLX spans markets no single pharma can cover, making a multi partner licensing model far more realistic than a single global licence. There are numerous real world examples of multi partner licensing structures in biopharma: TERRITORY - Immunex (Enbrel) / initially Amgen \u2192 US & Canada rights, then Wyeth (later Pfizer) \u2192 Europe + Rest of World rights FORMULATION - Gilead (Tamiflu) / initially Roche \u2192 Oral formulation rights, then Hetero & Teva, \u2192 sublicenses for additional formulations INDICATION - AstraZeneca (Lynparza) / Merck \u2192 initially Ovarian cancer rights, then subsequently obtained licenses for breast and pancreatic cancers. Each example above shows one originator, no single-party lock in and multiple partners or deals to acquire different rights. With so many variables in play, it is increasingly clear that Valirx is preserving the same optionality for CytoLytix. Mark is still promoting CytoLytix because he is targeting several partners \u2013 not just one. Everything suggests CLX is being shaped as a multi deal platform, with the first handshake simply opening the monetisation cycle -",
          "sentiment": 0.5,
          "engagement": "356",
          "price_at_post": "0.385",
          "thread_title": "CLX - multi deal structure",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D1488F3A-09F4-41C4-B45B-AF908B85E267"
        },
        "ingested_at": "2026-01-21T00:53:53.249294Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261042-paternos--8460207",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:59.021363",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "As standard, when Mark did the Dec webinar he emphasised nothing new, \u201cjust meat on the bones\u201d. However, often that meat can be pretty tasty. Blue Ribbon/VAL201 \u2013 \u201csynthesis almost complete\u201d (10m.30s). Then, \u201ca small amount (only \u00a350k) set aside for pre-clinical development of 201, the balance WILL then come from external investment into the asset\u201d (11m.55s). No \u201cMIGHT\u201d in that statement. The minimal outlay confirms that the VAL201 drug package is essentially finalised, and the entire development programme (preclinical \u2192 IND \u2192 partnering) is about to move forward. Mark has already confirmed Val will be diluting the asset, not Val PLC. With patents imminent, it\u2019s a clear signal that Blue Ribbon is not just a corporate shell \u2014 it\u2019s actively progressing VAL201 toward monetisation. Given Val\u2019s recent multi facet RNS style, the imminent update could well bundle new patent status with partnership confirmation. The last significant VAL201 update in 2021 saw the Val SP exceed 50p.",
          "sentiment": 0.5,
          "engagement": "354",
          "price_at_post": "0.365",
          "thread_title": "Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-16T22:22:09.312565Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261539-Porky9--1004500",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.735888",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Err nope Only thing that will bring hard cash into the company of any meaningful amount in the next 8 weeks will be new placing money - sorry Regarding your continual pumps and fluffy updates, jam tommorrow dream fantasy posts, NONE of it can pay the bills now, end of. Anyone with any brains will be working the sells into any mupets trading this that are oblivious to the dire need for cash to keep the lights on and the pending essential discounted placing that has to happen to support the lifestyles here to keep the gravy train going. Tick Tock, Tick Tock",
          "sentiment": 0.0,
          "engagement": "7,463",
          "price_at_post": "0.35",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-16T22:22:09.312538Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261804-uxm484--6586835",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.735465",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Plenty of news to come at a tiny valuation and likely this month. Cash until at least July that without warrants, revenue, deals, grants. Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-16T22:22:09.312511Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261952-Notpotal--6501034",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.735041",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Porky, unlike some holders, I still keep you around for the entertainment value.  Calling Nick and other traders \u2018muppets\u2019 is certainly \u2026.\u201dcreative\u201d. \ud83d\ude00 Jaspal S and Stephen W dipping just under the 3% is nothing more than freeing up a couple of million to trade. There\u2019s no great sell-off and no drama. Most of us aren\u2019t brave enough to risk missing an RNS for the sake of a few hundred quid. Get your 40 winks while you can. Many sleepless nights await over the next few months.   \ud83e\udd71 Pleasant dreams.",
          "sentiment": 0.5,
          "engagement": "73",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-16T22:22:09.312485Z"
      },
      {
        "event_id": "SOCIAL-14Jan20260919-Porky9-75963525",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.734619",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@Notpotalot Nick is a VERY experienced prolific investor. Frankly, i doff my cap to him as he called the trade perfectly in at .25 and out at .40. Beautiful. The Muppets are the traders in on the back of the Zac Mir pump without any research in blind on the dead cat bounce they will get burnt if still holding. As for Stephen and Jaspal at u3% they now dont have to declare BUT IMO they have about 8 weeks to slowly work the sells in to ensure they are out (just holding warrants options) before that next raise drops as they will be diluted to oblivion as sure as night is day. They can only drip sells in slowly to avoid the brokers hammering them at discount. You try selling big volumes of this close to the raise, or at anytime for that matter, you need to do it on a bounce really, sell whilst traders are buying. This is NOT an investment, its a short term punt. The reason its not an investment is because it can't generate revenue (well none in the last 15 yrs anyhow)  and is reliant on raise after raise after raise to maintain lifestyles. As I say, tick tock. Tick tock countdown already started imo.",
          "sentiment": 0.0,
          "engagement": "7,463",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-16T22:22:09.312458Z"
      },
      {
        "event_id": "SOCIAL-14Jan20260954-uxm484--6586835",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.734187",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Plenty of news to come at a tiny valuation and likely this month. Cash until at least July that without warrants, revenue, deals, grants. Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-16T22:22:09.312432Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261107-ratcliff--3042344",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.733762",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "UXM - cutting and pasting the same post repeatedly is not convincing, but to humour you I had a listen to the link you have monotonously posted. It's not persuasive or convincing - Starts off about the 'objectives we have set' and 'milestones we're looking to achieve.' Then there's a bit about the group structure - this is rearranging the deck chairs on the Titanic isn't it? They've had more rearrangements over the decades, it's just a distraction now - meetings are the practical alternative to work. The we hear 'The objective is...' and 'If suitable...'  So nothing at all certain. Then he says BC201 and Val301 have 'not been spun out yet, but would benefit from all of the development work undertaken on Val201.' So BC201 and Val301 still of no interest (except maybe on Antiques Roadshow) and if Val201 had even a glimmer of potential it would have done something since it was quietly shelved - was that 6 years ago or 8? It's been stagnant for so long, the rest of the industry has moved on. The he says 'There is strong interest in endometriosis treatments.' True. There's strong interest in a lot of things, but stating a fact doesn't tie it to VAL. 'We have two new evaluations under consideration.' And...? I\u2019ve got a lot of things under consideration, but whether they get any further is often very uncertain. 'The vision is...' - A lot of people have visions, but a vision isn't even a plan. It's a nice idea at best. 'Our strategy is to do this based on identifying the highest quality assets we can find and afford.' That's like saying 'come round to my place for a meal' and when you get there you say 'There\u2019s a tin of Pedigree Chum between the four of us - it was the highest quality I could find on the available budget.' The he's going to have a system which 'allows us to prioritise selection of assets.' How early stage is all this? And no money to do it with.. Next we see \u2018The Team\u2019 but no mention of their salaries. Then a review of last year - no mention of the placings. Talk of last year's cost savings and redundancies - but if you are cutting 200k a year and laying people off, what were you wasting the money on in the first place? Or have you sold your food to pay the heating bill? Then he says 'Our runway through 2026' - sorry - that 'runway' stops in a couple of months without a placing. The 2026 Xmas do is potentially in the Job Centre unless money comes in very soon. Time is money. They seem dangerously short of both. Again.",
          "sentiment": 0.0,
          "engagement": "11,390",
          "price_at_post": "0.355",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-16T22:22:09.312405Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261145-Marty130-32644306",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.733302",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Be good to see the directors buying some of the stock..",
          "sentiment": 0.0,
          "engagement": "1,223",
          "price_at_post": "0.355",
          "thread_title": "Directors deals",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=DC2D2A2F-B451-4EEF-B7C8-9C80695D4033"
        },
        "ingested_at": "2026-01-16T22:22:09.312378Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261224-paternos-12128703",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.732888",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "A \u00a33m microcap with a cash runway till H2 even before factoring in R&D tax credits, potential grant funding, additional Inaphaea income or warrant cash now within reach. Outgoings reduced by \u00a3200k PA following a team restructuring last year. Val\u2019s expansion into NAMs and advanced AI tech, supported by strong academic partnerships, aligns directly with revised US & UK gov\u2019t guidelines to reduce animal testing. This positions Val as a front runner for non dilutive grants and innovation funding, with a CEO geared to capitalise on this opportunity. The 1/9/25 RNS confirmed ongoing discussions with several potential partners to progress Cytolytix, including a major pharma. Val owns 60% of CLX with 10% owned by co-inventor, Dr Charles Chen (Senior Scientist at Astrazeneca). Val also has a 54% share of an Ambrose deal potentially worth up to \u00a316m, and a Biobank of 476 PDCs valued at \u00a310k per PDC cell-line upon commercialisation, plus commercial rights entitlement. Valirx has assets in several key cancer indications, all with huge global markets: 201/prostate ($11.3Bn*), CLX (primarily TNBC ($1.5Bn*), ovarian ($2.5Bn*) but also prostate, 301/endometriosis ($1.9Bn**), and 401-Ambrose/pancreatic ($2.9Bn**). Sources: *webinar, **GMI. Several RNS updates are imminent: CLX patents \u201cin coming weeks.\u201d (RNS 1/9/25), Dundee/Queen Mary project (extended to 9/2/26), StingRay (approx Feb \u201926 per Aug video), Blue Ribbon SPV - \u201cSeveral patents envisaged for 201\u201d, and the next evaluation/SPV \u201cimminent with discussions already at a mature stage\u201d. The Omios RNS (3/6/25) stated \u201c\u2026 expected to take up to 12 months. On conclusion of the evaluation, Omios has an option to enter into an Oncolytic Peptide License Agreement to continue using Cytolytix technology.\u201d Yet another potential source of income. In addition, the Val/Dominion repurposing project (teaching an old drug new tricks) has identified 200 FDA approved non-oncology drugs which already have phase 1 clinical data and are showing activity against various cancer PDCs. 10 of these candidates are now being fast-tracked. The median upfront deal size for pre-clinical IND ready assets was $110m in 2025. For phase 2 this increased to $775m. (Dec webinar). For context, Val\u2019s SP exceeded 55p in 2021 with only one key asset (VAL201). Currently, including the repurposing project, Val now has 200+ potential assets plus a valuable Biobank. Also, Mark has restructured evaluation agreements whereby if Val chooses not to progress an asset (eg StingRay, McGill/IRICoR), Inaphaea retains the data and can still monetise should a 3rd party take the asset forward. Multiple monetisation routes now sit across the pipeline, supported by a commercially-savvy CEO who now owns 7% of the company. Valirx \u2013 a microcap with midcap potential.",
          "sentiment": 0.5,
          "engagement": "354",
          "price_at_post": "0.355",
          "thread_title": "Why invest? \u2013 FINANCIAL",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=8931CA86-EC8C-43F3-AA7F-54C7D7FD717E"
        },
        "ingested_at": "2026-01-16T22:22:09.312352Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261313-paternos-18061158",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.732440",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "When Mark became CEO, ValirRx was effectively dormant - few assets in play, minimal Board investment and limited vision. He set about a major restructuring: rebuilding the team, reshaping the asset base and above all, resetting the mindset. Fast forward 17 months and Val is reborn. A microcap expanding into developing fields of oncology, yet every action taken has a cost/benefit analysis and timescale consideration. If concluded that a project cannot be monetised early, it is shelved or paused. Commercial decisions overrule all others. Valirx is now plugged into some of the most advanced platforms in modern drug development: \u2022\tpatient avatars (TwinEdge) \u2022\tmicrofluidics/3D tissue culture models (Screenin3D, Ignota & VoxCell) \u2022\trepurposing (Ignota, Altus & Dominion) \u2022\tpersonalised immunotherapy (PredictRx / Dominion) \u2022\tpro-senescence drugs (Dundee / Queen Mary Uni) \u2022\tClickmer technology/HER2 protein (Apis Assay) \u2022\tLMTK3 kinase targeting (StingRay). The most recent evaluation, a 2nd-gen RNA helicase inhibitor (McGill/IRICoR), brings Val into collaboration with major international research organisations. Last year, Mark identified a shift away from animal-testing and moved early to establish capability partners supporting NAMs and cutting-edge AI. Recent US & UK Gov\u2019t regulatory changes now actively favour such platforms with Europe to follow this year. Once again, Val anticipated this trend before much of the market. Meanwhile, the Advisory Board has been upgraded from academics and towards industry experts who can provide insight into Big Pharma priorities and identify new commercial pathways such as in veterinary science - quicker to market while opening a parallel revenue path thru\u2019 comparative oncology, further de risking the route to human oncology. Mark has also added a clause into evaluation agreements whereby if Val decides not to progress an asset eg StingRay, McGill/IRICoR, then Inaphaea retains the data and can still monetise should a 3rd party take the asset forward. Val is no longer waiting for opportunity; it is engineering it.",
          "sentiment": 0.5,
          "engagement": "354",
          "price_at_post": "0.385",
          "thread_title": "Why invest? \u2013 THE SCIENCE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=058BF091-3235-424B-9C46-FA00ED6BC8D5"
        },
        "ingested_at": "2026-01-16T22:22:09.312325Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261430-nomlungu--8703082",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.731971",
        "source": "LSE_CHAT",
        "data": {
          "author": "nomlungu",
          "content": "People should just ignore Rat... he is just jealous that he does not have the losses to use to reduce his tax liabilities. That 80% drop in the last tax year will have been very valuable for some; I think him moaning around the time that taxes are due for the 2024/25 year is a dead give away. \ud83d\udcc9 \u2757",
          "sentiment": 0.0,
          "engagement": "23,924",
          "price_at_post": "0.395",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-16T22:22:09.312299Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261432-mikee_p--2096704",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.731565",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "1 HR. Channel is all ya need.",
          "sentiment": 0.0,
          "engagement": "1,885",
          "price_at_post": "0.395",
          "thread_title": "Easy trade this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=81274FD9-0226-45F3-8CEA-B1F91E33B4A2"
        },
        "ingested_at": "2026-01-16T22:22:09.312272Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261503-Mr0nions-51724186",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.731157",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mr0nions",
          "content": "Because of this  post, I'm holding position.  Good luck all.",
          "sentiment": 0.0,
          "engagement": "1,961",
          "price_at_post": "0.41",
          "thread_title": "RE: Why invest? \u2013 THE SCIENCE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=058BF091-3235-424B-9C46-FA00ED6BC8D5"
        },
        "ingested_at": "2026-01-16T22:22:09.312245Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261507-ratcliff-58436319",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.730745",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "You swine Nomlungu. You've rumbled me.",
          "sentiment": 0.0,
          "engagement": "11,390",
          "price_at_post": "0.41",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-16T22:22:09.312218Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261719-Porky9-70054918",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.730340",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "And just a few reasons why not to believe the BS from the resident rampers here and why you should avoid:- * Lifestyle Business * Ridiculous Admin costs * Continual Raises and continual dilution * More than 20 Raises, 3 lots of 125:1 Consolidation events * business concept never proven * Rented lab space and zero revenue in 15 years * About 8 weeks cash runway left with yet another raise due anytime soon to keep the gravy train going. * if new investors or brokers say enough is enough and call time due to clients continually losing money then its admin and you could lose your entire investment. * materially overpriced as absoluly nothing here to invest in, its the emperors new clothes you are buying. 201 is older than hens teeth, no interest in 15 years and CLX years off and more cash required. Labs meanwhile doesnt know what an invoice is. * Poor decision making, lack of any commercial acumen *No real focus, practically everyone is work from home with multiple jobs. * Short term punts only not a long hold due to above. * loads of stock held for broker fees that will need to be drip fed into anyone buying. In all avoid at all costs unless you like dilution",
          "sentiment": 0.0,
          "engagement": "7,463",
          "price_at_post": "0.385",
          "thread_title": "Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-16T22:22:09.312191Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261733-uxm484-46471876",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.729871",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "All lies. Watch the video previously posted. Past management issues but new management outstanding.  Cash until H2 without the add ons. CEO heavily invested over 250k. Negotiating with a major biotech in regards to a deal for CLX001. Lab space is to help progress the assets to eventually get a deal not to make instant revenue. Any research on CLX001 done against a valuation of 2 million and cash burn just over a million would know this is a great opportunity. Brokers only had 20k stock. Hardly lots of stock. Great decision making. Derisking assets with partnership deals.  Which other biotech has so much spending less than 2 million. With warrants at a premium to the current price hopefully no more dilutions.",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.385",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-16T22:22:09.312164Z"
      },
      {
        "event_id": "SOCIAL-14Jan20262049-ratcliff--4693226",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.729441",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Whatever it is you're smoking UXM, it's powerful stuff.",
          "sentiment": 0.0,
          "engagement": "11,390",
          "price_at_post": "0.385",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-16T22:22:09.312136Z"
      },
      {
        "event_id": "SOCIAL-15Jan20260857-Notpotal-27155801",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.729023",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "\u201cYou can't go back and change the beginning, but you can start where you are and change the ending.\" \u2013 C.S. Lewis Early in his tenure, Mark acknowledged mistakes had been made \u2014 and while he couldn\u2019t rewrite the past, he could reshape the future. 17 months later, Val is reborn, with money in the bank, a rebuilt team, high calibre assets and a SH base that deserves success after years of one-way support. A few resident historians cling to their preferred mythology, inventing a minimal cash runway because the real picture is too uncomfortable to accept: a cash runway to H2 even without R&D tax credits, additional Inaphaea income, grants or exercised warrants. This is also before the wave of RNS due over the coming weeks. Unlike those posting fiction, Mark has backed his conviction with his own money \u2014 now holding 7% of the company. \u201cWhat matters now is not where we\u2019ve been, but where we\u2019re going.\u201d",
          "sentiment": 0.5,
          "engagement": "73",
          "price_at_post": "0.365",
          "thread_title": "Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-16T22:22:09.312088Z"
      },
      {
        "event_id": "SOCIAL-15Jan20260920-RayPoint--9062316",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.728601",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Living in fantasy land",
          "sentiment": 0.0,
          "engagement": "5,050",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-16T22:22:09.312061Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261050-Rebster4--2588584",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.728192",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rebster408",
          "content": "Its groundhog day again This is a binary bet...and Poky has called it right in the past and I thinks he's spot on again... 201 is older than me!!! place your bets... the wheel is spinning and will stop within the next 8 weeks All will become clear within the next two months...",
          "sentiment": 0.0,
          "engagement": "1,173",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-16T22:22:09.312033Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261059-viera-62193937",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.727761",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Are you PM in disguise ? Who in  their right mind would buy any company on Aim with only 3 or 4 months cash runway? You sound so so desperate for a rally to sell out !",
          "sentiment": 0.0,
          "engagement": "1,549",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-16T22:22:09.312006Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261201-ratcliff--2036769",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.727345",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "UXM - differences of opinion are generally understandable, but to say in your post 'All lies' is blatantly true and misleading, and as usual does nothing to bolster your credibility. Two of the things you say in that post are particularly inaccurate - 'Great decision making. Derisking assets with partnership deals. Which other biotech has so much spending less than 2 million.' - They are looking for deals (or claim to be anyway) but nothing so far has contributed anything to even cover the outgoings, let alone provide money for further work or expansion (hence the redundancies etc) Secondly - 'With warrants at a premium to the current price hopefully no more dilutions' - warrants don't kick in and generate cash the moment the sp goes above them as you and the others in your group seem to imply. In the unlikely event of the sp rising above that point and remaining so, it just might be worth warrant holders exercising them so they could buy shares at below the then-current price, but to sell them they'd need to be able to be sure the sp was strong enough to withstand the effect of the sells. You know that, so stop trying to imply that the mere existence of warrants is a long-term fool proof source of near or long term capital. Then again, if this company was fool proof you wouldn't be here I imagine.",
          "sentiment": 0.0,
          "engagement": "11,390",
          "price_at_post": "0.365",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-16T22:22:09.311979Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261207-ratcliff-71605073",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.726903",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Slight typo there - should read blatantly UNTRUE and misleading!",
          "sentiment": 0.0,
          "engagement": "11,390",
          "price_at_post": "0.365",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-16T22:22:09.311952Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261222-Notpotal-92122714",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.726496",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "\u201cYou sound so desperate\u201d says the man who\u2019s last 60 posts have been on a share he isn\u2019t invested in. \ud83d\ude02\ud83d\ude02\ud83d\ude02",
          "sentiment": 0.5,
          "engagement": "73",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-16T22:22:09.311924Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261935-uxm484-65329776",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.726068",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "No, but the holders all want the warrants exercised so we can do a 10 bagger in 12 months without a fund raise. For me i am really happy here with  the progression. We are definitely early in a news rich periods where all the negative posters are posting overtime and are only posting as they missed out on the last fundraise hoping for an even lower price. We will likely get a few meaningful RNS very soon. Brakes are now off\u2026",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "0.36",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-16T22:22:09.311894Z"
      },
      {
        "event_id": "SOCIAL-Today2100-Gilders0--9107409",
        "event_type": "social_post",
        "date": "2026-01-16T22:21:53.725629",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gilders01",
          "content": "Shirkers Shirking, Traders Trading.",
          "sentiment": 0.0,
          "engagement": "1,156",
          "price_at_post": "0.385",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-16T22:22:09.311858Z"
      },
      {
        "event_id": "SOCIAL-9Jan20260738-GoldieLo-35087743",
        "event_type": "social_post",
        "date": "2026-01-11T15:05:59.798384",
        "source": "LSE_CHAT",
        "data": {
          "author": "GoldieLock",
          "content": "NewCo will seek external non-dilutive and dilutive funding and ValiRx (and potentially other investors arranged by ValiRx) may, subject to availability of funds, provide up to \u00a32 million of seed funding (\"Seed Funding\"). Any such Seed Funding would be provided in tranches in line with the cash requirements, in exchange for further equity under a development plan provided by the Company. Funding other than the Seed Funding shall dilute all shares pari passu.",
          "sentiment": 0.0,
          "engagement": "1,327",
          "price_at_post": "0.41",
          "thread_title": "Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-12T22:05:10.446644Z"
      },
      {
        "event_id": "SOCIAL-9Jan20260738-GoldieLo-78528091",
        "event_type": "social_post",
        "date": "2026-01-11T15:05:59.798384",
        "source": "LSE_CHAT",
        "data": {
          "author": "GoldieLock",
          "content": "NewCo will seek external non-dilutive and dilutive funding and ValiRx (and potentially other investors arranged by ValiRx) may, subject to availability of funds, provide up to \u00a32 million of seed funding (\"Seed Funding\"). Any such Seed Funding would be provided in tranches in line with the cash requirements, in exchange for further equity under a development plan provided by the Company. Funding other than the Seed Funding shall dilute all shares pari passu.",
          "sentiment": 0.0,
          "engagement": "1,327",
          "price_at_post": "0.41",
          "thread_title": "Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-16T22:22:09.312996Z"
      },
      {
        "event_id": "SOCIAL-9Jan20260745-Badsterm-11279406",
        "event_type": "social_post",
        "date": "2026-01-11T15:05:59.797958",
        "source": "LSE_CHAT",
        "data": {
          "author": "Badsterman",
          "content": "You're an idiot. The shares in \"Newco\" would be diluted to provide funding, not Valirx. In any case the agreement is for nine months, by which time Val will have run out of cash anyway. \"IRICoR will establish a Canadian registered, wholly owned, subsidiary (\"NewCo\")\" READ THE RNS.",
          "sentiment": 0.0,
          "engagement": "927",
          "price_at_post": "0.41",
          "thread_title": "RE: Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-12T22:05:10.446589Z"
      },
      {
        "event_id": "SOCIAL-9Jan20260745-Badsterm-19212422",
        "event_type": "social_post",
        "date": "2026-01-11T15:05:59.797958",
        "source": "LSE_CHAT",
        "data": {
          "author": "Badsterman",
          "content": "You're an idiot. The shares in \"Newco\" would be diluted to provide funding, not Valirx. In any case the agreement is for nine months, by which time Val will have run out of cash anyway. \"IRICoR will establish a Canadian registered, wholly owned, subsidiary (\"NewCo\")\" READ THE RNS.",
          "sentiment": 0.0,
          "engagement": "927",
          "price_at_post": "0.41",
          "thread_title": "RE: Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-16T22:22:09.312969Z"
      },
      {
        "event_id": "SOCIAL-9Jan20260757-GoldieLo-22323961",
        "event_type": "social_post",
        "date": "2026-01-11T15:05:59.797540",
        "source": "LSE_CHAT",
        "data": {
          "author": "GoldieLock",
          "content": "No. You are the fool. The phrase \"subject to availability of funds\" is the most important part of that sentence. It is a classic \"legal out.\" It tells you that while ValiRx wants to put up \u00a32 million, they don't necessarily have that cash sitting in the bank ready to go right now. To get that \u00a32 million, ValiRx essentially has three options: 1. Use existing cash: If they have it (unlikely to be the full amount given their typical burn rate). 2. External partners: They mentioned \"other investors arranged by ValiRx\" might step in. 3. A Placing (Equity Raise): If they can't find the money elsewhere and decide this project is a priority, they would need to raise more capital by issuing new shares.",
          "sentiment": 0.0,
          "engagement": "1,327",
          "price_at_post": "0.425",
          "thread_title": "RE: Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-12T22:05:10.446533Z"
      },
      {
        "event_id": "SOCIAL-9Jan20260757-GoldieLo-87686831",
        "event_type": "social_post",
        "date": "2026-01-11T15:05:59.797540",
        "source": "LSE_CHAT",
        "data": {
          "author": "GoldieLock",
          "content": "No. You are the fool. The phrase \"subject to availability of funds\" is the most important part of that sentence. It is a classic \"legal out.\" It tells you that while ValiRx wants to put up \u00a32 million, they don't necessarily have that cash sitting in the bank ready to go right now. To get that \u00a32 million, ValiRx essentially has three options: 1. Use existing cash: If they have it (unlikely to be the full amount given their typical burn rate). 2. External partners: They mentioned \"other investors arranged by ValiRx\" might step in. 3. A Placing (Equity Raise): If they can't find the money elsewhere and decide this project is a priority, they would need to raise more capital by issuing new shares.",
          "sentiment": 0.0,
          "engagement": "1,327",
          "price_at_post": "0.425",
          "thread_title": "RE: Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-16T22:22:09.312943Z"
      },
      {
        "event_id": "SOCIAL-9Jan20260812-ratcliff-66238882",
        "event_type": "social_post",
        "date": "2026-01-11T15:05:59.797083",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Looks like the string of hope-raising RNSs ahead of the next placing is starting even earlier than anticipated. Stand by for more fluffy announcements that 'could generate up to x billion pounds in five years subject to funding, institutional investment etc etc.' This will run in tandem with lots of pumping posts with 'if', 'could', 'might' and 'maybe' as a framework.",
          "sentiment": 0.0,
          "engagement": "11,385",
          "price_at_post": "0.415",
          "thread_title": "RE: Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-12T22:05:10.446479Z"
      },
      {
        "event_id": "SOCIAL-9Jan20260812-ratcliff--8085113",
        "event_type": "social_post",
        "date": "2026-01-11T15:05:59.797083",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Looks like the string of hope-raising RNSs ahead of the next placing is starting even earlier than anticipated. Stand by for more fluffy announcements that 'could generate up to x billion pounds in five years subject to funding, institutional investment etc etc.' This will run in tandem with lots of pumping posts with 'if', 'could', 'might' and 'maybe' as a framework.",
          "sentiment": 0.0,
          "engagement": "11,385",
          "price_at_post": "0.415",
          "thread_title": "RE: Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-16T22:22:09.312915Z"
      },
      {
        "event_id": "SOCIAL-9Jan20260816-Badsterm-21351909",
        "event_type": "social_post",
        "date": "2026-01-11T15:05:59.796583",
        "source": "LSE_CHAT",
        "data": {
          "author": "Badsterman",
          "content": "No, Your thread is clearly entitled \"Placing coming, what we thinking? 0.2\" Why would Valirx raise funds for an evaluation that has nine months before it's even completed and the results known? We all know Val probably have five months cash (debatable) at most. Your thread title is scaremongering nonsense.",
          "sentiment": 0.0,
          "engagement": "927",
          "price_at_post": "0.415",
          "thread_title": "RE: Placing coming - what we thinking? 0.2?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=31B00B57-20E0-448D-A43B-32671509F49C"
        },
        "ingested_at": "2026-01-12T22:05:10.446422Z"
      },
      {
        "event_id": "SOCIAL-23Jan20262133-paternos-35760129",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.646223",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Seven consecutive \u201cblocked\u201d posts on a blue day tells me everything I need to know. LOL The desperation of the naysayers knows no bounds \u2013 and the newsflow hasn\u2019t even started yet. I fear for the sanity of Porky and his parrots over the coming months. With an absolute minimum cash runway into July already confirmed and multiple RNS imminent, Porky could well self-check in to the local abattoir. The lorry reversing toward the sty, isn\u2019t delivering feed. \ud83d\udc37 \ud83e\udee8 \u26a1 \ud83c\udf2d Anyone for a bacon butty or sausage cob?",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.385",
          "thread_title": "The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-24T01:33:18.664603+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261807-Porky9--5421348",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.646670",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@Nick I totally agree with you. If anyone can trade this you can. But I have to hand it to mark, the money just keeps on coming, I mean its shocking really, there is absolutely nothing here to invest in, it really is the emporers new clothes, but he keeps getting the cash and with over 20 raises, what's another one? I still think .15 or .20 but ultimately you would think the brokers would say, hang on a minute you never deliver on anything you say, our clients are losing money off our broker notes to buy, enough is enough but I guess as long as they get their fees they couldn't care less.",
          "sentiment": 0.0,
          "engagement": "7,466",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-24T01:33:18.664639+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261719-RayPoint-33654447",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.647089",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "It does explain all the voices in my head \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-24T01:33:18.664675+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261714-ratcliff-29697690",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.647517",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Viera - are you RayPointer and me as well?",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-24T01:33:18.664703+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261704-viera--4173301",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.647968",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "But why would anyone give this lot any money Porky  ? They earn 100k whilst having other part time jobs. Been 20 years of promises but zero revenue . There will be zero revenue in before April when the next begging bowl comes out . I was at 5pct with Theoremx and that failed . I\u2019m at zero pct with Ambrose ! Anyone holding this as we enter Feb/March needs to see a dr. Any monies raised goes to directors as not enough to make any investments. I will NOT be buying at any price . It\u2019s a shambles . Sorry",
          "sentiment": 0.0,
          "engagement": "1,550",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-24T01:33:18.664722+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261454-Porky9--3812518",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.648402",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "They dont have a pot to pee in, its a phoenix business and frankly if they raise cash it will be for themselves, not to give away to VAL - BE REAL. Would imagine meetings being scheduled by VAL with placing brokers shortly, can't be far off now - my call this time is another \u00a31m at .15 to .20 tops - give them another 5/6 months more gravy train assuming brokers can find more mugs to support the lifestyles.",
          "sentiment": 0.0,
          "engagement": "7,466",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-24T01:33:18.664741+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261440-ratcliff--4727384",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.648817",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "I was asking myouryourself the same question. But I knew that, as did Iyou.",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-24T01:33:18.664759+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261415-RayPoint-38763891",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.649253",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Are these people actually employed by Ambrose? Last time Ambrose received capital investments (as I recall, in the region of 900,000) they trumpeted the fact on their website. Yet, at March last year, they only had 25k in the bank. Subsequent to March last year,  there have been no announcements of further investments. I ask myself (i.e. Rats) how this all adds up.",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-24T01:33:18.664777+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261403-Notpotal-76523805",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.649678",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Nice to see momentum at Ambrose. They certainly are building a very strong team. However, this highlights another positive for Valirx. VAL401 is the result of a reformulation of the anti-psychotic drug, Risperidone into an oncology drug. One solitary repositioned drug has resulted in a potential multi-million deal. No wonder in the webinar Mark said he was excited regarding the Val/Dominion repurposing project. This collaboration has identified approx 200 FDA approved non oncology drugs which are showing anti-cancer against various Inaphaea PDCs. Ten of these candidates are now being fast tracked for deeper evaluation. Mark even mentioned looking to partner the prime repurposing asset this year. Because these compounds are clinically validated and safety de-risked, the probability of progressing to meaningful clinical proof of concept is far higher than in creating oncology drugs from scratch - positioning the Val/Dom alliance for multiple rapid, low cost shots on goal.",
          "sentiment": 0.5,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-24T01:33:18.664795+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261359-ratcliff--6163962",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.650086",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "True O alter ego. He even knows where my investments are. (Or should that be 'our' investments)",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-24T01:33:18.664813+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261356-RayPoint-62039572",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.650503",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "You can't fool uxm, he's so sharp \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-24T01:33:18.664831+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261348-uxm484--4692766",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.650918",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Ratcliffe are you Raypointer? Both invested in Scancell. Both are not invested in Valirx.",
          "sentiment": 0.0,
          "engagement": "1,009",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-24T01:33:18.664849+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261333-ratcliff-51355206",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.651345",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "The number of employees and the financial state is a bit concerning isn't it? They weren't flush in 2024's accounts, and they're worse in the 2025 ones. So back to the question - what are 500,000 odd shares in Ambrose actually worth? Potentially even less than 500,000 Val shares...? https://find-and-update.company-information.service.gov.uk/company/14409383/filing-history",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-24T01:33:18.664867+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261310-RayPoint--2442442",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.651773",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "The reason I ask is that if I look at Ambrose Healthcare on Companies House, I find the same name with the same month of birth: Tobias Adam WILSON WATERWORTH - born October 1964 Spookily, this person only has 1 director appointment - Ambrose Healthcare, the other 21 are missing! https://find-and-update.company-information.service.gov.uk/officers/SAWjapGOj9HbCMsLuSFBZeqVYiU/appointments Does anyone else find this rather strange?",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-24T01:33:18.664884+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261254-RayPoint--8431064",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.652198",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Could this be the CEO of Ambrose Healthcare? https://find-and-update.company-information.service.gov.uk/officers/JzAELIfnpaXPIZjjnhqdRjwB9KM/appointments",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-24T01:33:18.664902+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260857-Rebster4-36929408",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.652606",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rebster408",
          "content": "Probably cos Ambrose only have about \u00a325k in capital and assets in 2025... not a pot to p155 in...",
          "sentiment": 0.0,
          "engagement": "1,174",
          "price_at_post": "0.375",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-24T01:33:18.664920+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260757-uxm484-65280123",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.653034",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "I understand they get a share of Ambrose  not just Val401. News on other clinical compounds increases the value of the shares therefore more valuable than just getting cash for Val401. Valirx will have options to sell some shares initially to get some cash.",
          "sentiment": 0.0,
          "engagement": "1,009",
          "price_at_post": "0.375",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-24T01:33:18.664939+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262226-ratcliff-98600530",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.653624",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Why were Val given shares not cash by Ambrose? What are 576,000 Ambrose shares worth? Can they be sold to raise much-needed cash? How much cash had been raised for Val in the 7 months since that announcement? If it was a deal of any real worth, why did Val have to do a placing a few months later, and how come it's heading towards another one in a matter of weeks on current estimations?",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.375",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-24T01:33:18.664957+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262019-paternos--6749389",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.654069",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "A lucrative VAL401 licensing deal was announced on 20/6/25: \u201c ValiRx will receive 576,000 ordinary shares in Ambrose with clinical and commercial milestone payments to be made to Valiseek totalling a value of up to \u00a316 million plus royalties.\u201d Valirx owns 54% of Valiseek. Ambrose has a pipeline consisting of just TWO products: VAL401 (pancreatic cancer) and Renzapride (cystic fibrosis), both currently at phase 2 clinical. Today, Ambrose announced two further additions to their already impressive team: Dr. Janette Thomas joins as Director of Manufacturing Operations and Wendy Richings-Barrow as Director of Regulatory Affairs. \u201cThese appointments reflect our continued focus on building a world class team to deliver solutions for patients with rare conditions with no approved treatments.\u201d The Ambrose team already had a strong backbone: Chairman, Toby Waterworth has been part of leadership teams in multiple life science companies that have generated close to $1 billion in shareholder value. CEO Dr Hazel Jones was formerly Chief of Staff for AstraZeneca\u2019s Oncology R&D Leadership Team. Chief of Staff Virag Stephens an ex PMO Director at AZN and has strong fundraising expertise while Mike Webb led departments of up to 150 scientists in a 30-year career at GSK. Dr. Nick Meyers has 30 years\u2019 experience as a Program Director. In 2024, Ambrose was acknowledged by its peers when it won the Best Startup Biotech Company Award at the prestigious OBN Awards in London. Since then, it has grown significantly and confirmed it is exploring potential Middle-East listings. One of the partners on their webpage is SEHA (Abu Dhabi Health Services), a subsidiary of Pure-Health the largest integrated healthcare network in the UAE. (total assets $13B). Another partner is listed as Aparito, part of the Eli Lilly group. As Ambrose strengthens its leadership and global partnerships, Valirx is strategically placed to benefit from every milestone achieved on the VAL401 journey.",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.375",
          "thread_title": "The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-24T01:33:18.664975+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261513-paternos--4159965",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.654610",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "\u201cValix is in discussions with several potential partners to progress CytoLytix, including a major pharma\u201d. So, why is Mark, currently in California, continuing to promote the compound so actively both in the UK and overseas? While it\u2019s plausible a major pharma might seek exclusivity, the most realistic outcome is exclusive rights carved by territory, formulation, indication, or even species (human/veterinary)\u2014leaving room for multiple, parallel deals outside that scope. Indication splits are historically used when partners specialise in different therapeutic areas (eg ovarian only). Geographic exclusivity is even more common. The TrX/201 deal eventually failed when Mark attempted to remove Taiwan from the original LOI. The veterinary angle highlighted in recent webinars reinforces that CLX spans markets no single pharma can cover, making a multi partner licensing model far more realistic than a single global licence. There are numerous real world examples of multi partner licensing structures in biopharma: TERRITORY - Immunex (Enbrel) / initially Amgen \u2192 US & Canada rights, then Wyeth (later Pfizer) \u2192 Europe + Rest of World rights FORMULATION - Gilead (Tamiflu) / initially Roche \u2192 Oral formulation rights, then Hetero & Teva, \u2192 sublicenses for additional formulations INDICATION - AstraZeneca (Lynparza) / Merck \u2192 initially Ovarian cancer rights, then subsequently obtained licenses for breast and pancreatic cancers. Each example above shows one originator, no single-party lock in and multiple partners or deals to acquire different rights. With so many variables in play, it is increasingly clear that Valirx is preserving the same optionality for CytoLytix. Mark is still promoting CytoLytix because he is targeting several partners \u2013 not just one. Everything suggests CLX is being shaped as a multi deal platform, with the first handshake simply opening the monetisation cycle -",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.385",
          "thread_title": "CLX - multi deal structure",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D1488F3A-09F4-41C4-B45B-AF908B85E267"
        },
        "ingested_at": "2026-01-24T01:33:18.664993+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261459-Notpotal-82609893",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.655026",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Some clever trading going on here \u2013 those selling at 0.37p will soon be able to buy back at 0.39p. \ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "RE: Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-01-24T01:33:18.665012+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261329-Porky9--9035798",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.655478",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@PP Yes, and as long as the rain holds off should be able to get some golf in on expenses. Who needs Zoom and Teams when you can have a nice all expenses trip to the US. Lovely. Keep pumping it, only a few weeks now to go before next placing @notpotatlot Only Update you will get shortly that isn't fluff, will be the placing news or the next 125:1 consolidation event which has to be well over due now. Keep ramping it though, the gravy train needs to stay on the tracks, there are lifestyles here that need to be maintained.",
          "sentiment": 0.0,
          "engagement": "7,466",
          "price_at_post": "0.385",
          "thread_title": "RE: Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-01-24T01:33:18.665030+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260943-paternos-30947897",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.655913",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Mark re JPM in San Fran -  \u201cI have meetings lined up with our partner Omios Biologics so looking forward to catching up with Aldo Pourchet (CEO).\u201d In the Omios RNS (3/6/25), the evaluation was \u201cexpected to run up to 12 months, after which Omios can exercise its license option to continue using Cytolytix technology.\u201d Across both the June and Dec webinars, Mark emphasised CLX synergy with the Omios virus for potential to treat canine HSA, a clear signal that Omios sits firmly in the frame for a CLX licence. Valirx\u2019s revamped Advisory Board reinforces this direction, now with a notable weighting toward veterinary oncology and commercial expertise. The composition reflects a deliberate strategy to position CLX across both human and animal oncology. When your advisory structure is rebuilt around people who understand canine cancers, comparative oncology, and veterinary commercial pathways, it becomes clear Valirx is preparing for licensing routes across both human and veterinary markets. As a co-founder of VolitionRx, Mark transformed a human cancer test into a canine diagnostic test (Nu.Q) before negotiating a licencing deal with Heska for $26m. What price a cure? Human and veterinary oncology operate in separate regulatory and commercial channels. Most major pharmas, inc. AZN, Roche, GSK, AbbVie do NOT have any vet divisions. Even those historically involved have spun off their animal health units (Pfizer \u2192 Zoetis, Eli Lilly \u2192 Elanco). By envisaging veterinary opportunities for CLX, Mark is implicitly confirming the compound won\u2019t be a one partner asset; the split infrastructures required make multiple CytoLytix deals the only realistic outcome. GLA, DYOR, AIMO",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.385",
          "thread_title": "Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-01-24T01:33:18.665048+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261543-Notpotal--3985843",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.656343",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "I notice a 71430 buy at 15.14 and a similar sell 4 mins later for a \u00a321 loss. Great to see Porky has started trading again!  \ud83e\udd23\ud83e\udd23\ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "Welcome back, Porky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=FE350133-0204-48E9-9785-7F80407B3421"
        },
        "ingested_at": "2026-01-24T01:33:18.665066+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261534-Notpotal-50388179",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.656760",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Val is obliged to RNS as it a change to No. shares in issue. Hardly the company\u2019s fault if a holder sees such value that he wants to buy above the current SP. Mind you, I\u2019m expecting a TR1 tomorrow to confirm Mark\u2019s holding has increased by 80,000 shares. \ud83e\udd23 If this is the reaction to \u00a3400 of warrants, heaven help Porky\u2019s groupies when the next material RNS arrives.  \ud83e\udee8 \ud83d\ude28 \ud83d\ude22\ud83d\ude2d",
          "sentiment": 0.5,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-24T01:33:18.665084+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261709-Porky9--7967132",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.373661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "What, do you think he is going to release news of the placing already, possible but they normally leave it right until the death, so proabably a few more weeks yet but you never know, you could be right.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.355",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-29T09:48:15.298766+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261448-Notpotal--5540599",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.374477",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Is that a Friday RNS I can smell.... Or has Porky had an accident? \ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.35",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-29T09:48:15.298811+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262254-viera--3219290",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.375315",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Pm changed his name to pp It\u2019s basically ME copy and paste . As he said ME has produced one RNS in months . We all know what the next RNS of note will be . ME needs to cut costs further and do something with 201. Good luck all.",
          "sentiment": 0.0,
          "engagement": "1,552",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-29T09:48:15.298850+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261720-RayPoint--6718600",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.376112",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Pater It's funny to see, in a thread entitled \"The Ambrose Dream Team\" and started by yourself , that neither the Dream Team nor VAL401 get a mention in your latest post.",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-29T09:48:15.298890+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261632-ratcliff-64142693",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.376907",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "'When the SP inevitably hits 1.6p plus there will be further buying pressure as placees exercise their 1.3p warrant options. Some will then sell for a quick profit but by then the SP will be in the 2p range. All this without the flush of positive news expected over the coming months.' Sounds good? Sounds worth buying into? Well actually it's a paternostpauper quote from 16th January 2025. But the share price then was 0.875, sliding gently down another post-placing ski-slope graph.  And what's the biggest news since then? Oh yes, another placing - predicted by P9 and derided by PP. Until it happened. On past history Porky's predictions seem a pretty reasonable bet. PP's posts are just reformulated bin dippings - he might as well just copy and paste on a pumping merry-go-round.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-29T09:48:15.298931+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261512-Porky9--4488029",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.377717",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Always entertaining, like watching fantasy island @PP is our very own Mr Roarke and @nopot is Tattoo.  Not sure who @uxm plays, probably the aircraft pilot as he only turns up to share the fantasy once a week or so. The gap will be between .15 and .20 as that will be where the placing shares land, thats of course if ME can pull it off again. Jury out this time.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-29T09:48:15.298970+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261503-paternos--6132959",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.378553",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Good post UXM.  Always entertaining to see trader Nick post again - his 63rd consecutive LSE post - and every one on Val. He might as well hang up a banner \u201croll up, roll up \u2013 bargain of a lifetime!\u201d \ud83e\udd23\ud83e\udd23\ud83e\udd23 Val has issued just one positive RNS since the placing, yet the SP has climbed 67% from those 0.23p lows. Even with 2 major holders dipping below the 3% threshold to facilitate some short-term trading, the SP still hovers near 0.4p. Every day that passes without an RNS increases the likelihood of one the following day as multiple programs mature: CytoLytix patent updates, formulation decisions, Blue Ribbon/VAL201 partnering (by diluting the asset, not VAL plc), 3k repurposing update (top candidate partnering?), further grant updates (ME has strong history), next evaluation and SPV (confirmed in webinar), Inaphaea income (PredictRx/ PDC sales), updates on the Dundee/Queen Mary pro-senescence project and StingRay (decision imminent). The motherlode remains early partnering/grant funding for CLX, a 2026 milestone confirmed by the CEO in the recent webinar. As the June anniversary nears, Omios have to decide whether they wish to exercise their option of a license agreement to continue using CLX tech. It looks promising as both Mark and Omios CEO Dr Aldo Pourchet had meetings arranged at the JPM in San Fran. More than once, Mark has referenced the Omios virus as an entry point to veterinary oncology due to its potential for treating canine HSA, while Dr Pourchet posted: \u201cWe are targeting triple negative breast cancers (CLX primary indication), all of which have the biomarker that makes them susceptible to our therapy. It\u2019s our most advanced program\u201d (Oct NYU interview). With multiple CytoLytix licenses up for grabs, Omios look set to start the ball rolling. The decisive factor which totally undermines the detractors\u2019 fearmongering is the financial position: a cash runway that extends till H2 excluding warrant income, R&D tax credits, grants, or additional Inaphaea income. That completely negates any March/April placing argument. Mind you, naysayers never let a few facts ruin their narrative. GLA DYOR",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-29T09:48:15.299007+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20261956-uxm484--8178703",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.379412",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Watch the video. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025 Chart analysis shows a nice gap at 1.4p. Past management issues but new management is outstanding.  Cash until H2 without the add ons such as grant money, revenue and warrant money. CEO heavily invested over 250k. Negotiating with a major biotech in regards to a deal for CLX001. Lab space is to help progress the assets to eventually get a deal not to make instant revenue. Any research on CLX001 done against a valuation of 2 million and cash burn just over a million would know this is a great opportunity. Great decision making. Derisking assets with partnership deals. Which other biotech has so much and spending less than 2 million. With warrants at a premium to the current price hopefully no more dilutions. Expecting significant news in the coming days/weeks. Tiny valuation and cash burn is tiny with assets of significant value.",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-29T09:48:15.299045+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20261515-viera-62870983",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.380239",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Problem my friend is ME hasn\u2019t got a proper hold of Costs paying a non BOD member and non scientist 100k  paying best mates that produce zero revenue is a disgrace . It shows a lack of respect for shareholders . Where are all the promised lab contracts . ME has surrounded himself with \u201cyes \u201c men. Shame he ousted Adrian as he had the commercial nous to make a difference . Adam also lost interest as was treated so badly by the BOD. I predict more confetti in April /May . Porky knows this co better than anyone . If he and Adrian joined the BOD I would consider investing but I\u2019ve lost faith in the current BOD who promise the world and deliver FA. Deliver some revenue asap or step down .",
          "sentiment": 0.0,
          "engagement": "1,552",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-29T09:48:15.299082+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20261416-ratcliff--4385554",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.381020",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Interesting that you've posted notgotalot - in December you distinctly said \"I\u2019ll take some time out and won\u2019t be back until the next decent RNS.\" Presume you've restarted posting because you've lost hope in there being a decent RNS.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-29T09:48:15.299143+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20260843-Notpotal--3550470",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.381814",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "each conspi****** on here is in self-denial mode - a mechanism where a person ignores or distorts reality to avoid anxiety and stress. they refuse to accept the situation simply because it doesn\u2019t support their agendas and so resort to posting fiction. whether it is by inventing a 50% lower cash runway, alleging fictitious staff at ambrose, claims of ceo golf jollies and overpaid team members or alleging lse posters are on the val payroll. desperate posts by the uninvested are now treated with the contempt they deserve. just when you think they\u2019re as low as they can get \u2013 they pick up a spade. by resorting to deception, they have lost any remaining credibility they may have had, while each day news edges closer.",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-29T09:48:15.299179+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20262102-ratcliff-66996042",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.382589",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "It would also be interesting to know why the posting of relevant financial facts from those observing is described as 'panic.' Surely the only panic is among those trying to snare the naive with fantasy predictions so they can get out fast with a profit - and now realising that the supply of gullible newbies is drying up.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-29T09:48:15.299216+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261925-RayPoint--5248109",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.383379",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "So what's the crack, pp? I would be interested to know your view on how Ambrose are paying salaries to the Dream Team without having any money in the bank",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-29T09:48:15.299253+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261832-paternos-14359209",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.384211",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "@  spantrout - Great call. Valirx - 10m,50s in. \u201cA lot of return on that one!....DYOR but in all probability, if it\u2019s going to have some game-changing news, then \u2026.that would be 1.4p.\u201d Not sure of the news he is he is referring to? Maybe the new patents, partnering (CLX,201), repurposing top 10, StingRay, further grants, or expansion into veterinary oncology? Possibly it\u2019s the the 2nd evaluation and new SPV or even the CEO buying 7% of the company. I suppose it could be that Mark E has recently been on stage presenting alongside some of the biggest names in pharma, or the fact the CEO has a history of delivering success (Nu.Q test sold for $26m). !.4p is an interesting SP \u2013 that would not only see the 0.5p warrants in play but also the 1.3p warrants, easily extending the runway into 2027. Mind you realistically, a few easily pleased would exit for a quick 300%+ profit. I guess the uninvested posting day and night trying to supress the SP hasn\u2019t gone unnoticed either. Karma can be a wonderful thing! Happy days DYOR, GLA.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.385",
          "thread_title": "RE: Coverage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=1C527045-FD63-41D2-B4BE-ED55425FC93C"
        },
        "ingested_at": "2026-01-29T09:48:15.299290+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261714-Notpotal-13679619",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.385010",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "pp previously purged porky\u2019s parrots\u2019 pack of preposterous posts pedalled in panic, perhaps predictably. i promptly prepared a poem for porky to peruse at his pleasure. pundit porky posted a pack of pathetic, poorly proven poppy****. a pack of pathetic, poorly proven poppy**** pundit porky posted. when pundit porky posted a pack of pathetic, poorly proven poppy****, perhaps he\u2019ll point to proof behind the pathetic poppy**** pundit porky posted?",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.385",
          "thread_title": "Porky\u2019s Peddled Pile of Piffle",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=93B08DEA-F499-4237-AF7E-B5143BC8D67E"
        },
        "ingested_at": "2026-01-29T09:48:15.299328+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261625-spantrou-85464927",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.385791",
        "source": "LSE_CHAT",
        "data": {
          "author": "spantrout",
          "content": "Https://youtu.be/HrYMuqPFA20",
          "sentiment": 0.0,
          "engagement": "13,977",
          "price_at_post": "0.385",
          "thread_title": "Coverage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=1C527045-FD63-41D2-B4BE-ED55425FC93C"
        },
        "ingested_at": "2026-01-29T09:48:15.299365+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261403-Porky9-25665321",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.386613",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@PP You really are a busted flush, its like groundhog day:- Pump the boards with nonsense about million dollar licensing deals, how the cash is well managed and will last many months more than it does, how there will be all these marvelous license deals lined up, exaggerate the interest and how fantastic it all is. Then RNS drops,  placing at discount issued, you vanish for a few weeks, let the dust settle and then you pop up again and repeat the above. I totally get those in the business want the gravy train to continue, lifestyles at risk but have you no conscience that small investors that may not earn the sort of money the board here gets here for these cushy  work from home jobs, are going to lose their hard earned cash being sucked into this? Its morally not right. Next RNS will be the next discounted placing, can't be far off now, a few weeks at most imo.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-29T09:48:15.299402+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261529-RayPoint-73693711",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.157704",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "I hear that green fees are pretty steep in California",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-29T09:48:15.299439+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261434-ratcliff-32199525",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.158130",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "No problem RP - I'm wondering who paid 0.50 for a few shares worth about 25 percent less from the start, but I suppose 400 quid pays for the week's teabags and digestives.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-29T09:48:15.299476+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261413-RayPoint--7449595",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.158544",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Sorry Rats. I misinterpreted your post.",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-29T09:48:15.299514+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261412-RayPoint-12019556",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.158961",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "\"Probably about 450 quid...\" Rats, stop ramping! The gross proceeds were \u00a3400",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-29T09:48:15.299551+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261357-spantrou-39037133",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.159474",
        "source": "LSE_CHAT",
        "data": {
          "author": "spantrout",
          "content": "\u00a39.99 for rns",
          "sentiment": 0.0,
          "engagement": "13,977",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-29T09:48:15.299589+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261311-ratcliff-32834697",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.159890",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Probably about 450 quid...",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-29T09:48:15.299633+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261216-steve196-75476642",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.160315",
        "source": "LSE_CHAT",
        "data": {
          "author": "steve196",
          "content": "How much does it cost to release an RNS just for \u00a3400 of warrants?",
          "sentiment": 0.0,
          "engagement": "2,761",
          "price_at_post": "0.385",
          "thread_title": "Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-29T09:48:15.299672+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261935-uxm484-53369989",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.160734",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "No, but the holders all want the warrants exercised so we can do a 10 bagger in 12 months without a fund raise. For me i am really happy here with  the progression. We are definitely early in a news rich periods where all the negative posters are posting overtime and are only posting as they missed out on the last fundraise hoping for an even lower price. We will likely get a few meaningful RNS very soon. Brakes are now off\u2026",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.36",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-29T09:48:15.299710+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261222-Notpotal-77280697",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.261915",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "\u201cYou sound so desperate\u201d says the man who\u2019s last 60 posts have been on a share he isn\u2019t invested in. \ud83d\ude02\ud83d\ude02\ud83d\ude02",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-29T09:48:15.299748+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261207-ratcliff--9513125",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.262733",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Slight typo there - should read blatantly UNTRUE and misleading!",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.365",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-29T09:48:15.299786+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261201-ratcliff--3103452",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.263581",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "UXM - differences of opinion are generally understandable, but to say in your post 'All lies' is blatantly true and misleading, and as usual does nothing to bolster your credibility. Two of the things you say in that post are particularly inaccurate - 'Great decision making. Derisking assets with partnership deals. Which other biotech has so much spending less than 2 million.' - They are looking for deals (or claim to be anyway) but nothing so far has contributed anything to even cover the outgoings, let alone provide money for further work or expansion (hence the redundancies etc) Secondly - 'With warrants at a premium to the current price hopefully no more dilutions' - warrants don't kick in and generate cash the moment the sp goes above them as you and the others in your group seem to imply. In the unlikely event of the sp rising above that point and remaining so, it just might be worth warrant holders exercising them so they could buy shares at below the then-current price, but to sell them they'd need to be able to be sure the sp was strong enough to withstand the effect of the sells. You know that, so stop trying to imply that the mere existence of warrants is a long-term fool proof source of near or long term capital. Then again, if this company was fool proof you wouldn't be here I imagine.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.365",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-29T09:48:15.299824+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261059-viera--1692059",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.264399",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Are you PM in disguise ? Who in  their right mind would buy any company on Aim with only 3 or 4 months cash runway? You sound so so desperate for a rally to sell out !",
          "sentiment": 0.0,
          "engagement": "1,552",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-29T09:48:15.299862+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261050-Rebster4--4398934",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.265221",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rebster408",
          "content": "Its groundhog day again This is a binary bet...and Poky has called it right in the past and I thinks he's spot on again... 201 is older than me!!! place your bets... the wheel is spinning and will stop within the next 8 weeks All will become clear within the next two months...",
          "sentiment": 0.0,
          "engagement": "1,174",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-29T09:48:15.299901+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260920-RayPoint-68310920",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.266008",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Living in fantasy land",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-29T09:48:15.299940+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260857-Notpotal-11732885",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.266824",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "\u201cYou can't go back and change the beginning, but you can start where you are and change the ending.\" \u2013 C.S. Lewis Early in his tenure, Mark acknowledged mistakes had been made \u2014 and while he couldn\u2019t rewrite the past, he could reshape the future. 17 months later, Val is reborn, with money in the bank, a rebuilt team, high calibre assets and a SH base that deserves success after years of one-way support. A few resident historians cling to their preferred mythology, inventing a minimal cash runway because the real picture is too uncomfortable to accept: a cash runway to H2 even without R&D tax credits, additional Inaphaea income, grants or exercised warrants. This is also before the wave of RNS due over the coming weeks. Unlike those posting fiction, Mark has backed his conviction with his own money \u2014 now holding 7% of the company. \u201cWhat matters now is not where we\u2019ve been, but where we\u2019re going.\u201d",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.365",
          "thread_title": "Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-29T09:48:15.299979+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20262049-ratcliff--3704467",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.267621",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Whatever it is you're smoking UXM, it's powerful stuff.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-29T09:48:15.300018+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261733-uxm484-74543581",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.268458",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "All lies. Watch the video previously posted. Past management issues but new management outstanding.  Cash until H2 without the add ons. CEO heavily invested over 250k. Negotiating with a major biotech in regards to a deal for CLX001. Lab space is to help progress the assets to eventually get a deal not to make instant revenue. Any research on CLX001 done against a valuation of 2 million and cash burn just over a million would know this is a great opportunity. Brokers only had 20k stock. Hardly lots of stock. Great decision making. Derisking assets with partnership deals.  Which other biotech has so much spending less than 2 million. With warrants at a premium to the current price hopefully no more dilutions.",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.385",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-29T09:48:15.300056+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261719-Porky9-41497517",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.269349",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "And just a few reasons why not to believe the BS from the resident rampers here and why you should avoid:- * Lifestyle Business * Ridiculous Admin costs * Continual Raises and continual dilution * More than 20 Raises, 3 lots of 125:1 Consolidation events * business concept never proven * Rented lab space and zero revenue in 15 years * About 8 weeks cash runway left with yet another raise due anytime soon to keep the gravy train going. * if new investors or brokers say enough is enough and call time due to clients continually losing money then its admin and you could lose your entire investment. * materially overpriced as absoluly nothing here to invest in, its the emperors new clothes you are buying. 201 is older than hens teeth, no interest in 15 years and CLX years off and more cash required. Labs meanwhile doesnt know what an invoice is. * Poor decision making, lack of any commercial acumen *No real focus, practically everyone is work from home with multiple jobs. * Short term punts only not a long hold due to above. * loads of stock held for broker fees that will need to be drip fed into anyone buying. In all avoid at all costs unless you like dilution",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.385",
          "thread_title": "Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-29T09:48:15.300093+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261507-ratcliff--9191744",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.270143",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "You swine Nomlungu. You've rumbled me.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.41",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-29T09:48:15.300146+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261503-Mr0nions--2437582",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.270906",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mr0nions",
          "content": "Because of this  post, I'm holding position.  Good luck all.",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "0.41",
          "thread_title": "RE: Why invest? \u2013 THE SCIENCE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=058BF091-3235-424B-9C46-FA00ED6BC8D5"
        },
        "ingested_at": "2026-01-29T09:48:15.300184+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261432-mikee_p-75470070",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.271701",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "1 HR. Channel is all ya need.",
          "sentiment": 0.0,
          "engagement": "1,893",
          "price_at_post": "0.395",
          "thread_title": "Easy trade this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=81274FD9-0226-45F3-8CEA-B1F91E33B4A2"
        },
        "ingested_at": "2026-01-29T09:48:15.300222+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261430-nomlungu-14807587",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.272502",
        "source": "LSE_CHAT",
        "data": {
          "author": "nomlungu",
          "content": "People should just ignore Rat... he is just jealous that he does not have the losses to use to reduce his tax liabilities. That 80% drop in the last tax year will have been very valuable for some; I think him moaning around the time that taxes are due for the 2024/25 year is a dead give away. \ud83d\udcc9 \u2757",
          "sentiment": 0.0,
          "engagement": "23,976",
          "price_at_post": "0.395",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-29T09:48:15.300260+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261313-paternos--2797363",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.273388",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "When Mark became CEO, ValirRx was effectively dormant - few assets in play, minimal Board investment and limited vision. He set about a major restructuring: rebuilding the team, reshaping the asset base and above all, resetting the mindset. Fast forward 17 months and Val is reborn. A microcap expanding into developing fields of oncology, yet every action taken has a cost/benefit analysis and timescale consideration. If concluded that a project cannot be monetised early, it is shelved or paused. Commercial decisions overrule all others. Valirx is now plugged into some of the most advanced platforms in modern drug development: \u2022\tpatient avatars (TwinEdge) \u2022\tmicrofluidics/3D tissue culture models (Screenin3D, Ignota & VoxCell) \u2022\trepurposing (Ignota, Altus & Dominion) \u2022\tpersonalised immunotherapy (PredictRx / Dominion) \u2022\tpro-senescence drugs (Dundee / Queen Mary Uni) \u2022\tClickmer technology/HER2 protein (Apis Assay) \u2022\tLMTK3 kinase targeting (StingRay). The most recent evaluation, a 2nd-gen RNA helicase inhibitor (McGill/IRICoR), brings Val into collaboration with major international research organisations. Last year, Mark identified a shift away from animal-testing and moved early to establish capability partners supporting NAMs and cutting-edge AI. Recent US & UK Gov\u2019t regulatory changes now actively favour such platforms with Europe to follow this year. Once again, Val anticipated this trend before much of the market. Meanwhile, the Advisory Board has been upgraded from academics and towards industry experts who can provide insight into Big Pharma priorities and identify new commercial pathways such as in veterinary science - quicker to market while opening a parallel revenue path thru\u2019 comparative oncology, further de risking the route to human oncology. Mark has also added a clause into evaluation agreements whereby if Val decides not to progress an asset eg StingRay, McGill/IRICoR, then Inaphaea retains the data and can still monetise should a 3rd party take the asset forward. Val is no longer waiting for opportunity; it is engineering it.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.385",
          "thread_title": "Why invest? \u2013 THE SCIENCE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=058BF091-3235-424B-9C46-FA00ED6BC8D5"
        },
        "ingested_at": "2026-01-29T09:48:15.300298+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261224-paternos-31171533",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.274229",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "A \u00a33m microcap with a cash runway till H2 even before factoring in R&D tax credits, potential grant funding, additional Inaphaea income or warrant cash now within reach. Outgoings reduced by \u00a3200k PA following a team restructuring last year. Val\u2019s expansion into NAMs and advanced AI tech, supported by strong academic partnerships, aligns directly with revised US & UK gov\u2019t guidelines to reduce animal testing. This positions Val as a front runner for non dilutive grants and innovation funding, with a CEO geared to capitalise on this opportunity. The 1/9/25 RNS confirmed ongoing discussions with several potential partners to progress Cytolytix, including a major pharma. Val owns 60% of CLX with 10% owned by co-inventor, Dr Charles Chen (Senior Scientist at Astrazeneca). Val also has a 54% share of an Ambrose deal potentially worth up to \u00a316m, and a Biobank of 476 PDCs valued at \u00a310k per PDC cell-line upon commercialisation, plus commercial rights entitlement. Valirx has assets in several key cancer indications, all with huge global markets: 201/prostate ($11.3Bn*), CLX (primarily TNBC ($1.5Bn*), ovarian ($2.5Bn*) but also prostate, 301/endometriosis ($1.9Bn**), and 401-Ambrose/pancreatic ($2.9Bn**). Sources: *webinar, **GMI. Several RNS updates are imminent: CLX patents \u201cin coming weeks.\u201d (RNS 1/9/25), Dundee/Queen Mary project (extended to 9/2/26), StingRay (approx Feb \u201926 per Aug video), Blue Ribbon SPV - \u201cSeveral patents envisaged for 201\u201d, and the next evaluation/SPV \u201cimminent with discussions already at a mature stage\u201d. The Omios RNS (3/6/25) stated \u201c\u2026 expected to take up to 12 months. On conclusion of the evaluation, Omios has an option to enter into an Oncolytic Peptide License Agreement to continue using Cytolytix technology.\u201d Yet another potential source of income. In addition, the Val/Dominion repurposing project (teaching an old drug new tricks) has identified 200 FDA approved non-oncology drugs which already have phase 1 clinical data and are showing activity against various cancer PDCs. 10 of these candidates are now being fast-tracked. The median upfront deal size for pre-clinical IND ready assets was $110m in 2025. For phase 2 this increased to $775m. (Dec webinar). For context, Val\u2019s SP exceeded 55p in 2021 with only one key asset (VAL201). Currently, including the repurposing project, Val now has 200+ potential assets plus a valuable Biobank. Also, Mark has restructured evaluation agreements whereby if Val chooses not to progress an asset (eg StingRay, McGill/IRICoR), Inaphaea retains the data and can still monetise should a 3rd party take the asset forward. Multiple monetisation routes now sit across the pipeline, supported by a commercially-savvy CEO who now owns 7% of the company. Valirx \u2013 a microcap with midcap potential.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.355",
          "thread_title": "Why invest? \u2013 FINANCIAL",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=8931CA86-EC8C-43F3-AA7F-54C7D7FD717E"
        },
        "ingested_at": "2026-01-29T09:48:15.300336+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261145-Marty130--4718521",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.274986",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Be good to see the directors buying some of the stock..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "0.355",
          "thread_title": "Directors deals",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=DC2D2A2F-B451-4EEF-B7C8-9C80695D4033"
        },
        "ingested_at": "2026-01-29T09:48:15.300371+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261107-ratcliff-15914792",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.275854",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "UXM - cutting and pasting the same post repeatedly is not convincing, but to humour you I had a listen to the link you have monotonously posted. It's not persuasive or convincing - Starts off about the 'objectives we have set' and 'milestones we're looking to achieve.' Then there's a bit about the group structure - this is rearranging the deck chairs on the Titanic isn't it? They've had more rearrangements over the decades, it's just a distraction now - meetings are the practical alternative to work. The we hear 'The objective is...' and 'If suitable...'  So nothing at all certain. Then he says BC201 and Val301 have 'not been spun out yet, but would benefit from all of the development work undertaken on Val201.' So BC201 and Val301 still of no interest (except maybe on Antiques Roadshow) and if Val201 had even a glimmer of potential it would have done something since it was quietly shelved - was that 6 years ago or 8? It's been stagnant for so long, the rest of the industry has moved on. The he says 'There is strong interest in endometriosis treatments.' True. There's strong interest in a lot of things, but stating a fact doesn't tie it to VAL. 'We have two new evaluations under consideration.' And...? I\u2019ve got a lot of things under consideration, but whether they get any further is often very uncertain. 'The vision is...' - A lot of people have visions, but a vision isn't even a plan. It's a nice idea at best. 'Our strategy is to do this based on identifying the highest quality assets we can find and afford.' That's like saying 'come round to my place for a meal' and when you get there you say 'There\u2019s a tin of Pedigree Chum between the four of us - it was the highest quality I could find on the available budget.' The he's going to have a system which 'allows us to prioritise selection of assets.' How early stage is all this? And no money to do it with.. Next we see \u2018The Team\u2019 but no mention of their salaries. Then a review of last year - no mention of the placings. Talk of last year's cost savings and redundancies - but if you are cutting 200k a year and laying people off, what were you wasting the money on in the first place? Or have you sold your food to pay the heating bill? Then he says 'Our runway through 2026' - sorry - that 'runway' stops in a couple of months without a placing. The 2026 Xmas do is potentially in the Job Centre unless money comes in very soon. Time is money. They seem dangerously short of both. Again.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.355",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-29T09:48:15.300408+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260954-uxm484--3551280",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.276634",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Plenty of news to come at a tiny valuation and likely this month. Cash until at least July that without warrants, revenue, deals, grants. Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-29T09:48:15.300446+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260919-Porky9-21442951",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.277452",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@Notpotalot Nick is a VERY experienced prolific investor. Frankly, i doff my cap to him as he called the trade perfectly in at .25 and out at .40. Beautiful. The Muppets are the traders in on the back of the Zac Mir pump without any research in blind on the dead cat bounce they will get burnt if still holding. As for Stephen and Jaspal at u3% they now dont have to declare BUT IMO they have about 8 weeks to slowly work the sells in to ensure they are out (just holding warrants options) before that next raise drops as they will be diluted to oblivion as sure as night is day. They can only drip sells in slowly to avoid the brokers hammering them at discount. You try selling big volumes of this close to the raise, or at anytime for that matter, you need to do it on a bounce really, sell whilst traders are buying. This is NOT an investment, its a short term punt. The reason its not an investment is because it can't generate revenue (well none in the last 15 yrs anyhow)  and is reliant on raise after raise after raise to maintain lifestyles. As I say, tick tock. Tick tock countdown already started imo.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-29T09:48:15.300482+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261952-Notpotal--3004997",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.278260",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Porky, unlike some holders, I still keep you around for the entertainment value.  Calling Nick and other traders \u2018muppets\u2019 is certainly \u2026.\u201dcreative\u201d. \ud83d\ude00 Jaspal S and Stephen W dipping just under the 3% is nothing more than freeing up a couple of million to trade. There\u2019s no great sell-off and no drama. Most of us aren\u2019t brave enough to risk missing an RNS for the sake of a few hundred quid. Get your 40 winks while you can. Many sleepless nights await over the next few months.   \ud83e\udd71 Pleasant dreams.",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-29T09:48:15.300520+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261804-uxm484--3551280",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.279044",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Plenty of news to come at a tiny valuation and likely this month. Cash until at least July that without warrants, revenue, deals, grants. Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-29T09:48:15.300557+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261539-Porky9--7843460",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.279866",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Err nope Only thing that will bring hard cash into the company of any meaningful amount in the next 8 weeks will be new placing money - sorry Regarding your continual pumps and fluffy updates, jam tommorrow dream fantasy posts, NONE of it can pay the bills now, end of. Anyone with any brains will be working the sells into any mupets trading this that are oblivious to the dire need for cash to keep the lights on and the pending essential discounted placing that has to happen to support the lifestyles here to keep the gravy train going. Tick Tock, Tick Tock",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.35",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-29T09:48:15.300596+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261042-paternos-83075637",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.280667",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "As standard, when Mark did the Dec webinar he emphasised nothing new, \u201cjust meat on the bones\u201d. However, often that meat can be pretty tasty. Blue Ribbon/VAL201 \u2013 \u201csynthesis almost complete\u201d (10m.30s). Then, \u201ca small amount (only \u00a350k) set aside for pre-clinical development of 201, the balance WILL then come from external investment into the asset\u201d (11m.55s). No \u201cMIGHT\u201d in that statement. The minimal outlay confirms that the VAL201 drug package is essentially finalised, and the entire development programme (preclinical \u2192 IND \u2192 partnering) is about to move forward. Mark has already confirmed Val will be diluting the asset, not Val PLC. With patents imminent, it\u2019s a clear signal that Blue Ribbon is not just a corporate shell \u2014 it\u2019s actively progressing VAL201 toward monetisation. Given Val\u2019s recent multi facet RNS style, the imminent update could well bundle new patent status with partnership confirmation. The last significant VAL201 update in 2021 saw the Val SP exceed 50p.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.365",
          "thread_title": "Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-29T09:48:15.300633+00:00"
      },
      {
        "event_id": "SOCIAL-10Jan20261920-Kaeren--6639482",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.281449",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kaeren",
          "content": "All great thx.",
          "sentiment": 0.0,
          "engagement": "10,948",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-29T09:48:15.300670+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262133-paternos-62400134",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.646223",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Seven consecutive \u201cblocked\u201d posts on a blue day tells me everything I need to know. LOL The desperation of the naysayers knows no bounds \u2013 and the newsflow hasn\u2019t even started yet. I fear for the sanity of Porky and his parrots over the coming months. With an absolute minimum cash runway into July already confirmed and multiple RNS imminent, Porky could well self-check in to the local abattoir. The lorry reversing toward the sty, isn\u2019t delivering feed. \ud83d\udc37 \ud83e\udee8 \u26a1 \ud83c\udf2d Anyone for a bacon butty or sausage cob?",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.385",
          "thread_title": "The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-29T09:48:15.300709+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261807-Porky9-50047808",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.646670",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@Nick I totally agree with you. If anyone can trade this you can. But I have to hand it to mark, the money just keeps on coming, I mean its shocking really, there is absolutely nothing here to invest in, it really is the emporers new clothes, but he keeps getting the cash and with over 20 raises, what's another one? I still think .15 or .20 but ultimately you would think the brokers would say, hang on a minute you never deliver on anything you say, our clients are losing money off our broker notes to buy, enough is enough but I guess as long as they get their fees they couldn't care less.",
          "sentiment": 0.0,
          "engagement": "7,466",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-29T09:48:15.300746+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261719-RayPoint-53837200",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.647089",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "It does explain all the voices in my head \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-29T09:48:15.300785+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261714-ratcliff--5249198",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.647517",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Viera - are you RayPointer and me as well?",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-29T09:48:15.300824+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261704-viera--6670619",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.647968",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "But why would anyone give this lot any money Porky  ? They earn 100k whilst having other part time jobs. Been 20 years of promises but zero revenue . There will be zero revenue in before April when the next begging bowl comes out . I was at 5pct with Theoremx and that failed . I\u2019m at zero pct with Ambrose ! Anyone holding this as we enter Feb/March needs to see a dr. Any monies raised goes to directors as not enough to make any investments. I will NOT be buying at any price . It\u2019s a shambles . Sorry",
          "sentiment": 0.0,
          "engagement": "1,550",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-29T09:48:15.300862+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261454-Porky9--6334775",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.648402",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "They dont have a pot to pee in, its a phoenix business and frankly if they raise cash it will be for themselves, not to give away to VAL - BE REAL. Would imagine meetings being scheduled by VAL with placing brokers shortly, can't be far off now - my call this time is another \u00a31m at .15 to .20 tops - give them another 5/6 months more gravy train assuming brokers can find more mugs to support the lifestyles.",
          "sentiment": 0.0,
          "engagement": "7,466",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-29T09:48:15.300900+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261440-ratcliff--4439682",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.648817",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "I was asking myouryourself the same question. But I knew that, as did Iyou.",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-29T09:48:15.300939+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261415-RayPoint--1080997",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.649253",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Are these people actually employed by Ambrose? Last time Ambrose received capital investments (as I recall, in the region of 900,000) they trumpeted the fact on their website. Yet, at March last year, they only had 25k in the bank. Subsequent to March last year,  there have been no announcements of further investments. I ask myself (i.e. Rats) how this all adds up.",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-29T09:48:15.300978+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261403-Notpotal-78190970",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.649678",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Nice to see momentum at Ambrose. They certainly are building a very strong team. However, this highlights another positive for Valirx. VAL401 is the result of a reformulation of the anti-psychotic drug, Risperidone into an oncology drug. One solitary repositioned drug has resulted in a potential multi-million deal. No wonder in the webinar Mark said he was excited regarding the Val/Dominion repurposing project. This collaboration has identified approx 200 FDA approved non oncology drugs which are showing anti-cancer against various Inaphaea PDCs. Ten of these candidates are now being fast tracked for deeper evaluation. Mark even mentioned looking to partner the prime repurposing asset this year. Because these compounds are clinically validated and safety de-risked, the probability of progressing to meaningful clinical proof of concept is far higher than in creating oncology drugs from scratch - positioning the Val/Dom alliance for multiple rapid, low cost shots on goal.",
          "sentiment": 0.5,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-29T09:48:15.301016+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261359-ratcliff--8657354",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.650086",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "True O alter ego. He even knows where my investments are. (Or should that be 'our' investments)",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-29T09:48:15.301055+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261356-RayPoint--5565163",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.650503",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "You can't fool uxm, he's so sharp \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-29T09:48:15.301093+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261348-uxm484-79482663",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.650918",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Ratcliffe are you Raypointer? Both invested in Scancell. Both are not invested in Valirx.",
          "sentiment": 0.0,
          "engagement": "1,009",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-29T09:48:15.301145+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261333-ratcliff--9044191",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.651345",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "The number of employees and the financial state is a bit concerning isn't it? They weren't flush in 2024's accounts, and they're worse in the 2025 ones. So back to the question - what are 500,000 odd shares in Ambrose actually worth? Potentially even less than 500,000 Val shares...? https://find-and-update.company-information.service.gov.uk/company/14409383/filing-history",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-29T09:48:15.301184+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261310-RayPoint--2837290",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.651773",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "The reason I ask is that if I look at Ambrose Healthcare on Companies House, I find the same name with the same month of birth: Tobias Adam WILSON WATERWORTH - born October 1964 Spookily, this person only has 1 director appointment - Ambrose Healthcare, the other 21 are missing! https://find-and-update.company-information.service.gov.uk/officers/SAWjapGOj9HbCMsLuSFBZeqVYiU/appointments Does anyone else find this rather strange?",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-29T09:48:15.301222+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261254-RayPoint-37041564",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.652198",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Could this be the CEO of Ambrose Healthcare? https://find-and-update.company-information.service.gov.uk/officers/JzAELIfnpaXPIZjjnhqdRjwB9KM/appointments",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-29T09:48:15.301261+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260857-Rebster4--2898592",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.652606",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rebster408",
          "content": "Probably cos Ambrose only have about \u00a325k in capital and assets in 2025... not a pot to p155 in...",
          "sentiment": 0.0,
          "engagement": "1,174",
          "price_at_post": "0.375",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-29T09:48:15.301299+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260757-uxm484--6595545",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.653034",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "I understand they get a share of Ambrose  not just Val401. News on other clinical compounds increases the value of the shares therefore more valuable than just getting cash for Val401. Valirx will have options to sell some shares initially to get some cash.",
          "sentiment": 0.0,
          "engagement": "1,009",
          "price_at_post": "0.375",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-29T09:48:15.301336+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262226-ratcliff-33525835",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.653624",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Why were Val given shares not cash by Ambrose? What are 576,000 Ambrose shares worth? Can they be sold to raise much-needed cash? How much cash had been raised for Val in the 7 months since that announcement? If it was a deal of any real worth, why did Val have to do a placing a few months later, and how come it's heading towards another one in a matter of weeks on current estimations?",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.375",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-29T09:48:15.301376+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262019-paternos--3478212",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.654069",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "A lucrative VAL401 licensing deal was announced on 20/6/25: \u201c ValiRx will receive 576,000 ordinary shares in Ambrose with clinical and commercial milestone payments to be made to Valiseek totalling a value of up to \u00a316 million plus royalties.\u201d Valirx owns 54% of Valiseek. Ambrose has a pipeline consisting of just TWO products: VAL401 (pancreatic cancer) and Renzapride (cystic fibrosis), both currently at phase 2 clinical. Today, Ambrose announced two further additions to their already impressive team: Dr. Janette Thomas joins as Director of Manufacturing Operations and Wendy Richings-Barrow as Director of Regulatory Affairs. \u201cThese appointments reflect our continued focus on building a world class team to deliver solutions for patients with rare conditions with no approved treatments.\u201d The Ambrose team already had a strong backbone: Chairman, Toby Waterworth has been part of leadership teams in multiple life science companies that have generated close to $1 billion in shareholder value. CEO Dr Hazel Jones was formerly Chief of Staff for AstraZeneca\u2019s Oncology R&D Leadership Team. Chief of Staff Virag Stephens an ex PMO Director at AZN and has strong fundraising expertise while Mike Webb led departments of up to 150 scientists in a 30-year career at GSK. Dr. Nick Meyers has 30 years\u2019 experience as a Program Director. In 2024, Ambrose was acknowledged by its peers when it won the Best Startup Biotech Company Award at the prestigious OBN Awards in London. Since then, it has grown significantly and confirmed it is exploring potential Middle-East listings. One of the partners on their webpage is SEHA (Abu Dhabi Health Services), a subsidiary of Pure-Health the largest integrated healthcare network in the UAE. (total assets $13B). Another partner is listed as Aparito, part of the Eli Lilly group. As Ambrose strengthens its leadership and global partnerships, Valirx is strategically placed to benefit from every milestone achieved on the VAL401 journey.",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.375",
          "thread_title": "The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-29T09:48:15.301415+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261513-paternos--2882543",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.654610",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "\u201cValix is in discussions with several potential partners to progress CytoLytix, including a major pharma\u201d. So, why is Mark, currently in California, continuing to promote the compound so actively both in the UK and overseas? While it\u2019s plausible a major pharma might seek exclusivity, the most realistic outcome is exclusive rights carved by territory, formulation, indication, or even species (human/veterinary)\u2014leaving room for multiple, parallel deals outside that scope. Indication splits are historically used when partners specialise in different therapeutic areas (eg ovarian only). Geographic exclusivity is even more common. The TrX/201 deal eventually failed when Mark attempted to remove Taiwan from the original LOI. The veterinary angle highlighted in recent webinars reinforces that CLX spans markets no single pharma can cover, making a multi partner licensing model far more realistic than a single global licence. There are numerous real world examples of multi partner licensing structures in biopharma: TERRITORY - Immunex (Enbrel) / initially Amgen \u2192 US & Canada rights, then Wyeth (later Pfizer) \u2192 Europe + Rest of World rights FORMULATION - Gilead (Tamiflu) / initially Roche \u2192 Oral formulation rights, then Hetero & Teva, \u2192 sublicenses for additional formulations INDICATION - AstraZeneca (Lynparza) / Merck \u2192 initially Ovarian cancer rights, then subsequently obtained licenses for breast and pancreatic cancers. Each example above shows one originator, no single-party lock in and multiple partners or deals to acquire different rights. With so many variables in play, it is increasingly clear that Valirx is preserving the same optionality for CytoLytix. Mark is still promoting CytoLytix because he is targeting several partners \u2013 not just one. Everything suggests CLX is being shaped as a multi deal platform, with the first handshake simply opening the monetisation cycle -",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.385",
          "thread_title": "CLX - multi deal structure",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D1488F3A-09F4-41C4-B45B-AF908B85E267"
        },
        "ingested_at": "2026-01-29T09:48:15.301452+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261459-Notpotal--8127238",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.655026",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Some clever trading going on here \u2013 those selling at 0.37p will soon be able to buy back at 0.39p. \ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "RE: Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-01-29T09:48:15.301491+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261329-Porky9-67506186",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.655478",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@PP Yes, and as long as the rain holds off should be able to get some golf in on expenses. Who needs Zoom and Teams when you can have a nice all expenses trip to the US. Lovely. Keep pumping it, only a few weeks now to go before next placing @notpotatlot Only Update you will get shortly that isn't fluff, will be the placing news or the next 125:1 consolidation event which has to be well over due now. Keep ramping it though, the gravy train needs to stay on the tracks, there are lifestyles here that need to be maintained.",
          "sentiment": 0.0,
          "engagement": "7,466",
          "price_at_post": "0.385",
          "thread_title": "RE: Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-01-29T09:48:15.301529+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260943-paternos--6908783",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.655913",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Mark re JPM in San Fran -  \u201cI have meetings lined up with our partner Omios Biologics so looking forward to catching up with Aldo Pourchet (CEO).\u201d In the Omios RNS (3/6/25), the evaluation was \u201cexpected to run up to 12 months, after which Omios can exercise its license option to continue using Cytolytix technology.\u201d Across both the June and Dec webinars, Mark emphasised CLX synergy with the Omios virus for potential to treat canine HSA, a clear signal that Omios sits firmly in the frame for a CLX licence. Valirx\u2019s revamped Advisory Board reinforces this direction, now with a notable weighting toward veterinary oncology and commercial expertise. The composition reflects a deliberate strategy to position CLX across both human and animal oncology. When your advisory structure is rebuilt around people who understand canine cancers, comparative oncology, and veterinary commercial pathways, it becomes clear Valirx is preparing for licensing routes across both human and veterinary markets. As a co-founder of VolitionRx, Mark transformed a human cancer test into a canine diagnostic test (Nu.Q) before negotiating a licencing deal with Heska for $26m. What price a cure? Human and veterinary oncology operate in separate regulatory and commercial channels. Most major pharmas, inc. AZN, Roche, GSK, AbbVie do NOT have any vet divisions. Even those historically involved have spun off their animal health units (Pfizer \u2192 Zoetis, Eli Lilly \u2192 Elanco). By envisaging veterinary opportunities for CLX, Mark is implicitly confirming the compound won\u2019t be a one partner asset; the split infrastructures required make multiple CytoLytix deals the only realistic outcome. GLA, DYOR, AIMO",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.385",
          "thread_title": "Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-01-29T09:48:15.301568+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261543-Notpotal-57186906",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.656343",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "I notice a 71430 buy at 15.14 and a similar sell 4 mins later for a \u00a321 loss. Great to see Porky has started trading again!  \ud83e\udd23\ud83e\udd23\ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "Welcome back, Porky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=FE350133-0204-48E9-9785-7F80407B3421"
        },
        "ingested_at": "2026-01-29T09:48:15.301606+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261534-Notpotal--2445309",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.656760",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Val is obliged to RNS as it a change to No. shares in issue. Hardly the company\u2019s fault if a holder sees such value that he wants to buy above the current SP. Mind you, I\u2019m expecting a TR1 tomorrow to confirm Mark\u2019s holding has increased by 80,000 shares. \ud83e\udd23 If this is the reaction to \u00a3400 of warrants, heaven help Porky\u2019s groupies when the next material RNS arrives.  \ud83e\udee8 \ud83d\ude28 \ud83d\ude22\ud83d\ude2d",
          "sentiment": 0.5,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-29T09:48:15.301645+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261811-viera--1078265",
        "event_type": "social_post",
        "date": "2026-01-30T22:38:35.634037",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "You sold the spike brilliantly Stephen . Knowing we have had no announcements and another year of zero revenue . You and porky have called it here . What do the directors get paid for here exactly ? Shambles . The BOD needs strengthening .",
          "sentiment": 0.0,
          "engagement": "1,553",
          "price_at_post": "0.35",
          "thread_title": "RE: Ambrose Q1 Newsletter - FYI",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=DD644FF4-EB58-4811-9E0F-61E17204B69A"
        },
        "ingested_at": "2026-01-30T22:38:45.279286+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261626-Uncanny-30168959",
        "event_type": "social_post",
        "date": "2026-01-30T22:38:35.634577",
        "source": "LSE_CHAT",
        "data": {
          "author": "Uncanny",
          "content": "Ambrose Healthcare | 2025 Highlights and What\u2019s Ahead in 2026 Dear Colleague / Partner, As we begin 2026, we would like to share a brief reflection on the past year at Ambrose Healthcare and outline what lies ahead in delivering its mission, to bring new therapeutics to rare disease patients who currently have no approved drug treatment. Our last update was shared in October 2025. Since then, meaningful progress has been made across our programmes, partnerships, and team, all in support of our mission to bring treatments to patients living with rare and underserved conditions. 2025 at a Glance During 2025, Ambrose focused on building strong scientific, operational, and partnership foundations to support the next phase of development: Continued preparation for the Renzapride Phase 2 trial for the treatment of the Gastrointestinal Manifestations of Cystic Fibrosis (GMCF), including regulatory planning and UK clinical engagement Exercised the licensing option for VAL401, securing global rights for development and commercialisation for treatment of cancers. 20% of cancers are classified as rare diseases. Ambrose is focusing initially on development for the treatment of pancreatic cancer Strengthened leadership, governance, and delivery capability Expanded engagement with clinicians, researchers, and funding partners across the UK and internationally Much of this work took place behind the scenes, laying the groundwork for accelerated progress in 2026. Scientific Leadership We are pleased to be working closely with Professor Bu Hayee, Kings Hospital, London who oversees the GMCF treatment centre for the Southeast of England and is supporting Ambrose as a Scientific Advisor for development of Renzapride for GMCF, providing valuable clinical insight as the programme progresses. We were deeply saddened by the passing of Professor Brian Feagan during 2025. Professor Feagan was internationally respected for his leadership in clinical trial design and execution. His early engagement with Ambrose and belief in rigorous, patient-centred development left a lasting impact on our work and thinking. Looking Ahead to 2026 In the year ahead, Ambrose Healthcare will focus on disciplined execution and collaboration, with priorities including: Advancing Renzapride toward initiating its Phase 2 study Preparing VAL401 for Phase 2 clinical development Pursuing investment as well as public and charitable grant funding, including a recent formal invitation to submit a major UK grant application for Renzapride Continuing to build trusted partnerships with clinicians, academic groups, and research organisations These activities reflect Ambrose\u2019s commitment to capital-efficient development and strong alignment with the UK life sciences ecosystem. Planning Named Patient Supply We are also planning to initiate Named Patient Supply (NPS) activities. Named Patient Supply enables access to Good Manufacturing Practice-manufac",
          "sentiment": 0.0,
          "engagement": "3,308",
          "price_at_post": "0.35",
          "thread_title": "Ambrose Q1 Newsletter - FYI",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=DD644FF4-EB58-4811-9E0F-61E17204B69A"
        },
        "ingested_at": "2026-01-30T22:38:45.279311+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261709-Porky9-10531916",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.373661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "What, do you think he is going to release news of the placing already, possible but they normally leave it right until the death, so proabably a few more weeks yet but you never know, you could be right.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.355",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-30T22:38:45.279331+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261448-Notpotal--8957907",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.374477",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Is that a Friday RNS I can smell.... Or has Porky had an accident? \ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.35",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-30T22:38:45.279357+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262254-viera--1891774",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.375315",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Pm changed his name to pp It\u2019s basically ME copy and paste . As he said ME has produced one RNS in months . We all know what the next RNS of note will be . ME needs to cut costs further and do something with 201. Good luck all.",
          "sentiment": 0.0,
          "engagement": "1,552",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-30T22:38:45.279376+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261720-RayPoint-22445971",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.376112",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Pater It's funny to see, in a thread entitled \"The Ambrose Dream Team\" and started by yourself , that neither the Dream Team nor VAL401 get a mention in your latest post.",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-30T22:38:45.279395+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261632-ratcliff-79065828",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.376907",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "'When the SP inevitably hits 1.6p plus there will be further buying pressure as placees exercise their 1.3p warrant options. Some will then sell for a quick profit but by then the SP will be in the 2p range. All this without the flush of positive news expected over the coming months.' Sounds good? Sounds worth buying into? Well actually it's a paternostpauper quote from 16th January 2025. But the share price then was 0.875, sliding gently down another post-placing ski-slope graph.  And what's the biggest news since then? Oh yes, another placing - predicted by P9 and derided by PP. Until it happened. On past history Porky's predictions seem a pretty reasonable bet. PP's posts are just reformulated bin dippings - he might as well just copy and paste on a pumping merry-go-round.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-30T22:38:45.279413+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261512-Porky9-57522018",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.377717",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Always entertaining, like watching fantasy island @PP is our very own Mr Roarke and @nopot is Tattoo.  Not sure who @uxm plays, probably the aircraft pilot as he only turns up to share the fantasy once a week or so. The gap will be between .15 and .20 as that will be where the placing shares land, thats of course if ME can pull it off again. Jury out this time.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-30T22:38:45.279431+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261503-paternos--3029097",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.378553",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Good post UXM.  Always entertaining to see trader Nick post again - his 63rd consecutive LSE post - and every one on Val. He might as well hang up a banner \u201croll up, roll up \u2013 bargain of a lifetime!\u201d \ud83e\udd23\ud83e\udd23\ud83e\udd23 Val has issued just one positive RNS since the placing, yet the SP has climbed 67% from those 0.23p lows. Even with 2 major holders dipping below the 3% threshold to facilitate some short-term trading, the SP still hovers near 0.4p. Every day that passes without an RNS increases the likelihood of one the following day as multiple programs mature: CytoLytix patent updates, formulation decisions, Blue Ribbon/VAL201 partnering (by diluting the asset, not VAL plc), 3k repurposing update (top candidate partnering?), further grant updates (ME has strong history), next evaluation and SPV (confirmed in webinar), Inaphaea income (PredictRx/ PDC sales), updates on the Dundee/Queen Mary pro-senescence project and StingRay (decision imminent). The motherlode remains early partnering/grant funding for CLX, a 2026 milestone confirmed by the CEO in the recent webinar. As the June anniversary nears, Omios have to decide whether they wish to exercise their option of a license agreement to continue using CLX tech. It looks promising as both Mark and Omios CEO Dr Aldo Pourchet had meetings arranged at the JPM in San Fran. More than once, Mark has referenced the Omios virus as an entry point to veterinary oncology due to its potential for treating canine HSA, while Dr Pourchet posted: \u201cWe are targeting triple negative breast cancers (CLX primary indication), all of which have the biomarker that makes them susceptible to our therapy. It\u2019s our most advanced program\u201d (Oct NYU interview). With multiple CytoLytix licenses up for grabs, Omios look set to start the ball rolling. The decisive factor which totally undermines the detractors\u2019 fearmongering is the financial position: a cash runway that extends till H2 excluding warrant income, R&D tax credits, grants, or additional Inaphaea income. That completely negates any March/April placing argument. Mind you, naysayers never let a few facts ruin their narrative. GLA DYOR",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-30T22:38:45.279449+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20261956-uxm484--9077367",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.379412",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Watch the video. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025 Chart analysis shows a nice gap at 1.4p. Past management issues but new management is outstanding.  Cash until H2 without the add ons such as grant money, revenue and warrant money. CEO heavily invested over 250k. Negotiating with a major biotech in regards to a deal for CLX001. Lab space is to help progress the assets to eventually get a deal not to make instant revenue. Any research on CLX001 done against a valuation of 2 million and cash burn just over a million would know this is a great opportunity. Great decision making. Derisking assets with partnership deals. Which other biotech has so much and spending less than 2 million. With warrants at a premium to the current price hopefully no more dilutions. Expecting significant news in the coming days/weeks. Tiny valuation and cash burn is tiny with assets of significant value.",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-30T22:38:45.279466+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20261515-viera--4120380",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.380239",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Problem my friend is ME hasn\u2019t got a proper hold of Costs paying a non BOD member and non scientist 100k  paying best mates that produce zero revenue is a disgrace . It shows a lack of respect for shareholders . Where are all the promised lab contracts . ME has surrounded himself with \u201cyes \u201c men. Shame he ousted Adrian as he had the commercial nous to make a difference . Adam also lost interest as was treated so badly by the BOD. I predict more confetti in April /May . Porky knows this co better than anyone . If he and Adrian joined the BOD I would consider investing but I\u2019ve lost faith in the current BOD who promise the world and deliver FA. Deliver some revenue asap or step down .",
          "sentiment": 0.0,
          "engagement": "1,552",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-30T22:38:45.279485+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20261416-ratcliff--5537187",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.381020",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Interesting that you've posted notgotalot - in December you distinctly said \"I\u2019ll take some time out and won\u2019t be back until the next decent RNS.\" Presume you've restarted posting because you've lost hope in there being a decent RNS.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-30T22:38:45.279503+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20260843-Notpotal-26221807",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.381814",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "each conspi****** on here is in self-denial mode - a mechanism where a person ignores or distorts reality to avoid anxiety and stress. they refuse to accept the situation simply because it doesn\u2019t support their agendas and so resort to posting fiction. whether it is by inventing a 50% lower cash runway, alleging fictitious staff at ambrose, claims of ceo golf jollies and overpaid team members or alleging lse posters are on the val payroll. desperate posts by the uninvested are now treated with the contempt they deserve. just when you think they\u2019re as low as they can get \u2013 they pick up a spade. by resorting to deception, they have lost any remaining credibility they may have had, while each day news edges closer.",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-30T22:38:45.279521+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20262102-ratcliff-66539321",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.382589",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "It would also be interesting to know why the posting of relevant financial facts from those observing is described as 'panic.' Surely the only panic is among those trying to snare the naive with fantasy predictions so they can get out fast with a profit - and now realising that the supply of gullible newbies is drying up.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-30T22:38:45.279539+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261925-RayPoint--7884501",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.383379",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "So what's the crack, pp? I would be interested to know your view on how Ambrose are paying salaries to the Dream Team without having any money in the bank",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-30T22:38:45.279557+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261832-paternos-67071663",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.384211",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "@  spantrout - Great call. Valirx - 10m,50s in. \u201cA lot of return on that one!....DYOR but in all probability, if it\u2019s going to have some game-changing news, then \u2026.that would be 1.4p.\u201d Not sure of the news he is he is referring to? Maybe the new patents, partnering (CLX,201), repurposing top 10, StingRay, further grants, or expansion into veterinary oncology? Possibly it\u2019s the the 2nd evaluation and new SPV or even the CEO buying 7% of the company. I suppose it could be that Mark E has recently been on stage presenting alongside some of the biggest names in pharma, or the fact the CEO has a history of delivering success (Nu.Q test sold for $26m). !.4p is an interesting SP \u2013 that would not only see the 0.5p warrants in play but also the 1.3p warrants, easily extending the runway into 2027. Mind you realistically, a few easily pleased would exit for a quick 300%+ profit. I guess the uninvested posting day and night trying to supress the SP hasn\u2019t gone unnoticed either. Karma can be a wonderful thing! Happy days DYOR, GLA.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.385",
          "thread_title": "RE: Coverage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=1C527045-FD63-41D2-B4BE-ED55425FC93C"
        },
        "ingested_at": "2026-01-30T22:38:45.279574+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261714-Notpotal--9167141",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.385010",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "pp previously purged porky\u2019s parrots\u2019 pack of preposterous posts pedalled in panic, perhaps predictably. i promptly prepared a poem for porky to peruse at his pleasure. pundit porky posted a pack of pathetic, poorly proven poppy****. a pack of pathetic, poorly proven poppy**** pundit porky posted. when pundit porky posted a pack of pathetic, poorly proven poppy****, perhaps he\u2019ll point to proof behind the pathetic poppy**** pundit porky posted?",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.385",
          "thread_title": "Porky\u2019s Peddled Pile of Piffle",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=93B08DEA-F499-4237-AF7E-B5143BC8D67E"
        },
        "ingested_at": "2026-01-30T22:38:45.279592+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261625-spantrou-20104620",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.385791",
        "source": "LSE_CHAT",
        "data": {
          "author": "spantrout",
          "content": "Https://youtu.be/HrYMuqPFA20",
          "sentiment": 0.0,
          "engagement": "13,977",
          "price_at_post": "0.385",
          "thread_title": "Coverage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=1C527045-FD63-41D2-B4BE-ED55425FC93C"
        },
        "ingested_at": "2026-01-30T22:38:45.279610+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261403-Porky9-33475707",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.386613",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@PP You really are a busted flush, its like groundhog day:- Pump the boards with nonsense about million dollar licensing deals, how the cash is well managed and will last many months more than it does, how there will be all these marvelous license deals lined up, exaggerate the interest and how fantastic it all is. Then RNS drops,  placing at discount issued, you vanish for a few weeks, let the dust settle and then you pop up again and repeat the above. I totally get those in the business want the gravy train to continue, lifestyles at risk but have you no conscience that small investors that may not earn the sort of money the board here gets here for these cushy  work from home jobs, are going to lose their hard earned cash being sucked into this? Its morally not right. Next RNS will be the next discounted placing, can't be far off now, a few weeks at most imo.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-30T22:38:45.279628+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261529-RayPoint-11794330",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.157704",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "I hear that green fees are pretty steep in California",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-30T22:38:45.279645+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261434-ratcliff--8446722",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.158130",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "No problem RP - I'm wondering who paid 0.50 for a few shares worth about 25 percent less from the start, but I suppose 400 quid pays for the week's teabags and digestives.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-30T22:38:45.279663+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261413-RayPoint-84073155",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.158544",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Sorry Rats. I misinterpreted your post.",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-30T22:38:45.279681+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261412-RayPoint--1327039",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.158961",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "\"Probably about 450 quid...\" Rats, stop ramping! The gross proceeds were \u00a3400",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-30T22:38:45.279699+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261357-spantrou-74529561",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.159474",
        "source": "LSE_CHAT",
        "data": {
          "author": "spantrout",
          "content": "\u00a39.99 for rns",
          "sentiment": 0.0,
          "engagement": "13,977",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-30T22:38:45.279716+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261311-ratcliff--2450728",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.159890",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Probably about 450 quid...",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-30T22:38:45.279734+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261216-steve196-16648290",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.160315",
        "source": "LSE_CHAT",
        "data": {
          "author": "steve196",
          "content": "How much does it cost to release an RNS just for \u00a3400 of warrants?",
          "sentiment": 0.0,
          "engagement": "2,761",
          "price_at_post": "0.385",
          "thread_title": "Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-30T22:38:45.279752+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261935-uxm484--1594639",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.160734",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "No, but the holders all want the warrants exercised so we can do a 10 bagger in 12 months without a fund raise. For me i am really happy here with  the progression. We are definitely early in a news rich periods where all the negative posters are posting overtime and are only posting as they missed out on the last fundraise hoping for an even lower price. We will likely get a few meaningful RNS very soon. Brakes are now off\u2026",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.36",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-30T22:38:45.279770+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261222-Notpotal--8206078",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.261915",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "\u201cYou sound so desperate\u201d says the man who\u2019s last 60 posts have been on a share he isn\u2019t invested in. \ud83d\ude02\ud83d\ude02\ud83d\ude02",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-30T22:38:45.279788+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261207-ratcliff--9100134",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.262733",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Slight typo there - should read blatantly UNTRUE and misleading!",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.365",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-30T22:38:45.279806+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261201-ratcliff--2968479",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.263581",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "UXM - differences of opinion are generally understandable, but to say in your post 'All lies' is blatantly true and misleading, and as usual does nothing to bolster your credibility. Two of the things you say in that post are particularly inaccurate - 'Great decision making. Derisking assets with partnership deals. Which other biotech has so much spending less than 2 million.' - They are looking for deals (or claim to be anyway) but nothing so far has contributed anything to even cover the outgoings, let alone provide money for further work or expansion (hence the redundancies etc) Secondly - 'With warrants at a premium to the current price hopefully no more dilutions' - warrants don't kick in and generate cash the moment the sp goes above them as you and the others in your group seem to imply. In the unlikely event of the sp rising above that point and remaining so, it just might be worth warrant holders exercising them so they could buy shares at below the then-current price, but to sell them they'd need to be able to be sure the sp was strong enough to withstand the effect of the sells. You know that, so stop trying to imply that the mere existence of warrants is a long-term fool proof source of near or long term capital. Then again, if this company was fool proof you wouldn't be here I imagine.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.365",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-30T22:38:45.279824+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261059-viera--8317442",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.264399",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Are you PM in disguise ? Who in  their right mind would buy any company on Aim with only 3 or 4 months cash runway? You sound so so desperate for a rally to sell out !",
          "sentiment": 0.0,
          "engagement": "1,552",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-30T22:38:45.279842+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261050-Rebster4-58726201",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.265221",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rebster408",
          "content": "Its groundhog day again This is a binary bet...and Poky has called it right in the past and I thinks he's spot on again... 201 is older than me!!! place your bets... the wheel is spinning and will stop within the next 8 weeks All will become clear within the next two months...",
          "sentiment": 0.0,
          "engagement": "1,174",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-30T22:38:45.279860+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260920-RayPoint-45506010",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.266008",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Living in fantasy land",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-30T22:38:45.279877+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260857-Notpotal--8738869",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.266824",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "\u201cYou can't go back and change the beginning, but you can start where you are and change the ending.\" \u2013 C.S. Lewis Early in his tenure, Mark acknowledged mistakes had been made \u2014 and while he couldn\u2019t rewrite the past, he could reshape the future. 17 months later, Val is reborn, with money in the bank, a rebuilt team, high calibre assets and a SH base that deserves success after years of one-way support. A few resident historians cling to their preferred mythology, inventing a minimal cash runway because the real picture is too uncomfortable to accept: a cash runway to H2 even without R&D tax credits, additional Inaphaea income, grants or exercised warrants. This is also before the wave of RNS due over the coming weeks. Unlike those posting fiction, Mark has backed his conviction with his own money \u2014 now holding 7% of the company. \u201cWhat matters now is not where we\u2019ve been, but where we\u2019re going.\u201d",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.365",
          "thread_title": "Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-01-30T22:38:45.279895+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20262049-ratcliff--4022859",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.267621",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Whatever it is you're smoking UXM, it's powerful stuff.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-30T22:38:45.279913+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261733-uxm484--6739234",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.268458",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "All lies. Watch the video previously posted. Past management issues but new management outstanding.  Cash until H2 without the add ons. CEO heavily invested over 250k. Negotiating with a major biotech in regards to a deal for CLX001. Lab space is to help progress the assets to eventually get a deal not to make instant revenue. Any research on CLX001 done against a valuation of 2 million and cash burn just over a million would know this is a great opportunity. Brokers only had 20k stock. Hardly lots of stock. Great decision making. Derisking assets with partnership deals.  Which other biotech has so much spending less than 2 million. With warrants at a premium to the current price hopefully no more dilutions.",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.385",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-30T22:38:45.279931+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261719-Porky9--5831788",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.269349",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "And just a few reasons why not to believe the BS from the resident rampers here and why you should avoid:- * Lifestyle Business * Ridiculous Admin costs * Continual Raises and continual dilution * More than 20 Raises, 3 lots of 125:1 Consolidation events * business concept never proven * Rented lab space and zero revenue in 15 years * About 8 weeks cash runway left with yet another raise due anytime soon to keep the gravy train going. * if new investors or brokers say enough is enough and call time due to clients continually losing money then its admin and you could lose your entire investment. * materially overpriced as absoluly nothing here to invest in, its the emperors new clothes you are buying. 201 is older than hens teeth, no interest in 15 years and CLX years off and more cash required. Labs meanwhile doesnt know what an invoice is. * Poor decision making, lack of any commercial acumen *No real focus, practically everyone is work from home with multiple jobs. * Short term punts only not a long hold due to above. * loads of stock held for broker fees that will need to be drip fed into anyone buying. In all avoid at all costs unless you like dilution",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.385",
          "thread_title": "Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-01-30T22:38:45.279949+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261507-ratcliff--4945691",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.270143",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "You swine Nomlungu. You've rumbled me.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.41",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-30T22:38:45.279967+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261503-Mr0nions-42899027",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.270906",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mr0nions",
          "content": "Because of this  post, I'm holding position.  Good luck all.",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "0.41",
          "thread_title": "RE: Why invest? \u2013 THE SCIENCE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=058BF091-3235-424B-9C46-FA00ED6BC8D5"
        },
        "ingested_at": "2026-01-30T22:38:45.279985+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261432-mikee_p-90175492",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.271701",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "1 HR. Channel is all ya need.",
          "sentiment": 0.0,
          "engagement": "1,893",
          "price_at_post": "0.395",
          "thread_title": "Easy trade this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=81274FD9-0226-45F3-8CEA-B1F91E33B4A2"
        },
        "ingested_at": "2026-01-30T22:38:45.280003+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261430-nomlungu--2572694",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.272502",
        "source": "LSE_CHAT",
        "data": {
          "author": "nomlungu",
          "content": "People should just ignore Rat... he is just jealous that he does not have the losses to use to reduce his tax liabilities. That 80% drop in the last tax year will have been very valuable for some; I think him moaning around the time that taxes are due for the 2024/25 year is a dead give away. \ud83d\udcc9 \u2757",
          "sentiment": 0.0,
          "engagement": "23,976",
          "price_at_post": "0.395",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-30T22:38:45.280021+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261313-paternos-12024051",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.273388",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "When Mark became CEO, ValirRx was effectively dormant - few assets in play, minimal Board investment and limited vision. He set about a major restructuring: rebuilding the team, reshaping the asset base and above all, resetting the mindset. Fast forward 17 months and Val is reborn. A microcap expanding into developing fields of oncology, yet every action taken has a cost/benefit analysis and timescale consideration. If concluded that a project cannot be monetised early, it is shelved or paused. Commercial decisions overrule all others. Valirx is now plugged into some of the most advanced platforms in modern drug development: \u2022\tpatient avatars (TwinEdge) \u2022\tmicrofluidics/3D tissue culture models (Screenin3D, Ignota & VoxCell) \u2022\trepurposing (Ignota, Altus & Dominion) \u2022\tpersonalised immunotherapy (PredictRx / Dominion) \u2022\tpro-senescence drugs (Dundee / Queen Mary Uni) \u2022\tClickmer technology/HER2 protein (Apis Assay) \u2022\tLMTK3 kinase targeting (StingRay). The most recent evaluation, a 2nd-gen RNA helicase inhibitor (McGill/IRICoR), brings Val into collaboration with major international research organisations. Last year, Mark identified a shift away from animal-testing and moved early to establish capability partners supporting NAMs and cutting-edge AI. Recent US & UK Gov\u2019t regulatory changes now actively favour such platforms with Europe to follow this year. Once again, Val anticipated this trend before much of the market. Meanwhile, the Advisory Board has been upgraded from academics and towards industry experts who can provide insight into Big Pharma priorities and identify new commercial pathways such as in veterinary science - quicker to market while opening a parallel revenue path thru\u2019 comparative oncology, further de risking the route to human oncology. Mark has also added a clause into evaluation agreements whereby if Val decides not to progress an asset eg StingRay, McGill/IRICoR, then Inaphaea retains the data and can still monetise should a 3rd party take the asset forward. Val is no longer waiting for opportunity; it is engineering it.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.385",
          "thread_title": "Why invest? \u2013 THE SCIENCE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=058BF091-3235-424B-9C46-FA00ED6BC8D5"
        },
        "ingested_at": "2026-01-30T22:38:45.280039+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261224-paternos--8565463",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.274229",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "A \u00a33m microcap with a cash runway till H2 even before factoring in R&D tax credits, potential grant funding, additional Inaphaea income or warrant cash now within reach. Outgoings reduced by \u00a3200k PA following a team restructuring last year. Val\u2019s expansion into NAMs and advanced AI tech, supported by strong academic partnerships, aligns directly with revised US & UK gov\u2019t guidelines to reduce animal testing. This positions Val as a front runner for non dilutive grants and innovation funding, with a CEO geared to capitalise on this opportunity. The 1/9/25 RNS confirmed ongoing discussions with several potential partners to progress Cytolytix, including a major pharma. Val owns 60% of CLX with 10% owned by co-inventor, Dr Charles Chen (Senior Scientist at Astrazeneca). Val also has a 54% share of an Ambrose deal potentially worth up to \u00a316m, and a Biobank of 476 PDCs valued at \u00a310k per PDC cell-line upon commercialisation, plus commercial rights entitlement. Valirx has assets in several key cancer indications, all with huge global markets: 201/prostate ($11.3Bn*), CLX (primarily TNBC ($1.5Bn*), ovarian ($2.5Bn*) but also prostate, 301/endometriosis ($1.9Bn**), and 401-Ambrose/pancreatic ($2.9Bn**). Sources: *webinar, **GMI. Several RNS updates are imminent: CLX patents \u201cin coming weeks.\u201d (RNS 1/9/25), Dundee/Queen Mary project (extended to 9/2/26), StingRay (approx Feb \u201926 per Aug video), Blue Ribbon SPV - \u201cSeveral patents envisaged for 201\u201d, and the next evaluation/SPV \u201cimminent with discussions already at a mature stage\u201d. The Omios RNS (3/6/25) stated \u201c\u2026 expected to take up to 12 months. On conclusion of the evaluation, Omios has an option to enter into an Oncolytic Peptide License Agreement to continue using Cytolytix technology.\u201d Yet another potential source of income. In addition, the Val/Dominion repurposing project (teaching an old drug new tricks) has identified 200 FDA approved non-oncology drugs which already have phase 1 clinical data and are showing activity against various cancer PDCs. 10 of these candidates are now being fast-tracked. The median upfront deal size for pre-clinical IND ready assets was $110m in 2025. For phase 2 this increased to $775m. (Dec webinar). For context, Val\u2019s SP exceeded 55p in 2021 with only one key asset (VAL201). Currently, including the repurposing project, Val now has 200+ potential assets plus a valuable Biobank. Also, Mark has restructured evaluation agreements whereby if Val chooses not to progress an asset (eg StingRay, McGill/IRICoR), Inaphaea retains the data and can still monetise should a 3rd party take the asset forward. Multiple monetisation routes now sit across the pipeline, supported by a commercially-savvy CEO who now owns 7% of the company. Valirx \u2013 a microcap with midcap potential.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.355",
          "thread_title": "Why invest? \u2013 FINANCIAL",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=8931CA86-EC8C-43F3-AA7F-54C7D7FD717E"
        },
        "ingested_at": "2026-01-30T22:38:45.280057+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261145-Marty130--4680688",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.274986",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Be good to see the directors buying some of the stock..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "0.355",
          "thread_title": "Directors deals",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=DC2D2A2F-B451-4EEF-B7C8-9C80695D4033"
        },
        "ingested_at": "2026-01-30T22:38:45.280075+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261107-ratcliff--4226429",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.275854",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "UXM - cutting and pasting the same post repeatedly is not convincing, but to humour you I had a listen to the link you have monotonously posted. It's not persuasive or convincing - Starts off about the 'objectives we have set' and 'milestones we're looking to achieve.' Then there's a bit about the group structure - this is rearranging the deck chairs on the Titanic isn't it? They've had more rearrangements over the decades, it's just a distraction now - meetings are the practical alternative to work. The we hear 'The objective is...' and 'If suitable...'  So nothing at all certain. Then he says BC201 and Val301 have 'not been spun out yet, but would benefit from all of the development work undertaken on Val201.' So BC201 and Val301 still of no interest (except maybe on Antiques Roadshow) and if Val201 had even a glimmer of potential it would have done something since it was quietly shelved - was that 6 years ago or 8? It's been stagnant for so long, the rest of the industry has moved on. The he says 'There is strong interest in endometriosis treatments.' True. There's strong interest in a lot of things, but stating a fact doesn't tie it to VAL. 'We have two new evaluations under consideration.' And...? I\u2019ve got a lot of things under consideration, but whether they get any further is often very uncertain. 'The vision is...' - A lot of people have visions, but a vision isn't even a plan. It's a nice idea at best. 'Our strategy is to do this based on identifying the highest quality assets we can find and afford.' That's like saying 'come round to my place for a meal' and when you get there you say 'There\u2019s a tin of Pedigree Chum between the four of us - it was the highest quality I could find on the available budget.' The he's going to have a system which 'allows us to prioritise selection of assets.' How early stage is all this? And no money to do it with.. Next we see \u2018The Team\u2019 but no mention of their salaries. Then a review of last year - no mention of the placings. Talk of last year's cost savings and redundancies - but if you are cutting 200k a year and laying people off, what were you wasting the money on in the first place? Or have you sold your food to pay the heating bill? Then he says 'Our runway through 2026' - sorry - that 'runway' stops in a couple of months without a placing. The 2026 Xmas do is potentially in the Job Centre unless money comes in very soon. Time is money. They seem dangerously short of both. Again.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.355",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-30T22:38:45.280093+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260954-uxm484--6624766",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.276634",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Plenty of news to come at a tiny valuation and likely this month. Cash until at least July that without warrants, revenue, deals, grants. Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-30T22:38:45.280139+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260919-Porky9--4724049",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.277452",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@Notpotalot Nick is a VERY experienced prolific investor. Frankly, i doff my cap to him as he called the trade perfectly in at .25 and out at .40. Beautiful. The Muppets are the traders in on the back of the Zac Mir pump without any research in blind on the dead cat bounce they will get burnt if still holding. As for Stephen and Jaspal at u3% they now dont have to declare BUT IMO they have about 8 weeks to slowly work the sells in to ensure they are out (just holding warrants options) before that next raise drops as they will be diluted to oblivion as sure as night is day. They can only drip sells in slowly to avoid the brokers hammering them at discount. You try selling big volumes of this close to the raise, or at anytime for that matter, you need to do it on a bounce really, sell whilst traders are buying. This is NOT an investment, its a short term punt. The reason its not an investment is because it can't generate revenue (well none in the last 15 yrs anyhow)  and is reliant on raise after raise after raise to maintain lifestyles. As I say, tick tock. Tick tock countdown already started imo.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-30T22:38:45.280162+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261952-Notpotal-33033893",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.278260",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Porky, unlike some holders, I still keep you around for the entertainment value.  Calling Nick and other traders \u2018muppets\u2019 is certainly \u2026.\u201dcreative\u201d. \ud83d\ude00 Jaspal S and Stephen W dipping just under the 3% is nothing more than freeing up a couple of million to trade. There\u2019s no great sell-off and no drama. Most of us aren\u2019t brave enough to risk missing an RNS for the sake of a few hundred quid. Get your 40 winks while you can. Many sleepless nights await over the next few months.   \ud83e\udd71 Pleasant dreams.",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-30T22:38:45.280191+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261804-uxm484--6624766",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.279044",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Plenty of news to come at a tiny valuation and likely this month. Cash until at least July that without warrants, revenue, deals, grants. Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-30T22:38:45.280223+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261539-Porky9--2143937",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.279866",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Err nope Only thing that will bring hard cash into the company of any meaningful amount in the next 8 weeks will be new placing money - sorry Regarding your continual pumps and fluffy updates, jam tommorrow dream fantasy posts, NONE of it can pay the bills now, end of. Anyone with any brains will be working the sells into any mupets trading this that are oblivious to the dire need for cash to keep the lights on and the pending essential discounted placing that has to happen to support the lifestyles here to keep the gravy train going. Tick Tock, Tick Tock",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.35",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-30T22:38:45.280243+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261042-paternos--5764778",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.280667",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "As standard, when Mark did the Dec webinar he emphasised nothing new, \u201cjust meat on the bones\u201d. However, often that meat can be pretty tasty. Blue Ribbon/VAL201 \u2013 \u201csynthesis almost complete\u201d (10m.30s). Then, \u201ca small amount (only \u00a350k) set aside for pre-clinical development of 201, the balance WILL then come from external investment into the asset\u201d (11m.55s). No \u201cMIGHT\u201d in that statement. The minimal outlay confirms that the VAL201 drug package is essentially finalised, and the entire development programme (preclinical \u2192 IND \u2192 partnering) is about to move forward. Mark has already confirmed Val will be diluting the asset, not Val PLC. With patents imminent, it\u2019s a clear signal that Blue Ribbon is not just a corporate shell \u2014 it\u2019s actively progressing VAL201 toward monetisation. Given Val\u2019s recent multi facet RNS style, the imminent update could well bundle new patent status with partnership confirmation. The last significant VAL201 update in 2021 saw the Val SP exceed 50p.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.365",
          "thread_title": "Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-01-30T22:38:45.280261+00:00"
      },
      {
        "event_id": "SOCIAL-10Jan20261920-Kaeren-85625567",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.281449",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kaeren",
          "content": "All great thx.",
          "sentiment": 0.0,
          "engagement": "10,948",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-01-30T22:38:45.280294+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262133-paternos-34496885",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.646223",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Seven consecutive \u201cblocked\u201d posts on a blue day tells me everything I need to know. LOL The desperation of the naysayers knows no bounds \u2013 and the newsflow hasn\u2019t even started yet. I fear for the sanity of Porky and his parrots over the coming months. With an absolute minimum cash runway into July already confirmed and multiple RNS imminent, Porky could well self-check in to the local abattoir. The lorry reversing toward the sty, isn\u2019t delivering feed. \ud83d\udc37 \ud83e\udee8 \u26a1 \ud83c\udf2d Anyone for a bacon butty or sausage cob?",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.385",
          "thread_title": "The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-01-30T22:38:45.280317+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261807-Porky9-20516103",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.646670",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@Nick I totally agree with you. If anyone can trade this you can. But I have to hand it to mark, the money just keeps on coming, I mean its shocking really, there is absolutely nothing here to invest in, it really is the emporers new clothes, but he keeps getting the cash and with over 20 raises, what's another one? I still think .15 or .20 but ultimately you would think the brokers would say, hang on a minute you never deliver on anything you say, our clients are losing money off our broker notes to buy, enough is enough but I guess as long as they get their fees they couldn't care less.",
          "sentiment": 0.0,
          "engagement": "7,466",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-30T22:38:45.280335+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261719-RayPoint-27785930",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.647089",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "It does explain all the voices in my head \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-30T22:38:45.280353+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261714-ratcliff-85633305",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.647517",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Viera - are you RayPointer and me as well?",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-30T22:38:45.280372+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261704-viera--3741105",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.647968",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "But why would anyone give this lot any money Porky  ? They earn 100k whilst having other part time jobs. Been 20 years of promises but zero revenue . There will be zero revenue in before April when the next begging bowl comes out . I was at 5pct with Theoremx and that failed . I\u2019m at zero pct with Ambrose ! Anyone holding this as we enter Feb/March needs to see a dr. Any monies raised goes to directors as not enough to make any investments. I will NOT be buying at any price . It\u2019s a shambles . Sorry",
          "sentiment": 0.0,
          "engagement": "1,550",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-30T22:38:45.280390+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261454-Porky9-78527936",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.648402",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "They dont have a pot to pee in, its a phoenix business and frankly if they raise cash it will be for themselves, not to give away to VAL - BE REAL. Would imagine meetings being scheduled by VAL with placing brokers shortly, can't be far off now - my call this time is another \u00a31m at .15 to .20 tops - give them another 5/6 months more gravy train assuming brokers can find more mugs to support the lifestyles.",
          "sentiment": 0.0,
          "engagement": "7,466",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-30T22:38:45.280408+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261440-ratcliff-17963152",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.648817",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "I was asking myouryourself the same question. But I knew that, as did Iyou.",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-30T22:38:45.280426+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261415-RayPoint-81336873",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.649253",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Are these people actually employed by Ambrose? Last time Ambrose received capital investments (as I recall, in the region of 900,000) they trumpeted the fact on their website. Yet, at March last year, they only had 25k in the bank. Subsequent to March last year,  there have been no announcements of further investments. I ask myself (i.e. Rats) how this all adds up.",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-30T22:38:45.280444+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261403-Notpotal-58759609",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.649678",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Nice to see momentum at Ambrose. They certainly are building a very strong team. However, this highlights another positive for Valirx. VAL401 is the result of a reformulation of the anti-psychotic drug, Risperidone into an oncology drug. One solitary repositioned drug has resulted in a potential multi-million deal. No wonder in the webinar Mark said he was excited regarding the Val/Dominion repurposing project. This collaboration has identified approx 200 FDA approved non oncology drugs which are showing anti-cancer against various Inaphaea PDCs. Ten of these candidates are now being fast tracked for deeper evaluation. Mark even mentioned looking to partner the prime repurposing asset this year. Because these compounds are clinically validated and safety de-risked, the probability of progressing to meaningful clinical proof of concept is far higher than in creating oncology drugs from scratch - positioning the Val/Dom alliance for multiple rapid, low cost shots on goal.",
          "sentiment": 0.5,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-30T22:38:45.280462+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261359-ratcliff--3773080",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.650086",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "True O alter ego. He even knows where my investments are. (Or should that be 'our' investments)",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-30T22:38:45.280480+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261356-RayPoint-83077938",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.650503",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "You can't fool uxm, he's so sharp \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-30T22:38:45.280499+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261348-uxm484--4028393",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.650918",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Ratcliffe are you Raypointer? Both invested in Scancell. Both are not invested in Valirx.",
          "sentiment": 0.0,
          "engagement": "1,009",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-30T22:38:45.280517+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261333-ratcliff--2974947",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.651345",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "The number of employees and the financial state is a bit concerning isn't it? They weren't flush in 2024's accounts, and they're worse in the 2025 ones. So back to the question - what are 500,000 odd shares in Ambrose actually worth? Potentially even less than 500,000 Val shares...? https://find-and-update.company-information.service.gov.uk/company/14409383/filing-history",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-30T22:38:45.280534+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261310-RayPoint-39679691",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.651773",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "The reason I ask is that if I look at Ambrose Healthcare on Companies House, I find the same name with the same month of birth: Tobias Adam WILSON WATERWORTH - born October 1964 Spookily, this person only has 1 director appointment - Ambrose Healthcare, the other 21 are missing! https://find-and-update.company-information.service.gov.uk/officers/SAWjapGOj9HbCMsLuSFBZeqVYiU/appointments Does anyone else find this rather strange?",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-30T22:38:45.280552+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261254-RayPoint--2687277",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.652198",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Could this be the CEO of Ambrose Healthcare? https://find-and-update.company-information.service.gov.uk/officers/JzAELIfnpaXPIZjjnhqdRjwB9KM/appointments",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-30T22:38:45.280570+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260857-Rebster4--6228547",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.652606",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rebster408",
          "content": "Probably cos Ambrose only have about \u00a325k in capital and assets in 2025... not a pot to p155 in...",
          "sentiment": 0.0,
          "engagement": "1,174",
          "price_at_post": "0.375",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-30T22:38:45.280592+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260757-uxm484--6135195",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.653034",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "I understand they get a share of Ambrose  not just Val401. News on other clinical compounds increases the value of the shares therefore more valuable than just getting cash for Val401. Valirx will have options to sell some shares initially to get some cash.",
          "sentiment": 0.0,
          "engagement": "1,009",
          "price_at_post": "0.375",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-30T22:38:45.280611+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262226-ratcliff--6001650",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.653624",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Why were Val given shares not cash by Ambrose? What are 576,000 Ambrose shares worth? Can they be sold to raise much-needed cash? How much cash had been raised for Val in the 7 months since that announcement? If it was a deal of any real worth, why did Val have to do a placing a few months later, and how come it's heading towards another one in a matter of weeks on current estimations?",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.375",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-30T22:38:45.280629+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262019-paternos--4236315",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.654069",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "A lucrative VAL401 licensing deal was announced on 20/6/25: \u201c ValiRx will receive 576,000 ordinary shares in Ambrose with clinical and commercial milestone payments to be made to Valiseek totalling a value of up to \u00a316 million plus royalties.\u201d Valirx owns 54% of Valiseek. Ambrose has a pipeline consisting of just TWO products: VAL401 (pancreatic cancer) and Renzapride (cystic fibrosis), both currently at phase 2 clinical. Today, Ambrose announced two further additions to their already impressive team: Dr. Janette Thomas joins as Director of Manufacturing Operations and Wendy Richings-Barrow as Director of Regulatory Affairs. \u201cThese appointments reflect our continued focus on building a world class team to deliver solutions for patients with rare conditions with no approved treatments.\u201d The Ambrose team already had a strong backbone: Chairman, Toby Waterworth has been part of leadership teams in multiple life science companies that have generated close to $1 billion in shareholder value. CEO Dr Hazel Jones was formerly Chief of Staff for AstraZeneca\u2019s Oncology R&D Leadership Team. Chief of Staff Virag Stephens an ex PMO Director at AZN and has strong fundraising expertise while Mike Webb led departments of up to 150 scientists in a 30-year career at GSK. Dr. Nick Meyers has 30 years\u2019 experience as a Program Director. In 2024, Ambrose was acknowledged by its peers when it won the Best Startup Biotech Company Award at the prestigious OBN Awards in London. Since then, it has grown significantly and confirmed it is exploring potential Middle-East listings. One of the partners on their webpage is SEHA (Abu Dhabi Health Services), a subsidiary of Pure-Health the largest integrated healthcare network in the UAE. (total assets $13B). Another partner is listed as Aparito, part of the Eli Lilly group. As Ambrose strengthens its leadership and global partnerships, Valirx is strategically placed to benefit from every milestone achieved on the VAL401 journey.",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.375",
          "thread_title": "The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-01-30T22:38:45.280647+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261513-paternos--4691451",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.654610",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "\u201cValix is in discussions with several potential partners to progress CytoLytix, including a major pharma\u201d. So, why is Mark, currently in California, continuing to promote the compound so actively both in the UK and overseas? While it\u2019s plausible a major pharma might seek exclusivity, the most realistic outcome is exclusive rights carved by territory, formulation, indication, or even species (human/veterinary)\u2014leaving room for multiple, parallel deals outside that scope. Indication splits are historically used when partners specialise in different therapeutic areas (eg ovarian only). Geographic exclusivity is even more common. The TrX/201 deal eventually failed when Mark attempted to remove Taiwan from the original LOI. The veterinary angle highlighted in recent webinars reinforces that CLX spans markets no single pharma can cover, making a multi partner licensing model far more realistic than a single global licence. There are numerous real world examples of multi partner licensing structures in biopharma: TERRITORY - Immunex (Enbrel) / initially Amgen \u2192 US & Canada rights, then Wyeth (later Pfizer) \u2192 Europe + Rest of World rights FORMULATION - Gilead (Tamiflu) / initially Roche \u2192 Oral formulation rights, then Hetero & Teva, \u2192 sublicenses for additional formulations INDICATION - AstraZeneca (Lynparza) / Merck \u2192 initially Ovarian cancer rights, then subsequently obtained licenses for breast and pancreatic cancers. Each example above shows one originator, no single-party lock in and multiple partners or deals to acquire different rights. With so many variables in play, it is increasingly clear that Valirx is preserving the same optionality for CytoLytix. Mark is still promoting CytoLytix because he is targeting several partners \u2013 not just one. Everything suggests CLX is being shaped as a multi deal platform, with the first handshake simply opening the monetisation cycle -",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.385",
          "thread_title": "CLX - multi deal structure",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D1488F3A-09F4-41C4-B45B-AF908B85E267"
        },
        "ingested_at": "2026-01-30T22:38:45.280665+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261459-Notpotal-58092339",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.655026",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Some clever trading going on here \u2013 those selling at 0.37p will soon be able to buy back at 0.39p. \ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "RE: Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-01-30T22:38:45.280683+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261329-Porky9--4072728",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.655478",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@PP Yes, and as long as the rain holds off should be able to get some golf in on expenses. Who needs Zoom and Teams when you can have a nice all expenses trip to the US. Lovely. Keep pumping it, only a few weeks now to go before next placing @notpotatlot Only Update you will get shortly that isn't fluff, will be the placing news or the next 125:1 consolidation event which has to be well over due now. Keep ramping it though, the gravy train needs to stay on the tracks, there are lifestyles here that need to be maintained.",
          "sentiment": 0.0,
          "engagement": "7,466",
          "price_at_post": "0.385",
          "thread_title": "RE: Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-01-30T22:38:45.280700+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260943-paternos--3371173",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.655913",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Mark re JPM in San Fran -  \u201cI have meetings lined up with our partner Omios Biologics so looking forward to catching up with Aldo Pourchet (CEO).\u201d In the Omios RNS (3/6/25), the evaluation was \u201cexpected to run up to 12 months, after which Omios can exercise its license option to continue using Cytolytix technology.\u201d Across both the June and Dec webinars, Mark emphasised CLX synergy with the Omios virus for potential to treat canine HSA, a clear signal that Omios sits firmly in the frame for a CLX licence. Valirx\u2019s revamped Advisory Board reinforces this direction, now with a notable weighting toward veterinary oncology and commercial expertise. The composition reflects a deliberate strategy to position CLX across both human and animal oncology. When your advisory structure is rebuilt around people who understand canine cancers, comparative oncology, and veterinary commercial pathways, it becomes clear Valirx is preparing for licensing routes across both human and veterinary markets. As a co-founder of VolitionRx, Mark transformed a human cancer test into a canine diagnostic test (Nu.Q) before negotiating a licencing deal with Heska for $26m. What price a cure? Human and veterinary oncology operate in separate regulatory and commercial channels. Most major pharmas, inc. AZN, Roche, GSK, AbbVie do NOT have any vet divisions. Even those historically involved have spun off their animal health units (Pfizer \u2192 Zoetis, Eli Lilly \u2192 Elanco). By envisaging veterinary opportunities for CLX, Mark is implicitly confirming the compound won\u2019t be a one partner asset; the split infrastructures required make multiple CytoLytix deals the only realistic outcome. GLA, DYOR, AIMO",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.385",
          "thread_title": "Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-01-30T22:38:45.280718+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261543-Notpotal-58618350",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.656343",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "I notice a 71430 buy at 15.14 and a similar sell 4 mins later for a \u00a321 loss. Great to see Porky has started trading again!  \ud83e\udd23\ud83e\udd23\ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "Welcome back, Porky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=FE350133-0204-48E9-9785-7F80407B3421"
        },
        "ingested_at": "2026-01-30T22:38:45.280736+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261534-Notpotal--5049790",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.656760",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Val is obliged to RNS as it a change to No. shares in issue. Hardly the company\u2019s fault if a holder sees such value that he wants to buy above the current SP. Mind you, I\u2019m expecting a TR1 tomorrow to confirm Mark\u2019s holding has increased by 80,000 shares. \ud83e\udd23 If this is the reaction to \u00a3400 of warrants, heaven help Porky\u2019s groupies when the next material RNS arrives.  \ud83e\udee8 \ud83d\ude28 \ud83d\ude22\ud83d\ude2d",
          "sentiment": 0.5,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-01-30T22:38:45.280754+00:00"
      },
      {
        "event_id": "SOCIAL-Today1535-viera--1291780",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.574183",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "I do loveya notpot. I post replies to you and pp hence 67 posts ! I\u2019ve also got repetitive syndrome I apologise . I do laugh at your posts as Val has zero revenue ,huge cost base ,years of years of promises which all have been broken . A loss making lab and a CEO  who pays staff to contribute zero to the bottom line . It\u2019s a shambles. I\u2019m absolutely flabbergasted that investors continually donate money to employees salaries when they produce FA. You couldn\u2019t make it up my friend . Have a great weekend Let\u2019s hope it stops raining Xxxx",
          "sentiment": 0.0,
          "engagement": "1,556",
          "price_at_post": "0.345",
          "thread_title": "RE: Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-06T22:33:52.752664+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262209-Notpotal--7140609",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.574764",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Very amusing to see the uninvested have such strong views on Val. Such a shame Porky didn\u2019t have the same consideration while sucking thousands of gullible punters into other investment disasters. Perhaps considering compensating all those innocents dragged in? At this point, Porky will probably give another history lesson but, while Val is still trading and doing quite nicely, no news on 4D or HARL reinstatement yet. Meanwhile back in the real world - 40 separate projects ongoing at Inaphaea, \u00a3200k pa cost savings, money in the bank into H2 with R&D tax credits expected but as yet unconfirmed, Inaphaea income excluded and grants applications pending (as confirmed by Prof Mark\u2019s statement, not Prof Porky\u2019s Santa wish\ud83e\udd23), partnering planned for CLX, 201, and the lead repurposing asset \u2013 all of which will further reduce costs, tailored for grants under new guidelines, another evaluation and SPV imminent (already ring-fenced), the recent McGill Univ & IRICoR  evaluation is the first with global players, multiple RNS updates due and an SP bouncing around in the mid-0.30s even before the RNS news flow starts. Understandably upsetting for the pink one. Having devoted the last 4 years and thousands of posts hoping to destroy Val, a new CEO comes in and undoes all that work in less than 18 months. Porky\u2019s partner (in crime?) Nick, has made a small fortune trading the share over the years and still ONLY posts on this share \u2013 check history - 67 consecutive and counting. He obviously sees great value here, despite all his apparent bed-wetting. The way Porky and Nick tag team this board, you\u2019d swear they were coordinating over the same cup of tea. \ud83e\udd14 Happy dreams, you two! \ud83d\ude34",
          "sentiment": 0.5,
          "engagement": "81",
          "price_at_post": "0.345",
          "thread_title": "RE: Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-06T22:33:52.752706+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261739-viera--4118396",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.575230",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Pp is pm Paid to post on LSE Until the next  raise (I think c April ) Then he goes missing as he\u2019s embarrassed . Then changes  his name and rinse repeat . He has no humility . Been bullish since 30p but holds no shares so what does he care ,has lost all his readers 98pct of their hard earned cash. Shambles",
          "sentiment": 0.0,
          "engagement": "1,556",
          "price_at_post": "0.345",
          "thread_title": "RE: Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-06T22:33:52.752740+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261450-Porky9-42092319",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.575649",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@pp - nobody gives a **** about posts on linked-in - unless you are looking for a job or trying to recruit someone from a competitor that is all it is good for - a recruitment tool. the guy needs to stop wasting his time posting crap on social media and get some bloody focus on the important issues and then publish some proper update news via the rns service. talk about lack of perspective. this is exactly what i am talking about - zero commercial acumen - sorry",
          "sentiment": 0.0,
          "engagement": "7,471",
          "price_at_post": "0.345",
          "thread_title": "RE: Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-06T22:33:52.752774+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261351-paternos--5211277",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.576063",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Inaphaea has just released a short video re the collaboration with the Open University re prostate cancer.  Funded by a Knowledge Transfer Voucher (RNS 7/8/25) this is yet another example of non-dilutive funding to progress assets using cutting edge technology that would otherwise be beyond the company\u2019s reach. https://lnkd.in/eXGeSPQq",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.345",
          "thread_title": "Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-06T22:33:52.752794+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20262042-paternos-68655277",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.576513",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "\u201cImportant day in the calendar for patients, families and those of us working in the sector. The UK government has announced a directive to increase 5 year survival for cancer patients to 75% by 2035. This will take a a huge effort in terms of screening for early detection and diagnostics to allow curative surgery, improvements in surgical technique, such as robot assisted approaches and developments of affordable, accessible therapies. VALIRX PLC and its subsidiaries, including Inaphaea BioLabs, Cytoltix and Blue Ribbon Bio are working hard to play our part in the discovery and development of next generation therapies. These include our novel oncolytic peptide program (targeting Triple Negative Breast Cancer), a first in class, non-genomic androgen receptor signalling inhibitor and a series of repurposed drugs from Inaphaea BioLabs 3K screen program. We work closely with leading academic institutions to source, assess and develop cutting edge approaches with pan cancer potential. Our latest deal is with McGill University and IRICoR for a second generation RNA Helicase inhibitor ( https://lnkd.in/ei5xwSpx) Big shout out to our dedicated Inaphaea BioLabs team including Head of Scientific operations Melissa Barr, Lead Scientist - Translational Biology and Academic Collaboration, Amelia Hatfield and Lab tech Dylan Jones as well as VALIRX PLC's Director of Research, Michelle B.. There are currently 40 projects running in the labs at Inaphaea BioLabs covering our group therapeutic programmes and development of our non-animal based, New Approach Methodologies (NAMs) for drug screening with our unique bank of Patient Derived Cell models. We couldn't do this without the support of our partners including TwinEdge Bioscience (Digital twin/Patient Avatars), ScreenIn3D (Lab on a chip platform), VoxCell (vascularised 3D tumour models), Spanios (organoid models), BioReperia (zebrafish models), Ignota Labs (in silico tox screening) and development partner Dominion Biotech as well as our shareholders. It's been a hectic 18 months since I took over as CEO but we've focussed on refining our strategy, identifying high quality assets, building a strong team and expanding our capability partner network. We have a some major milestones set for 2026 and we look forward to being part of the solution and helping deliver patient benefits.\u201d",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.35",
          "thread_title": "Today\u2019s Linkedin update from Mark E",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E9D6BAF9-FFFC-4611-82EB-4E1B71731FB2"
        },
        "ingested_at": "2026-02-06T22:33:52.752813+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261943-ratcliff--3627302",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.576919",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "That's the way - cut and paste some good long pieces in the hope of burying anything that doesn't fit the agenda.",
          "sentiment": 0.0,
          "engagement": "11,411",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-06T22:33:52.752830+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261832-paternos-23903356",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.577382",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Grant schemes are increasingly geared towards small companies - when it comes to eligibility, size truly matters. Recent UK oncology research grants to SMEs reflect sustained investment in cutting edge cancer research, with Innovate UK and the Biomedical Catalyst programme providing much of the funding. Recent awards to UK microcap/small biopharmas include: Momentous Therapeutics Ltd (immunotherapy) - \u00a32m grant Theolytics Ltd (ovarian cancer therapy) - \u00a32m Mestag Therapeutics Ltd (immunotherapy) - \u00a31.5m Revolver Therapeutics Ltd (peptide therapy) - \u00a3550k Epitopea Ltd (breast cancer stromal cells / immunotherapy) - \u00a3500k VacV Biotherapeutics Ltd (oncolytic viruses) - \u00a3500k Antikor Biopharma Ltd (ovarian immunotherapy) - \u00a3500k The above awards show clear emphasis on immunotherapy, peptide based therapeutics, and oncolytic virus platforms. Val\u2019s work not only aligns with these priority areas but also extends into difficult to treat cancers such as pancreatic, ovarian, triple negative breast, and prostate \u2014 indications where new therapeutic approaches are urgently needed. This strengthens Val\u2019s fit within the priority areas repeatedly backed by UK grant bodies. The grants aren\u2019t handouts; they\u2019re strategic investments in the UK\u2019s future. A successful cancer therapy can deliver multi billion pound global sales and position the UK as a leader in next generation oncology. Regulators are now actively encouraging NAM adoption and funders are rewarding small oncology-focussed companies that have strong academic links. Valirx is exceptionally well-positioned to secure substantial grants, extend the cash runway and reinforce financial stability. GLA, DYOR",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-06T22:33:52.752848+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261827-paternos-49259979",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.577808",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "To all the green bar brigade out there, you will get zero engagement from me. I have no desire to convert you and history lessons really don\u2019t interest me. Feel free to post your drivel as all I can see is 6 consecutive green \u201cThis message has been filtered, please adjust your filters to view\u201d. Han Solo couldn\u2019t land a helicopter on your imaginary runway. \ud83d\ude01 \ud83d\ude01 \ud83d\ude01 To those actually invested, whether traders or otherwise, with all the news pending, the coming weeks and months are likely to be transformational. GLA, DYOR",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-06T22:33:52.752866+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261740-viera--5137716",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.578232",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Grant could pay the 100k we pay to our BDM who organises ME trips abroad and placings . Both been a resounding success ! @shambles Paternoster aka PM will go into ramp mode now as we approach QTR 2 and the inevitable begging bowl comes out .",
          "sentiment": 0.0,
          "engagement": "1,556",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-06T22:33:52.752884+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261735-ratcliff--1027102",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.578647",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Probably thinking like Pan Am did - the only state airlines that never made a loss, they recorded a 'negative profit.' Maybe he's talking 'negative growth.' I'm sure he'll elaborate on his claim pretty soon and to everyone's satisfaction anyway.",
          "sentiment": 0.0,
          "engagement": "11,411",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-06T22:33:52.752902+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261729-RayPoint--6141172",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.579062",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Well put Rats. The other sentence I take pater to task on is: \"The combination of Mark\u2019s grant winning experience and the UK\u2019s revised grant landscape creates a clear opportunity for Valirx as it enters its next phase of growth.\" Pater, pray tell us about Valirx's previous phases of growth.",
          "sentiment": 0.0,
          "engagement": "5,087",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-06T22:33:52.752919+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261605-ratcliff--3679429",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.579478",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "To be fair RP, applying for grants is a very sensible thing to do. However there must be an element of due diligence and examination of the company applying, and somewhere in the paperwork there will probably be a section which asks 'What would the grant be used for?' This is where the potential donor writes something like 'to accelerate the development of our compound XYZ' or 'to fund the production of our drug to use in the imminent 500 patient Phase 3 trial.' If the box reads 'to stave off imminent insolvency and to avoid another placing' or 'to pay salaries, expenses and bonuses' I imagine the progress of the application tends to grind to a halt.",
          "sentiment": 0.0,
          "engagement": "11,411",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-06T22:33:52.752937+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261408-RayPoint--2462939",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.579907",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Just looking at the first company on your list i.e. Momentous Therapeutics Ltd (immunotherapy) - \u00a32m grant I notice that they have a world-renowned scientist on their BOD. This may go some way to explaining the grant they received. That plus the cutting edge research they are undertaking on the immune system. Here he is: https://www.meduniwien.ac.at/web/en/ueber-uns/news/2025/news-in-june-2025/christoph-huber-receives-german-cancer-aid-award/",
          "sentiment": 0.0,
          "engagement": "5,087",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-06T22:33:52.752954+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261132-Porky9--6355035",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.580333",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "So you are keeping everything crossed that some free grant cash will land in the next couple of weeks to stave off the discounted placing. just incredible really that the focus is on how to get free grant cash to keep the gravy train moving forwards. How about a focus on making the business viable - now that would be refreshing. In all honesty, i would not award this business grant money to waste, it doesnt need it. They have an endless supply of free money from continual discounted placings on the AIM. Any grant money IMO should only go to ground breaking innovations, small private biotechs that have no means to raise cash easily not to this lot to indirectly get spunked up the wall on jollys aboard and ridiculous admin and bonus costs. This next placing will be interesting for sure; a) can he pull it off yet again or will brokers call time on it, b) will the support be out there c) how much of a beating can existing long term holders take whilst the business fails to deliver on its pledges. IF he gets it away, yet again, the discount has to be brutal surely; .15 to .20 ?",
          "sentiment": 0.0,
          "engagement": "7,471",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-06T22:33:52.752972+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261005-paternos-23903356",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.580795",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Grant schemes are increasingly geared towards small companies - when it comes to eligibility, size truly matters. Recent UK oncology research grants to SMEs reflect sustained investment in cutting edge cancer research, with Innovate UK and the Biomedical Catalyst programme providing much of the funding. Recent awards to UK microcap/small biopharmas include: Momentous Therapeutics Ltd (immunotherapy) - \u00a32m grant Theolytics Ltd (ovarian cancer therapy) - \u00a32m Mestag Therapeutics Ltd (immunotherapy) - \u00a31.5m Revolver Therapeutics Ltd (peptide therapy) - \u00a3550k Epitopea Ltd (breast cancer stromal cells / immunotherapy) - \u00a3500k VacV Biotherapeutics Ltd (oncolytic viruses) - \u00a3500k Antikor Biopharma Ltd (ovarian immunotherapy) - \u00a3500k The above awards show clear emphasis on immunotherapy, peptide based therapeutics, and oncolytic virus platforms. Val\u2019s work not only aligns with these priority areas but also extends into difficult to treat cancers such as pancreatic, ovarian, triple negative breast, and prostate \u2014 indications where new therapeutic approaches are urgently needed. This strengthens Val\u2019s fit within the priority areas repeatedly backed by UK grant bodies. The grants aren\u2019t handouts; they\u2019re strategic investments in the UK\u2019s future. A successful cancer therapy can deliver multi billion pound global sales and position the UK as a leader in next generation oncology. Regulators are now actively encouraging NAM adoption and funders are rewarding small oncology-focussed companies that have strong academic links. Valirx is exceptionally well-positioned to secure substantial grants, extend the cash runway and reinforce financial stability. GLA, DYOR",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.35",
          "thread_title": "UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-06T22:33:52.752989+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260807-paternos-80090378",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.581218",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Many of Mark\u2019s presentations have highlighted the potential of grant-funding, with the 14/10/25 RNS confirming a \u00a3250k award. This followed a KTV Open Univ award only 2 months earlier and Mark has stated further grant applications are pending. The Inaphaea RNS (18/9/25) on the repurposing top10, noted \u201c\u2026 discussions with potential licensees as well as an application for non-dilutive grant funding to support further development of these and other assets\u201d. In addition to ongoing partnering discussions, CytoLytix updates invariably reference grant opportunities. As MD of OncoLytika, Mark has a strong history of securing significant grants, including Eureka Eurostar funding, demonstrating a proven ability to win competitive international grants. Recent changes to UK and int\u2019l grant frameworks \u2014 including the UK\u2019s modernised Official Development Assistance (ODA) strategy, refreshed criteria, and new SME friendly collaboration rules \u2014 have opened funding routes that previously excluded early stage biopharma companies. These shifts prioritise oncology projects with demonstrable patient relevance, human relevant New Approach Methodologies (NAMs), and academia/SME partnerships, all of which align directly with Val\u2019s revised operating model. The combination of Mark\u2019s grant winning experience and the UK\u2019s revised grant landscape creates a clear opportunity for Valirx as it enters its next phase of growth.",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.355",
          "thread_title": "The New Grant Landscape",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=2EC60BA4-C275-47D5-901A-D8BA32B59D52"
        },
        "ingested_at": "2026-02-06T22:33:52.753007+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261811-viera--4032458",
        "event_type": "social_post",
        "date": "2026-01-30T22:38:35.634037",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "You sold the spike brilliantly Stephen . Knowing we have had no announcements and another year of zero revenue . You and porky have called it here . What do the directors get paid for here exactly ? Shambles . The BOD needs strengthening .",
          "sentiment": 0.0,
          "engagement": "1,553",
          "price_at_post": "0.35",
          "thread_title": "RE: Ambrose Q1 Newsletter - FYI",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=DD644FF4-EB58-4811-9E0F-61E17204B69A"
        },
        "ingested_at": "2026-02-06T22:33:52.753026+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261626-Uncanny--2902823",
        "event_type": "social_post",
        "date": "2026-01-30T22:38:35.634577",
        "source": "LSE_CHAT",
        "data": {
          "author": "Uncanny",
          "content": "Ambrose Healthcare | 2025 Highlights and What\u2019s Ahead in 2026 Dear Colleague / Partner, As we begin 2026, we would like to share a brief reflection on the past year at Ambrose Healthcare and outline what lies ahead in delivering its mission, to bring new therapeutics to rare disease patients who currently have no approved drug treatment. Our last update was shared in October 2025. Since then, meaningful progress has been made across our programmes, partnerships, and team, all in support of our mission to bring treatments to patients living with rare and underserved conditions. 2025 at a Glance During 2025, Ambrose focused on building strong scientific, operational, and partnership foundations to support the next phase of development: Continued preparation for the Renzapride Phase 2 trial for the treatment of the Gastrointestinal Manifestations of Cystic Fibrosis (GMCF), including regulatory planning and UK clinical engagement Exercised the licensing option for VAL401, securing global rights for development and commercialisation for treatment of cancers. 20% of cancers are classified as rare diseases. Ambrose is focusing initially on development for the treatment of pancreatic cancer Strengthened leadership, governance, and delivery capability Expanded engagement with clinicians, researchers, and funding partners across the UK and internationally Much of this work took place behind the scenes, laying the groundwork for accelerated progress in 2026. Scientific Leadership We are pleased to be working closely with Professor Bu Hayee, Kings Hospital, London who oversees the GMCF treatment centre for the Southeast of England and is supporting Ambrose as a Scientific Advisor for development of Renzapride for GMCF, providing valuable clinical insight as the programme progresses. We were deeply saddened by the passing of Professor Brian Feagan during 2025. Professor Feagan was internationally respected for his leadership in clinical trial design and execution. His early engagement with Ambrose and belief in rigorous, patient-centred development left a lasting impact on our work and thinking. Looking Ahead to 2026 In the year ahead, Ambrose Healthcare will focus on disciplined execution and collaboration, with priorities including: Advancing Renzapride toward initiating its Phase 2 study Preparing VAL401 for Phase 2 clinical development Pursuing investment as well as public and charitable grant funding, including a recent formal invitation to submit a major UK grant application for Renzapride Continuing to build trusted partnerships with clinicians, academic groups, and research organisations These activities reflect Ambrose\u2019s commitment to capital-efficient development and strong alignment with the UK life sciences ecosystem. Planning Named Patient Supply We are also planning to initiate Named Patient Supply (NPS) activities. Named Patient Supply enables access to Good Manufacturing Practice-manufac",
          "sentiment": 0.0,
          "engagement": "3,308",
          "price_at_post": "0.35",
          "thread_title": "Ambrose Q1 Newsletter - FYI",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=DD644FF4-EB58-4811-9E0F-61E17204B69A"
        },
        "ingested_at": "2026-02-06T22:33:52.753045+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261709-Porky9-43657856",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.373661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "What, do you think he is going to release news of the placing already, possible but they normally leave it right until the death, so proabably a few more weeks yet but you never know, you could be right.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.355",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-06T22:33:52.753063+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261448-Notpotal-16379229",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.374477",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Is that a Friday RNS I can smell.... Or has Porky had an accident? \ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.35",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-06T22:33:52.753081+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262254-viera--5019620",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.375315",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Pm changed his name to pp It\u2019s basically ME copy and paste . As he said ME has produced one RNS in months . We all know what the next RNS of note will be . ME needs to cut costs further and do something with 201. Good luck all.",
          "sentiment": 0.0,
          "engagement": "1,552",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-06T22:33:52.753112+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261720-RayPoint--4892621",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.376112",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Pater It's funny to see, in a thread entitled \"The Ambrose Dream Team\" and started by yourself , that neither the Dream Team nor VAL401 get a mention in your latest post.",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-06T22:33:52.753136+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261632-ratcliff--8942055",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.376907",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "'When the SP inevitably hits 1.6p plus there will be further buying pressure as placees exercise their 1.3p warrant options. Some will then sell for a quick profit but by then the SP will be in the 2p range. All this without the flush of positive news expected over the coming months.' Sounds good? Sounds worth buying into? Well actually it's a paternostpauper quote from 16th January 2025. But the share price then was 0.875, sliding gently down another post-placing ski-slope graph.  And what's the biggest news since then? Oh yes, another placing - predicted by P9 and derided by PP. Until it happened. On past history Porky's predictions seem a pretty reasonable bet. PP's posts are just reformulated bin dippings - he might as well just copy and paste on a pumping merry-go-round.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-06T22:33:52.753154+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261512-Porky9--6740079",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.377717",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Always entertaining, like watching fantasy island @PP is our very own Mr Roarke and @nopot is Tattoo.  Not sure who @uxm plays, probably the aircraft pilot as he only turns up to share the fantasy once a week or so. The gap will be between .15 and .20 as that will be where the placing shares land, thats of course if ME can pull it off again. Jury out this time.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-06T22:33:52.753172+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261503-paternos--6115463",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.378553",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Good post UXM.  Always entertaining to see trader Nick post again - his 63rd consecutive LSE post - and every one on Val. He might as well hang up a banner \u201croll up, roll up \u2013 bargain of a lifetime!\u201d \ud83e\udd23\ud83e\udd23\ud83e\udd23 Val has issued just one positive RNS since the placing, yet the SP has climbed 67% from those 0.23p lows. Even with 2 major holders dipping below the 3% threshold to facilitate some short-term trading, the SP still hovers near 0.4p. Every day that passes without an RNS increases the likelihood of one the following day as multiple programs mature: CytoLytix patent updates, formulation decisions, Blue Ribbon/VAL201 partnering (by diluting the asset, not VAL plc), 3k repurposing update (top candidate partnering?), further grant updates (ME has strong history), next evaluation and SPV (confirmed in webinar), Inaphaea income (PredictRx/ PDC sales), updates on the Dundee/Queen Mary pro-senescence project and StingRay (decision imminent). The motherlode remains early partnering/grant funding for CLX, a 2026 milestone confirmed by the CEO in the recent webinar. As the June anniversary nears, Omios have to decide whether they wish to exercise their option of a license agreement to continue using CLX tech. It looks promising as both Mark and Omios CEO Dr Aldo Pourchet had meetings arranged at the JPM in San Fran. More than once, Mark has referenced the Omios virus as an entry point to veterinary oncology due to its potential for treating canine HSA, while Dr Pourchet posted: \u201cWe are targeting triple negative breast cancers (CLX primary indication), all of which have the biomarker that makes them susceptible to our therapy. It\u2019s our most advanced program\u201d (Oct NYU interview). With multiple CytoLytix licenses up for grabs, Omios look set to start the ball rolling. The decisive factor which totally undermines the detractors\u2019 fearmongering is the financial position: a cash runway that extends till H2 excluding warrant income, R&D tax credits, grants, or additional Inaphaea income. That completely negates any March/April placing argument. Mind you, naysayers never let a few facts ruin their narrative. GLA DYOR",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-06T22:33:52.753190+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20261956-uxm484--3439796",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.379412",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Watch the video. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025 Chart analysis shows a nice gap at 1.4p. Past management issues but new management is outstanding.  Cash until H2 without the add ons such as grant money, revenue and warrant money. CEO heavily invested over 250k. Negotiating with a major biotech in regards to a deal for CLX001. Lab space is to help progress the assets to eventually get a deal not to make instant revenue. Any research on CLX001 done against a valuation of 2 million and cash burn just over a million would know this is a great opportunity. Great decision making. Derisking assets with partnership deals. Which other biotech has so much and spending less than 2 million. With warrants at a premium to the current price hopefully no more dilutions. Expecting significant news in the coming days/weeks. Tiny valuation and cash burn is tiny with assets of significant value.",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-06T22:33:52.753208+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20261515-viera--3051714",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.380239",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Problem my friend is ME hasn\u2019t got a proper hold of Costs paying a non BOD member and non scientist 100k  paying best mates that produce zero revenue is a disgrace . It shows a lack of respect for shareholders . Where are all the promised lab contracts . ME has surrounded himself with \u201cyes \u201c men. Shame he ousted Adrian as he had the commercial nous to make a difference . Adam also lost interest as was treated so badly by the BOD. I predict more confetti in April /May . Porky knows this co better than anyone . If he and Adrian joined the BOD I would consider investing but I\u2019ve lost faith in the current BOD who promise the world and deliver FA. Deliver some revenue asap or step down .",
          "sentiment": 0.0,
          "engagement": "1,552",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-06T22:33:52.753226+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20261416-ratcliff--7052508",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.381020",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Interesting that you've posted notgotalot - in December you distinctly said \"I\u2019ll take some time out and won\u2019t be back until the next decent RNS.\" Presume you've restarted posting because you've lost hope in there being a decent RNS.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-06T22:33:52.753244+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20260843-Notpotal--1873196",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.381814",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "each conspi****** on here is in self-denial mode - a mechanism where a person ignores or distorts reality to avoid anxiety and stress. they refuse to accept the situation simply because it doesn\u2019t support their agendas and so resort to posting fiction. whether it is by inventing a 50% lower cash runway, alleging fictitious staff at ambrose, claims of ceo golf jollies and overpaid team members or alleging lse posters are on the val payroll. desperate posts by the uninvested are now treated with the contempt they deserve. just when you think they\u2019re as low as they can get \u2013 they pick up a spade. by resorting to deception, they have lost any remaining credibility they may have had, while each day news edges closer.",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-06T22:33:52.753262+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20262102-ratcliff-22873675",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.382589",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "It would also be interesting to know why the posting of relevant financial facts from those observing is described as 'panic.' Surely the only panic is among those trying to snare the naive with fantasy predictions so they can get out fast with a profit - and now realising that the supply of gullible newbies is drying up.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-06T22:33:52.753280+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261925-RayPoint-88735808",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.383379",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "So what's the crack, pp? I would be interested to know your view on how Ambrose are paying salaries to the Dream Team without having any money in the bank",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-06T22:33:52.753298+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261832-paternos--6429279",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.384211",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "@  spantrout - Great call. Valirx - 10m,50s in. \u201cA lot of return on that one!....DYOR but in all probability, if it\u2019s going to have some game-changing news, then \u2026.that would be 1.4p.\u201d Not sure of the news he is he is referring to? Maybe the new patents, partnering (CLX,201), repurposing top 10, StingRay, further grants, or expansion into veterinary oncology? Possibly it\u2019s the the 2nd evaluation and new SPV or even the CEO buying 7% of the company. I suppose it could be that Mark E has recently been on stage presenting alongside some of the biggest names in pharma, or the fact the CEO has a history of delivering success (Nu.Q test sold for $26m). !.4p is an interesting SP \u2013 that would not only see the 0.5p warrants in play but also the 1.3p warrants, easily extending the runway into 2027. Mind you realistically, a few easily pleased would exit for a quick 300%+ profit. I guess the uninvested posting day and night trying to supress the SP hasn\u2019t gone unnoticed either. Karma can be a wonderful thing! Happy days DYOR, GLA.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.385",
          "thread_title": "RE: Coverage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=1C527045-FD63-41D2-B4BE-ED55425FC93C"
        },
        "ingested_at": "2026-02-06T22:33:52.753315+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261714-Notpotal--5730360",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.385010",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "pp previously purged porky\u2019s parrots\u2019 pack of preposterous posts pedalled in panic, perhaps predictably. i promptly prepared a poem for porky to peruse at his pleasure. pundit porky posted a pack of pathetic, poorly proven poppy****. a pack of pathetic, poorly proven poppy**** pundit porky posted. when pundit porky posted a pack of pathetic, poorly proven poppy****, perhaps he\u2019ll point to proof behind the pathetic poppy**** pundit porky posted?",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.385",
          "thread_title": "Porky\u2019s Peddled Pile of Piffle",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=93B08DEA-F499-4237-AF7E-B5143BC8D67E"
        },
        "ingested_at": "2026-02-06T22:33:52.753333+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261625-spantrou--6730497",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.385791",
        "source": "LSE_CHAT",
        "data": {
          "author": "spantrout",
          "content": "Https://youtu.be/HrYMuqPFA20",
          "sentiment": 0.0,
          "engagement": "13,977",
          "price_at_post": "0.385",
          "thread_title": "Coverage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=1C527045-FD63-41D2-B4BE-ED55425FC93C"
        },
        "ingested_at": "2026-02-06T22:33:52.753351+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261403-Porky9-48802927",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.386613",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@PP You really are a busted flush, its like groundhog day:- Pump the boards with nonsense about million dollar licensing deals, how the cash is well managed and will last many months more than it does, how there will be all these marvelous license deals lined up, exaggerate the interest and how fantastic it all is. Then RNS drops,  placing at discount issued, you vanish for a few weeks, let the dust settle and then you pop up again and repeat the above. I totally get those in the business want the gravy train to continue, lifestyles at risk but have you no conscience that small investors that may not earn the sort of money the board here gets here for these cushy  work from home jobs, are going to lose their hard earned cash being sucked into this? Its morally not right. Next RNS will be the next discounted placing, can't be far off now, a few weeks at most imo.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-06T22:33:52.753368+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261529-RayPoint-22621449",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.157704",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "I hear that green fees are pretty steep in California",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-06T22:33:52.753386+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261434-ratcliff-56225539",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.158130",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "No problem RP - I'm wondering who paid 0.50 for a few shares worth about 25 percent less from the start, but I suppose 400 quid pays for the week's teabags and digestives.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-06T22:33:52.753404+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261413-RayPoint-49848808",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.158544",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Sorry Rats. I misinterpreted your post.",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-06T22:33:52.753421+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261412-RayPoint--7612221",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.158961",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "\"Probably about 450 quid...\" Rats, stop ramping! The gross proceeds were \u00a3400",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-06T22:33:52.753439+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261357-spantrou--6151881",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.159474",
        "source": "LSE_CHAT",
        "data": {
          "author": "spantrout",
          "content": "\u00a39.99 for rns",
          "sentiment": 0.0,
          "engagement": "13,977",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-06T22:33:52.753457+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261311-ratcliff-46815517",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.159890",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Probably about 450 quid...",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-06T22:33:52.753475+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261216-steve196--7711205",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.160315",
        "source": "LSE_CHAT",
        "data": {
          "author": "steve196",
          "content": "How much does it cost to release an RNS just for \u00a3400 of warrants?",
          "sentiment": 0.0,
          "engagement": "2,761",
          "price_at_post": "0.385",
          "thread_title": "Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-06T22:33:52.753494+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261935-uxm484-70174719",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.160734",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "No, but the holders all want the warrants exercised so we can do a 10 bagger in 12 months without a fund raise. For me i am really happy here with  the progression. We are definitely early in a news rich periods where all the negative posters are posting overtime and are only posting as they missed out on the last fundraise hoping for an even lower price. We will likely get a few meaningful RNS very soon. Brakes are now off\u2026",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.36",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-06T22:33:52.753512+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261222-Notpotal-34347769",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.261915",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "\u201cYou sound so desperate\u201d says the man who\u2019s last 60 posts have been on a share he isn\u2019t invested in. \ud83d\ude02\ud83d\ude02\ud83d\ude02",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-06T22:33:52.753530+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261207-ratcliff-59319463",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.262733",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Slight typo there - should read blatantly UNTRUE and misleading!",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.365",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-02-06T22:33:52.753549+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261201-ratcliff--2765982",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.263581",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "UXM - differences of opinion are generally understandable, but to say in your post 'All lies' is blatantly true and misleading, and as usual does nothing to bolster your credibility. Two of the things you say in that post are particularly inaccurate - 'Great decision making. Derisking assets with partnership deals. Which other biotech has so much spending less than 2 million.' - They are looking for deals (or claim to be anyway) but nothing so far has contributed anything to even cover the outgoings, let alone provide money for further work or expansion (hence the redundancies etc) Secondly - 'With warrants at a premium to the current price hopefully no more dilutions' - warrants don't kick in and generate cash the moment the sp goes above them as you and the others in your group seem to imply. In the unlikely event of the sp rising above that point and remaining so, it just might be worth warrant holders exercising them so they could buy shares at below the then-current price, but to sell them they'd need to be able to be sure the sp was strong enough to withstand the effect of the sells. You know that, so stop trying to imply that the mere existence of warrants is a long-term fool proof source of near or long term capital. Then again, if this company was fool proof you wouldn't be here I imagine.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.365",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-02-06T22:33:52.753567+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261059-viera-79787245",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.264399",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Are you PM in disguise ? Who in  their right mind would buy any company on Aim with only 3 or 4 months cash runway? You sound so so desperate for a rally to sell out !",
          "sentiment": 0.0,
          "engagement": "1,552",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-06T22:33:52.753585+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261050-Rebster4-23141502",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.265221",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rebster408",
          "content": "Its groundhog day again This is a binary bet...and Poky has called it right in the past and I thinks he's spot on again... 201 is older than me!!! place your bets... the wheel is spinning and will stop within the next 8 weeks All will become clear within the next two months...",
          "sentiment": 0.0,
          "engagement": "1,174",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-06T22:33:52.753603+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260920-RayPoint--7172691",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.266008",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Living in fantasy land",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-06T22:33:52.753621+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260857-Notpotal--4971021",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.266824",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "\u201cYou can't go back and change the beginning, but you can start where you are and change the ending.\" \u2013 C.S. Lewis Early in his tenure, Mark acknowledged mistakes had been made \u2014 and while he couldn\u2019t rewrite the past, he could reshape the future. 17 months later, Val is reborn, with money in the bank, a rebuilt team, high calibre assets and a SH base that deserves success after years of one-way support. A few resident historians cling to their preferred mythology, inventing a minimal cash runway because the real picture is too uncomfortable to accept: a cash runway to H2 even without R&D tax credits, additional Inaphaea income, grants or exercised warrants. This is also before the wave of RNS due over the coming weeks. Unlike those posting fiction, Mark has backed his conviction with his own money \u2014 now holding 7% of the company. \u201cWhat matters now is not where we\u2019ve been, but where we\u2019re going.\u201d",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.365",
          "thread_title": "Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-06T22:33:52.753639+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20262049-ratcliff--8854334",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.267621",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Whatever it is you're smoking UXM, it's powerful stuff.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-02-06T22:33:52.753657+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261733-uxm484-80165746",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.268458",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "All lies. Watch the video previously posted. Past management issues but new management outstanding.  Cash until H2 without the add ons. CEO heavily invested over 250k. Negotiating with a major biotech in regards to a deal for CLX001. Lab space is to help progress the assets to eventually get a deal not to make instant revenue. Any research on CLX001 done against a valuation of 2 million and cash burn just over a million would know this is a great opportunity. Brokers only had 20k stock. Hardly lots of stock. Great decision making. Derisking assets with partnership deals.  Which other biotech has so much spending less than 2 million. With warrants at a premium to the current price hopefully no more dilutions.",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.385",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-02-06T22:33:52.753675+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261719-Porky9--2257780",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.269349",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "And just a few reasons why not to believe the BS from the resident rampers here and why you should avoid:- * Lifestyle Business * Ridiculous Admin costs * Continual Raises and continual dilution * More than 20 Raises, 3 lots of 125:1 Consolidation events * business concept never proven * Rented lab space and zero revenue in 15 years * About 8 weeks cash runway left with yet another raise due anytime soon to keep the gravy train going. * if new investors or brokers say enough is enough and call time due to clients continually losing money then its admin and you could lose your entire investment. * materially overpriced as absoluly nothing here to invest in, its the emperors new clothes you are buying. 201 is older than hens teeth, no interest in 15 years and CLX years off and more cash required. Labs meanwhile doesnt know what an invoice is. * Poor decision making, lack of any commercial acumen *No real focus, practically everyone is work from home with multiple jobs. * Short term punts only not a long hold due to above. * loads of stock held for broker fees that will need to be drip fed into anyone buying. In all avoid at all costs unless you like dilution",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.385",
          "thread_title": "Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-02-06T22:33:52.753693+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261507-ratcliff-54206802",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.270143",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "You swine Nomlungu. You've rumbled me.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.41",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-06T22:33:52.753712+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261503-Mr0nions--9213642",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.270906",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mr0nions",
          "content": "Because of this  post, I'm holding position.  Good luck all.",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "0.41",
          "thread_title": "RE: Why invest? \u2013 THE SCIENCE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=058BF091-3235-424B-9C46-FA00ED6BC8D5"
        },
        "ingested_at": "2026-02-06T22:33:52.753730+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261432-mikee_p--5293064",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.271701",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "1 HR. Channel is all ya need.",
          "sentiment": 0.0,
          "engagement": "1,893",
          "price_at_post": "0.395",
          "thread_title": "Easy trade this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=81274FD9-0226-45F3-8CEA-B1F91E33B4A2"
        },
        "ingested_at": "2026-02-06T22:33:52.753748+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261430-nomlungu--8068788",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.272502",
        "source": "LSE_CHAT",
        "data": {
          "author": "nomlungu",
          "content": "People should just ignore Rat... he is just jealous that he does not have the losses to use to reduce his tax liabilities. That 80% drop in the last tax year will have been very valuable for some; I think him moaning around the time that taxes are due for the 2024/25 year is a dead give away. \ud83d\udcc9 \u2757",
          "sentiment": 0.0,
          "engagement": "23,976",
          "price_at_post": "0.395",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-06T22:33:52.753767+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261313-paternos-60118297",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.273388",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "When Mark became CEO, ValirRx was effectively dormant - few assets in play, minimal Board investment and limited vision. He set about a major restructuring: rebuilding the team, reshaping the asset base and above all, resetting the mindset. Fast forward 17 months and Val is reborn. A microcap expanding into developing fields of oncology, yet every action taken has a cost/benefit analysis and timescale consideration. If concluded that a project cannot be monetised early, it is shelved or paused. Commercial decisions overrule all others. Valirx is now plugged into some of the most advanced platforms in modern drug development: \u2022\tpatient avatars (TwinEdge) \u2022\tmicrofluidics/3D tissue culture models (Screenin3D, Ignota & VoxCell) \u2022\trepurposing (Ignota, Altus & Dominion) \u2022\tpersonalised immunotherapy (PredictRx / Dominion) \u2022\tpro-senescence drugs (Dundee / Queen Mary Uni) \u2022\tClickmer technology/HER2 protein (Apis Assay) \u2022\tLMTK3 kinase targeting (StingRay). The most recent evaluation, a 2nd-gen RNA helicase inhibitor (McGill/IRICoR), brings Val into collaboration with major international research organisations. Last year, Mark identified a shift away from animal-testing and moved early to establish capability partners supporting NAMs and cutting-edge AI. Recent US & UK Gov\u2019t regulatory changes now actively favour such platforms with Europe to follow this year. Once again, Val anticipated this trend before much of the market. Meanwhile, the Advisory Board has been upgraded from academics and towards industry experts who can provide insight into Big Pharma priorities and identify new commercial pathways such as in veterinary science - quicker to market while opening a parallel revenue path thru\u2019 comparative oncology, further de risking the route to human oncology. Mark has also added a clause into evaluation agreements whereby if Val decides not to progress an asset eg StingRay, McGill/IRICoR, then Inaphaea retains the data and can still monetise should a 3rd party take the asset forward. Val is no longer waiting for opportunity; it is engineering it.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.385",
          "thread_title": "Why invest? \u2013 THE SCIENCE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=058BF091-3235-424B-9C46-FA00ED6BC8D5"
        },
        "ingested_at": "2026-02-06T22:33:52.753784+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261224-paternos-86964603",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.274229",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "A \u00a33m microcap with a cash runway till H2 even before factoring in R&D tax credits, potential grant funding, additional Inaphaea income or warrant cash now within reach. Outgoings reduced by \u00a3200k PA following a team restructuring last year. Val\u2019s expansion into NAMs and advanced AI tech, supported by strong academic partnerships, aligns directly with revised US & UK gov\u2019t guidelines to reduce animal testing. This positions Val as a front runner for non dilutive grants and innovation funding, with a CEO geared to capitalise on this opportunity. The 1/9/25 RNS confirmed ongoing discussions with several potential partners to progress Cytolytix, including a major pharma. Val owns 60% of CLX with 10% owned by co-inventor, Dr Charles Chen (Senior Scientist at Astrazeneca). Val also has a 54% share of an Ambrose deal potentially worth up to \u00a316m, and a Biobank of 476 PDCs valued at \u00a310k per PDC cell-line upon commercialisation, plus commercial rights entitlement. Valirx has assets in several key cancer indications, all with huge global markets: 201/prostate ($11.3Bn*), CLX (primarily TNBC ($1.5Bn*), ovarian ($2.5Bn*) but also prostate, 301/endometriosis ($1.9Bn**), and 401-Ambrose/pancreatic ($2.9Bn**). Sources: *webinar, **GMI. Several RNS updates are imminent: CLX patents \u201cin coming weeks.\u201d (RNS 1/9/25), Dundee/Queen Mary project (extended to 9/2/26), StingRay (approx Feb \u201926 per Aug video), Blue Ribbon SPV - \u201cSeveral patents envisaged for 201\u201d, and the next evaluation/SPV \u201cimminent with discussions already at a mature stage\u201d. The Omios RNS (3/6/25) stated \u201c\u2026 expected to take up to 12 months. On conclusion of the evaluation, Omios has an option to enter into an Oncolytic Peptide License Agreement to continue using Cytolytix technology.\u201d Yet another potential source of income. In addition, the Val/Dominion repurposing project (teaching an old drug new tricks) has identified 200 FDA approved non-oncology drugs which already have phase 1 clinical data and are showing activity against various cancer PDCs. 10 of these candidates are now being fast-tracked. The median upfront deal size for pre-clinical IND ready assets was $110m in 2025. For phase 2 this increased to $775m. (Dec webinar). For context, Val\u2019s SP exceeded 55p in 2021 with only one key asset (VAL201). Currently, including the repurposing project, Val now has 200+ potential assets plus a valuable Biobank. Also, Mark has restructured evaluation agreements whereby if Val chooses not to progress an asset (eg StingRay, McGill/IRICoR), Inaphaea retains the data and can still monetise should a 3rd party take the asset forward. Multiple monetisation routes now sit across the pipeline, supported by a commercially-savvy CEO who now owns 7% of the company. Valirx \u2013 a microcap with midcap potential.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.355",
          "thread_title": "Why invest? \u2013 FINANCIAL",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=8931CA86-EC8C-43F3-AA7F-54C7D7FD717E"
        },
        "ingested_at": "2026-02-06T22:33:52.753802+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261145-Marty130-34405259",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.274986",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Be good to see the directors buying some of the stock..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "0.355",
          "thread_title": "Directors deals",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=DC2D2A2F-B451-4EEF-B7C8-9C80695D4033"
        },
        "ingested_at": "2026-02-06T22:33:52.753820+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261107-ratcliff-73223680",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.275854",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "UXM - cutting and pasting the same post repeatedly is not convincing, but to humour you I had a listen to the link you have monotonously posted. It's not persuasive or convincing - Starts off about the 'objectives we have set' and 'milestones we're looking to achieve.' Then there's a bit about the group structure - this is rearranging the deck chairs on the Titanic isn't it? They've had more rearrangements over the decades, it's just a distraction now - meetings are the practical alternative to work. The we hear 'The objective is...' and 'If suitable...'  So nothing at all certain. Then he says BC201 and Val301 have 'not been spun out yet, but would benefit from all of the development work undertaken on Val201.' So BC201 and Val301 still of no interest (except maybe on Antiques Roadshow) and if Val201 had even a glimmer of potential it would have done something since it was quietly shelved - was that 6 years ago or 8? It's been stagnant for so long, the rest of the industry has moved on. The he says 'There is strong interest in endometriosis treatments.' True. There's strong interest in a lot of things, but stating a fact doesn't tie it to VAL. 'We have two new evaluations under consideration.' And...? I\u2019ve got a lot of things under consideration, but whether they get any further is often very uncertain. 'The vision is...' - A lot of people have visions, but a vision isn't even a plan. It's a nice idea at best. 'Our strategy is to do this based on identifying the highest quality assets we can find and afford.' That's like saying 'come round to my place for a meal' and when you get there you say 'There\u2019s a tin of Pedigree Chum between the four of us - it was the highest quality I could find on the available budget.' The he's going to have a system which 'allows us to prioritise selection of assets.' How early stage is all this? And no money to do it with.. Next we see \u2018The Team\u2019 but no mention of their salaries. Then a review of last year - no mention of the placings. Talk of last year's cost savings and redundancies - but if you are cutting 200k a year and laying people off, what were you wasting the money on in the first place? Or have you sold your food to pay the heating bill? Then he says 'Our runway through 2026' - sorry - that 'runway' stops in a couple of months without a placing. The 2026 Xmas do is potentially in the Job Centre unless money comes in very soon. Time is money. They seem dangerously short of both. Again.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.355",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-06T22:33:52.753838+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260954-uxm484-42893108",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.276634",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Plenty of news to come at a tiny valuation and likely this month. Cash until at least July that without warrants, revenue, deals, grants. Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-06T22:33:52.753862+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260919-Porky9--2302548",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.277452",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@Notpotalot Nick is a VERY experienced prolific investor. Frankly, i doff my cap to him as he called the trade perfectly in at .25 and out at .40. Beautiful. The Muppets are the traders in on the back of the Zac Mir pump without any research in blind on the dead cat bounce they will get burnt if still holding. As for Stephen and Jaspal at u3% they now dont have to declare BUT IMO they have about 8 weeks to slowly work the sells in to ensure they are out (just holding warrants options) before that next raise drops as they will be diluted to oblivion as sure as night is day. They can only drip sells in slowly to avoid the brokers hammering them at discount. You try selling big volumes of this close to the raise, or at anytime for that matter, you need to do it on a bounce really, sell whilst traders are buying. This is NOT an investment, its a short term punt. The reason its not an investment is because it can't generate revenue (well none in the last 15 yrs anyhow)  and is reliant on raise after raise after raise to maintain lifestyles. As I say, tick tock. Tick tock countdown already started imo.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-06T22:33:52.753880+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261952-Notpotal-50182573",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.278260",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Porky, unlike some holders, I still keep you around for the entertainment value.  Calling Nick and other traders \u2018muppets\u2019 is certainly \u2026.\u201dcreative\u201d. \ud83d\ude00 Jaspal S and Stephen W dipping just under the 3% is nothing more than freeing up a couple of million to trade. There\u2019s no great sell-off and no drama. Most of us aren\u2019t brave enough to risk missing an RNS for the sake of a few hundred quid. Get your 40 winks while you can. Many sleepless nights await over the next few months.   \ud83e\udd71 Pleasant dreams.",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-06T22:33:52.753898+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261804-uxm484-42893108",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.279044",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Plenty of news to come at a tiny valuation and likely this month. Cash until at least July that without warrants, revenue, deals, grants. Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-06T22:33:52.753916+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261539-Porky9-44200385",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.279866",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Err nope Only thing that will bring hard cash into the company of any meaningful amount in the next 8 weeks will be new placing money - sorry Regarding your continual pumps and fluffy updates, jam tommorrow dream fantasy posts, NONE of it can pay the bills now, end of. Anyone with any brains will be working the sells into any mupets trading this that are oblivious to the dire need for cash to keep the lights on and the pending essential discounted placing that has to happen to support the lifestyles here to keep the gravy train going. Tick Tock, Tick Tock",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.35",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-06T22:33:52.753934+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261042-paternos-83072581",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.280667",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "As standard, when Mark did the Dec webinar he emphasised nothing new, \u201cjust meat on the bones\u201d. However, often that meat can be pretty tasty. Blue Ribbon/VAL201 \u2013 \u201csynthesis almost complete\u201d (10m.30s). Then, \u201ca small amount (only \u00a350k) set aside for pre-clinical development of 201, the balance WILL then come from external investment into the asset\u201d (11m.55s). No \u201cMIGHT\u201d in that statement. The minimal outlay confirms that the VAL201 drug package is essentially finalised, and the entire development programme (preclinical \u2192 IND \u2192 partnering) is about to move forward. Mark has already confirmed Val will be diluting the asset, not Val PLC. With patents imminent, it\u2019s a clear signal that Blue Ribbon is not just a corporate shell \u2014 it\u2019s actively progressing VAL201 toward monetisation. Given Val\u2019s recent multi facet RNS style, the imminent update could well bundle new patent status with partnership confirmation. The last significant VAL201 update in 2021 saw the Val SP exceed 50p.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.365",
          "thread_title": "Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-06T22:33:52.753952+00:00"
      },
      {
        "event_id": "SOCIAL-10Jan20261920-Kaeren-42896042",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.281449",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kaeren",
          "content": "All great thx.",
          "sentiment": 0.0,
          "engagement": "10,948",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-02-06T22:33:52.753970+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262133-paternos--4831446",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.646223",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Seven consecutive \u201cblocked\u201d posts on a blue day tells me everything I need to know. LOL The desperation of the naysayers knows no bounds \u2013 and the newsflow hasn\u2019t even started yet. I fear for the sanity of Porky and his parrots over the coming months. With an absolute minimum cash runway into July already confirmed and multiple RNS imminent, Porky could well self-check in to the local abattoir. The lorry reversing toward the sty, isn\u2019t delivering feed. \ud83d\udc37 \ud83e\udee8 \u26a1 \ud83c\udf2d Anyone for a bacon butty or sausage cob?",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.385",
          "thread_title": "The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-06T22:33:52.753987+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261807-Porky9--8207132",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.646670",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@Nick I totally agree with you. If anyone can trade this you can. But I have to hand it to mark, the money just keeps on coming, I mean its shocking really, there is absolutely nothing here to invest in, it really is the emporers new clothes, but he keeps getting the cash and with over 20 raises, what's another one? I still think .15 or .20 but ultimately you would think the brokers would say, hang on a minute you never deliver on anything you say, our clients are losing money off our broker notes to buy, enough is enough but I guess as long as they get their fees they couldn't care less.",
          "sentiment": 0.0,
          "engagement": "7,466",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-06T22:33:52.754005+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261719-RayPoint--3833519",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.647089",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "It does explain all the voices in my head \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-06T22:33:52.754023+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261714-ratcliff-79482797",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.647517",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Viera - are you RayPointer and me as well?",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-06T22:33:52.754041+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261704-viera--2751508",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.647968",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "But why would anyone give this lot any money Porky  ? They earn 100k whilst having other part time jobs. Been 20 years of promises but zero revenue . There will be zero revenue in before April when the next begging bowl comes out . I was at 5pct with Theoremx and that failed . I\u2019m at zero pct with Ambrose ! Anyone holding this as we enter Feb/March needs to see a dr. Any monies raised goes to directors as not enough to make any investments. I will NOT be buying at any price . It\u2019s a shambles . Sorry",
          "sentiment": 0.0,
          "engagement": "1,550",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-06T22:33:52.754059+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261454-Porky9--7035417",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.648402",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "They dont have a pot to pee in, its a phoenix business and frankly if they raise cash it will be for themselves, not to give away to VAL - BE REAL. Would imagine meetings being scheduled by VAL with placing brokers shortly, can't be far off now - my call this time is another \u00a31m at .15 to .20 tops - give them another 5/6 months more gravy train assuming brokers can find more mugs to support the lifestyles.",
          "sentiment": 0.0,
          "engagement": "7,466",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-06T22:33:52.754077+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261440-ratcliff--3174482",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.648817",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "I was asking myouryourself the same question. But I knew that, as did Iyou.",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-06T22:33:52.754095+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261415-RayPoint--5590563",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.649253",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Are these people actually employed by Ambrose? Last time Ambrose received capital investments (as I recall, in the region of 900,000) they trumpeted the fact on their website. Yet, at March last year, they only had 25k in the bank. Subsequent to March last year,  there have been no announcements of further investments. I ask myself (i.e. Rats) how this all adds up.",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-06T22:33:52.754131+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261403-Notpotal-55702369",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.649678",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Nice to see momentum at Ambrose. They certainly are building a very strong team. However, this highlights another positive for Valirx. VAL401 is the result of a reformulation of the anti-psychotic drug, Risperidone into an oncology drug. One solitary repositioned drug has resulted in a potential multi-million deal. No wonder in the webinar Mark said he was excited regarding the Val/Dominion repurposing project. This collaboration has identified approx 200 FDA approved non oncology drugs which are showing anti-cancer against various Inaphaea PDCs. Ten of these candidates are now being fast tracked for deeper evaluation. Mark even mentioned looking to partner the prime repurposing asset this year. Because these compounds are clinically validated and safety de-risked, the probability of progressing to meaningful clinical proof of concept is far higher than in creating oncology drugs from scratch - positioning the Val/Dom alliance for multiple rapid, low cost shots on goal.",
          "sentiment": 0.5,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-06T22:33:52.754149+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261359-ratcliff--2803056",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.650086",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "True O alter ego. He even knows where my investments are. (Or should that be 'our' investments)",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-06T22:33:52.754167+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261356-RayPoint--4338500",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.650503",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "You can't fool uxm, he's so sharp \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-06T22:33:52.754185+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261348-uxm484-49320695",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.650918",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Ratcliffe are you Raypointer? Both invested in Scancell. Both are not invested in Valirx.",
          "sentiment": 0.0,
          "engagement": "1,009",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-06T22:33:52.754202+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261333-ratcliff-53939326",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.651345",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "The number of employees and the financial state is a bit concerning isn't it? They weren't flush in 2024's accounts, and they're worse in the 2025 ones. So back to the question - what are 500,000 odd shares in Ambrose actually worth? Potentially even less than 500,000 Val shares...? https://find-and-update.company-information.service.gov.uk/company/14409383/filing-history",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-06T22:33:52.754221+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261310-RayPoint-18242247",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.651773",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "The reason I ask is that if I look at Ambrose Healthcare on Companies House, I find the same name with the same month of birth: Tobias Adam WILSON WATERWORTH - born October 1964 Spookily, this person only has 1 director appointment - Ambrose Healthcare, the other 21 are missing! https://find-and-update.company-information.service.gov.uk/officers/SAWjapGOj9HbCMsLuSFBZeqVYiU/appointments Does anyone else find this rather strange?",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-06T22:33:52.754239+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261254-RayPoint--8733459",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.652198",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Could this be the CEO of Ambrose Healthcare? https://find-and-update.company-information.service.gov.uk/officers/JzAELIfnpaXPIZjjnhqdRjwB9KM/appointments",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-06T22:33:52.754256+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260857-Rebster4--3170943",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.652606",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rebster408",
          "content": "Probably cos Ambrose only have about \u00a325k in capital and assets in 2025... not a pot to p155 in...",
          "sentiment": 0.0,
          "engagement": "1,174",
          "price_at_post": "0.375",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-06T22:33:52.754274+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260757-uxm484--6839138",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.653034",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "I understand they get a share of Ambrose  not just Val401. News on other clinical compounds increases the value of the shares therefore more valuable than just getting cash for Val401. Valirx will have options to sell some shares initially to get some cash.",
          "sentiment": 0.0,
          "engagement": "1,009",
          "price_at_post": "0.375",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-06T22:33:52.754292+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262226-ratcliff--6013703",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.653624",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Why were Val given shares not cash by Ambrose? What are 576,000 Ambrose shares worth? Can they be sold to raise much-needed cash? How much cash had been raised for Val in the 7 months since that announcement? If it was a deal of any real worth, why did Val have to do a placing a few months later, and how come it's heading towards another one in a matter of weeks on current estimations?",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.375",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-06T22:33:52.754310+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262019-paternos-81144669",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.654069",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "A lucrative VAL401 licensing deal was announced on 20/6/25: \u201c ValiRx will receive 576,000 ordinary shares in Ambrose with clinical and commercial milestone payments to be made to Valiseek totalling a value of up to \u00a316 million plus royalties.\u201d Valirx owns 54% of Valiseek. Ambrose has a pipeline consisting of just TWO products: VAL401 (pancreatic cancer) and Renzapride (cystic fibrosis), both currently at phase 2 clinical. Today, Ambrose announced two further additions to their already impressive team: Dr. Janette Thomas joins as Director of Manufacturing Operations and Wendy Richings-Barrow as Director of Regulatory Affairs. \u201cThese appointments reflect our continued focus on building a world class team to deliver solutions for patients with rare conditions with no approved treatments.\u201d The Ambrose team already had a strong backbone: Chairman, Toby Waterworth has been part of leadership teams in multiple life science companies that have generated close to $1 billion in shareholder value. CEO Dr Hazel Jones was formerly Chief of Staff for AstraZeneca\u2019s Oncology R&D Leadership Team. Chief of Staff Virag Stephens an ex PMO Director at AZN and has strong fundraising expertise while Mike Webb led departments of up to 150 scientists in a 30-year career at GSK. Dr. Nick Meyers has 30 years\u2019 experience as a Program Director. In 2024, Ambrose was acknowledged by its peers when it won the Best Startup Biotech Company Award at the prestigious OBN Awards in London. Since then, it has grown significantly and confirmed it is exploring potential Middle-East listings. One of the partners on their webpage is SEHA (Abu Dhabi Health Services), a subsidiary of Pure-Health the largest integrated healthcare network in the UAE. (total assets $13B). Another partner is listed as Aparito, part of the Eli Lilly group. As Ambrose strengthens its leadership and global partnerships, Valirx is strategically placed to benefit from every milestone achieved on the VAL401 journey.",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.375",
          "thread_title": "The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-06T22:33:52.754327+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261513-paternos--8558526",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.654610",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "\u201cValix is in discussions with several potential partners to progress CytoLytix, including a major pharma\u201d. So, why is Mark, currently in California, continuing to promote the compound so actively both in the UK and overseas? While it\u2019s plausible a major pharma might seek exclusivity, the most realistic outcome is exclusive rights carved by territory, formulation, indication, or even species (human/veterinary)\u2014leaving room for multiple, parallel deals outside that scope. Indication splits are historically used when partners specialise in different therapeutic areas (eg ovarian only). Geographic exclusivity is even more common. The TrX/201 deal eventually failed when Mark attempted to remove Taiwan from the original LOI. The veterinary angle highlighted in recent webinars reinforces that CLX spans markets no single pharma can cover, making a multi partner licensing model far more realistic than a single global licence. There are numerous real world examples of multi partner licensing structures in biopharma: TERRITORY - Immunex (Enbrel) / initially Amgen \u2192 US & Canada rights, then Wyeth (later Pfizer) \u2192 Europe + Rest of World rights FORMULATION - Gilead (Tamiflu) / initially Roche \u2192 Oral formulation rights, then Hetero & Teva, \u2192 sublicenses for additional formulations INDICATION - AstraZeneca (Lynparza) / Merck \u2192 initially Ovarian cancer rights, then subsequently obtained licenses for breast and pancreatic cancers. Each example above shows one originator, no single-party lock in and multiple partners or deals to acquire different rights. With so many variables in play, it is increasingly clear that Valirx is preserving the same optionality for CytoLytix. Mark is still promoting CytoLytix because he is targeting several partners \u2013 not just one. Everything suggests CLX is being shaped as a multi deal platform, with the first handshake simply opening the monetisation cycle -",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.385",
          "thread_title": "CLX - multi deal structure",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D1488F3A-09F4-41C4-B45B-AF908B85E267"
        },
        "ingested_at": "2026-02-06T22:33:52.754344+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261459-Notpotal-45699600",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.655026",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Some clever trading going on here \u2013 those selling at 0.37p will soon be able to buy back at 0.39p. \ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "RE: Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-02-06T22:33:52.754362+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261329-Porky9-25616809",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.655478",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@PP Yes, and as long as the rain holds off should be able to get some golf in on expenses. Who needs Zoom and Teams when you can have a nice all expenses trip to the US. Lovely. Keep pumping it, only a few weeks now to go before next placing @notpotatlot Only Update you will get shortly that isn't fluff, will be the placing news or the next 125:1 consolidation event which has to be well over due now. Keep ramping it though, the gravy train needs to stay on the tracks, there are lifestyles here that need to be maintained.",
          "sentiment": 0.0,
          "engagement": "7,466",
          "price_at_post": "0.385",
          "thread_title": "RE: Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-02-06T22:33:52.754380+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260943-paternos-28522961",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.655913",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Mark re JPM in San Fran -  \u201cI have meetings lined up with our partner Omios Biologics so looking forward to catching up with Aldo Pourchet (CEO).\u201d In the Omios RNS (3/6/25), the evaluation was \u201cexpected to run up to 12 months, after which Omios can exercise its license option to continue using Cytolytix technology.\u201d Across both the June and Dec webinars, Mark emphasised CLX synergy with the Omios virus for potential to treat canine HSA, a clear signal that Omios sits firmly in the frame for a CLX licence. Valirx\u2019s revamped Advisory Board reinforces this direction, now with a notable weighting toward veterinary oncology and commercial expertise. The composition reflects a deliberate strategy to position CLX across both human and animal oncology. When your advisory structure is rebuilt around people who understand canine cancers, comparative oncology, and veterinary commercial pathways, it becomes clear Valirx is preparing for licensing routes across both human and veterinary markets. As a co-founder of VolitionRx, Mark transformed a human cancer test into a canine diagnostic test (Nu.Q) before negotiating a licencing deal with Heska for $26m. What price a cure? Human and veterinary oncology operate in separate regulatory and commercial channels. Most major pharmas, inc. AZN, Roche, GSK, AbbVie do NOT have any vet divisions. Even those historically involved have spun off their animal health units (Pfizer \u2192 Zoetis, Eli Lilly \u2192 Elanco). By envisaging veterinary opportunities for CLX, Mark is implicitly confirming the compound won\u2019t be a one partner asset; the split infrastructures required make multiple CytoLytix deals the only realistic outcome. GLA, DYOR, AIMO",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.385",
          "thread_title": "Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-02-06T22:33:52.754398+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261543-Notpotal--8229864",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.656343",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "I notice a 71430 buy at 15.14 and a similar sell 4 mins later for a \u00a321 loss. Great to see Porky has started trading again!  \ud83e\udd23\ud83e\udd23\ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "Welcome back, Porky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=FE350133-0204-48E9-9785-7F80407B3421"
        },
        "ingested_at": "2026-02-06T22:33:52.754416+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261534-Notpotal--4925400",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.656760",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Val is obliged to RNS as it a change to No. shares in issue. Hardly the company\u2019s fault if a holder sees such value that he wants to buy above the current SP. Mind you, I\u2019m expecting a TR1 tomorrow to confirm Mark\u2019s holding has increased by 80,000 shares. \ud83e\udd23 If this is the reaction to \u00a3400 of warrants, heaven help Porky\u2019s groupies when the next material RNS arrives.  \ud83e\udee8 \ud83d\ude28 \ud83d\ude22\ud83d\ude2d",
          "sentiment": 0.5,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-06T22:33:52.754434+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261535-viera--1036298",
        "event_type": "social_post",
        "date": "2026-02-09T22:52:21.394292",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "I do loveya notpot. I post replies to you and pp hence 67 posts ! I\u2019ve also got repetitive syndrome I apologise . I do laugh at your posts as Val has zero revenue ,huge cost base ,years of years of promises which all have been broken . A loss making lab and a CEO  who pays staff to contribute zero to the bottom line . It\u2019s a shambles. I\u2019m absolutely flabbergasted that investors continually donate money to employees salaries when they produce FA. You couldn\u2019t make it up my friend . Have a great weekend Let\u2019s hope it stops raining Xxxx",
          "sentiment": 0.0,
          "engagement": "1,556",
          "price_at_post": "0.345",
          "thread_title": "RE: Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-09T22:52:28.963232+00:00"
      },
      {
        "event_id": "SOCIAL-Today1535-viera--1036298",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.574183",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "I do loveya notpot. I post replies to you and pp hence 67 posts ! I\u2019ve also got repetitive syndrome I apologise . I do laugh at your posts as Val has zero revenue ,huge cost base ,years of years of promises which all have been broken . A loss making lab and a CEO  who pays staff to contribute zero to the bottom line . It\u2019s a shambles. I\u2019m absolutely flabbergasted that investors continually donate money to employees salaries when they produce FA. You couldn\u2019t make it up my friend . Have a great weekend Let\u2019s hope it stops raining Xxxx",
          "sentiment": 0.0,
          "engagement": "1,556",
          "price_at_post": "0.345",
          "thread_title": "RE: Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-09T22:52:28.963270+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262209-Notpotal-65893897",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.574764",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Very amusing to see the uninvested have such strong views on Val. Such a shame Porky didn\u2019t have the same consideration while sucking thousands of gullible punters into other investment disasters. Perhaps considering compensating all those innocents dragged in? At this point, Porky will probably give another history lesson but, while Val is still trading and doing quite nicely, no news on 4D or HARL reinstatement yet. Meanwhile back in the real world - 40 separate projects ongoing at Inaphaea, \u00a3200k pa cost savings, money in the bank into H2 with R&D tax credits expected but as yet unconfirmed, Inaphaea income excluded and grants applications pending (as confirmed by Prof Mark\u2019s statement, not Prof Porky\u2019s Santa wish\ud83e\udd23), partnering planned for CLX, 201, and the lead repurposing asset \u2013 all of which will further reduce costs, tailored for grants under new guidelines, another evaluation and SPV imminent (already ring-fenced), the recent McGill Univ & IRICoR  evaluation is the first with global players, multiple RNS updates due and an SP bouncing around in the mid-0.30s even before the RNS news flow starts. Understandably upsetting for the pink one. Having devoted the last 4 years and thousands of posts hoping to destroy Val, a new CEO comes in and undoes all that work in less than 18 months. Porky\u2019s partner (in crime?) Nick, has made a small fortune trading the share over the years and still ONLY posts on this share \u2013 check history - 67 consecutive and counting. He obviously sees great value here, despite all his apparent bed-wetting. The way Porky and Nick tag team this board, you\u2019d swear they were coordinating over the same cup of tea. \ud83e\udd14 Happy dreams, you two! \ud83d\ude34",
          "sentiment": 0.5,
          "engagement": "81",
          "price_at_post": "0.345",
          "thread_title": "RE: Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-09T22:52:28.963303+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261739-viera--2025461",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.575230",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Pp is pm Paid to post on LSE Until the next  raise (I think c April ) Then he goes missing as he\u2019s embarrassed . Then changes  his name and rinse repeat . He has no humility . Been bullish since 30p but holds no shares so what does he care ,has lost all his readers 98pct of their hard earned cash. Shambles",
          "sentiment": 0.0,
          "engagement": "1,556",
          "price_at_post": "0.345",
          "thread_title": "RE: Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-09T22:52:28.963335+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261450-Porky9--8457080",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.575649",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@pp - nobody gives a **** about posts on linked-in - unless you are looking for a job or trying to recruit someone from a competitor that is all it is good for - a recruitment tool. the guy needs to stop wasting his time posting crap on social media and get some bloody focus on the important issues and then publish some proper update news via the rns service. talk about lack of perspective. this is exactly what i am talking about - zero commercial acumen - sorry",
          "sentiment": 0.0,
          "engagement": "7,471",
          "price_at_post": "0.345",
          "thread_title": "RE: Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-09T22:52:28.963366+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261351-paternos--1913856",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.576063",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Inaphaea has just released a short video re the collaboration with the Open University re prostate cancer.  Funded by a Knowledge Transfer Voucher (RNS 7/8/25) this is yet another example of non-dilutive funding to progress assets using cutting edge technology that would otherwise be beyond the company\u2019s reach. https://lnkd.in/eXGeSPQq",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.345",
          "thread_title": "Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-09T22:52:28.963398+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20262042-paternos-62498469",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.576513",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "\u201cImportant day in the calendar for patients, families and those of us working in the sector. The UK government has announced a directive to increase 5 year survival for cancer patients to 75% by 2035. This will take a a huge effort in terms of screening for early detection and diagnostics to allow curative surgery, improvements in surgical technique, such as robot assisted approaches and developments of affordable, accessible therapies. VALIRX PLC and its subsidiaries, including Inaphaea BioLabs, Cytoltix and Blue Ribbon Bio are working hard to play our part in the discovery and development of next generation therapies. These include our novel oncolytic peptide program (targeting Triple Negative Breast Cancer), a first in class, non-genomic androgen receptor signalling inhibitor and a series of repurposed drugs from Inaphaea BioLabs 3K screen program. We work closely with leading academic institutions to source, assess and develop cutting edge approaches with pan cancer potential. Our latest deal is with McGill University and IRICoR for a second generation RNA Helicase inhibitor ( https://lnkd.in/ei5xwSpx) Big shout out to our dedicated Inaphaea BioLabs team including Head of Scientific operations Melissa Barr, Lead Scientist - Translational Biology and Academic Collaboration, Amelia Hatfield and Lab tech Dylan Jones as well as VALIRX PLC's Director of Research, Michelle B.. There are currently 40 projects running in the labs at Inaphaea BioLabs covering our group therapeutic programmes and development of our non-animal based, New Approach Methodologies (NAMs) for drug screening with our unique bank of Patient Derived Cell models. We couldn't do this without the support of our partners including TwinEdge Bioscience (Digital twin/Patient Avatars), ScreenIn3D (Lab on a chip platform), VoxCell (vascularised 3D tumour models), Spanios (organoid models), BioReperia (zebrafish models), Ignota Labs (in silico tox screening) and development partner Dominion Biotech as well as our shareholders. It's been a hectic 18 months since I took over as CEO but we've focussed on refining our strategy, identifying high quality assets, building a strong team and expanding our capability partner network. We have a some major milestones set for 2026 and we look forward to being part of the solution and helping deliver patient benefits.\u201d",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.35",
          "thread_title": "Today\u2019s Linkedin update from Mark E",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E9D6BAF9-FFFC-4611-82EB-4E1B71731FB2"
        },
        "ingested_at": "2026-02-09T22:52:28.963429+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261943-ratcliff--5736873",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.576919",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "That's the way - cut and paste some good long pieces in the hope of burying anything that doesn't fit the agenda.",
          "sentiment": 0.0,
          "engagement": "11,411",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-09T22:52:28.963460+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261832-paternos--9027205",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.577382",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Grant schemes are increasingly geared towards small companies - when it comes to eligibility, size truly matters. Recent UK oncology research grants to SMEs reflect sustained investment in cutting edge cancer research, with Innovate UK and the Biomedical Catalyst programme providing much of the funding. Recent awards to UK microcap/small biopharmas include: Momentous Therapeutics Ltd (immunotherapy) - \u00a32m grant Theolytics Ltd (ovarian cancer therapy) - \u00a32m Mestag Therapeutics Ltd (immunotherapy) - \u00a31.5m Revolver Therapeutics Ltd (peptide therapy) - \u00a3550k Epitopea Ltd (breast cancer stromal cells / immunotherapy) - \u00a3500k VacV Biotherapeutics Ltd (oncolytic viruses) - \u00a3500k Antikor Biopharma Ltd (ovarian immunotherapy) - \u00a3500k The above awards show clear emphasis on immunotherapy, peptide based therapeutics, and oncolytic virus platforms. Val\u2019s work not only aligns with these priority areas but also extends into difficult to treat cancers such as pancreatic, ovarian, triple negative breast, and prostate \u2014 indications where new therapeutic approaches are urgently needed. This strengthens Val\u2019s fit within the priority areas repeatedly backed by UK grant bodies. The grants aren\u2019t handouts; they\u2019re strategic investments in the UK\u2019s future. A successful cancer therapy can deliver multi billion pound global sales and position the UK as a leader in next generation oncology. Regulators are now actively encouraging NAM adoption and funders are rewarding small oncology-focussed companies that have strong academic links. Valirx is exceptionally well-positioned to secure substantial grants, extend the cash runway and reinforce financial stability. GLA, DYOR",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-09T22:52:28.963491+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261827-paternos-56136493",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.577808",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "To all the green bar brigade out there, you will get zero engagement from me. I have no desire to convert you and history lessons really don\u2019t interest me. Feel free to post your drivel as all I can see is 6 consecutive green \u201cThis message has been filtered, please adjust your filters to view\u201d. Han Solo couldn\u2019t land a helicopter on your imaginary runway. \ud83d\ude01 \ud83d\ude01 \ud83d\ude01 To those actually invested, whether traders or otherwise, with all the news pending, the coming weeks and months are likely to be transformational. GLA, DYOR",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-09T22:52:28.963522+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261740-viera--2502314",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.578232",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Grant could pay the 100k we pay to our BDM who organises ME trips abroad and placings . Both been a resounding success ! @shambles Paternoster aka PM will go into ramp mode now as we approach QTR 2 and the inevitable begging bowl comes out .",
          "sentiment": 0.0,
          "engagement": "1,556",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-09T22:52:28.963553+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261735-ratcliff--3078492",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.578647",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Probably thinking like Pan Am did - the only state airlines that never made a loss, they recorded a 'negative profit.' Maybe he's talking 'negative growth.' I'm sure he'll elaborate on his claim pretty soon and to everyone's satisfaction anyway.",
          "sentiment": 0.0,
          "engagement": "11,411",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-09T22:52:28.963584+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261729-RayPoint-76426509",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.579062",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Well put Rats. The other sentence I take pater to task on is: \"The combination of Mark\u2019s grant winning experience and the UK\u2019s revised grant landscape creates a clear opportunity for Valirx as it enters its next phase of growth.\" Pater, pray tell us about Valirx's previous phases of growth.",
          "sentiment": 0.0,
          "engagement": "5,087",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-09T22:52:28.963614+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261605-ratcliff-40382588",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.579478",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "To be fair RP, applying for grants is a very sensible thing to do. However there must be an element of due diligence and examination of the company applying, and somewhere in the paperwork there will probably be a section which asks 'What would the grant be used for?' This is where the potential donor writes something like 'to accelerate the development of our compound XYZ' or 'to fund the production of our drug to use in the imminent 500 patient Phase 3 trial.' If the box reads 'to stave off imminent insolvency and to avoid another placing' or 'to pay salaries, expenses and bonuses' I imagine the progress of the application tends to grind to a halt.",
          "sentiment": 0.0,
          "engagement": "11,411",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-09T22:52:28.963645+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261408-RayPoint-21326422",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.579907",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Just looking at the first company on your list i.e. Momentous Therapeutics Ltd (immunotherapy) - \u00a32m grant I notice that they have a world-renowned scientist on their BOD. This may go some way to explaining the grant they received. That plus the cutting edge research they are undertaking on the immune system. Here he is: https://www.meduniwien.ac.at/web/en/ueber-uns/news/2025/news-in-june-2025/christoph-huber-receives-german-cancer-aid-award/",
          "sentiment": 0.0,
          "engagement": "5,087",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-09T22:52:28.963676+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261132-Porky9-41802774",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.580333",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "So you are keeping everything crossed that some free grant cash will land in the next couple of weeks to stave off the discounted placing. just incredible really that the focus is on how to get free grant cash to keep the gravy train moving forwards. How about a focus on making the business viable - now that would be refreshing. In all honesty, i would not award this business grant money to waste, it doesnt need it. They have an endless supply of free money from continual discounted placings on the AIM. Any grant money IMO should only go to ground breaking innovations, small private biotechs that have no means to raise cash easily not to this lot to indirectly get spunked up the wall on jollys aboard and ridiculous admin and bonus costs. This next placing will be interesting for sure; a) can he pull it off yet again or will brokers call time on it, b) will the support be out there c) how much of a beating can existing long term holders take whilst the business fails to deliver on its pledges. IF he gets it away, yet again, the discount has to be brutal surely; .15 to .20 ?",
          "sentiment": 0.0,
          "engagement": "7,471",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-09T22:52:28.963707+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261005-paternos--9027205",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.580795",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Grant schemes are increasingly geared towards small companies - when it comes to eligibility, size truly matters. Recent UK oncology research grants to SMEs reflect sustained investment in cutting edge cancer research, with Innovate UK and the Biomedical Catalyst programme providing much of the funding. Recent awards to UK microcap/small biopharmas include: Momentous Therapeutics Ltd (immunotherapy) - \u00a32m grant Theolytics Ltd (ovarian cancer therapy) - \u00a32m Mestag Therapeutics Ltd (immunotherapy) - \u00a31.5m Revolver Therapeutics Ltd (peptide therapy) - \u00a3550k Epitopea Ltd (breast cancer stromal cells / immunotherapy) - \u00a3500k VacV Biotherapeutics Ltd (oncolytic viruses) - \u00a3500k Antikor Biopharma Ltd (ovarian immunotherapy) - \u00a3500k The above awards show clear emphasis on immunotherapy, peptide based therapeutics, and oncolytic virus platforms. Val\u2019s work not only aligns with these priority areas but also extends into difficult to treat cancers such as pancreatic, ovarian, triple negative breast, and prostate \u2014 indications where new therapeutic approaches are urgently needed. This strengthens Val\u2019s fit within the priority areas repeatedly backed by UK grant bodies. The grants aren\u2019t handouts; they\u2019re strategic investments in the UK\u2019s future. A successful cancer therapy can deliver multi billion pound global sales and position the UK as a leader in next generation oncology. Regulators are now actively encouraging NAM adoption and funders are rewarding small oncology-focussed companies that have strong academic links. Valirx is exceptionally well-positioned to secure substantial grants, extend the cash runway and reinforce financial stability. GLA, DYOR",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.35",
          "thread_title": "UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-09T22:52:28.963738+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260807-paternos-23984229",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.581218",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Many of Mark\u2019s presentations have highlighted the potential of grant-funding, with the 14/10/25 RNS confirming a \u00a3250k award. This followed a KTV Open Univ award only 2 months earlier and Mark has stated further grant applications are pending. The Inaphaea RNS (18/9/25) on the repurposing top10, noted \u201c\u2026 discussions with potential licensees as well as an application for non-dilutive grant funding to support further development of these and other assets\u201d. In addition to ongoing partnering discussions, CytoLytix updates invariably reference grant opportunities. As MD of OncoLytika, Mark has a strong history of securing significant grants, including Eureka Eurostar funding, demonstrating a proven ability to win competitive international grants. Recent changes to UK and int\u2019l grant frameworks \u2014 including the UK\u2019s modernised Official Development Assistance (ODA) strategy, refreshed criteria, and new SME friendly collaboration rules \u2014 have opened funding routes that previously excluded early stage biopharma companies. These shifts prioritise oncology projects with demonstrable patient relevance, human relevant New Approach Methodologies (NAMs), and academia/SME partnerships, all of which align directly with Val\u2019s revised operating model. The combination of Mark\u2019s grant winning experience and the UK\u2019s revised grant landscape creates a clear opportunity for Valirx as it enters its next phase of growth.",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.355",
          "thread_title": "The New Grant Landscape",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=2EC60BA4-C275-47D5-901A-D8BA32B59D52"
        },
        "ingested_at": "2026-02-09T22:52:28.963769+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261811-viera-57829316",
        "event_type": "social_post",
        "date": "2026-01-30T22:38:35.634037",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "You sold the spike brilliantly Stephen . Knowing we have had no announcements and another year of zero revenue . You and porky have called it here . What do the directors get paid for here exactly ? Shambles . The BOD needs strengthening .",
          "sentiment": 0.0,
          "engagement": "1,553",
          "price_at_post": "0.35",
          "thread_title": "RE: Ambrose Q1 Newsletter - FYI",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=DD644FF4-EB58-4811-9E0F-61E17204B69A"
        },
        "ingested_at": "2026-02-09T22:52:28.963799+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261626-Uncanny--8064133",
        "event_type": "social_post",
        "date": "2026-01-30T22:38:35.634577",
        "source": "LSE_CHAT",
        "data": {
          "author": "Uncanny",
          "content": "Ambrose Healthcare | 2025 Highlights and What\u2019s Ahead in 2026 Dear Colleague / Partner, As we begin 2026, we would like to share a brief reflection on the past year at Ambrose Healthcare and outline what lies ahead in delivering its mission, to bring new therapeutics to rare disease patients who currently have no approved drug treatment. Our last update was shared in October 2025. Since then, meaningful progress has been made across our programmes, partnerships, and team, all in support of our mission to bring treatments to patients living with rare and underserved conditions. 2025 at a Glance During 2025, Ambrose focused on building strong scientific, operational, and partnership foundations to support the next phase of development: Continued preparation for the Renzapride Phase 2 trial for the treatment of the Gastrointestinal Manifestations of Cystic Fibrosis (GMCF), including regulatory planning and UK clinical engagement Exercised the licensing option for VAL401, securing global rights for development and commercialisation for treatment of cancers. 20% of cancers are classified as rare diseases. Ambrose is focusing initially on development for the treatment of pancreatic cancer Strengthened leadership, governance, and delivery capability Expanded engagement with clinicians, researchers, and funding partners across the UK and internationally Much of this work took place behind the scenes, laying the groundwork for accelerated progress in 2026. Scientific Leadership We are pleased to be working closely with Professor Bu Hayee, Kings Hospital, London who oversees the GMCF treatment centre for the Southeast of England and is supporting Ambrose as a Scientific Advisor for development of Renzapride for GMCF, providing valuable clinical insight as the programme progresses. We were deeply saddened by the passing of Professor Brian Feagan during 2025. Professor Feagan was internationally respected for his leadership in clinical trial design and execution. His early engagement with Ambrose and belief in rigorous, patient-centred development left a lasting impact on our work and thinking. Looking Ahead to 2026 In the year ahead, Ambrose Healthcare will focus on disciplined execution and collaboration, with priorities including: Advancing Renzapride toward initiating its Phase 2 study Preparing VAL401 for Phase 2 clinical development Pursuing investment as well as public and charitable grant funding, including a recent formal invitation to submit a major UK grant application for Renzapride Continuing to build trusted partnerships with clinicians, academic groups, and research organisations These activities reflect Ambrose\u2019s commitment to capital-efficient development and strong alignment with the UK life sciences ecosystem. Planning Named Patient Supply We are also planning to initiate Named Patient Supply (NPS) activities. Named Patient Supply enables access to Good Manufacturing Practice-manufac",
          "sentiment": 0.0,
          "engagement": "3,308",
          "price_at_post": "0.35",
          "thread_title": "Ambrose Q1 Newsletter - FYI",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=DD644FF4-EB58-4811-9E0F-61E17204B69A"
        },
        "ingested_at": "2026-02-09T22:52:28.963830+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261709-Porky9-92139696",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.373661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "What, do you think he is going to release news of the placing already, possible but they normally leave it right until the death, so proabably a few more weeks yet but you never know, you could be right.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.355",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-09T22:52:28.963861+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261448-Notpotal-96886579",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.374477",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Is that a Friday RNS I can smell.... Or has Porky had an accident? \ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.35",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-09T22:52:28.963892+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262254-viera--3095304",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.375315",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Pm changed his name to pp It\u2019s basically ME copy and paste . As he said ME has produced one RNS in months . We all know what the next RNS of note will be . ME needs to cut costs further and do something with 201. Good luck all.",
          "sentiment": 0.0,
          "engagement": "1,552",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-09T22:52:28.963923+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261720-RayPoint--8528305",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.376112",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Pater It's funny to see, in a thread entitled \"The Ambrose Dream Team\" and started by yourself , that neither the Dream Team nor VAL401 get a mention in your latest post.",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-09T22:52:28.963954+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261632-ratcliff--5220320",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.376907",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "'When the SP inevitably hits 1.6p plus there will be further buying pressure as placees exercise their 1.3p warrant options. Some will then sell for a quick profit but by then the SP will be in the 2p range. All this without the flush of positive news expected over the coming months.' Sounds good? Sounds worth buying into? Well actually it's a paternostpauper quote from 16th January 2025. But the share price then was 0.875, sliding gently down another post-placing ski-slope graph.  And what's the biggest news since then? Oh yes, another placing - predicted by P9 and derided by PP. Until it happened. On past history Porky's predictions seem a pretty reasonable bet. PP's posts are just reformulated bin dippings - he might as well just copy and paste on a pumping merry-go-round.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-09T22:52:28.963984+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261512-Porky9--5750412",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.377717",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Always entertaining, like watching fantasy island @PP is our very own Mr Roarke and @nopot is Tattoo.  Not sure who @uxm plays, probably the aircraft pilot as he only turns up to share the fantasy once a week or so. The gap will be between .15 and .20 as that will be where the placing shares land, thats of course if ME can pull it off again. Jury out this time.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-09T22:52:28.964015+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261503-paternos-18208180",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.378553",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Good post UXM.  Always entertaining to see trader Nick post again - his 63rd consecutive LSE post - and every one on Val. He might as well hang up a banner \u201croll up, roll up \u2013 bargain of a lifetime!\u201d \ud83e\udd23\ud83e\udd23\ud83e\udd23 Val has issued just one positive RNS since the placing, yet the SP has climbed 67% from those 0.23p lows. Even with 2 major holders dipping below the 3% threshold to facilitate some short-term trading, the SP still hovers near 0.4p. Every day that passes without an RNS increases the likelihood of one the following day as multiple programs mature: CytoLytix patent updates, formulation decisions, Blue Ribbon/VAL201 partnering (by diluting the asset, not VAL plc), 3k repurposing update (top candidate partnering?), further grant updates (ME has strong history), next evaluation and SPV (confirmed in webinar), Inaphaea income (PredictRx/ PDC sales), updates on the Dundee/Queen Mary pro-senescence project and StingRay (decision imminent). The motherlode remains early partnering/grant funding for CLX, a 2026 milestone confirmed by the CEO in the recent webinar. As the June anniversary nears, Omios have to decide whether they wish to exercise their option of a license agreement to continue using CLX tech. It looks promising as both Mark and Omios CEO Dr Aldo Pourchet had meetings arranged at the JPM in San Fran. More than once, Mark has referenced the Omios virus as an entry point to veterinary oncology due to its potential for treating canine HSA, while Dr Pourchet posted: \u201cWe are targeting triple negative breast cancers (CLX primary indication), all of which have the biomarker that makes them susceptible to our therapy. It\u2019s our most advanced program\u201d (Oct NYU interview). With multiple CytoLytix licenses up for grabs, Omios look set to start the ball rolling. The decisive factor which totally undermines the detractors\u2019 fearmongering is the financial position: a cash runway that extends till H2 excluding warrant income, R&D tax credits, grants, or additional Inaphaea income. That completely negates any March/April placing argument. Mind you, naysayers never let a few facts ruin their narrative. GLA DYOR",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-09T22:52:28.964046+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20261956-uxm484-64848762",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.379412",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Watch the video. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025 Chart analysis shows a nice gap at 1.4p. Past management issues but new management is outstanding.  Cash until H2 without the add ons such as grant money, revenue and warrant money. CEO heavily invested over 250k. Negotiating with a major biotech in regards to a deal for CLX001. Lab space is to help progress the assets to eventually get a deal not to make instant revenue. Any research on CLX001 done against a valuation of 2 million and cash burn just over a million would know this is a great opportunity. Great decision making. Derisking assets with partnership deals. Which other biotech has so much and spending less than 2 million. With warrants at a premium to the current price hopefully no more dilutions. Expecting significant news in the coming days/weeks. Tiny valuation and cash burn is tiny with assets of significant value.",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-09T22:52:28.964077+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20261515-viera--6819516",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.380239",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Problem my friend is ME hasn\u2019t got a proper hold of Costs paying a non BOD member and non scientist 100k  paying best mates that produce zero revenue is a disgrace . It shows a lack of respect for shareholders . Where are all the promised lab contracts . ME has surrounded himself with \u201cyes \u201c men. Shame he ousted Adrian as he had the commercial nous to make a difference . Adam also lost interest as was treated so badly by the BOD. I predict more confetti in April /May . Porky knows this co better than anyone . If he and Adrian joined the BOD I would consider investing but I\u2019ve lost faith in the current BOD who promise the world and deliver FA. Deliver some revenue asap or step down .",
          "sentiment": 0.0,
          "engagement": "1,552",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-09T22:52:28.964125+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20261416-ratcliff--6845207",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.381020",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Interesting that you've posted notgotalot - in December you distinctly said \"I\u2019ll take some time out and won\u2019t be back until the next decent RNS.\" Presume you've restarted posting because you've lost hope in there being a decent RNS.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-09T22:52:28.964158+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20260843-Notpotal--1444099",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.381814",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "each conspi****** on here is in self-denial mode - a mechanism where a person ignores or distorts reality to avoid anxiety and stress. they refuse to accept the situation simply because it doesn\u2019t support their agendas and so resort to posting fiction. whether it is by inventing a 50% lower cash runway, alleging fictitious staff at ambrose, claims of ceo golf jollies and overpaid team members or alleging lse posters are on the val payroll. desperate posts by the uninvested are now treated with the contempt they deserve. just when you think they\u2019re as low as they can get \u2013 they pick up a spade. by resorting to deception, they have lost any remaining credibility they may have had, while each day news edges closer.",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-09T22:52:28.964189+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20262102-ratcliff--6550010",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.382589",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "It would also be interesting to know why the posting of relevant financial facts from those observing is described as 'panic.' Surely the only panic is among those trying to snare the naive with fantasy predictions so they can get out fast with a profit - and now realising that the supply of gullible newbies is drying up.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-09T22:52:28.964220+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261925-RayPoint--1774834",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.383379",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "So what's the crack, pp? I would be interested to know your view on how Ambrose are paying salaries to the Dream Team without having any money in the bank",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-09T22:52:28.964251+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261832-paternos-41537182",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.384211",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "@  spantrout - Great call. Valirx - 10m,50s in. \u201cA lot of return on that one!....DYOR but in all probability, if it\u2019s going to have some game-changing news, then \u2026.that would be 1.4p.\u201d Not sure of the news he is he is referring to? Maybe the new patents, partnering (CLX,201), repurposing top 10, StingRay, further grants, or expansion into veterinary oncology? Possibly it\u2019s the the 2nd evaluation and new SPV or even the CEO buying 7% of the company. I suppose it could be that Mark E has recently been on stage presenting alongside some of the biggest names in pharma, or the fact the CEO has a history of delivering success (Nu.Q test sold for $26m). !.4p is an interesting SP \u2013 that would not only see the 0.5p warrants in play but also the 1.3p warrants, easily extending the runway into 2027. Mind you realistically, a few easily pleased would exit for a quick 300%+ profit. I guess the uninvested posting day and night trying to supress the SP hasn\u2019t gone unnoticed either. Karma can be a wonderful thing! Happy days DYOR, GLA.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.385",
          "thread_title": "RE: Coverage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=1C527045-FD63-41D2-B4BE-ED55425FC93C"
        },
        "ingested_at": "2026-02-09T22:52:28.964281+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261714-Notpotal--4671377",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.385010",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "pp previously purged porky\u2019s parrots\u2019 pack of preposterous posts pedalled in panic, perhaps predictably. i promptly prepared a poem for porky to peruse at his pleasure. pundit porky posted a pack of pathetic, poorly proven poppy****. a pack of pathetic, poorly proven poppy**** pundit porky posted. when pundit porky posted a pack of pathetic, poorly proven poppy****, perhaps he\u2019ll point to proof behind the pathetic poppy**** pundit porky posted?",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.385",
          "thread_title": "Porky\u2019s Peddled Pile of Piffle",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=93B08DEA-F499-4237-AF7E-B5143BC8D67E"
        },
        "ingested_at": "2026-02-09T22:52:28.964313+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261625-spantrou--7855361",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.385791",
        "source": "LSE_CHAT",
        "data": {
          "author": "spantrout",
          "content": "Https://youtu.be/HrYMuqPFA20",
          "sentiment": 0.0,
          "engagement": "13,977",
          "price_at_post": "0.385",
          "thread_title": "Coverage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=1C527045-FD63-41D2-B4BE-ED55425FC93C"
        },
        "ingested_at": "2026-02-09T22:52:28.964344+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261403-Porky9-29600976",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.386613",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@PP You really are a busted flush, its like groundhog day:- Pump the boards with nonsense about million dollar licensing deals, how the cash is well managed and will last many months more than it does, how there will be all these marvelous license deals lined up, exaggerate the interest and how fantastic it all is. Then RNS drops,  placing at discount issued, you vanish for a few weeks, let the dust settle and then you pop up again and repeat the above. I totally get those in the business want the gravy train to continue, lifestyles at risk but have you no conscience that small investors that may not earn the sort of money the board here gets here for these cushy  work from home jobs, are going to lose their hard earned cash being sucked into this? Its morally not right. Next RNS will be the next discounted placing, can't be far off now, a few weeks at most imo.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-09T22:52:28.964374+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261529-RayPoint-24608973",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.157704",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "I hear that green fees are pretty steep in California",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-09T22:52:28.964405+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261434-ratcliff--1390771",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.158130",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "No problem RP - I'm wondering who paid 0.50 for a few shares worth about 25 percent less from the start, but I suppose 400 quid pays for the week's teabags and digestives.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-09T22:52:28.964436+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261413-RayPoint-78368361",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.158544",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Sorry Rats. I misinterpreted your post.",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-09T22:52:28.964467+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261412-RayPoint--8543117",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.158961",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "\"Probably about 450 quid...\" Rats, stop ramping! The gross proceeds were \u00a3400",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-09T22:52:28.964497+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261357-spantrou-71340804",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.159474",
        "source": "LSE_CHAT",
        "data": {
          "author": "spantrout",
          "content": "\u00a39.99 for rns",
          "sentiment": 0.0,
          "engagement": "13,977",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-09T22:52:28.964529+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261311-ratcliff--6849376",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.159890",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Probably about 450 quid...",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-09T22:52:28.964560+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261216-steve196-84734454",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.160315",
        "source": "LSE_CHAT",
        "data": {
          "author": "steve196",
          "content": "How much does it cost to release an RNS just for \u00a3400 of warrants?",
          "sentiment": 0.0,
          "engagement": "2,761",
          "price_at_post": "0.385",
          "thread_title": "Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-09T22:52:28.964590+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261935-uxm484-78965082",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.160734",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "No, but the holders all want the warrants exercised so we can do a 10 bagger in 12 months without a fund raise. For me i am really happy here with  the progression. We are definitely early in a news rich periods where all the negative posters are posting overtime and are only posting as they missed out on the last fundraise hoping for an even lower price. We will likely get a few meaningful RNS very soon. Brakes are now off\u2026",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.36",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-09T22:52:28.964621+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261222-Notpotal-67090924",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.261915",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "\u201cYou sound so desperate\u201d says the man who\u2019s last 60 posts have been on a share he isn\u2019t invested in. \ud83d\ude02\ud83d\ude02\ud83d\ude02",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-09T22:52:28.964652+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261207-ratcliff-64761857",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.262733",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Slight typo there - should read blatantly UNTRUE and misleading!",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.365",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-02-09T22:52:28.964683+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261201-ratcliff--4999986",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.263581",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "UXM - differences of opinion are generally understandable, but to say in your post 'All lies' is blatantly true and misleading, and as usual does nothing to bolster your credibility. Two of the things you say in that post are particularly inaccurate - 'Great decision making. Derisking assets with partnership deals. Which other biotech has so much spending less than 2 million.' - They are looking for deals (or claim to be anyway) but nothing so far has contributed anything to even cover the outgoings, let alone provide money for further work or expansion (hence the redundancies etc) Secondly - 'With warrants at a premium to the current price hopefully no more dilutions' - warrants don't kick in and generate cash the moment the sp goes above them as you and the others in your group seem to imply. In the unlikely event of the sp rising above that point and remaining so, it just might be worth warrant holders exercising them so they could buy shares at below the then-current price, but to sell them they'd need to be able to be sure the sp was strong enough to withstand the effect of the sells. You know that, so stop trying to imply that the mere existence of warrants is a long-term fool proof source of near or long term capital. Then again, if this company was fool proof you wouldn't be here I imagine.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.365",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-02-09T22:52:28.964714+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261059-viera-10052997",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.264399",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Are you PM in disguise ? Who in  their right mind would buy any company on Aim with only 3 or 4 months cash runway? You sound so so desperate for a rally to sell out !",
          "sentiment": 0.0,
          "engagement": "1,552",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-09T22:52:28.964756+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261050-Rebster4--4601270",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.265221",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rebster408",
          "content": "Its groundhog day again This is a binary bet...and Poky has called it right in the past and I thinks he's spot on again... 201 is older than me!!! place your bets... the wheel is spinning and will stop within the next 8 weeks All will become clear within the next two months...",
          "sentiment": 0.0,
          "engagement": "1,174",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-09T22:52:28.964788+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260920-RayPoint--2206961",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.266008",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Living in fantasy land",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-09T22:52:28.964819+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260857-Notpotal--8800037",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.266824",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "\u201cYou can't go back and change the beginning, but you can start where you are and change the ending.\" \u2013 C.S. Lewis Early in his tenure, Mark acknowledged mistakes had been made \u2014 and while he couldn\u2019t rewrite the past, he could reshape the future. 17 months later, Val is reborn, with money in the bank, a rebuilt team, high calibre assets and a SH base that deserves success after years of one-way support. A few resident historians cling to their preferred mythology, inventing a minimal cash runway because the real picture is too uncomfortable to accept: a cash runway to H2 even without R&D tax credits, additional Inaphaea income, grants or exercised warrants. This is also before the wave of RNS due over the coming weeks. Unlike those posting fiction, Mark has backed his conviction with his own money \u2014 now holding 7% of the company. \u201cWhat matters now is not where we\u2019ve been, but where we\u2019re going.\u201d",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.365",
          "thread_title": "Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-09T22:52:28.964850+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20262049-ratcliff-18525774",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.267621",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Whatever it is you're smoking UXM, it's powerful stuff.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-02-09T22:52:28.964881+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261733-uxm484--3980178",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.268458",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "All lies. Watch the video previously posted. Past management issues but new management outstanding.  Cash until H2 without the add ons. CEO heavily invested over 250k. Negotiating with a major biotech in regards to a deal for CLX001. Lab space is to help progress the assets to eventually get a deal not to make instant revenue. Any research on CLX001 done against a valuation of 2 million and cash burn just over a million would know this is a great opportunity. Brokers only had 20k stock. Hardly lots of stock. Great decision making. Derisking assets with partnership deals.  Which other biotech has so much spending less than 2 million. With warrants at a premium to the current price hopefully no more dilutions.",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.385",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-02-09T22:52:28.964913+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261719-Porky9-17726379",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.269349",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "And just a few reasons why not to believe the BS from the resident rampers here and why you should avoid:- * Lifestyle Business * Ridiculous Admin costs * Continual Raises and continual dilution * More than 20 Raises, 3 lots of 125:1 Consolidation events * business concept never proven * Rented lab space and zero revenue in 15 years * About 8 weeks cash runway left with yet another raise due anytime soon to keep the gravy train going. * if new investors or brokers say enough is enough and call time due to clients continually losing money then its admin and you could lose your entire investment. * materially overpriced as absoluly nothing here to invest in, its the emperors new clothes you are buying. 201 is older than hens teeth, no interest in 15 years and CLX years off and more cash required. Labs meanwhile doesnt know what an invoice is. * Poor decision making, lack of any commercial acumen *No real focus, practically everyone is work from home with multiple jobs. * Short term punts only not a long hold due to above. * loads of stock held for broker fees that will need to be drip fed into anyone buying. In all avoid at all costs unless you like dilution",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.385",
          "thread_title": "Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-02-09T22:52:28.964943+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261507-ratcliff--4064303",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.270143",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "You swine Nomlungu. You've rumbled me.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.41",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-09T22:52:28.964975+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261503-Mr0nions--8853087",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.270906",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mr0nions",
          "content": "Because of this  post, I'm holding position.  Good luck all.",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "0.41",
          "thread_title": "RE: Why invest? \u2013 THE SCIENCE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=058BF091-3235-424B-9C46-FA00ED6BC8D5"
        },
        "ingested_at": "2026-02-09T22:52:28.965007+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261432-mikee_p-46762878",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.271701",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "1 HR. Channel is all ya need.",
          "sentiment": 0.0,
          "engagement": "1,893",
          "price_at_post": "0.395",
          "thread_title": "Easy trade this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=81274FD9-0226-45F3-8CEA-B1F91E33B4A2"
        },
        "ingested_at": "2026-02-09T22:52:28.965039+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261430-nomlungu-10668090",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.272502",
        "source": "LSE_CHAT",
        "data": {
          "author": "nomlungu",
          "content": "People should just ignore Rat... he is just jealous that he does not have the losses to use to reduce his tax liabilities. That 80% drop in the last tax year will have been very valuable for some; I think him moaning around the time that taxes are due for the 2024/25 year is a dead give away. \ud83d\udcc9 \u2757",
          "sentiment": 0.0,
          "engagement": "23,976",
          "price_at_post": "0.395",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-09T22:52:28.965070+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261313-paternos-59925186",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.273388",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "When Mark became CEO, ValirRx was effectively dormant - few assets in play, minimal Board investment and limited vision. He set about a major restructuring: rebuilding the team, reshaping the asset base and above all, resetting the mindset. Fast forward 17 months and Val is reborn. A microcap expanding into developing fields of oncology, yet every action taken has a cost/benefit analysis and timescale consideration. If concluded that a project cannot be monetised early, it is shelved or paused. Commercial decisions overrule all others. Valirx is now plugged into some of the most advanced platforms in modern drug development: \u2022\tpatient avatars (TwinEdge) \u2022\tmicrofluidics/3D tissue culture models (Screenin3D, Ignota & VoxCell) \u2022\trepurposing (Ignota, Altus & Dominion) \u2022\tpersonalised immunotherapy (PredictRx / Dominion) \u2022\tpro-senescence drugs (Dundee / Queen Mary Uni) \u2022\tClickmer technology/HER2 protein (Apis Assay) \u2022\tLMTK3 kinase targeting (StingRay). The most recent evaluation, a 2nd-gen RNA helicase inhibitor (McGill/IRICoR), brings Val into collaboration with major international research organisations. Last year, Mark identified a shift away from animal-testing and moved early to establish capability partners supporting NAMs and cutting-edge AI. Recent US & UK Gov\u2019t regulatory changes now actively favour such platforms with Europe to follow this year. Once again, Val anticipated this trend before much of the market. Meanwhile, the Advisory Board has been upgraded from academics and towards industry experts who can provide insight into Big Pharma priorities and identify new commercial pathways such as in veterinary science - quicker to market while opening a parallel revenue path thru\u2019 comparative oncology, further de risking the route to human oncology. Mark has also added a clause into evaluation agreements whereby if Val decides not to progress an asset eg StingRay, McGill/IRICoR, then Inaphaea retains the data and can still monetise should a 3rd party take the asset forward. Val is no longer waiting for opportunity; it is engineering it.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.385",
          "thread_title": "Why invest? \u2013 THE SCIENCE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=058BF091-3235-424B-9C46-FA00ED6BC8D5"
        },
        "ingested_at": "2026-02-09T22:52:28.965112+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261224-paternos--5191067",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.274229",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "A \u00a33m microcap with a cash runway till H2 even before factoring in R&D tax credits, potential grant funding, additional Inaphaea income or warrant cash now within reach. Outgoings reduced by \u00a3200k PA following a team restructuring last year. Val\u2019s expansion into NAMs and advanced AI tech, supported by strong academic partnerships, aligns directly with revised US & UK gov\u2019t guidelines to reduce animal testing. This positions Val as a front runner for non dilutive grants and innovation funding, with a CEO geared to capitalise on this opportunity. The 1/9/25 RNS confirmed ongoing discussions with several potential partners to progress Cytolytix, including a major pharma. Val owns 60% of CLX with 10% owned by co-inventor, Dr Charles Chen (Senior Scientist at Astrazeneca). Val also has a 54% share of an Ambrose deal potentially worth up to \u00a316m, and a Biobank of 476 PDCs valued at \u00a310k per PDC cell-line upon commercialisation, plus commercial rights entitlement. Valirx has assets in several key cancer indications, all with huge global markets: 201/prostate ($11.3Bn*), CLX (primarily TNBC ($1.5Bn*), ovarian ($2.5Bn*) but also prostate, 301/endometriosis ($1.9Bn**), and 401-Ambrose/pancreatic ($2.9Bn**). Sources: *webinar, **GMI. Several RNS updates are imminent: CLX patents \u201cin coming weeks.\u201d (RNS 1/9/25), Dundee/Queen Mary project (extended to 9/2/26), StingRay (approx Feb \u201926 per Aug video), Blue Ribbon SPV - \u201cSeveral patents envisaged for 201\u201d, and the next evaluation/SPV \u201cimminent with discussions already at a mature stage\u201d. The Omios RNS (3/6/25) stated \u201c\u2026 expected to take up to 12 months. On conclusion of the evaluation, Omios has an option to enter into an Oncolytic Peptide License Agreement to continue using Cytolytix technology.\u201d Yet another potential source of income. In addition, the Val/Dominion repurposing project (teaching an old drug new tricks) has identified 200 FDA approved non-oncology drugs which already have phase 1 clinical data and are showing activity against various cancer PDCs. 10 of these candidates are now being fast-tracked. The median upfront deal size for pre-clinical IND ready assets was $110m in 2025. For phase 2 this increased to $775m. (Dec webinar). For context, Val\u2019s SP exceeded 55p in 2021 with only one key asset (VAL201). Currently, including the repurposing project, Val now has 200+ potential assets plus a valuable Biobank. Also, Mark has restructured evaluation agreements whereby if Val chooses not to progress an asset (eg StingRay, McGill/IRICoR), Inaphaea retains the data and can still monetise should a 3rd party take the asset forward. Multiple monetisation routes now sit across the pipeline, supported by a commercially-savvy CEO who now owns 7% of the company. Valirx \u2013 a microcap with midcap potential.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.355",
          "thread_title": "Why invest? \u2013 FINANCIAL",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=8931CA86-EC8C-43F3-AA7F-54C7D7FD717E"
        },
        "ingested_at": "2026-02-09T22:52:28.965145+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261145-Marty130--4877120",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.274986",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Be good to see the directors buying some of the stock..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "0.355",
          "thread_title": "Directors deals",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=DC2D2A2F-B451-4EEF-B7C8-9C80695D4033"
        },
        "ingested_at": "2026-02-09T22:52:28.965176+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261107-ratcliff--5491223",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.275854",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "UXM - cutting and pasting the same post repeatedly is not convincing, but to humour you I had a listen to the link you have monotonously posted. It's not persuasive or convincing - Starts off about the 'objectives we have set' and 'milestones we're looking to achieve.' Then there's a bit about the group structure - this is rearranging the deck chairs on the Titanic isn't it? They've had more rearrangements over the decades, it's just a distraction now - meetings are the practical alternative to work. The we hear 'The objective is...' and 'If suitable...'  So nothing at all certain. Then he says BC201 and Val301 have 'not been spun out yet, but would benefit from all of the development work undertaken on Val201.' So BC201 and Val301 still of no interest (except maybe on Antiques Roadshow) and if Val201 had even a glimmer of potential it would have done something since it was quietly shelved - was that 6 years ago or 8? It's been stagnant for so long, the rest of the industry has moved on. The he says 'There is strong interest in endometriosis treatments.' True. There's strong interest in a lot of things, but stating a fact doesn't tie it to VAL. 'We have two new evaluations under consideration.' And...? I\u2019ve got a lot of things under consideration, but whether they get any further is often very uncertain. 'The vision is...' - A lot of people have visions, but a vision isn't even a plan. It's a nice idea at best. 'Our strategy is to do this based on identifying the highest quality assets we can find and afford.' That's like saying 'come round to my place for a meal' and when you get there you say 'There\u2019s a tin of Pedigree Chum between the four of us - it was the highest quality I could find on the available budget.' The he's going to have a system which 'allows us to prioritise selection of assets.' How early stage is all this? And no money to do it with.. Next we see \u2018The Team\u2019 but no mention of their salaries. Then a review of last year - no mention of the placings. Talk of last year's cost savings and redundancies - but if you are cutting 200k a year and laying people off, what were you wasting the money on in the first place? Or have you sold your food to pay the heating bill? Then he says 'Our runway through 2026' - sorry - that 'runway' stops in a couple of months without a placing. The 2026 Xmas do is potentially in the Job Centre unless money comes in very soon. Time is money. They seem dangerously short of both. Again.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.355",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-09T22:52:28.965207+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260954-uxm484-77000077",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.276634",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Plenty of news to come at a tiny valuation and likely this month. Cash until at least July that without warrants, revenue, deals, grants. Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-09T22:52:28.965239+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260919-Porky9-71577315",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.277452",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@Notpotalot Nick is a VERY experienced prolific investor. Frankly, i doff my cap to him as he called the trade perfectly in at .25 and out at .40. Beautiful. The Muppets are the traders in on the back of the Zac Mir pump without any research in blind on the dead cat bounce they will get burnt if still holding. As for Stephen and Jaspal at u3% they now dont have to declare BUT IMO they have about 8 weeks to slowly work the sells in to ensure they are out (just holding warrants options) before that next raise drops as they will be diluted to oblivion as sure as night is day. They can only drip sells in slowly to avoid the brokers hammering them at discount. You try selling big volumes of this close to the raise, or at anytime for that matter, you need to do it on a bounce really, sell whilst traders are buying. This is NOT an investment, its a short term punt. The reason its not an investment is because it can't generate revenue (well none in the last 15 yrs anyhow)  and is reliant on raise after raise after raise to maintain lifestyles. As I say, tick tock. Tick tock countdown already started imo.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-09T22:52:28.965269+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261952-Notpotal-20755869",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.278260",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Porky, unlike some holders, I still keep you around for the entertainment value.  Calling Nick and other traders \u2018muppets\u2019 is certainly \u2026.\u201dcreative\u201d. \ud83d\ude00 Jaspal S and Stephen W dipping just under the 3% is nothing more than freeing up a couple of million to trade. There\u2019s no great sell-off and no drama. Most of us aren\u2019t brave enough to risk missing an RNS for the sake of a few hundred quid. Get your 40 winks while you can. Many sleepless nights await over the next few months.   \ud83e\udd71 Pleasant dreams.",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-09T22:52:28.965300+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261804-uxm484-77000077",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.279044",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Plenty of news to come at a tiny valuation and likely this month. Cash until at least July that without warrants, revenue, deals, grants. Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-09T22:52:28.965331+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261539-Porky9--6108824",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.279866",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Err nope Only thing that will bring hard cash into the company of any meaningful amount in the next 8 weeks will be new placing money - sorry Regarding your continual pumps and fluffy updates, jam tommorrow dream fantasy posts, NONE of it can pay the bills now, end of. Anyone with any brains will be working the sells into any mupets trading this that are oblivious to the dire need for cash to keep the lights on and the pending essential discounted placing that has to happen to support the lifestyles here to keep the gravy train going. Tick Tock, Tick Tock",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.35",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-09T22:52:28.965362+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261042-paternos--6163498",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.280667",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "As standard, when Mark did the Dec webinar he emphasised nothing new, \u201cjust meat on the bones\u201d. However, often that meat can be pretty tasty. Blue Ribbon/VAL201 \u2013 \u201csynthesis almost complete\u201d (10m.30s). Then, \u201ca small amount (only \u00a350k) set aside for pre-clinical development of 201, the balance WILL then come from external investment into the asset\u201d (11m.55s). No \u201cMIGHT\u201d in that statement. The minimal outlay confirms that the VAL201 drug package is essentially finalised, and the entire development programme (preclinical \u2192 IND \u2192 partnering) is about to move forward. Mark has already confirmed Val will be diluting the asset, not Val PLC. With patents imminent, it\u2019s a clear signal that Blue Ribbon is not just a corporate shell \u2014 it\u2019s actively progressing VAL201 toward monetisation. Given Val\u2019s recent multi facet RNS style, the imminent update could well bundle new patent status with partnership confirmation. The last significant VAL201 update in 2021 saw the Val SP exceed 50p.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.365",
          "thread_title": "Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-09T22:52:28.965393+00:00"
      },
      {
        "event_id": "SOCIAL-10Jan20261920-Kaeren-40583563",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.281449",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kaeren",
          "content": "All great thx.",
          "sentiment": 0.0,
          "engagement": "10,948",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-02-09T22:52:28.965424+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262133-paternos--2643011",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.646223",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Seven consecutive \u201cblocked\u201d posts on a blue day tells me everything I need to know. LOL The desperation of the naysayers knows no bounds \u2013 and the newsflow hasn\u2019t even started yet. I fear for the sanity of Porky and his parrots over the coming months. With an absolute minimum cash runway into July already confirmed and multiple RNS imminent, Porky could well self-check in to the local abattoir. The lorry reversing toward the sty, isn\u2019t delivering feed. \ud83d\udc37 \ud83e\udee8 \u26a1 \ud83c\udf2d Anyone for a bacon butty or sausage cob?",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.385",
          "thread_title": "The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-09T22:52:28.965455+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261807-Porky9-45780832",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.646670",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@Nick I totally agree with you. If anyone can trade this you can. But I have to hand it to mark, the money just keeps on coming, I mean its shocking really, there is absolutely nothing here to invest in, it really is the emporers new clothes, but he keeps getting the cash and with over 20 raises, what's another one? I still think .15 or .20 but ultimately you would think the brokers would say, hang on a minute you never deliver on anything you say, our clients are losing money off our broker notes to buy, enough is enough but I guess as long as they get their fees they couldn't care less.",
          "sentiment": 0.0,
          "engagement": "7,466",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-09T22:52:28.965486+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261719-RayPoint-60849622",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.647089",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "It does explain all the voices in my head \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-09T22:52:28.965517+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261714-ratcliff--9181187",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.647517",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Viera - are you RayPointer and me as well?",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-09T22:52:28.965549+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261704-viera--6044270",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.647968",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "But why would anyone give this lot any money Porky  ? They earn 100k whilst having other part time jobs. Been 20 years of promises but zero revenue . There will be zero revenue in before April when the next begging bowl comes out . I was at 5pct with Theoremx and that failed . I\u2019m at zero pct with Ambrose ! Anyone holding this as we enter Feb/March needs to see a dr. Any monies raised goes to directors as not enough to make any investments. I will NOT be buying at any price . It\u2019s a shambles . Sorry",
          "sentiment": 0.0,
          "engagement": "1,550",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-09T22:52:28.965579+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261454-Porky9--9202168",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.648402",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "They dont have a pot to pee in, its a phoenix business and frankly if they raise cash it will be for themselves, not to give away to VAL - BE REAL. Would imagine meetings being scheduled by VAL with placing brokers shortly, can't be far off now - my call this time is another \u00a31m at .15 to .20 tops - give them another 5/6 months more gravy train assuming brokers can find more mugs to support the lifestyles.",
          "sentiment": 0.0,
          "engagement": "7,466",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-09T22:52:28.965609+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261440-ratcliff-67633386",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.648817",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "I was asking myouryourself the same question. But I knew that, as did Iyou.",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-09T22:52:28.965641+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261415-RayPoint--4399450",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.649253",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Are these people actually employed by Ambrose? Last time Ambrose received capital investments (as I recall, in the region of 900,000) they trumpeted the fact on their website. Yet, at March last year, they only had 25k in the bank. Subsequent to March last year,  there have been no announcements of further investments. I ask myself (i.e. Rats) how this all adds up.",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-09T22:52:28.965671+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261403-Notpotal-12413019",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.649678",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Nice to see momentum at Ambrose. They certainly are building a very strong team. However, this highlights another positive for Valirx. VAL401 is the result of a reformulation of the anti-psychotic drug, Risperidone into an oncology drug. One solitary repositioned drug has resulted in a potential multi-million deal. No wonder in the webinar Mark said he was excited regarding the Val/Dominion repurposing project. This collaboration has identified approx 200 FDA approved non oncology drugs which are showing anti-cancer against various Inaphaea PDCs. Ten of these candidates are now being fast tracked for deeper evaluation. Mark even mentioned looking to partner the prime repurposing asset this year. Because these compounds are clinically validated and safety de-risked, the probability of progressing to meaningful clinical proof of concept is far higher than in creating oncology drugs from scratch - positioning the Val/Dom alliance for multiple rapid, low cost shots on goal.",
          "sentiment": 0.5,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-09T22:52:28.965701+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261359-ratcliff-38757429",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.650086",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "True O alter ego. He even knows where my investments are. (Or should that be 'our' investments)",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-09T22:52:28.965732+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261356-RayPoint--4476890",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.650503",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "You can't fool uxm, he's so sharp \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-09T22:52:28.965763+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261348-uxm484--6459795",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.650918",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Ratcliffe are you Raypointer? Both invested in Scancell. Both are not invested in Valirx.",
          "sentiment": 0.0,
          "engagement": "1,009",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-09T22:52:28.965793+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261333-ratcliff--2371757",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.651345",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "The number of employees and the financial state is a bit concerning isn't it? They weren't flush in 2024's accounts, and they're worse in the 2025 ones. So back to the question - what are 500,000 odd shares in Ambrose actually worth? Potentially even less than 500,000 Val shares...? https://find-and-update.company-information.service.gov.uk/company/14409383/filing-history",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-09T22:52:28.965824+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261310-RayPoint-16209220",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.651773",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "The reason I ask is that if I look at Ambrose Healthcare on Companies House, I find the same name with the same month of birth: Tobias Adam WILSON WATERWORTH - born October 1964 Spookily, this person only has 1 director appointment - Ambrose Healthcare, the other 21 are missing! https://find-and-update.company-information.service.gov.uk/officers/SAWjapGOj9HbCMsLuSFBZeqVYiU/appointments Does anyone else find this rather strange?",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-09T22:52:28.965855+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261254-RayPoint--2682350",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.652198",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Could this be the CEO of Ambrose Healthcare? https://find-and-update.company-information.service.gov.uk/officers/JzAELIfnpaXPIZjjnhqdRjwB9KM/appointments",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-09T22:52:28.965886+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260857-Rebster4--3207266",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.652606",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rebster408",
          "content": "Probably cos Ambrose only have about \u00a325k in capital and assets in 2025... not a pot to p155 in...",
          "sentiment": 0.0,
          "engagement": "1,174",
          "price_at_post": "0.375",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-09T22:52:28.965917+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260757-uxm484-91331670",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.653034",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "I understand they get a share of Ambrose  not just Val401. News on other clinical compounds increases the value of the shares therefore more valuable than just getting cash for Val401. Valirx will have options to sell some shares initially to get some cash.",
          "sentiment": 0.0,
          "engagement": "1,009",
          "price_at_post": "0.375",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-09T22:52:28.965949+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262226-ratcliff--4455496",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.653624",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Why were Val given shares not cash by Ambrose? What are 576,000 Ambrose shares worth? Can they be sold to raise much-needed cash? How much cash had been raised for Val in the 7 months since that announcement? If it was a deal of any real worth, why did Val have to do a placing a few months later, and how come it's heading towards another one in a matter of weeks on current estimations?",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.375",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-09T22:52:28.965980+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262019-paternos--2712569",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.654069",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "A lucrative VAL401 licensing deal was announced on 20/6/25: \u201c ValiRx will receive 576,000 ordinary shares in Ambrose with clinical and commercial milestone payments to be made to Valiseek totalling a value of up to \u00a316 million plus royalties.\u201d Valirx owns 54% of Valiseek. Ambrose has a pipeline consisting of just TWO products: VAL401 (pancreatic cancer) and Renzapride (cystic fibrosis), both currently at phase 2 clinical. Today, Ambrose announced two further additions to their already impressive team: Dr. Janette Thomas joins as Director of Manufacturing Operations and Wendy Richings-Barrow as Director of Regulatory Affairs. \u201cThese appointments reflect our continued focus on building a world class team to deliver solutions for patients with rare conditions with no approved treatments.\u201d The Ambrose team already had a strong backbone: Chairman, Toby Waterworth has been part of leadership teams in multiple life science companies that have generated close to $1 billion in shareholder value. CEO Dr Hazel Jones was formerly Chief of Staff for AstraZeneca\u2019s Oncology R&D Leadership Team. Chief of Staff Virag Stephens an ex PMO Director at AZN and has strong fundraising expertise while Mike Webb led departments of up to 150 scientists in a 30-year career at GSK. Dr. Nick Meyers has 30 years\u2019 experience as a Program Director. In 2024, Ambrose was acknowledged by its peers when it won the Best Startup Biotech Company Award at the prestigious OBN Awards in London. Since then, it has grown significantly and confirmed it is exploring potential Middle-East listings. One of the partners on their webpage is SEHA (Abu Dhabi Health Services), a subsidiary of Pure-Health the largest integrated healthcare network in the UAE. (total assets $13B). Another partner is listed as Aparito, part of the Eli Lilly group. As Ambrose strengthens its leadership and global partnerships, Valirx is strategically placed to benefit from every milestone achieved on the VAL401 journey.",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.375",
          "thread_title": "The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-09T22:52:28.966011+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261513-paternos--1725294",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.654610",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "\u201cValix is in discussions with several potential partners to progress CytoLytix, including a major pharma\u201d. So, why is Mark, currently in California, continuing to promote the compound so actively both in the UK and overseas? While it\u2019s plausible a major pharma might seek exclusivity, the most realistic outcome is exclusive rights carved by territory, formulation, indication, or even species (human/veterinary)\u2014leaving room for multiple, parallel deals outside that scope. Indication splits are historically used when partners specialise in different therapeutic areas (eg ovarian only). Geographic exclusivity is even more common. The TrX/201 deal eventually failed when Mark attempted to remove Taiwan from the original LOI. The veterinary angle highlighted in recent webinars reinforces that CLX spans markets no single pharma can cover, making a multi partner licensing model far more realistic than a single global licence. There are numerous real world examples of multi partner licensing structures in biopharma: TERRITORY - Immunex (Enbrel) / initially Amgen \u2192 US & Canada rights, then Wyeth (later Pfizer) \u2192 Europe + Rest of World rights FORMULATION - Gilead (Tamiflu) / initially Roche \u2192 Oral formulation rights, then Hetero & Teva, \u2192 sublicenses for additional formulations INDICATION - AstraZeneca (Lynparza) / Merck \u2192 initially Ovarian cancer rights, then subsequently obtained licenses for breast and pancreatic cancers. Each example above shows one originator, no single-party lock in and multiple partners or deals to acquire different rights. With so many variables in play, it is increasingly clear that Valirx is preserving the same optionality for CytoLytix. Mark is still promoting CytoLytix because he is targeting several partners \u2013 not just one. Everything suggests CLX is being shaped as a multi deal platform, with the first handshake simply opening the monetisation cycle -",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.385",
          "thread_title": "CLX - multi deal structure",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D1488F3A-09F4-41C4-B45B-AF908B85E267"
        },
        "ingested_at": "2026-02-09T22:52:28.966042+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261459-Notpotal--6712228",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.655026",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Some clever trading going on here \u2013 those selling at 0.37p will soon be able to buy back at 0.39p. \ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "RE: Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-02-09T22:52:28.966074+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261329-Porky9-72267893",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.655478",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@PP Yes, and as long as the rain holds off should be able to get some golf in on expenses. Who needs Zoom and Teams when you can have a nice all expenses trip to the US. Lovely. Keep pumping it, only a few weeks now to go before next placing @notpotatlot Only Update you will get shortly that isn't fluff, will be the placing news or the next 125:1 consolidation event which has to be well over due now. Keep ramping it though, the gravy train needs to stay on the tracks, there are lifestyles here that need to be maintained.",
          "sentiment": 0.0,
          "engagement": "7,466",
          "price_at_post": "0.385",
          "thread_title": "RE: Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-02-09T22:52:28.966116+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260943-paternos--4362606",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.655913",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Mark re JPM in San Fran -  \u201cI have meetings lined up with our partner Omios Biologics so looking forward to catching up with Aldo Pourchet (CEO).\u201d In the Omios RNS (3/6/25), the evaluation was \u201cexpected to run up to 12 months, after which Omios can exercise its license option to continue using Cytolytix technology.\u201d Across both the June and Dec webinars, Mark emphasised CLX synergy with the Omios virus for potential to treat canine HSA, a clear signal that Omios sits firmly in the frame for a CLX licence. Valirx\u2019s revamped Advisory Board reinforces this direction, now with a notable weighting toward veterinary oncology and commercial expertise. The composition reflects a deliberate strategy to position CLX across both human and animal oncology. When your advisory structure is rebuilt around people who understand canine cancers, comparative oncology, and veterinary commercial pathways, it becomes clear Valirx is preparing for licensing routes across both human and veterinary markets. As a co-founder of VolitionRx, Mark transformed a human cancer test into a canine diagnostic test (Nu.Q) before negotiating a licencing deal with Heska for $26m. What price a cure? Human and veterinary oncology operate in separate regulatory and commercial channels. Most major pharmas, inc. AZN, Roche, GSK, AbbVie do NOT have any vet divisions. Even those historically involved have spun off their animal health units (Pfizer \u2192 Zoetis, Eli Lilly \u2192 Elanco). By envisaging veterinary opportunities for CLX, Mark is implicitly confirming the compound won\u2019t be a one partner asset; the split infrastructures required make multiple CytoLytix deals the only realistic outcome. GLA, DYOR, AIMO",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.385",
          "thread_title": "Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-02-09T22:52:28.966151+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261543-Notpotal--8892446",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.656343",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "I notice a 71430 buy at 15.14 and a similar sell 4 mins later for a \u00a321 loss. Great to see Porky has started trading again!  \ud83e\udd23\ud83e\udd23\ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "Welcome back, Porky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=FE350133-0204-48E9-9785-7F80407B3421"
        },
        "ingested_at": "2026-02-09T22:52:28.966182+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261534-Notpotal-55028569",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.656760",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Val is obliged to RNS as it a change to No. shares in issue. Hardly the company\u2019s fault if a holder sees such value that he wants to buy above the current SP. Mind you, I\u2019m expecting a TR1 tomorrow to confirm Mark\u2019s holding has increased by 80,000 shares. \ud83e\udd23 If this is the reaction to \u00a3400 of warrants, heaven help Porky\u2019s groupies when the next material RNS arrives.  \ud83e\udee8 \ud83d\ude28 \ud83d\ude22\ud83d\ude2d",
          "sentiment": 0.5,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-09T22:52:28.966212+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261535-viera-24221364",
        "event_type": "social_post",
        "date": "2026-02-09T22:52:21.394292",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "I do loveya notpot. I post replies to you and pp hence 67 posts ! I\u2019ve also got repetitive syndrome I apologise . I do laugh at your posts as Val has zero revenue ,huge cost base ,years of years of promises which all have been broken . A loss making lab and a CEO  who pays staff to contribute zero to the bottom line . It\u2019s a shambles. I\u2019m absolutely flabbergasted that investors continually donate money to employees salaries when they produce FA. You couldn\u2019t make it up my friend . Have a great weekend Let\u2019s hope it stops raining Xxxx",
          "sentiment": 0.0,
          "engagement": "1,556",
          "price_at_post": "0.345",
          "thread_title": "RE: Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-10T22:27:47.940342+00:00"
      },
      {
        "event_id": "SOCIAL-Today1535-viera-24221364",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.574183",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "I do loveya notpot. I post replies to you and pp hence 67 posts ! I\u2019ve also got repetitive syndrome I apologise . I do laugh at your posts as Val has zero revenue ,huge cost base ,years of years of promises which all have been broken . A loss making lab and a CEO  who pays staff to contribute zero to the bottom line . It\u2019s a shambles. I\u2019m absolutely flabbergasted that investors continually donate money to employees salaries when they produce FA. You couldn\u2019t make it up my friend . Have a great weekend Let\u2019s hope it stops raining Xxxx",
          "sentiment": 0.0,
          "engagement": "1,556",
          "price_at_post": "0.345",
          "thread_title": "RE: Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-10T22:27:47.940390+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262209-Notpotal-23116733",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.574764",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Very amusing to see the uninvested have such strong views on Val. Such a shame Porky didn\u2019t have the same consideration while sucking thousands of gullible punters into other investment disasters. Perhaps considering compensating all those innocents dragged in? At this point, Porky will probably give another history lesson but, while Val is still trading and doing quite nicely, no news on 4D or HARL reinstatement yet. Meanwhile back in the real world - 40 separate projects ongoing at Inaphaea, \u00a3200k pa cost savings, money in the bank into H2 with R&D tax credits expected but as yet unconfirmed, Inaphaea income excluded and grants applications pending (as confirmed by Prof Mark\u2019s statement, not Prof Porky\u2019s Santa wish\ud83e\udd23), partnering planned for CLX, 201, and the lead repurposing asset \u2013 all of which will further reduce costs, tailored for grants under new guidelines, another evaluation and SPV imminent (already ring-fenced), the recent McGill Univ & IRICoR  evaluation is the first with global players, multiple RNS updates due and an SP bouncing around in the mid-0.30s even before the RNS news flow starts. Understandably upsetting for the pink one. Having devoted the last 4 years and thousands of posts hoping to destroy Val, a new CEO comes in and undoes all that work in less than 18 months. Porky\u2019s partner (in crime?) Nick, has made a small fortune trading the share over the years and still ONLY posts on this share \u2013 check history - 67 consecutive and counting. He obviously sees great value here, despite all his apparent bed-wetting. The way Porky and Nick tag team this board, you\u2019d swear they were coordinating over the same cup of tea. \ud83e\udd14 Happy dreams, you two! \ud83d\ude34",
          "sentiment": 0.5,
          "engagement": "81",
          "price_at_post": "0.345",
          "thread_title": "RE: Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-10T22:27:47.940430+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261739-viera--5303847",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.575230",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Pp is pm Paid to post on LSE Until the next  raise (I think c April ) Then he goes missing as he\u2019s embarrassed . Then changes  his name and rinse repeat . He has no humility . Been bullish since 30p but holds no shares so what does he care ,has lost all his readers 98pct of their hard earned cash. Shambles",
          "sentiment": 0.0,
          "engagement": "1,556",
          "price_at_post": "0.345",
          "thread_title": "RE: Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-10T22:27:47.940464+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261450-Porky9-68260816",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.575649",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@pp - nobody gives a **** about posts on linked-in - unless you are looking for a job or trying to recruit someone from a competitor that is all it is good for - a recruitment tool. the guy needs to stop wasting his time posting crap on social media and get some bloody focus on the important issues and then publish some proper update news via the rns service. talk about lack of perspective. this is exactly what i am talking about - zero commercial acumen - sorry",
          "sentiment": 0.0,
          "engagement": "7,471",
          "price_at_post": "0.345",
          "thread_title": "RE: Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-10T22:27:47.940497+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261351-paternos-50278860",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.576063",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Inaphaea has just released a short video re the collaboration with the Open University re prostate cancer.  Funded by a Knowledge Transfer Voucher (RNS 7/8/25) this is yet another example of non-dilutive funding to progress assets using cutting edge technology that would otherwise be beyond the company\u2019s reach. https://lnkd.in/eXGeSPQq",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.345",
          "thread_title": "Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-10T22:27:47.940529+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20262042-paternos-17136235",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.576513",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "\u201cImportant day in the calendar for patients, families and those of us working in the sector. The UK government has announced a directive to increase 5 year survival for cancer patients to 75% by 2035. This will take a a huge effort in terms of screening for early detection and diagnostics to allow curative surgery, improvements in surgical technique, such as robot assisted approaches and developments of affordable, accessible therapies. VALIRX PLC and its subsidiaries, including Inaphaea BioLabs, Cytoltix and Blue Ribbon Bio are working hard to play our part in the discovery and development of next generation therapies. These include our novel oncolytic peptide program (targeting Triple Negative Breast Cancer), a first in class, non-genomic androgen receptor signalling inhibitor and a series of repurposed drugs from Inaphaea BioLabs 3K screen program. We work closely with leading academic institutions to source, assess and develop cutting edge approaches with pan cancer potential. Our latest deal is with McGill University and IRICoR for a second generation RNA Helicase inhibitor ( https://lnkd.in/ei5xwSpx) Big shout out to our dedicated Inaphaea BioLabs team including Head of Scientific operations Melissa Barr, Lead Scientist - Translational Biology and Academic Collaboration, Amelia Hatfield and Lab tech Dylan Jones as well as VALIRX PLC's Director of Research, Michelle B.. There are currently 40 projects running in the labs at Inaphaea BioLabs covering our group therapeutic programmes and development of our non-animal based, New Approach Methodologies (NAMs) for drug screening with our unique bank of Patient Derived Cell models. We couldn't do this without the support of our partners including TwinEdge Bioscience (Digital twin/Patient Avatars), ScreenIn3D (Lab on a chip platform), VoxCell (vascularised 3D tumour models), Spanios (organoid models), BioReperia (zebrafish models), Ignota Labs (in silico tox screening) and development partner Dominion Biotech as well as our shareholders. It's been a hectic 18 months since I took over as CEO but we've focussed on refining our strategy, identifying high quality assets, building a strong team and expanding our capability partner network. We have a some major milestones set for 2026 and we look forward to being part of the solution and helping deliver patient benefits.\u201d",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.35",
          "thread_title": "Today\u2019s Linkedin update from Mark E",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E9D6BAF9-FFFC-4611-82EB-4E1B71731FB2"
        },
        "ingested_at": "2026-02-10T22:27:47.940563+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261943-ratcliff-72927070",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.576919",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "That's the way - cut and paste some good long pieces in the hope of burying anything that doesn't fit the agenda.",
          "sentiment": 0.0,
          "engagement": "11,411",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-10T22:27:47.940597+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261832-paternos--3500886",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.577382",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Grant schemes are increasingly geared towards small companies - when it comes to eligibility, size truly matters. Recent UK oncology research grants to SMEs reflect sustained investment in cutting edge cancer research, with Innovate UK and the Biomedical Catalyst programme providing much of the funding. Recent awards to UK microcap/small biopharmas include: Momentous Therapeutics Ltd (immunotherapy) - \u00a32m grant Theolytics Ltd (ovarian cancer therapy) - \u00a32m Mestag Therapeutics Ltd (immunotherapy) - \u00a31.5m Revolver Therapeutics Ltd (peptide therapy) - \u00a3550k Epitopea Ltd (breast cancer stromal cells / immunotherapy) - \u00a3500k VacV Biotherapeutics Ltd (oncolytic viruses) - \u00a3500k Antikor Biopharma Ltd (ovarian immunotherapy) - \u00a3500k The above awards show clear emphasis on immunotherapy, peptide based therapeutics, and oncolytic virus platforms. Val\u2019s work not only aligns with these priority areas but also extends into difficult to treat cancers such as pancreatic, ovarian, triple negative breast, and prostate \u2014 indications where new therapeutic approaches are urgently needed. This strengthens Val\u2019s fit within the priority areas repeatedly backed by UK grant bodies. The grants aren\u2019t handouts; they\u2019re strategic investments in the UK\u2019s future. A successful cancer therapy can deliver multi billion pound global sales and position the UK as a leader in next generation oncology. Regulators are now actively encouraging NAM adoption and funders are rewarding small oncology-focussed companies that have strong academic links. Valirx is exceptionally well-positioned to secure substantial grants, extend the cash runway and reinforce financial stability. GLA, DYOR",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-10T22:27:47.940630+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261827-paternos--4341545",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.577808",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "To all the green bar brigade out there, you will get zero engagement from me. I have no desire to convert you and history lessons really don\u2019t interest me. Feel free to post your drivel as all I can see is 6 consecutive green \u201cThis message has been filtered, please adjust your filters to view\u201d. Han Solo couldn\u2019t land a helicopter on your imaginary runway. \ud83d\ude01 \ud83d\ude01 \ud83d\ude01 To those actually invested, whether traders or otherwise, with all the news pending, the coming weeks and months are likely to be transformational. GLA, DYOR",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-10T22:27:47.940661+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261740-viera-58036019",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.578232",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Grant could pay the 100k we pay to our BDM who organises ME trips abroad and placings . Both been a resounding success ! @shambles Paternoster aka PM will go into ramp mode now as we approach QTR 2 and the inevitable begging bowl comes out .",
          "sentiment": 0.0,
          "engagement": "1,556",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-10T22:27:47.940698+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261735-ratcliff--7727969",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.578647",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Probably thinking like Pan Am did - the only state airlines that never made a loss, they recorded a 'negative profit.' Maybe he's talking 'negative growth.' I'm sure he'll elaborate on his claim pretty soon and to everyone's satisfaction anyway.",
          "sentiment": 0.0,
          "engagement": "11,411",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-10T22:27:47.940732+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261729-RayPoint--8624805",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.579062",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Well put Rats. The other sentence I take pater to task on is: \"The combination of Mark\u2019s grant winning experience and the UK\u2019s revised grant landscape creates a clear opportunity for Valirx as it enters its next phase of growth.\" Pater, pray tell us about Valirx's previous phases of growth.",
          "sentiment": 0.0,
          "engagement": "5,087",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-10T22:27:47.940752+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261605-ratcliff--1828327",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.579478",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "To be fair RP, applying for grants is a very sensible thing to do. However there must be an element of due diligence and examination of the company applying, and somewhere in the paperwork there will probably be a section which asks 'What would the grant be used for?' This is where the potential donor writes something like 'to accelerate the development of our compound XYZ' or 'to fund the production of our drug to use in the imminent 500 patient Phase 3 trial.' If the box reads 'to stave off imminent insolvency and to avoid another placing' or 'to pay salaries, expenses and bonuses' I imagine the progress of the application tends to grind to a halt.",
          "sentiment": 0.0,
          "engagement": "11,411",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-10T22:27:47.940770+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261408-RayPoint-58774642",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.579907",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Just looking at the first company on your list i.e. Momentous Therapeutics Ltd (immunotherapy) - \u00a32m grant I notice that they have a world-renowned scientist on their BOD. This may go some way to explaining the grant they received. That plus the cutting edge research they are undertaking on the immune system. Here he is: https://www.meduniwien.ac.at/web/en/ueber-uns/news/2025/news-in-june-2025/christoph-huber-receives-german-cancer-aid-award/",
          "sentiment": 0.0,
          "engagement": "5,087",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-10T22:27:47.940788+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261132-Porky9-81544200",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.580333",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "So you are keeping everything crossed that some free grant cash will land in the next couple of weeks to stave off the discounted placing. just incredible really that the focus is on how to get free grant cash to keep the gravy train moving forwards. How about a focus on making the business viable - now that would be refreshing. In all honesty, i would not award this business grant money to waste, it doesnt need it. They have an endless supply of free money from continual discounted placings on the AIM. Any grant money IMO should only go to ground breaking innovations, small private biotechs that have no means to raise cash easily not to this lot to indirectly get spunked up the wall on jollys aboard and ridiculous admin and bonus costs. This next placing will be interesting for sure; a) can he pull it off yet again or will brokers call time on it, b) will the support be out there c) how much of a beating can existing long term holders take whilst the business fails to deliver on its pledges. IF he gets it away, yet again, the discount has to be brutal surely; .15 to .20 ?",
          "sentiment": 0.0,
          "engagement": "7,471",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-10T22:27:47.940806+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261005-paternos--3500886",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.580795",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Grant schemes are increasingly geared towards small companies - when it comes to eligibility, size truly matters. Recent UK oncology research grants to SMEs reflect sustained investment in cutting edge cancer research, with Innovate UK and the Biomedical Catalyst programme providing much of the funding. Recent awards to UK microcap/small biopharmas include: Momentous Therapeutics Ltd (immunotherapy) - \u00a32m grant Theolytics Ltd (ovarian cancer therapy) - \u00a32m Mestag Therapeutics Ltd (immunotherapy) - \u00a31.5m Revolver Therapeutics Ltd (peptide therapy) - \u00a3550k Epitopea Ltd (breast cancer stromal cells / immunotherapy) - \u00a3500k VacV Biotherapeutics Ltd (oncolytic viruses) - \u00a3500k Antikor Biopharma Ltd (ovarian immunotherapy) - \u00a3500k The above awards show clear emphasis on immunotherapy, peptide based therapeutics, and oncolytic virus platforms. Val\u2019s work not only aligns with these priority areas but also extends into difficult to treat cancers such as pancreatic, ovarian, triple negative breast, and prostate \u2014 indications where new therapeutic approaches are urgently needed. This strengthens Val\u2019s fit within the priority areas repeatedly backed by UK grant bodies. The grants aren\u2019t handouts; they\u2019re strategic investments in the UK\u2019s future. A successful cancer therapy can deliver multi billion pound global sales and position the UK as a leader in next generation oncology. Regulators are now actively encouraging NAM adoption and funders are rewarding small oncology-focussed companies that have strong academic links. Valirx is exceptionally well-positioned to secure substantial grants, extend the cash runway and reinforce financial stability. GLA, DYOR",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.35",
          "thread_title": "UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-10T22:27:47.940824+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260807-paternos-51647980",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.581218",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Many of Mark\u2019s presentations have highlighted the potential of grant-funding, with the 14/10/25 RNS confirming a \u00a3250k award. This followed a KTV Open Univ award only 2 months earlier and Mark has stated further grant applications are pending. The Inaphaea RNS (18/9/25) on the repurposing top10, noted \u201c\u2026 discussions with potential licensees as well as an application for non-dilutive grant funding to support further development of these and other assets\u201d. In addition to ongoing partnering discussions, CytoLytix updates invariably reference grant opportunities. As MD of OncoLytika, Mark has a strong history of securing significant grants, including Eureka Eurostar funding, demonstrating a proven ability to win competitive international grants. Recent changes to UK and int\u2019l grant frameworks \u2014 including the UK\u2019s modernised Official Development Assistance (ODA) strategy, refreshed criteria, and new SME friendly collaboration rules \u2014 have opened funding routes that previously excluded early stage biopharma companies. These shifts prioritise oncology projects with demonstrable patient relevance, human relevant New Approach Methodologies (NAMs), and academia/SME partnerships, all of which align directly with Val\u2019s revised operating model. The combination of Mark\u2019s grant winning experience and the UK\u2019s revised grant landscape creates a clear opportunity for Valirx as it enters its next phase of growth.",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.355",
          "thread_title": "The New Grant Landscape",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=2EC60BA4-C275-47D5-901A-D8BA32B59D52"
        },
        "ingested_at": "2026-02-10T22:27:47.940841+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261811-viera-32095511",
        "event_type": "social_post",
        "date": "2026-01-30T22:38:35.634037",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "You sold the spike brilliantly Stephen . Knowing we have had no announcements and another year of zero revenue . You and porky have called it here . What do the directors get paid for here exactly ? Shambles . The BOD needs strengthening .",
          "sentiment": 0.0,
          "engagement": "1,553",
          "price_at_post": "0.35",
          "thread_title": "RE: Ambrose Q1 Newsletter - FYI",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=DD644FF4-EB58-4811-9E0F-61E17204B69A"
        },
        "ingested_at": "2026-02-10T22:27:47.940868+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261626-Uncanny--3935543",
        "event_type": "social_post",
        "date": "2026-01-30T22:38:35.634577",
        "source": "LSE_CHAT",
        "data": {
          "author": "Uncanny",
          "content": "Ambrose Healthcare | 2025 Highlights and What\u2019s Ahead in 2026 Dear Colleague / Partner, As we begin 2026, we would like to share a brief reflection on the past year at Ambrose Healthcare and outline what lies ahead in delivering its mission, to bring new therapeutics to rare disease patients who currently have no approved drug treatment. Our last update was shared in October 2025. Since then, meaningful progress has been made across our programmes, partnerships, and team, all in support of our mission to bring treatments to patients living with rare and underserved conditions. 2025 at a Glance During 2025, Ambrose focused on building strong scientific, operational, and partnership foundations to support the next phase of development: Continued preparation for the Renzapride Phase 2 trial for the treatment of the Gastrointestinal Manifestations of Cystic Fibrosis (GMCF), including regulatory planning and UK clinical engagement Exercised the licensing option for VAL401, securing global rights for development and commercialisation for treatment of cancers. 20% of cancers are classified as rare diseases. Ambrose is focusing initially on development for the treatment of pancreatic cancer Strengthened leadership, governance, and delivery capability Expanded engagement with clinicians, researchers, and funding partners across the UK and internationally Much of this work took place behind the scenes, laying the groundwork for accelerated progress in 2026. Scientific Leadership We are pleased to be working closely with Professor Bu Hayee, Kings Hospital, London who oversees the GMCF treatment centre for the Southeast of England and is supporting Ambrose as a Scientific Advisor for development of Renzapride for GMCF, providing valuable clinical insight as the programme progresses. We were deeply saddened by the passing of Professor Brian Feagan during 2025. Professor Feagan was internationally respected for his leadership in clinical trial design and execution. His early engagement with Ambrose and belief in rigorous, patient-centred development left a lasting impact on our work and thinking. Looking Ahead to 2026 In the year ahead, Ambrose Healthcare will focus on disciplined execution and collaboration, with priorities including: Advancing Renzapride toward initiating its Phase 2 study Preparing VAL401 for Phase 2 clinical development Pursuing investment as well as public and charitable grant funding, including a recent formal invitation to submit a major UK grant application for Renzapride Continuing to build trusted partnerships with clinicians, academic groups, and research organisations These activities reflect Ambrose\u2019s commitment to capital-efficient development and strong alignment with the UK life sciences ecosystem. Planning Named Patient Supply We are also planning to initiate Named Patient Supply (NPS) activities. Named Patient Supply enables access to Good Manufacturing Practice-manufac",
          "sentiment": 0.0,
          "engagement": "3,308",
          "price_at_post": "0.35",
          "thread_title": "Ambrose Q1 Newsletter - FYI",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=DD644FF4-EB58-4811-9E0F-61E17204B69A"
        },
        "ingested_at": "2026-02-10T22:27:47.940897+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261709-Porky9-88443923",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.373661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "What, do you think he is going to release news of the placing already, possible but they normally leave it right until the death, so proabably a few more weeks yet but you never know, you could be right.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.355",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-10T22:27:47.940915+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261448-Notpotal--6676979",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.374477",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Is that a Friday RNS I can smell.... Or has Porky had an accident? \ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.35",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-10T22:27:47.940934+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262254-viera--2936059",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.375315",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Pm changed his name to pp It\u2019s basically ME copy and paste . As he said ME has produced one RNS in months . We all know what the next RNS of note will be . ME needs to cut costs further and do something with 201. Good luck all.",
          "sentiment": 0.0,
          "engagement": "1,552",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-10T22:27:47.940952+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261720-RayPoint--6429833",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.376112",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Pater It's funny to see, in a thread entitled \"The Ambrose Dream Team\" and started by yourself , that neither the Dream Team nor VAL401 get a mention in your latest post.",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-10T22:27:47.940971+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261632-ratcliff--1273855",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.376907",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "'When the SP inevitably hits 1.6p plus there will be further buying pressure as placees exercise their 1.3p warrant options. Some will then sell for a quick profit but by then the SP will be in the 2p range. All this without the flush of positive news expected over the coming months.' Sounds good? Sounds worth buying into? Well actually it's a paternostpauper quote from 16th January 2025. But the share price then was 0.875, sliding gently down another post-placing ski-slope graph.  And what's the biggest news since then? Oh yes, another placing - predicted by P9 and derided by PP. Until it happened. On past history Porky's predictions seem a pretty reasonable bet. PP's posts are just reformulated bin dippings - he might as well just copy and paste on a pumping merry-go-round.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-10T22:27:47.940992+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261512-Porky9-70419867",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.377717",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Always entertaining, like watching fantasy island @PP is our very own Mr Roarke and @nopot is Tattoo.  Not sure who @uxm plays, probably the aircraft pilot as he only turns up to share the fantasy once a week or so. The gap will be between .15 and .20 as that will be where the placing shares land, thats of course if ME can pull it off again. Jury out this time.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-10T22:27:47.941024+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261503-paternos--1368612",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.378553",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Good post UXM.  Always entertaining to see trader Nick post again - his 63rd consecutive LSE post - and every one on Val. He might as well hang up a banner \u201croll up, roll up \u2013 bargain of a lifetime!\u201d \ud83e\udd23\ud83e\udd23\ud83e\udd23 Val has issued just one positive RNS since the placing, yet the SP has climbed 67% from those 0.23p lows. Even with 2 major holders dipping below the 3% threshold to facilitate some short-term trading, the SP still hovers near 0.4p. Every day that passes without an RNS increases the likelihood of one the following day as multiple programs mature: CytoLytix patent updates, formulation decisions, Blue Ribbon/VAL201 partnering (by diluting the asset, not VAL plc), 3k repurposing update (top candidate partnering?), further grant updates (ME has strong history), next evaluation and SPV (confirmed in webinar), Inaphaea income (PredictRx/ PDC sales), updates on the Dundee/Queen Mary pro-senescence project and StingRay (decision imminent). The motherlode remains early partnering/grant funding for CLX, a 2026 milestone confirmed by the CEO in the recent webinar. As the June anniversary nears, Omios have to decide whether they wish to exercise their option of a license agreement to continue using CLX tech. It looks promising as both Mark and Omios CEO Dr Aldo Pourchet had meetings arranged at the JPM in San Fran. More than once, Mark has referenced the Omios virus as an entry point to veterinary oncology due to its potential for treating canine HSA, while Dr Pourchet posted: \u201cWe are targeting triple negative breast cancers (CLX primary indication), all of which have the biomarker that makes them susceptible to our therapy. It\u2019s our most advanced program\u201d (Oct NYU interview). With multiple CytoLytix licenses up for grabs, Omios look set to start the ball rolling. The decisive factor which totally undermines the detractors\u2019 fearmongering is the financial position: a cash runway that extends till H2 excluding warrant income, R&D tax credits, grants, or additional Inaphaea income. That completely negates any March/April placing argument. Mind you, naysayers never let a few facts ruin their narrative. GLA DYOR",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-10T22:27:47.941043+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20261956-uxm484-32500617",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.379412",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Watch the video. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025 Chart analysis shows a nice gap at 1.4p. Past management issues but new management is outstanding.  Cash until H2 without the add ons such as grant money, revenue and warrant money. CEO heavily invested over 250k. Negotiating with a major biotech in regards to a deal for CLX001. Lab space is to help progress the assets to eventually get a deal not to make instant revenue. Any research on CLX001 done against a valuation of 2 million and cash burn just over a million would know this is a great opportunity. Great decision making. Derisking assets with partnership deals. Which other biotech has so much and spending less than 2 million. With warrants at a premium to the current price hopefully no more dilutions. Expecting significant news in the coming days/weeks. Tiny valuation and cash burn is tiny with assets of significant value.",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-10T22:27:47.941061+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20261515-viera-60764529",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.380239",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Problem my friend is ME hasn\u2019t got a proper hold of Costs paying a non BOD member and non scientist 100k  paying best mates that produce zero revenue is a disgrace . It shows a lack of respect for shareholders . Where are all the promised lab contracts . ME has surrounded himself with \u201cyes \u201c men. Shame he ousted Adrian as he had the commercial nous to make a difference . Adam also lost interest as was treated so badly by the BOD. I predict more confetti in April /May . Porky knows this co better than anyone . If he and Adrian joined the BOD I would consider investing but I\u2019ve lost faith in the current BOD who promise the world and deliver FA. Deliver some revenue asap or step down .",
          "sentiment": 0.0,
          "engagement": "1,552",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-10T22:27:47.941079+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20261416-ratcliff--7298681",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.381020",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Interesting that you've posted notgotalot - in December you distinctly said \"I\u2019ll take some time out and won\u2019t be back until the next decent RNS.\" Presume you've restarted posting because you've lost hope in there being a decent RNS.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-10T22:27:47.941112+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20260843-Notpotal--3777844",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.381814",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "each conspi****** on here is in self-denial mode - a mechanism where a person ignores or distorts reality to avoid anxiety and stress. they refuse to accept the situation simply because it doesn\u2019t support their agendas and so resort to posting fiction. whether it is by inventing a 50% lower cash runway, alleging fictitious staff at ambrose, claims of ceo golf jollies and overpaid team members or alleging lse posters are on the val payroll. desperate posts by the uninvested are now treated with the contempt they deserve. just when you think they\u2019re as low as they can get \u2013 they pick up a spade. by resorting to deception, they have lost any remaining credibility they may have had, while each day news edges closer.",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-10T22:27:47.941145+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20262102-ratcliff--5020986",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.382589",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "It would also be interesting to know why the posting of relevant financial facts from those observing is described as 'panic.' Surely the only panic is among those trying to snare the naive with fantasy predictions so they can get out fast with a profit - and now realising that the supply of gullible newbies is drying up.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-10T22:27:47.941174+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261925-RayPoint-86671882",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.383379",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "So what's the crack, pp? I would be interested to know your view on how Ambrose are paying salaries to the Dream Team without having any money in the bank",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-10T22:27:47.941192+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261832-paternos-54589789",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.384211",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "@  spantrout - Great call. Valirx - 10m,50s in. \u201cA lot of return on that one!....DYOR but in all probability, if it\u2019s going to have some game-changing news, then \u2026.that would be 1.4p.\u201d Not sure of the news he is he is referring to? Maybe the new patents, partnering (CLX,201), repurposing top 10, StingRay, further grants, or expansion into veterinary oncology? Possibly it\u2019s the the 2nd evaluation and new SPV or even the CEO buying 7% of the company. I suppose it could be that Mark E has recently been on stage presenting alongside some of the biggest names in pharma, or the fact the CEO has a history of delivering success (Nu.Q test sold for $26m). !.4p is an interesting SP \u2013 that would not only see the 0.5p warrants in play but also the 1.3p warrants, easily extending the runway into 2027. Mind you realistically, a few easily pleased would exit for a quick 300%+ profit. I guess the uninvested posting day and night trying to supress the SP hasn\u2019t gone unnoticed either. Karma can be a wonderful thing! Happy days DYOR, GLA.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.385",
          "thread_title": "RE: Coverage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=1C527045-FD63-41D2-B4BE-ED55425FC93C"
        },
        "ingested_at": "2026-02-10T22:27:47.941210+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261714-Notpotal-75772725",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.385010",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "pp previously purged porky\u2019s parrots\u2019 pack of preposterous posts pedalled in panic, perhaps predictably. i promptly prepared a poem for porky to peruse at his pleasure. pundit porky posted a pack of pathetic, poorly proven poppy****. a pack of pathetic, poorly proven poppy**** pundit porky posted. when pundit porky posted a pack of pathetic, poorly proven poppy****, perhaps he\u2019ll point to proof behind the pathetic poppy**** pundit porky posted?",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.385",
          "thread_title": "Porky\u2019s Peddled Pile of Piffle",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=93B08DEA-F499-4237-AF7E-B5143BC8D67E"
        },
        "ingested_at": "2026-02-10T22:27:47.941228+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261625-spantrou-22130532",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.385791",
        "source": "LSE_CHAT",
        "data": {
          "author": "spantrout",
          "content": "Https://youtu.be/HrYMuqPFA20",
          "sentiment": 0.0,
          "engagement": "13,977",
          "price_at_post": "0.385",
          "thread_title": "Coverage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=1C527045-FD63-41D2-B4BE-ED55425FC93C"
        },
        "ingested_at": "2026-02-10T22:27:47.941247+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261403-Porky9-48123788",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.386613",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@PP You really are a busted flush, its like groundhog day:- Pump the boards with nonsense about million dollar licensing deals, how the cash is well managed and will last many months more than it does, how there will be all these marvelous license deals lined up, exaggerate the interest and how fantastic it all is. Then RNS drops,  placing at discount issued, you vanish for a few weeks, let the dust settle and then you pop up again and repeat the above. I totally get those in the business want the gravy train to continue, lifestyles at risk but have you no conscience that small investors that may not earn the sort of money the board here gets here for these cushy  work from home jobs, are going to lose their hard earned cash being sucked into this? Its morally not right. Next RNS will be the next discounted placing, can't be far off now, a few weeks at most imo.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-10T22:27:47.941268+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261529-RayPoint--5550222",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.157704",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "I hear that green fees are pretty steep in California",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-10T22:27:47.941299+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261434-ratcliff-90773554",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.158130",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "No problem RP - I'm wondering who paid 0.50 for a few shares worth about 25 percent less from the start, but I suppose 400 quid pays for the week's teabags and digestives.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-10T22:27:47.941318+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261413-RayPoint-20423150",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.158544",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Sorry Rats. I misinterpreted your post.",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-10T22:27:47.941335+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261412-RayPoint-58436062",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.158961",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "\"Probably about 450 quid...\" Rats, stop ramping! The gross proceeds were \u00a3400",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-10T22:27:47.941353+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261357-spantrou-45130311",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.159474",
        "source": "LSE_CHAT",
        "data": {
          "author": "spantrout",
          "content": "\u00a39.99 for rns",
          "sentiment": 0.0,
          "engagement": "13,977",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-10T22:27:47.941381+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261311-ratcliff-79947604",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.159890",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Probably about 450 quid...",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-10T22:27:47.941406+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261216-steve196-59940861",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.160315",
        "source": "LSE_CHAT",
        "data": {
          "author": "steve196",
          "content": "How much does it cost to release an RNS just for \u00a3400 of warrants?",
          "sentiment": 0.0,
          "engagement": "2,761",
          "price_at_post": "0.385",
          "thread_title": "Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-10T22:27:47.941436+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261935-uxm484--7796627",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.160734",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "No, but the holders all want the warrants exercised so we can do a 10 bagger in 12 months without a fund raise. For me i am really happy here with  the progression. We are definitely early in a news rich periods where all the negative posters are posting overtime and are only posting as they missed out on the last fundraise hoping for an even lower price. We will likely get a few meaningful RNS very soon. Brakes are now off\u2026",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.36",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-10T22:27:47.941455+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261222-Notpotal--7224842",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.261915",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "\u201cYou sound so desperate\u201d says the man who\u2019s last 60 posts have been on a share he isn\u2019t invested in. \ud83d\ude02\ud83d\ude02\ud83d\ude02",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-10T22:27:47.941473+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261207-ratcliff--2065260",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.262733",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Slight typo there - should read blatantly UNTRUE and misleading!",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.365",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-02-10T22:27:47.941492+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261201-ratcliff--7860204",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.263581",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "UXM - differences of opinion are generally understandable, but to say in your post 'All lies' is blatantly true and misleading, and as usual does nothing to bolster your credibility. Two of the things you say in that post are particularly inaccurate - 'Great decision making. Derisking assets with partnership deals. Which other biotech has so much spending less than 2 million.' - They are looking for deals (or claim to be anyway) but nothing so far has contributed anything to even cover the outgoings, let alone provide money for further work or expansion (hence the redundancies etc) Secondly - 'With warrants at a premium to the current price hopefully no more dilutions' - warrants don't kick in and generate cash the moment the sp goes above them as you and the others in your group seem to imply. In the unlikely event of the sp rising above that point and remaining so, it just might be worth warrant holders exercising them so they could buy shares at below the then-current price, but to sell them they'd need to be able to be sure the sp was strong enough to withstand the effect of the sells. You know that, so stop trying to imply that the mere existence of warrants is a long-term fool proof source of near or long term capital. Then again, if this company was fool proof you wouldn't be here I imagine.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.365",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-02-10T22:27:47.941510+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261059-viera-65483412",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.264399",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Are you PM in disguise ? Who in  their right mind would buy any company on Aim with only 3 or 4 months cash runway? You sound so so desperate for a rally to sell out !",
          "sentiment": 0.0,
          "engagement": "1,552",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-10T22:27:47.941535+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261050-Rebster4--7298536",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.265221",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rebster408",
          "content": "Its groundhog day again This is a binary bet...and Poky has called it right in the past and I thinks he's spot on again... 201 is older than me!!! place your bets... the wheel is spinning and will stop within the next 8 weeks All will become clear within the next two months...",
          "sentiment": 0.0,
          "engagement": "1,174",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-10T22:27:47.941565+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260920-RayPoint--3304426",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.266008",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Living in fantasy land",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-10T22:27:47.941584+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260857-Notpotal--1907551",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.266824",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "\u201cYou can't go back and change the beginning, but you can start where you are and change the ending.\" \u2013 C.S. Lewis Early in his tenure, Mark acknowledged mistakes had been made \u2014 and while he couldn\u2019t rewrite the past, he could reshape the future. 17 months later, Val is reborn, with money in the bank, a rebuilt team, high calibre assets and a SH base that deserves success after years of one-way support. A few resident historians cling to their preferred mythology, inventing a minimal cash runway because the real picture is too uncomfortable to accept: a cash runway to H2 even without R&D tax credits, additional Inaphaea income, grants or exercised warrants. This is also before the wave of RNS due over the coming weeks. Unlike those posting fiction, Mark has backed his conviction with his own money \u2014 now holding 7% of the company. \u201cWhat matters now is not where we\u2019ve been, but where we\u2019re going.\u201d",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.365",
          "thread_title": "Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-10T22:27:47.941602+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20262049-ratcliff-33525003",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.267621",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Whatever it is you're smoking UXM, it's powerful stuff.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-02-10T22:27:47.941621+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261733-uxm484-82002748",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.268458",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "All lies. Watch the video previously posted. Past management issues but new management outstanding.  Cash until H2 without the add ons. CEO heavily invested over 250k. Negotiating with a major biotech in regards to a deal for CLX001. Lab space is to help progress the assets to eventually get a deal not to make instant revenue. Any research on CLX001 done against a valuation of 2 million and cash burn just over a million would know this is a great opportunity. Brokers only had 20k stock. Hardly lots of stock. Great decision making. Derisking assets with partnership deals.  Which other biotech has so much spending less than 2 million. With warrants at a premium to the current price hopefully no more dilutions.",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.385",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-02-10T22:27:47.941639+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261719-Porky9--9173450",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.269349",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "And just a few reasons why not to believe the BS from the resident rampers here and why you should avoid:- * Lifestyle Business * Ridiculous Admin costs * Continual Raises and continual dilution * More than 20 Raises, 3 lots of 125:1 Consolidation events * business concept never proven * Rented lab space and zero revenue in 15 years * About 8 weeks cash runway left with yet another raise due anytime soon to keep the gravy train going. * if new investors or brokers say enough is enough and call time due to clients continually losing money then its admin and you could lose your entire investment. * materially overpriced as absoluly nothing here to invest in, its the emperors new clothes you are buying. 201 is older than hens teeth, no interest in 15 years and CLX years off and more cash required. Labs meanwhile doesnt know what an invoice is. * Poor decision making, lack of any commercial acumen *No real focus, practically everyone is work from home with multiple jobs. * Short term punts only not a long hold due to above. * loads of stock held for broker fees that will need to be drip fed into anyone buying. In all avoid at all costs unless you like dilution",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.385",
          "thread_title": "Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-02-10T22:27:47.941659+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261507-ratcliff-65911030",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.270143",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "You swine Nomlungu. You've rumbled me.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.41",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-10T22:27:47.941692+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261503-Mr0nions-45695373",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.270906",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mr0nions",
          "content": "Because of this  post, I'm holding position.  Good luck all.",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "0.41",
          "thread_title": "RE: Why invest? \u2013 THE SCIENCE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=058BF091-3235-424B-9C46-FA00ED6BC8D5"
        },
        "ingested_at": "2026-02-10T22:27:47.941712+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261432-mikee_p-56926980",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.271701",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "1 HR. Channel is all ya need.",
          "sentiment": 0.0,
          "engagement": "1,893",
          "price_at_post": "0.395",
          "thread_title": "Easy trade this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=81274FD9-0226-45F3-8CEA-B1F91E33B4A2"
        },
        "ingested_at": "2026-02-10T22:27:47.941730+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261430-nomlungu-24528002",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.272502",
        "source": "LSE_CHAT",
        "data": {
          "author": "nomlungu",
          "content": "People should just ignore Rat... he is just jealous that he does not have the losses to use to reduce his tax liabilities. That 80% drop in the last tax year will have been very valuable for some; I think him moaning around the time that taxes are due for the 2024/25 year is a dead give away. \ud83d\udcc9 \u2757",
          "sentiment": 0.0,
          "engagement": "23,976",
          "price_at_post": "0.395",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-10T22:27:47.941749+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261313-paternos-32327457",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.273388",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "When Mark became CEO, ValirRx was effectively dormant - few assets in play, minimal Board investment and limited vision. He set about a major restructuring: rebuilding the team, reshaping the asset base and above all, resetting the mindset. Fast forward 17 months and Val is reborn. A microcap expanding into developing fields of oncology, yet every action taken has a cost/benefit analysis and timescale consideration. If concluded that a project cannot be monetised early, it is shelved or paused. Commercial decisions overrule all others. Valirx is now plugged into some of the most advanced platforms in modern drug development: \u2022\tpatient avatars (TwinEdge) \u2022\tmicrofluidics/3D tissue culture models (Screenin3D, Ignota & VoxCell) \u2022\trepurposing (Ignota, Altus & Dominion) \u2022\tpersonalised immunotherapy (PredictRx / Dominion) \u2022\tpro-senescence drugs (Dundee / Queen Mary Uni) \u2022\tClickmer technology/HER2 protein (Apis Assay) \u2022\tLMTK3 kinase targeting (StingRay). The most recent evaluation, a 2nd-gen RNA helicase inhibitor (McGill/IRICoR), brings Val into collaboration with major international research organisations. Last year, Mark identified a shift away from animal-testing and moved early to establish capability partners supporting NAMs and cutting-edge AI. Recent US & UK Gov\u2019t regulatory changes now actively favour such platforms with Europe to follow this year. Once again, Val anticipated this trend before much of the market. Meanwhile, the Advisory Board has been upgraded from academics and towards industry experts who can provide insight into Big Pharma priorities and identify new commercial pathways such as in veterinary science - quicker to market while opening a parallel revenue path thru\u2019 comparative oncology, further de risking the route to human oncology. Mark has also added a clause into evaluation agreements whereby if Val decides not to progress an asset eg StingRay, McGill/IRICoR, then Inaphaea retains the data and can still monetise should a 3rd party take the asset forward. Val is no longer waiting for opportunity; it is engineering it.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.385",
          "thread_title": "Why invest? \u2013 THE SCIENCE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=058BF091-3235-424B-9C46-FA00ED6BC8D5"
        },
        "ingested_at": "2026-02-10T22:27:47.941767+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261224-paternos--1170538",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.274229",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "A \u00a33m microcap with a cash runway till H2 even before factoring in R&D tax credits, potential grant funding, additional Inaphaea income or warrant cash now within reach. Outgoings reduced by \u00a3200k PA following a team restructuring last year. Val\u2019s expansion into NAMs and advanced AI tech, supported by strong academic partnerships, aligns directly with revised US & UK gov\u2019t guidelines to reduce animal testing. This positions Val as a front runner for non dilutive grants and innovation funding, with a CEO geared to capitalise on this opportunity. The 1/9/25 RNS confirmed ongoing discussions with several potential partners to progress Cytolytix, including a major pharma. Val owns 60% of CLX with 10% owned by co-inventor, Dr Charles Chen (Senior Scientist at Astrazeneca). Val also has a 54% share of an Ambrose deal potentially worth up to \u00a316m, and a Biobank of 476 PDCs valued at \u00a310k per PDC cell-line upon commercialisation, plus commercial rights entitlement. Valirx has assets in several key cancer indications, all with huge global markets: 201/prostate ($11.3Bn*), CLX (primarily TNBC ($1.5Bn*), ovarian ($2.5Bn*) but also prostate, 301/endometriosis ($1.9Bn**), and 401-Ambrose/pancreatic ($2.9Bn**). Sources: *webinar, **GMI. Several RNS updates are imminent: CLX patents \u201cin coming weeks.\u201d (RNS 1/9/25), Dundee/Queen Mary project (extended to 9/2/26), StingRay (approx Feb \u201926 per Aug video), Blue Ribbon SPV - \u201cSeveral patents envisaged for 201\u201d, and the next evaluation/SPV \u201cimminent with discussions already at a mature stage\u201d. The Omios RNS (3/6/25) stated \u201c\u2026 expected to take up to 12 months. On conclusion of the evaluation, Omios has an option to enter into an Oncolytic Peptide License Agreement to continue using Cytolytix technology.\u201d Yet another potential source of income. In addition, the Val/Dominion repurposing project (teaching an old drug new tricks) has identified 200 FDA approved non-oncology drugs which already have phase 1 clinical data and are showing activity against various cancer PDCs. 10 of these candidates are now being fast-tracked. The median upfront deal size for pre-clinical IND ready assets was $110m in 2025. For phase 2 this increased to $775m. (Dec webinar). For context, Val\u2019s SP exceeded 55p in 2021 with only one key asset (VAL201). Currently, including the repurposing project, Val now has 200+ potential assets plus a valuable Biobank. Also, Mark has restructured evaluation agreements whereby if Val chooses not to progress an asset (eg StingRay, McGill/IRICoR), Inaphaea retains the data and can still monetise should a 3rd party take the asset forward. Multiple monetisation routes now sit across the pipeline, supported by a commercially-savvy CEO who now owns 7% of the company. Valirx \u2013 a microcap with midcap potential.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.355",
          "thread_title": "Why invest? \u2013 FINANCIAL",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=8931CA86-EC8C-43F3-AA7F-54C7D7FD717E"
        },
        "ingested_at": "2026-02-10T22:27:47.941786+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261145-Marty130--5419880",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.274986",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Be good to see the directors buying some of the stock..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "0.355",
          "thread_title": "Directors deals",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=DC2D2A2F-B451-4EEF-B7C8-9C80695D4033"
        },
        "ingested_at": "2026-02-10T22:27:47.941820+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261107-ratcliff--5995799",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.275854",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "UXM - cutting and pasting the same post repeatedly is not convincing, but to humour you I had a listen to the link you have monotonously posted. It's not persuasive or convincing - Starts off about the 'objectives we have set' and 'milestones we're looking to achieve.' Then there's a bit about the group structure - this is rearranging the deck chairs on the Titanic isn't it? They've had more rearrangements over the decades, it's just a distraction now - meetings are the practical alternative to work. The we hear 'The objective is...' and 'If suitable...'  So nothing at all certain. Then he says BC201 and Val301 have 'not been spun out yet, but would benefit from all of the development work undertaken on Val201.' So BC201 and Val301 still of no interest (except maybe on Antiques Roadshow) and if Val201 had even a glimmer of potential it would have done something since it was quietly shelved - was that 6 years ago or 8? It's been stagnant for so long, the rest of the industry has moved on. The he says 'There is strong interest in endometriosis treatments.' True. There's strong interest in a lot of things, but stating a fact doesn't tie it to VAL. 'We have two new evaluations under consideration.' And...? I\u2019ve got a lot of things under consideration, but whether they get any further is often very uncertain. 'The vision is...' - A lot of people have visions, but a vision isn't even a plan. It's a nice idea at best. 'Our strategy is to do this based on identifying the highest quality assets we can find and afford.' That's like saying 'come round to my place for a meal' and when you get there you say 'There\u2019s a tin of Pedigree Chum between the four of us - it was the highest quality I could find on the available budget.' The he's going to have a system which 'allows us to prioritise selection of assets.' How early stage is all this? And no money to do it with.. Next we see \u2018The Team\u2019 but no mention of their salaries. Then a review of last year - no mention of the placings. Talk of last year's cost savings and redundancies - but if you are cutting 200k a year and laying people off, what were you wasting the money on in the first place? Or have you sold your food to pay the heating bill? Then he says 'Our runway through 2026' - sorry - that 'runway' stops in a couple of months without a placing. The 2026 Xmas do is potentially in the Job Centre unless money comes in very soon. Time is money. They seem dangerously short of both. Again.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.355",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-10T22:27:47.941840+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260954-uxm484-20314569",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.276634",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Plenty of news to come at a tiny valuation and likely this month. Cash until at least July that without warrants, revenue, deals, grants. Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-10T22:27:47.941859+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260919-Porky9-75988936",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.277452",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@Notpotalot Nick is a VERY experienced prolific investor. Frankly, i doff my cap to him as he called the trade perfectly in at .25 and out at .40. Beautiful. The Muppets are the traders in on the back of the Zac Mir pump without any research in blind on the dead cat bounce they will get burnt if still holding. As for Stephen and Jaspal at u3% they now dont have to declare BUT IMO they have about 8 weeks to slowly work the sells in to ensure they are out (just holding warrants options) before that next raise drops as they will be diluted to oblivion as sure as night is day. They can only drip sells in slowly to avoid the brokers hammering them at discount. You try selling big volumes of this close to the raise, or at anytime for that matter, you need to do it on a bounce really, sell whilst traders are buying. This is NOT an investment, its a short term punt. The reason its not an investment is because it can't generate revenue (well none in the last 15 yrs anyhow)  and is reliant on raise after raise after raise to maintain lifestyles. As I say, tick tock. Tick tock countdown already started imo.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-10T22:27:47.941877+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261952-Notpotal--2742812",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.278260",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Porky, unlike some holders, I still keep you around for the entertainment value.  Calling Nick and other traders \u2018muppets\u2019 is certainly \u2026.\u201dcreative\u201d. \ud83d\ude00 Jaspal S and Stephen W dipping just under the 3% is nothing more than freeing up a couple of million to trade. There\u2019s no great sell-off and no drama. Most of us aren\u2019t brave enough to risk missing an RNS for the sake of a few hundred quid. Get your 40 winks while you can. Many sleepless nights await over the next few months.   \ud83e\udd71 Pleasant dreams.",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-10T22:27:47.941895+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261804-uxm484-20314569",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.279044",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Plenty of news to come at a tiny valuation and likely this month. Cash until at least July that without warrants, revenue, deals, grants. Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-10T22:27:47.941914+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261539-Porky9--1390149",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.279866",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Err nope Only thing that will bring hard cash into the company of any meaningful amount in the next 8 weeks will be new placing money - sorry Regarding your continual pumps and fluffy updates, jam tommorrow dream fantasy posts, NONE of it can pay the bills now, end of. Anyone with any brains will be working the sells into any mupets trading this that are oblivious to the dire need for cash to keep the lights on and the pending essential discounted placing that has to happen to support the lifestyles here to keep the gravy train going. Tick Tock, Tick Tock",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.35",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-10T22:27:47.941947+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261042-paternos--4011947",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.280667",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "As standard, when Mark did the Dec webinar he emphasised nothing new, \u201cjust meat on the bones\u201d. However, often that meat can be pretty tasty. Blue Ribbon/VAL201 \u2013 \u201csynthesis almost complete\u201d (10m.30s). Then, \u201ca small amount (only \u00a350k) set aside for pre-clinical development of 201, the balance WILL then come from external investment into the asset\u201d (11m.55s). No \u201cMIGHT\u201d in that statement. The minimal outlay confirms that the VAL201 drug package is essentially finalised, and the entire development programme (preclinical \u2192 IND \u2192 partnering) is about to move forward. Mark has already confirmed Val will be diluting the asset, not Val PLC. With patents imminent, it\u2019s a clear signal that Blue Ribbon is not just a corporate shell \u2014 it\u2019s actively progressing VAL201 toward monetisation. Given Val\u2019s recent multi facet RNS style, the imminent update could well bundle new patent status with partnership confirmation. The last significant VAL201 update in 2021 saw the Val SP exceed 50p.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.365",
          "thread_title": "Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-10T22:27:47.941968+00:00"
      },
      {
        "event_id": "SOCIAL-10Jan20261920-Kaeren--1224765",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.281449",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kaeren",
          "content": "All great thx.",
          "sentiment": 0.0,
          "engagement": "10,948",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-02-10T22:27:47.941986+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262133-paternos-28865354",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.646223",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Seven consecutive \u201cblocked\u201d posts on a blue day tells me everything I need to know. LOL The desperation of the naysayers knows no bounds \u2013 and the newsflow hasn\u2019t even started yet. I fear for the sanity of Porky and his parrots over the coming months. With an absolute minimum cash runway into July already confirmed and multiple RNS imminent, Porky could well self-check in to the local abattoir. The lorry reversing toward the sty, isn\u2019t delivering feed. \ud83d\udc37 \ud83e\udee8 \u26a1 \ud83c\udf2d Anyone for a bacon butty or sausage cob?",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.385",
          "thread_title": "The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-10T22:27:47.942005+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261807-Porky9--8180399",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.646670",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@Nick I totally agree with you. If anyone can trade this you can. But I have to hand it to mark, the money just keeps on coming, I mean its shocking really, there is absolutely nothing here to invest in, it really is the emporers new clothes, but he keeps getting the cash and with over 20 raises, what's another one? I still think .15 or .20 but ultimately you would think the brokers would say, hang on a minute you never deliver on anything you say, our clients are losing money off our broker notes to buy, enough is enough but I guess as long as they get their fees they couldn't care less.",
          "sentiment": 0.0,
          "engagement": "7,466",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-10T22:27:47.942023+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261719-RayPoint--2631810",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.647089",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "It does explain all the voices in my head \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-10T22:27:47.942042+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261714-ratcliff--7410535",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.647517",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Viera - are you RayPointer and me as well?",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-10T22:27:47.942072+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261704-viera--2271080",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.647968",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "But why would anyone give this lot any money Porky  ? They earn 100k whilst having other part time jobs. Been 20 years of promises but zero revenue . There will be zero revenue in before April when the next begging bowl comes out . I was at 5pct with Theoremx and that failed . I\u2019m at zero pct with Ambrose ! Anyone holding this as we enter Feb/March needs to see a dr. Any monies raised goes to directors as not enough to make any investments. I will NOT be buying at any price . It\u2019s a shambles . Sorry",
          "sentiment": 0.0,
          "engagement": "1,550",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-10T22:27:47.942095+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261454-Porky9-87446401",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.648402",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "They dont have a pot to pee in, its a phoenix business and frankly if they raise cash it will be for themselves, not to give away to VAL - BE REAL. Would imagine meetings being scheduled by VAL with placing brokers shortly, can't be far off now - my call this time is another \u00a31m at .15 to .20 tops - give them another 5/6 months more gravy train assuming brokers can find more mugs to support the lifestyles.",
          "sentiment": 0.0,
          "engagement": "7,466",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-10T22:27:47.942128+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261440-ratcliff-26610386",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.648817",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "I was asking myouryourself the same question. But I knew that, as did Iyou.",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-10T22:27:47.942147+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261415-RayPoint-18373387",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.649253",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Are these people actually employed by Ambrose? Last time Ambrose received capital investments (as I recall, in the region of 900,000) they trumpeted the fact on their website. Yet, at March last year, they only had 25k in the bank. Subsequent to March last year,  there have been no announcements of further investments. I ask myself (i.e. Rats) how this all adds up.",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-10T22:27:47.942165+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261403-Notpotal-73877015",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.649678",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Nice to see momentum at Ambrose. They certainly are building a very strong team. However, this highlights another positive for Valirx. VAL401 is the result of a reformulation of the anti-psychotic drug, Risperidone into an oncology drug. One solitary repositioned drug has resulted in a potential multi-million deal. No wonder in the webinar Mark said he was excited regarding the Val/Dominion repurposing project. This collaboration has identified approx 200 FDA approved non oncology drugs which are showing anti-cancer against various Inaphaea PDCs. Ten of these candidates are now being fast tracked for deeper evaluation. Mark even mentioned looking to partner the prime repurposing asset this year. Because these compounds are clinically validated and safety de-risked, the probability of progressing to meaningful clinical proof of concept is far higher than in creating oncology drugs from scratch - positioning the Val/Dom alliance for multiple rapid, low cost shots on goal.",
          "sentiment": 0.5,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-10T22:27:47.942184+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261359-ratcliff-79042267",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.650086",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "True O alter ego. He even knows where my investments are. (Or should that be 'our' investments)",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-10T22:27:47.942211+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261356-RayPoint--3385583",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.650503",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "You can't fool uxm, he's so sharp \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-10T22:27:47.942239+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261348-uxm484-14781501",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.650918",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Ratcliffe are you Raypointer? Both invested in Scancell. Both are not invested in Valirx.",
          "sentiment": 0.0,
          "engagement": "1,009",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-10T22:27:47.942258+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261333-ratcliff--3530357",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.651345",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "The number of employees and the financial state is a bit concerning isn't it? They weren't flush in 2024's accounts, and they're worse in the 2025 ones. So back to the question - what are 500,000 odd shares in Ambrose actually worth? Potentially even less than 500,000 Val shares...? https://find-and-update.company-information.service.gov.uk/company/14409383/filing-history",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-10T22:27:47.942277+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261310-RayPoint-46917988",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.651773",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "The reason I ask is that if I look at Ambrose Healthcare on Companies House, I find the same name with the same month of birth: Tobias Adam WILSON WATERWORTH - born October 1964 Spookily, this person only has 1 director appointment - Ambrose Healthcare, the other 21 are missing! https://find-and-update.company-information.service.gov.uk/officers/SAWjapGOj9HbCMsLuSFBZeqVYiU/appointments Does anyone else find this rather strange?",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-10T22:27:47.942295+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261254-RayPoint--4024575",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.652198",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Could this be the CEO of Ambrose Healthcare? https://find-and-update.company-information.service.gov.uk/officers/JzAELIfnpaXPIZjjnhqdRjwB9KM/appointments",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-10T22:27:47.942314+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260857-Rebster4--6220765",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.652606",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rebster408",
          "content": "Probably cos Ambrose only have about \u00a325k in capital and assets in 2025... not a pot to p155 in...",
          "sentiment": 0.0,
          "engagement": "1,174",
          "price_at_post": "0.375",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-10T22:27:47.942340+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260757-uxm484-46381605",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.653034",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "I understand they get a share of Ambrose  not just Val401. News on other clinical compounds increases the value of the shares therefore more valuable than just getting cash for Val401. Valirx will have options to sell some shares initially to get some cash.",
          "sentiment": 0.0,
          "engagement": "1,009",
          "price_at_post": "0.375",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-10T22:27:47.942369+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262226-ratcliff-69514242",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.653624",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Why were Val given shares not cash by Ambrose? What are 576,000 Ambrose shares worth? Can they be sold to raise much-needed cash? How much cash had been raised for Val in the 7 months since that announcement? If it was a deal of any real worth, why did Val have to do a placing a few months later, and how come it's heading towards another one in a matter of weeks on current estimations?",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.375",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-10T22:27:47.942388+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262019-paternos--4855901",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.654069",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "A lucrative VAL401 licensing deal was announced on 20/6/25: \u201c ValiRx will receive 576,000 ordinary shares in Ambrose with clinical and commercial milestone payments to be made to Valiseek totalling a value of up to \u00a316 million plus royalties.\u201d Valirx owns 54% of Valiseek. Ambrose has a pipeline consisting of just TWO products: VAL401 (pancreatic cancer) and Renzapride (cystic fibrosis), both currently at phase 2 clinical. Today, Ambrose announced two further additions to their already impressive team: Dr. Janette Thomas joins as Director of Manufacturing Operations and Wendy Richings-Barrow as Director of Regulatory Affairs. \u201cThese appointments reflect our continued focus on building a world class team to deliver solutions for patients with rare conditions with no approved treatments.\u201d The Ambrose team already had a strong backbone: Chairman, Toby Waterworth has been part of leadership teams in multiple life science companies that have generated close to $1 billion in shareholder value. CEO Dr Hazel Jones was formerly Chief of Staff for AstraZeneca\u2019s Oncology R&D Leadership Team. Chief of Staff Virag Stephens an ex PMO Director at AZN and has strong fundraising expertise while Mike Webb led departments of up to 150 scientists in a 30-year career at GSK. Dr. Nick Meyers has 30 years\u2019 experience as a Program Director. In 2024, Ambrose was acknowledged by its peers when it won the Best Startup Biotech Company Award at the prestigious OBN Awards in London. Since then, it has grown significantly and confirmed it is exploring potential Middle-East listings. One of the partners on their webpage is SEHA (Abu Dhabi Health Services), a subsidiary of Pure-Health the largest integrated healthcare network in the UAE. (total assets $13B). Another partner is listed as Aparito, part of the Eli Lilly group. As Ambrose strengthens its leadership and global partnerships, Valirx is strategically placed to benefit from every milestone achieved on the VAL401 journey.",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.375",
          "thread_title": "The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-10T22:27:47.942406+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261513-paternos-37517317",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.654610",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "\u201cValix is in discussions with several potential partners to progress CytoLytix, including a major pharma\u201d. So, why is Mark, currently in California, continuing to promote the compound so actively both in the UK and overseas? While it\u2019s plausible a major pharma might seek exclusivity, the most realistic outcome is exclusive rights carved by territory, formulation, indication, or even species (human/veterinary)\u2014leaving room for multiple, parallel deals outside that scope. Indication splits are historically used when partners specialise in different therapeutic areas (eg ovarian only). Geographic exclusivity is even more common. The TrX/201 deal eventually failed when Mark attempted to remove Taiwan from the original LOI. The veterinary angle highlighted in recent webinars reinforces that CLX spans markets no single pharma can cover, making a multi partner licensing model far more realistic than a single global licence. There are numerous real world examples of multi partner licensing structures in biopharma: TERRITORY - Immunex (Enbrel) / initially Amgen \u2192 US & Canada rights, then Wyeth (later Pfizer) \u2192 Europe + Rest of World rights FORMULATION - Gilead (Tamiflu) / initially Roche \u2192 Oral formulation rights, then Hetero & Teva, \u2192 sublicenses for additional formulations INDICATION - AstraZeneca (Lynparza) / Merck \u2192 initially Ovarian cancer rights, then subsequently obtained licenses for breast and pancreatic cancers. Each example above shows one originator, no single-party lock in and multiple partners or deals to acquire different rights. With so many variables in play, it is increasingly clear that Valirx is preserving the same optionality for CytoLytix. Mark is still promoting CytoLytix because he is targeting several partners \u2013 not just one. Everything suggests CLX is being shaped as a multi deal platform, with the first handshake simply opening the monetisation cycle -",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.385",
          "thread_title": "CLX - multi deal structure",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D1488F3A-09F4-41C4-B45B-AF908B85E267"
        },
        "ingested_at": "2026-02-10T22:27:47.942424+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261459-Notpotal-72200683",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.655026",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Some clever trading going on here \u2013 those selling at 0.37p will soon be able to buy back at 0.39p. \ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "RE: Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-02-10T22:27:47.942443+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261329-Porky9--5122597",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.655478",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@PP Yes, and as long as the rain holds off should be able to get some golf in on expenses. Who needs Zoom and Teams when you can have a nice all expenses trip to the US. Lovely. Keep pumping it, only a few weeks now to go before next placing @notpotatlot Only Update you will get shortly that isn't fluff, will be the placing news or the next 125:1 consolidation event which has to be well over due now. Keep ramping it though, the gravy train needs to stay on the tracks, there are lifestyles here that need to be maintained.",
          "sentiment": 0.0,
          "engagement": "7,466",
          "price_at_post": "0.385",
          "thread_title": "RE: Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-02-10T22:27:47.942467+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260943-paternos-21638182",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.655913",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Mark re JPM in San Fran -  \u201cI have meetings lined up with our partner Omios Biologics so looking forward to catching up with Aldo Pourchet (CEO).\u201d In the Omios RNS (3/6/25), the evaluation was \u201cexpected to run up to 12 months, after which Omios can exercise its license option to continue using Cytolytix technology.\u201d Across both the June and Dec webinars, Mark emphasised CLX synergy with the Omios virus for potential to treat canine HSA, a clear signal that Omios sits firmly in the frame for a CLX licence. Valirx\u2019s revamped Advisory Board reinforces this direction, now with a notable weighting toward veterinary oncology and commercial expertise. The composition reflects a deliberate strategy to position CLX across both human and animal oncology. When your advisory structure is rebuilt around people who understand canine cancers, comparative oncology, and veterinary commercial pathways, it becomes clear Valirx is preparing for licensing routes across both human and veterinary markets. As a co-founder of VolitionRx, Mark transformed a human cancer test into a canine diagnostic test (Nu.Q) before negotiating a licencing deal with Heska for $26m. What price a cure? Human and veterinary oncology operate in separate regulatory and commercial channels. Most major pharmas, inc. AZN, Roche, GSK, AbbVie do NOT have any vet divisions. Even those historically involved have spun off their animal health units (Pfizer \u2192 Zoetis, Eli Lilly \u2192 Elanco). By envisaging veterinary opportunities for CLX, Mark is implicitly confirming the compound won\u2019t be a one partner asset; the split infrastructures required make multiple CytoLytix deals the only realistic outcome. GLA, DYOR, AIMO",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.385",
          "thread_title": "Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-02-10T22:27:47.942498+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261543-Notpotal--8081567",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.656343",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "I notice a 71430 buy at 15.14 and a similar sell 4 mins later for a \u00a321 loss. Great to see Porky has started trading again!  \ud83e\udd23\ud83e\udd23\ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "Welcome back, Porky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=FE350133-0204-48E9-9785-7F80407B3421"
        },
        "ingested_at": "2026-02-10T22:27:47.942517+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261534-Notpotal--6973019",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.656760",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Val is obliged to RNS as it a change to No. shares in issue. Hardly the company\u2019s fault if a holder sees such value that he wants to buy above the current SP. Mind you, I\u2019m expecting a TR1 tomorrow to confirm Mark\u2019s holding has increased by 80,000 shares. \ud83e\udd23 If this is the reaction to \u00a3400 of warrants, heaven help Porky\u2019s groupies when the next material RNS arrives.  \ud83e\udee8 \ud83d\ude28 \ud83d\ude22\ud83d\ude2d",
          "sentiment": 0.5,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-10T22:27:47.942536+00:00"
      },
      {
        "event_id": "SOCIAL-Today1706-Porky9-55292923",
        "event_type": "social_post",
        "date": "2026-02-11T17:20:56.599184",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "LMOL - TEMU Oh but bless em, they are trying to give it a quick spike pre placing to help get the stock sold into, LMOL who is kidding who here. is anyone still that gulliable ??? But you can fool some of the people some of the time, if they couldnt, time would have been called on this, long long ago. March placing 650m new shares at .15 to raise \u00a3 975k with retail offer of 150m shares to try and boost it to \u00a31.2m to extend the gravy train by another six months plus a few worthless warrants chucked in - watch this space. They dont like my prediction but i recon i am right on the money Shame its just gone 5pm might be a struggle getting claire to delete posts after 5 - Never mind the rampers can give it a go tomorrow and ME can always try some fluff news to try and stimulate interest, after all we are getting closer to the wire now. Have a good evening..",
          "sentiment": 0.0,
          "engagement": "7,474",
          "price_at_post": "0.33",
          "thread_title": "RE: Porky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E8A5556A-334C-4237-8D4A-8902D65CFFC3"
        },
        "ingested_at": "2026-02-11T17:21:05.911605+00:00"
      },
      {
        "event_id": "SOCIAL-Today1552-ratcliff-16703346",
        "event_type": "social_post",
        "date": "2026-02-11T17:20:56.599608",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Val = Temu pharma...",
          "sentiment": 0.0,
          "engagement": "11,415",
          "price_at_post": "0.335",
          "thread_title": "RE: Porky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E8A5556A-334C-4237-8D4A-8902D65CFFC3"
        },
        "ingested_at": "2026-02-11T17:21:05.911628+00:00"
      },
      {
        "event_id": "SOCIAL-Today1506-Kagefc-34076612",
        "event_type": "social_post",
        "date": "2026-02-11T17:20:56.600154",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kagefc",
          "content": "Rat =temu porky.",
          "sentiment": 0.0,
          "engagement": "261",
          "price_at_post": "0.335",
          "thread_title": "RE: Porky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E8A5556A-334C-4237-8D4A-8902D65CFFC3"
        },
        "ingested_at": "2026-02-11T17:21:05.911647+00:00"
      },
      {
        "event_id": "SOCIAL-Today1415-ratcliff--3681126",
        "event_type": "social_post",
        "date": "2026-02-11T17:20:56.600564",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "I think the main aim of the 'faithful' is to keep the board closer to their agenda in order to attract fresh sheep to be sheared.",
          "sentiment": 0.0,
          "engagement": "11,415",
          "price_at_post": "0.32",
          "thread_title": "RE: Porky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E8A5556A-334C-4237-8D4A-8902D65CFFC3"
        },
        "ingested_at": "2026-02-11T17:21:05.911665+00:00"
      },
      {
        "event_id": "SOCIAL-Today1349-Porky9-30589278",
        "event_type": "social_post",
        "date": "2026-02-11T17:20:56.600967",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Clearly they didnt like it - bet you i am reaaly close to what the placing comes in at. Thing is, lets face it, those that follow this forum have seen this so so many times now its bloody ridiculous, its not difficult to see exactly how this plays out lets face it. Talk about got the T-Shirt......, i think we have brought the T-Shirt, worn the T-Shirt, Washed the T-Shirt, recycled the T-Shirt and now 20 plus T-Shirts later are awaiting yet another one!!!",
          "sentiment": 0.0,
          "engagement": "7,474",
          "price_at_post": "0.32",
          "thread_title": "RE: Porky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E8A5556A-334C-4237-8D4A-8902D65CFFC3"
        },
        "ingested_at": "2026-02-11T17:21:05.911683+00:00"
      },
      {
        "event_id": "SOCIAL-Today1326-RayPoint--3403753",
        "event_type": "social_post",
        "date": "2026-02-11T17:20:56.601382",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "I thought that team ramp didn't read Porky's posts.",
          "sentiment": 0.0,
          "engagement": "5,091",
          "price_at_post": "0.32",
          "thread_title": "RE: Porky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E8A5556A-334C-4237-8D4A-8902D65CFFC3"
        },
        "ingested_at": "2026-02-11T17:21:05.911702+00:00"
      },
      {
        "event_id": "SOCIAL-Today1141-ratcliff--5223837",
        "event_type": "social_post",
        "date": "2026-02-11T17:20:56.601782",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "I suspect you hit a nerve with your now-removed post Porky. First one here in about five days and the balanced devotees have it taken down. Shame really, but it does suggest you may be right on the money there. Or lack of money, so to speak.",
          "sentiment": 0.0,
          "engagement": "11,415",
          "price_at_post": "0.32",
          "thread_title": "Porky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E8A5556A-334C-4237-8D4A-8902D65CFFC3"
        },
        "ingested_at": "2026-02-11T17:21:05.911719+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261535-viera--9213641",
        "event_type": "social_post",
        "date": "2026-02-09T22:52:21.394292",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "I do loveya notpot. I post replies to you and pp hence 67 posts ! I\u2019ve also got repetitive syndrome I apologise . I do laugh at your posts as Val has zero revenue ,huge cost base ,years of years of promises which all have been broken . A loss making lab and a CEO  who pays staff to contribute zero to the bottom line . It\u2019s a shambles. I\u2019m absolutely flabbergasted that investors continually donate money to employees salaries when they produce FA. You couldn\u2019t make it up my friend . Have a great weekend Let\u2019s hope it stops raining Xxxx",
          "sentiment": 0.0,
          "engagement": "1,556",
          "price_at_post": "0.345",
          "thread_title": "RE: Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-11T17:21:05.911738+00:00"
      },
      {
        "event_id": "SOCIAL-Today1535-viera--9213641",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.574183",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "I do loveya notpot. I post replies to you and pp hence 67 posts ! I\u2019ve also got repetitive syndrome I apologise . I do laugh at your posts as Val has zero revenue ,huge cost base ,years of years of promises which all have been broken . A loss making lab and a CEO  who pays staff to contribute zero to the bottom line . It\u2019s a shambles. I\u2019m absolutely flabbergasted that investors continually donate money to employees salaries when they produce FA. You couldn\u2019t make it up my friend . Have a great weekend Let\u2019s hope it stops raining Xxxx",
          "sentiment": 0.0,
          "engagement": "1,556",
          "price_at_post": "0.345",
          "thread_title": "RE: Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-11T17:21:05.911757+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262209-Notpotal-68274382",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.574764",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Very amusing to see the uninvested have such strong views on Val. Such a shame Porky didn\u2019t have the same consideration while sucking thousands of gullible punters into other investment disasters. Perhaps considering compensating all those innocents dragged in? At this point, Porky will probably give another history lesson but, while Val is still trading and doing quite nicely, no news on 4D or HARL reinstatement yet. Meanwhile back in the real world - 40 separate projects ongoing at Inaphaea, \u00a3200k pa cost savings, money in the bank into H2 with R&D tax credits expected but as yet unconfirmed, Inaphaea income excluded and grants applications pending (as confirmed by Prof Mark\u2019s statement, not Prof Porky\u2019s Santa wish\ud83e\udd23), partnering planned for CLX, 201, and the lead repurposing asset \u2013 all of which will further reduce costs, tailored for grants under new guidelines, another evaluation and SPV imminent (already ring-fenced), the recent McGill Univ & IRICoR  evaluation is the first with global players, multiple RNS updates due and an SP bouncing around in the mid-0.30s even before the RNS news flow starts. Understandably upsetting for the pink one. Having devoted the last 4 years and thousands of posts hoping to destroy Val, a new CEO comes in and undoes all that work in less than 18 months. Porky\u2019s partner (in crime?) Nick, has made a small fortune trading the share over the years and still ONLY posts on this share \u2013 check history - 67 consecutive and counting. He obviously sees great value here, despite all his apparent bed-wetting. The way Porky and Nick tag team this board, you\u2019d swear they were coordinating over the same cup of tea. \ud83e\udd14 Happy dreams, you two! \ud83d\ude34",
          "sentiment": 0.5,
          "engagement": "81",
          "price_at_post": "0.345",
          "thread_title": "RE: Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-11T17:21:05.911775+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261739-viera-25460799",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.575230",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Pp is pm Paid to post on LSE Until the next  raise (I think c April ) Then he goes missing as he\u2019s embarrassed . Then changes  his name and rinse repeat . He has no humility . Been bullish since 30p but holds no shares so what does he care ,has lost all his readers 98pct of their hard earned cash. Shambles",
          "sentiment": 0.0,
          "engagement": "1,556",
          "price_at_post": "0.345",
          "thread_title": "RE: Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-11T17:21:05.911792+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261450-Porky9-89706445",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.575649",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@pp - nobody gives a **** about posts on linked-in - unless you are looking for a job or trying to recruit someone from a competitor that is all it is good for - a recruitment tool. the guy needs to stop wasting his time posting crap on social media and get some bloody focus on the important issues and then publish some proper update news via the rns service. talk about lack of perspective. this is exactly what i am talking about - zero commercial acumen - sorry",
          "sentiment": 0.0,
          "engagement": "7,471",
          "price_at_post": "0.345",
          "thread_title": "RE: Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-11T17:21:05.911811+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261351-paternos-38600973",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.576063",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Inaphaea has just released a short video re the collaboration with the Open University re prostate cancer.  Funded by a Knowledge Transfer Voucher (RNS 7/8/25) this is yet another example of non-dilutive funding to progress assets using cutting edge technology that would otherwise be beyond the company\u2019s reach. https://lnkd.in/eXGeSPQq",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.345",
          "thread_title": "Another Linkedin update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=257842F7-2ADF-4324-9CE3-DEC336F715A1"
        },
        "ingested_at": "2026-02-11T17:21:05.911829+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20262042-paternos-66994456",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.576513",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "\u201cImportant day in the calendar for patients, families and those of us working in the sector. The UK government has announced a directive to increase 5 year survival for cancer patients to 75% by 2035. This will take a a huge effort in terms of screening for early detection and diagnostics to allow curative surgery, improvements in surgical technique, such as robot assisted approaches and developments of affordable, accessible therapies. VALIRX PLC and its subsidiaries, including Inaphaea BioLabs, Cytoltix and Blue Ribbon Bio are working hard to play our part in the discovery and development of next generation therapies. These include our novel oncolytic peptide program (targeting Triple Negative Breast Cancer), a first in class, non-genomic androgen receptor signalling inhibitor and a series of repurposed drugs from Inaphaea BioLabs 3K screen program. We work closely with leading academic institutions to source, assess and develop cutting edge approaches with pan cancer potential. Our latest deal is with McGill University and IRICoR for a second generation RNA Helicase inhibitor ( https://lnkd.in/ei5xwSpx) Big shout out to our dedicated Inaphaea BioLabs team including Head of Scientific operations Melissa Barr, Lead Scientist - Translational Biology and Academic Collaboration, Amelia Hatfield and Lab tech Dylan Jones as well as VALIRX PLC's Director of Research, Michelle B.. There are currently 40 projects running in the labs at Inaphaea BioLabs covering our group therapeutic programmes and development of our non-animal based, New Approach Methodologies (NAMs) for drug screening with our unique bank of Patient Derived Cell models. We couldn't do this without the support of our partners including TwinEdge Bioscience (Digital twin/Patient Avatars), ScreenIn3D (Lab on a chip platform), VoxCell (vascularised 3D tumour models), Spanios (organoid models), BioReperia (zebrafish models), Ignota Labs (in silico tox screening) and development partner Dominion Biotech as well as our shareholders. It's been a hectic 18 months since I took over as CEO but we've focussed on refining our strategy, identifying high quality assets, building a strong team and expanding our capability partner network. We have a some major milestones set for 2026 and we look forward to being part of the solution and helping deliver patient benefits.\u201d",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.35",
          "thread_title": "Today\u2019s Linkedin update from Mark E",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E9D6BAF9-FFFC-4611-82EB-4E1B71731FB2"
        },
        "ingested_at": "2026-02-11T17:21:05.911847+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261943-ratcliff--5482135",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.576919",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "That's the way - cut and paste some good long pieces in the hope of burying anything that doesn't fit the agenda.",
          "sentiment": 0.0,
          "engagement": "11,411",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-11T17:21:05.911865+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261832-paternos--3573451",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.577382",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Grant schemes are increasingly geared towards small companies - when it comes to eligibility, size truly matters. Recent UK oncology research grants to SMEs reflect sustained investment in cutting edge cancer research, with Innovate UK and the Biomedical Catalyst programme providing much of the funding. Recent awards to UK microcap/small biopharmas include: Momentous Therapeutics Ltd (immunotherapy) - \u00a32m grant Theolytics Ltd (ovarian cancer therapy) - \u00a32m Mestag Therapeutics Ltd (immunotherapy) - \u00a31.5m Revolver Therapeutics Ltd (peptide therapy) - \u00a3550k Epitopea Ltd (breast cancer stromal cells / immunotherapy) - \u00a3500k VacV Biotherapeutics Ltd (oncolytic viruses) - \u00a3500k Antikor Biopharma Ltd (ovarian immunotherapy) - \u00a3500k The above awards show clear emphasis on immunotherapy, peptide based therapeutics, and oncolytic virus platforms. Val\u2019s work not only aligns with these priority areas but also extends into difficult to treat cancers such as pancreatic, ovarian, triple negative breast, and prostate \u2014 indications where new therapeutic approaches are urgently needed. This strengthens Val\u2019s fit within the priority areas repeatedly backed by UK grant bodies. The grants aren\u2019t handouts; they\u2019re strategic investments in the UK\u2019s future. A successful cancer therapy can deliver multi billion pound global sales and position the UK as a leader in next generation oncology. Regulators are now actively encouraging NAM adoption and funders are rewarding small oncology-focussed companies that have strong academic links. Valirx is exceptionally well-positioned to secure substantial grants, extend the cash runway and reinforce financial stability. GLA, DYOR",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-11T17:21:05.911883+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261827-paternos-30058326",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.577808",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "To all the green bar brigade out there, you will get zero engagement from me. I have no desire to convert you and history lessons really don\u2019t interest me. Feel free to post your drivel as all I can see is 6 consecutive green \u201cThis message has been filtered, please adjust your filters to view\u201d. Han Solo couldn\u2019t land a helicopter on your imaginary runway. \ud83d\ude01 \ud83d\ude01 \ud83d\ude01 To those actually invested, whether traders or otherwise, with all the news pending, the coming weeks and months are likely to be transformational. GLA, DYOR",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-11T17:21:05.911900+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261740-viera--4996255",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.578232",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Grant could pay the 100k we pay to our BDM who organises ME trips abroad and placings . Both been a resounding success ! @shambles Paternoster aka PM will go into ramp mode now as we approach QTR 2 and the inevitable begging bowl comes out .",
          "sentiment": 0.0,
          "engagement": "1,556",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-11T17:21:05.911918+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261735-ratcliff--8529329",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.578647",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Probably thinking like Pan Am did - the only state airlines that never made a loss, they recorded a 'negative profit.' Maybe he's talking 'negative growth.' I'm sure he'll elaborate on his claim pretty soon and to everyone's satisfaction anyway.",
          "sentiment": 0.0,
          "engagement": "11,411",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-11T17:21:05.911936+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261729-RayPoint--9066889",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.579062",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Well put Rats. The other sentence I take pater to task on is: \"The combination of Mark\u2019s grant winning experience and the UK\u2019s revised grant landscape creates a clear opportunity for Valirx as it enters its next phase of growth.\" Pater, pray tell us about Valirx's previous phases of growth.",
          "sentiment": 0.0,
          "engagement": "5,087",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-11T17:21:05.911954+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261605-ratcliff--5554746",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.579478",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "To be fair RP, applying for grants is a very sensible thing to do. However there must be an element of due diligence and examination of the company applying, and somewhere in the paperwork there will probably be a section which asks 'What would the grant be used for?' This is where the potential donor writes something like 'to accelerate the development of our compound XYZ' or 'to fund the production of our drug to use in the imminent 500 patient Phase 3 trial.' If the box reads 'to stave off imminent insolvency and to avoid another placing' or 'to pay salaries, expenses and bonuses' I imagine the progress of the application tends to grind to a halt.",
          "sentiment": 0.0,
          "engagement": "11,411",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-11T17:21:05.911972+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261408-RayPoint--5829819",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.579907",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Just looking at the first company on your list i.e. Momentous Therapeutics Ltd (immunotherapy) - \u00a32m grant I notice that they have a world-renowned scientist on their BOD. This may go some way to explaining the grant they received. That plus the cutting edge research they are undertaking on the immune system. Here he is: https://www.meduniwien.ac.at/web/en/ueber-uns/news/2025/news-in-june-2025/christoph-huber-receives-german-cancer-aid-award/",
          "sentiment": 0.0,
          "engagement": "5,087",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-11T17:21:05.911989+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261132-Porky9-89091435",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.580333",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "So you are keeping everything crossed that some free grant cash will land in the next couple of weeks to stave off the discounted placing. just incredible really that the focus is on how to get free grant cash to keep the gravy train moving forwards. How about a focus on making the business viable - now that would be refreshing. In all honesty, i would not award this business grant money to waste, it doesnt need it. They have an endless supply of free money from continual discounted placings on the AIM. Any grant money IMO should only go to ground breaking innovations, small private biotechs that have no means to raise cash easily not to this lot to indirectly get spunked up the wall on jollys aboard and ridiculous admin and bonus costs. This next placing will be interesting for sure; a) can he pull it off yet again or will brokers call time on it, b) will the support be out there c) how much of a beating can existing long term holders take whilst the business fails to deliver on its pledges. IF he gets it away, yet again, the discount has to be brutal surely; .15 to .20 ?",
          "sentiment": 0.0,
          "engagement": "7,471",
          "price_at_post": "0.35",
          "thread_title": "RE: UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-11T17:21:05.912007+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261005-paternos--3573451",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.580795",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Grant schemes are increasingly geared towards small companies - when it comes to eligibility, size truly matters. Recent UK oncology research grants to SMEs reflect sustained investment in cutting edge cancer research, with Innovate UK and the Biomedical Catalyst programme providing much of the funding. Recent awards to UK microcap/small biopharmas include: Momentous Therapeutics Ltd (immunotherapy) - \u00a32m grant Theolytics Ltd (ovarian cancer therapy) - \u00a32m Mestag Therapeutics Ltd (immunotherapy) - \u00a31.5m Revolver Therapeutics Ltd (peptide therapy) - \u00a3550k Epitopea Ltd (breast cancer stromal cells / immunotherapy) - \u00a3500k VacV Biotherapeutics Ltd (oncolytic viruses) - \u00a3500k Antikor Biopharma Ltd (ovarian immunotherapy) - \u00a3500k The above awards show clear emphasis on immunotherapy, peptide based therapeutics, and oncolytic virus platforms. Val\u2019s work not only aligns with these priority areas but also extends into difficult to treat cancers such as pancreatic, ovarian, triple negative breast, and prostate \u2014 indications where new therapeutic approaches are urgently needed. This strengthens Val\u2019s fit within the priority areas repeatedly backed by UK grant bodies. The grants aren\u2019t handouts; they\u2019re strategic investments in the UK\u2019s future. A successful cancer therapy can deliver multi billion pound global sales and position the UK as a leader in next generation oncology. Regulators are now actively encouraging NAM adoption and funders are rewarding small oncology-focussed companies that have strong academic links. Valirx is exceptionally well-positioned to secure substantial grants, extend the cash runway and reinforce financial stability. GLA, DYOR",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.35",
          "thread_title": "UK Grants Favour Small Biopharmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=E1177D8E-DA5A-41FF-B2C2-9A2A90112A99"
        },
        "ingested_at": "2026-02-11T17:21:05.912025+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260807-paternos-44031427",
        "event_type": "social_post",
        "date": "2026-02-06T22:33:44.581218",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Many of Mark\u2019s presentations have highlighted the potential of grant-funding, with the 14/10/25 RNS confirming a \u00a3250k award. This followed a KTV Open Univ award only 2 months earlier and Mark has stated further grant applications are pending. The Inaphaea RNS (18/9/25) on the repurposing top10, noted \u201c\u2026 discussions with potential licensees as well as an application for non-dilutive grant funding to support further development of these and other assets\u201d. In addition to ongoing partnering discussions, CytoLytix updates invariably reference grant opportunities. As MD of OncoLytika, Mark has a strong history of securing significant grants, including Eureka Eurostar funding, demonstrating a proven ability to win competitive international grants. Recent changes to UK and int\u2019l grant frameworks \u2014 including the UK\u2019s modernised Official Development Assistance (ODA) strategy, refreshed criteria, and new SME friendly collaboration rules \u2014 have opened funding routes that previously excluded early stage biopharma companies. These shifts prioritise oncology projects with demonstrable patient relevance, human relevant New Approach Methodologies (NAMs), and academia/SME partnerships, all of which align directly with Val\u2019s revised operating model. The combination of Mark\u2019s grant winning experience and the UK\u2019s revised grant landscape creates a clear opportunity for Valirx as it enters its next phase of growth.",
          "sentiment": 0.5,
          "engagement": "366",
          "price_at_post": "0.355",
          "thread_title": "The New Grant Landscape",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=2EC60BA4-C275-47D5-901A-D8BA32B59D52"
        },
        "ingested_at": "2026-02-11T17:21:05.912042+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261811-viera--3790001",
        "event_type": "social_post",
        "date": "2026-01-30T22:38:35.634037",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "You sold the spike brilliantly Stephen . Knowing we have had no announcements and another year of zero revenue . You and porky have called it here . What do the directors get paid for here exactly ? Shambles . The BOD needs strengthening .",
          "sentiment": 0.0,
          "engagement": "1,553",
          "price_at_post": "0.35",
          "thread_title": "RE: Ambrose Q1 Newsletter - FYI",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=DD644FF4-EB58-4811-9E0F-61E17204B69A"
        },
        "ingested_at": "2026-02-11T17:21:05.912060+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261626-Uncanny-36923905",
        "event_type": "social_post",
        "date": "2026-01-30T22:38:35.634577",
        "source": "LSE_CHAT",
        "data": {
          "author": "Uncanny",
          "content": "Ambrose Healthcare | 2025 Highlights and What\u2019s Ahead in 2026 Dear Colleague / Partner, As we begin 2026, we would like to share a brief reflection on the past year at Ambrose Healthcare and outline what lies ahead in delivering its mission, to bring new therapeutics to rare disease patients who currently have no approved drug treatment. Our last update was shared in October 2025. Since then, meaningful progress has been made across our programmes, partnerships, and team, all in support of our mission to bring treatments to patients living with rare and underserved conditions. 2025 at a Glance During 2025, Ambrose focused on building strong scientific, operational, and partnership foundations to support the next phase of development: Continued preparation for the Renzapride Phase 2 trial for the treatment of the Gastrointestinal Manifestations of Cystic Fibrosis (GMCF), including regulatory planning and UK clinical engagement Exercised the licensing option for VAL401, securing global rights for development and commercialisation for treatment of cancers. 20% of cancers are classified as rare diseases. Ambrose is focusing initially on development for the treatment of pancreatic cancer Strengthened leadership, governance, and delivery capability Expanded engagement with clinicians, researchers, and funding partners across the UK and internationally Much of this work took place behind the scenes, laying the groundwork for accelerated progress in 2026. Scientific Leadership We are pleased to be working closely with Professor Bu Hayee, Kings Hospital, London who oversees the GMCF treatment centre for the Southeast of England and is supporting Ambrose as a Scientific Advisor for development of Renzapride for GMCF, providing valuable clinical insight as the programme progresses. We were deeply saddened by the passing of Professor Brian Feagan during 2025. Professor Feagan was internationally respected for his leadership in clinical trial design and execution. His early engagement with Ambrose and belief in rigorous, patient-centred development left a lasting impact on our work and thinking. Looking Ahead to 2026 In the year ahead, Ambrose Healthcare will focus on disciplined execution and collaboration, with priorities including: Advancing Renzapride toward initiating its Phase 2 study Preparing VAL401 for Phase 2 clinical development Pursuing investment as well as public and charitable grant funding, including a recent formal invitation to submit a major UK grant application for Renzapride Continuing to build trusted partnerships with clinicians, academic groups, and research organisations These activities reflect Ambrose\u2019s commitment to capital-efficient development and strong alignment with the UK life sciences ecosystem. Planning Named Patient Supply We are also planning to initiate Named Patient Supply (NPS) activities. Named Patient Supply enables access to Good Manufacturing Practice-manufac",
          "sentiment": 0.0,
          "engagement": "3,308",
          "price_at_post": "0.35",
          "thread_title": "Ambrose Q1 Newsletter - FYI",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=DD644FF4-EB58-4811-9E0F-61E17204B69A"
        },
        "ingested_at": "2026-02-11T17:21:05.912078+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261709-Porky9--5917279",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.373661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "What, do you think he is going to release news of the placing already, possible but they normally leave it right until the death, so proabably a few more weeks yet but you never know, you could be right.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.355",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-11T17:21:05.912096+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261448-Notpotal-52582671",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.374477",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Is that a Friday RNS I can smell.... Or has Porky had an accident? \ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.35",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-11T17:21:05.912141+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262254-viera-23523563",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.375315",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Pm changed his name to pp It\u2019s basically ME copy and paste . As he said ME has produced one RNS in months . We all know what the next RNS of note will be . ME needs to cut costs further and do something with 201. Good luck all.",
          "sentiment": 0.0,
          "engagement": "1,552",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-11T17:21:05.912159+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261720-RayPoint-61250843",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.376112",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Pater It's funny to see, in a thread entitled \"The Ambrose Dream Team\" and started by yourself , that neither the Dream Team nor VAL401 get a mention in your latest post.",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-11T17:21:05.912177+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261632-ratcliff--9050701",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.376907",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "'When the SP inevitably hits 1.6p plus there will be further buying pressure as placees exercise their 1.3p warrant options. Some will then sell for a quick profit but by then the SP will be in the 2p range. All this without the flush of positive news expected over the coming months.' Sounds good? Sounds worth buying into? Well actually it's a paternostpauper quote from 16th January 2025. But the share price then was 0.875, sliding gently down another post-placing ski-slope graph.  And what's the biggest news since then? Oh yes, another placing - predicted by P9 and derided by PP. Until it happened. On past history Porky's predictions seem a pretty reasonable bet. PP's posts are just reformulated bin dippings - he might as well just copy and paste on a pumping merry-go-round.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-11T17:21:05.912195+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261512-Porky9--7756893",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.377717",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Always entertaining, like watching fantasy island @PP is our very own Mr Roarke and @nopot is Tattoo.  Not sure who @uxm plays, probably the aircraft pilot as he only turns up to share the fantasy once a week or so. The gap will be between .15 and .20 as that will be where the placing shares land, thats of course if ME can pull it off again. Jury out this time.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-11T17:21:05.912213+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261503-paternos-62169214",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.378553",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Good post UXM.  Always entertaining to see trader Nick post again - his 63rd consecutive LSE post - and every one on Val. He might as well hang up a banner \u201croll up, roll up \u2013 bargain of a lifetime!\u201d \ud83e\udd23\ud83e\udd23\ud83e\udd23 Val has issued just one positive RNS since the placing, yet the SP has climbed 67% from those 0.23p lows. Even with 2 major holders dipping below the 3% threshold to facilitate some short-term trading, the SP still hovers near 0.4p. Every day that passes without an RNS increases the likelihood of one the following day as multiple programs mature: CytoLytix patent updates, formulation decisions, Blue Ribbon/VAL201 partnering (by diluting the asset, not VAL plc), 3k repurposing update (top candidate partnering?), further grant updates (ME has strong history), next evaluation and SPV (confirmed in webinar), Inaphaea income (PredictRx/ PDC sales), updates on the Dundee/Queen Mary pro-senescence project and StingRay (decision imminent). The motherlode remains early partnering/grant funding for CLX, a 2026 milestone confirmed by the CEO in the recent webinar. As the June anniversary nears, Omios have to decide whether they wish to exercise their option of a license agreement to continue using CLX tech. It looks promising as both Mark and Omios CEO Dr Aldo Pourchet had meetings arranged at the JPM in San Fran. More than once, Mark has referenced the Omios virus as an entry point to veterinary oncology due to its potential for treating canine HSA, while Dr Pourchet posted: \u201cWe are targeting triple negative breast cancers (CLX primary indication), all of which have the biomarker that makes them susceptible to our therapy. It\u2019s our most advanced program\u201d (Oct NYU interview). With multiple CytoLytix licenses up for grabs, Omios look set to start the ball rolling. The decisive factor which totally undermines the detractors\u2019 fearmongering is the financial position: a cash runway that extends till H2 excluding warrant income, R&D tax credits, grants, or additional Inaphaea income. That completely negates any March/April placing argument. Mind you, naysayers never let a few facts ruin their narrative. GLA DYOR",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-11T17:21:05.912231+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20261956-uxm484-44327366",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.379412",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Watch the video. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025 Chart analysis shows a nice gap at 1.4p. Past management issues but new management is outstanding.  Cash until H2 without the add ons such as grant money, revenue and warrant money. CEO heavily invested over 250k. Negotiating with a major biotech in regards to a deal for CLX001. Lab space is to help progress the assets to eventually get a deal not to make instant revenue. Any research on CLX001 done against a valuation of 2 million and cash burn just over a million would know this is a great opportunity. Great decision making. Derisking assets with partnership deals. Which other biotech has so much and spending less than 2 million. With warrants at a premium to the current price hopefully no more dilutions. Expecting significant news in the coming days/weeks. Tiny valuation and cash burn is tiny with assets of significant value.",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-11T17:21:05.912249+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20261515-viera-46849132",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.380239",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Problem my friend is ME hasn\u2019t got a proper hold of Costs paying a non BOD member and non scientist 100k  paying best mates that produce zero revenue is a disgrace . It shows a lack of respect for shareholders . Where are all the promised lab contracts . ME has surrounded himself with \u201cyes \u201c men. Shame he ousted Adrian as he had the commercial nous to make a difference . Adam also lost interest as was treated so badly by the BOD. I predict more confetti in April /May . Porky knows this co better than anyone . If he and Adrian joined the BOD I would consider investing but I\u2019ve lost faith in the current BOD who promise the world and deliver FA. Deliver some revenue asap or step down .",
          "sentiment": 0.0,
          "engagement": "1,552",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-11T17:21:05.912266+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20261416-ratcliff-26284100",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.381020",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Interesting that you've posted notgotalot - in December you distinctly said \"I\u2019ll take some time out and won\u2019t be back until the next decent RNS.\" Presume you've restarted posting because you've lost hope in there being a decent RNS.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-11T17:21:05.912284+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20260843-Notpotal-76064164",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.381814",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "each conspi****** on here is in self-denial mode - a mechanism where a person ignores or distorts reality to avoid anxiety and stress. they refuse to accept the situation simply because it doesn\u2019t support their agendas and so resort to posting fiction. whether it is by inventing a 50% lower cash runway, alleging fictitious staff at ambrose, claims of ceo golf jollies and overpaid team members or alleging lse posters are on the val payroll. desperate posts by the uninvested are now treated with the contempt they deserve. just when you think they\u2019re as low as they can get \u2013 they pick up a spade. by resorting to deception, they have lost any remaining credibility they may have had, while each day news edges closer.",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-11T17:21:05.912302+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20262102-ratcliff--9123040",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.382589",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "It would also be interesting to know why the posting of relevant financial facts from those observing is described as 'panic.' Surely the only panic is among those trying to snare the naive with fantasy predictions so they can get out fast with a profit - and now realising that the supply of gullible newbies is drying up.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-11T17:21:05.912319+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261925-RayPoint-75142619",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.383379",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "So what's the crack, pp? I would be interested to know your view on how Ambrose are paying salaries to the Dream Team without having any money in the bank",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-11T17:21:05.912337+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261832-paternos--5537954",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.384211",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "@  spantrout - Great call. Valirx - 10m,50s in. \u201cA lot of return on that one!....DYOR but in all probability, if it\u2019s going to have some game-changing news, then \u2026.that would be 1.4p.\u201d Not sure of the news he is he is referring to? Maybe the new patents, partnering (CLX,201), repurposing top 10, StingRay, further grants, or expansion into veterinary oncology? Possibly it\u2019s the the 2nd evaluation and new SPV or even the CEO buying 7% of the company. I suppose it could be that Mark E has recently been on stage presenting alongside some of the biggest names in pharma, or the fact the CEO has a history of delivering success (Nu.Q test sold for $26m). !.4p is an interesting SP \u2013 that would not only see the 0.5p warrants in play but also the 1.3p warrants, easily extending the runway into 2027. Mind you realistically, a few easily pleased would exit for a quick 300%+ profit. I guess the uninvested posting day and night trying to supress the SP hasn\u2019t gone unnoticed either. Karma can be a wonderful thing! Happy days DYOR, GLA.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.385",
          "thread_title": "RE: Coverage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=1C527045-FD63-41D2-B4BE-ED55425FC93C"
        },
        "ingested_at": "2026-02-11T17:21:05.912354+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261714-Notpotal-69347370",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.385010",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "pp previously purged porky\u2019s parrots\u2019 pack of preposterous posts pedalled in panic, perhaps predictably. i promptly prepared a poem for porky to peruse at his pleasure. pundit porky posted a pack of pathetic, poorly proven poppy****. a pack of pathetic, poorly proven poppy**** pundit porky posted. when pundit porky posted a pack of pathetic, poorly proven poppy****, perhaps he\u2019ll point to proof behind the pathetic poppy**** pundit porky posted?",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.385",
          "thread_title": "Porky\u2019s Peddled Pile of Piffle",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=93B08DEA-F499-4237-AF7E-B5143BC8D67E"
        },
        "ingested_at": "2026-02-11T17:21:05.912372+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261625-spantrou-86126345",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.385791",
        "source": "LSE_CHAT",
        "data": {
          "author": "spantrout",
          "content": "Https://youtu.be/HrYMuqPFA20",
          "sentiment": 0.0,
          "engagement": "13,977",
          "price_at_post": "0.385",
          "thread_title": "Coverage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=1C527045-FD63-41D2-B4BE-ED55425FC93C"
        },
        "ingested_at": "2026-02-11T17:21:05.912391+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261403-Porky9--1700101",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:08.386613",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@PP You really are a busted flush, its like groundhog day:- Pump the boards with nonsense about million dollar licensing deals, how the cash is well managed and will last many months more than it does, how there will be all these marvelous license deals lined up, exaggerate the interest and how fantastic it all is. Then RNS drops,  placing at discount issued, you vanish for a few weeks, let the dust settle and then you pop up again and repeat the above. I totally get those in the business want the gravy train to continue, lifestyles at risk but have you no conscience that small investors that may not earn the sort of money the board here gets here for these cushy  work from home jobs, are going to lose their hard earned cash being sucked into this? Its morally not right. Next RNS will be the next discounted placing, can't be far off now, a few weeks at most imo.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-11T17:21:05.912409+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261529-RayPoint--9011576",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.157704",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "I hear that green fees are pretty steep in California",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-11T17:21:05.912427+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261434-ratcliff-73984794",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.158130",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "No problem RP - I'm wondering who paid 0.50 for a few shares worth about 25 percent less from the start, but I suppose 400 quid pays for the week's teabags and digestives.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-11T17:21:05.912445+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261413-RayPoint-55719420",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.158544",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Sorry Rats. I misinterpreted your post.",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-11T17:21:05.912471+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261412-RayPoint-79154799",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.158961",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "\"Probably about 450 quid...\" Rats, stop ramping! The gross proceeds were \u00a3400",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-11T17:21:05.912490+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261357-spantrou-79620890",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.159474",
        "source": "LSE_CHAT",
        "data": {
          "author": "spantrout",
          "content": "\u00a39.99 for rns",
          "sentiment": 0.0,
          "engagement": "13,977",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-11T17:21:05.912508+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261311-ratcliff-84192493",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.159890",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Probably about 450 quid...",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-11T17:21:05.912526+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261216-steve196--3749555",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.160315",
        "source": "LSE_CHAT",
        "data": {
          "author": "steve196",
          "content": "How much does it cost to release an RNS just for \u00a3400 of warrants?",
          "sentiment": 0.0,
          "engagement": "2,761",
          "price_at_post": "0.385",
          "thread_title": "Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-11T17:21:05.912544+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261935-uxm484--4484631",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:12.160734",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "No, but the holders all want the warrants exercised so we can do a 10 bagger in 12 months without a fund raise. For me i am really happy here with  the progression. We are definitely early in a news rich periods where all the negative posters are posting overtime and are only posting as they missed out on the last fundraise hoping for an even lower price. We will likely get a few meaningful RNS very soon. Brakes are now off\u2026",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.36",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-11T17:21:05.912562+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261222-Notpotal--5377008",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.261915",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "\u201cYou sound so desperate\u201d says the man who\u2019s last 60 posts have been on a share he isn\u2019t invested in. \ud83d\ude02\ud83d\ude02\ud83d\ude02",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-11T17:21:05.912580+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261207-ratcliff--1312782",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.262733",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Slight typo there - should read blatantly UNTRUE and misleading!",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.365",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-02-11T17:21:05.912598+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261201-ratcliff--3606331",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.263581",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "UXM - differences of opinion are generally understandable, but to say in your post 'All lies' is blatantly true and misleading, and as usual does nothing to bolster your credibility. Two of the things you say in that post are particularly inaccurate - 'Great decision making. Derisking assets with partnership deals. Which other biotech has so much spending less than 2 million.' - They are looking for deals (or claim to be anyway) but nothing so far has contributed anything to even cover the outgoings, let alone provide money for further work or expansion (hence the redundancies etc) Secondly - 'With warrants at a premium to the current price hopefully no more dilutions' - warrants don't kick in and generate cash the moment the sp goes above them as you and the others in your group seem to imply. In the unlikely event of the sp rising above that point and remaining so, it just might be worth warrant holders exercising them so they could buy shares at below the then-current price, but to sell them they'd need to be able to be sure the sp was strong enough to withstand the effect of the sells. You know that, so stop trying to imply that the mere existence of warrants is a long-term fool proof source of near or long term capital. Then again, if this company was fool proof you wouldn't be here I imagine.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.365",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-02-11T17:21:05.912616+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261059-viera--1013776",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.264399",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "Are you PM in disguise ? Who in  their right mind would buy any company on Aim with only 3 or 4 months cash runway? You sound so so desperate for a rally to sell out !",
          "sentiment": 0.0,
          "engagement": "1,552",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-11T17:21:05.912634+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261050-Rebster4--1015074",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.265221",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rebster408",
          "content": "Its groundhog day again This is a binary bet...and Poky has called it right in the past and I thinks he's spot on again... 201 is older than me!!! place your bets... the wheel is spinning and will stop within the next 8 weeks All will become clear within the next two months...",
          "sentiment": 0.0,
          "engagement": "1,174",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-11T17:21:05.912653+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260920-RayPoint-47655561",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.266008",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Living in fantasy land",
          "sentiment": 0.0,
          "engagement": "5,073",
          "price_at_post": "0.365",
          "thread_title": "RE: Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-11T17:21:05.912671+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260857-Notpotal--3147772",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.266824",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "\u201cYou can't go back and change the beginning, but you can start where you are and change the ending.\" \u2013 C.S. Lewis Early in his tenure, Mark acknowledged mistakes had been made \u2014 and while he couldn\u2019t rewrite the past, he could reshape the future. 17 months later, Val is reborn, with money in the bank, a rebuilt team, high calibre assets and a SH base that deserves success after years of one-way support. A few resident historians cling to their preferred mythology, inventing a minimal cash runway because the real picture is too uncomfortable to accept: a cash runway to H2 even without R&D tax credits, additional Inaphaea income, grants or exercised warrants. This is also before the wave of RNS due over the coming weeks. Unlike those posting fiction, Mark has backed his conviction with his own money \u2014 now holding 7% of the company. \u201cWhat matters now is not where we\u2019ve been, but where we\u2019re going.\u201d",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.365",
          "thread_title": "Living in the past",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=46611D0F-9C9F-46FC-B0AF-02EC00A4EB07"
        },
        "ingested_at": "2026-02-11T17:21:05.912689+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20262049-ratcliff--7505221",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.267621",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Whatever it is you're smoking UXM, it's powerful stuff.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.385",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-02-11T17:21:05.912707+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261733-uxm484--4111906",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.268458",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "All lies. Watch the video previously posted. Past management issues but new management outstanding.  Cash until H2 without the add ons. CEO heavily invested over 250k. Negotiating with a major biotech in regards to a deal for CLX001. Lab space is to help progress the assets to eventually get a deal not to make instant revenue. Any research on CLX001 done against a valuation of 2 million and cash burn just over a million would know this is a great opportunity. Brokers only had 20k stock. Hardly lots of stock. Great decision making. Derisking assets with partnership deals.  Which other biotech has so much spending less than 2 million. With warrants at a premium to the current price hopefully no more dilutions.",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.385",
          "thread_title": "RE: Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-02-11T17:21:05.912725+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261719-Porky9--3353575",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.269349",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "And just a few reasons why not to believe the BS from the resident rampers here and why you should avoid:- * Lifestyle Business * Ridiculous Admin costs * Continual Raises and continual dilution * More than 20 Raises, 3 lots of 125:1 Consolidation events * business concept never proven * Rented lab space and zero revenue in 15 years * About 8 weeks cash runway left with yet another raise due anytime soon to keep the gravy train going. * if new investors or brokers say enough is enough and call time due to clients continually losing money then its admin and you could lose your entire investment. * materially overpriced as absoluly nothing here to invest in, its the emperors new clothes you are buying. 201 is older than hens teeth, no interest in 15 years and CLX years off and more cash required. Labs meanwhile doesnt know what an invoice is. * Poor decision making, lack of any commercial acumen *No real focus, practically everyone is work from home with multiple jobs. * Short term punts only not a long hold due to above. * loads of stock held for broker fees that will need to be drip fed into anyone buying. In all avoid at all costs unless you like dilution",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.385",
          "thread_title": "Why you should Avoid",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=A1F47F4F-4A97-4B34-B390-736E64EE1007"
        },
        "ingested_at": "2026-02-11T17:21:05.912744+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261507-ratcliff-34697236",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.270143",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "You swine Nomlungu. You've rumbled me.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.41",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-11T17:21:05.912762+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261503-Mr0nions-58191663",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.270906",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mr0nions",
          "content": "Because of this  post, I'm holding position.  Good luck all.",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "0.41",
          "thread_title": "RE: Why invest? \u2013 THE SCIENCE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=058BF091-3235-424B-9C46-FA00ED6BC8D5"
        },
        "ingested_at": "2026-02-11T17:21:05.912780+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261432-mikee_p--7786324",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.271701",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "1 HR. Channel is all ya need.",
          "sentiment": 0.0,
          "engagement": "1,893",
          "price_at_post": "0.395",
          "thread_title": "Easy trade this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=81274FD9-0226-45F3-8CEA-B1F91E33B4A2"
        },
        "ingested_at": "2026-02-11T17:21:05.912799+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261430-nomlungu--2383864",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.272502",
        "source": "LSE_CHAT",
        "data": {
          "author": "nomlungu",
          "content": "People should just ignore Rat... he is just jealous that he does not have the losses to use to reduce his tax liabilities. That 80% drop in the last tax year will have been very valuable for some; I think him moaning around the time that taxes are due for the 2024/25 year is a dead give away. \ud83d\udcc9 \u2757",
          "sentiment": 0.0,
          "engagement": "23,976",
          "price_at_post": "0.395",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-11T17:21:05.912817+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261313-paternos-43984271",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.273388",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "When Mark became CEO, ValirRx was effectively dormant - few assets in play, minimal Board investment and limited vision. He set about a major restructuring: rebuilding the team, reshaping the asset base and above all, resetting the mindset. Fast forward 17 months and Val is reborn. A microcap expanding into developing fields of oncology, yet every action taken has a cost/benefit analysis and timescale consideration. If concluded that a project cannot be monetised early, it is shelved or paused. Commercial decisions overrule all others. Valirx is now plugged into some of the most advanced platforms in modern drug development: \u2022\tpatient avatars (TwinEdge) \u2022\tmicrofluidics/3D tissue culture models (Screenin3D, Ignota & VoxCell) \u2022\trepurposing (Ignota, Altus & Dominion) \u2022\tpersonalised immunotherapy (PredictRx / Dominion) \u2022\tpro-senescence drugs (Dundee / Queen Mary Uni) \u2022\tClickmer technology/HER2 protein (Apis Assay) \u2022\tLMTK3 kinase targeting (StingRay). The most recent evaluation, a 2nd-gen RNA helicase inhibitor (McGill/IRICoR), brings Val into collaboration with major international research organisations. Last year, Mark identified a shift away from animal-testing and moved early to establish capability partners supporting NAMs and cutting-edge AI. Recent US & UK Gov\u2019t regulatory changes now actively favour such platforms with Europe to follow this year. Once again, Val anticipated this trend before much of the market. Meanwhile, the Advisory Board has been upgraded from academics and towards industry experts who can provide insight into Big Pharma priorities and identify new commercial pathways such as in veterinary science - quicker to market while opening a parallel revenue path thru\u2019 comparative oncology, further de risking the route to human oncology. Mark has also added a clause into evaluation agreements whereby if Val decides not to progress an asset eg StingRay, McGill/IRICoR, then Inaphaea retains the data and can still monetise should a 3rd party take the asset forward. Val is no longer waiting for opportunity; it is engineering it.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.385",
          "thread_title": "Why invest? \u2013 THE SCIENCE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=058BF091-3235-424B-9C46-FA00ED6BC8D5"
        },
        "ingested_at": "2026-02-11T17:21:05.912835+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261224-paternos-65375065",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.274229",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "A \u00a33m microcap with a cash runway till H2 even before factoring in R&D tax credits, potential grant funding, additional Inaphaea income or warrant cash now within reach. Outgoings reduced by \u00a3200k PA following a team restructuring last year. Val\u2019s expansion into NAMs and advanced AI tech, supported by strong academic partnerships, aligns directly with revised US & UK gov\u2019t guidelines to reduce animal testing. This positions Val as a front runner for non dilutive grants and innovation funding, with a CEO geared to capitalise on this opportunity. The 1/9/25 RNS confirmed ongoing discussions with several potential partners to progress Cytolytix, including a major pharma. Val owns 60% of CLX with 10% owned by co-inventor, Dr Charles Chen (Senior Scientist at Astrazeneca). Val also has a 54% share of an Ambrose deal potentially worth up to \u00a316m, and a Biobank of 476 PDCs valued at \u00a310k per PDC cell-line upon commercialisation, plus commercial rights entitlement. Valirx has assets in several key cancer indications, all with huge global markets: 201/prostate ($11.3Bn*), CLX (primarily TNBC ($1.5Bn*), ovarian ($2.5Bn*) but also prostate, 301/endometriosis ($1.9Bn**), and 401-Ambrose/pancreatic ($2.9Bn**). Sources: *webinar, **GMI. Several RNS updates are imminent: CLX patents \u201cin coming weeks.\u201d (RNS 1/9/25), Dundee/Queen Mary project (extended to 9/2/26), StingRay (approx Feb \u201926 per Aug video), Blue Ribbon SPV - \u201cSeveral patents envisaged for 201\u201d, and the next evaluation/SPV \u201cimminent with discussions already at a mature stage\u201d. The Omios RNS (3/6/25) stated \u201c\u2026 expected to take up to 12 months. On conclusion of the evaluation, Omios has an option to enter into an Oncolytic Peptide License Agreement to continue using Cytolytix technology.\u201d Yet another potential source of income. In addition, the Val/Dominion repurposing project (teaching an old drug new tricks) has identified 200 FDA approved non-oncology drugs which already have phase 1 clinical data and are showing activity against various cancer PDCs. 10 of these candidates are now being fast-tracked. The median upfront deal size for pre-clinical IND ready assets was $110m in 2025. For phase 2 this increased to $775m. (Dec webinar). For context, Val\u2019s SP exceeded 55p in 2021 with only one key asset (VAL201). Currently, including the repurposing project, Val now has 200+ potential assets plus a valuable Biobank. Also, Mark has restructured evaluation agreements whereby if Val chooses not to progress an asset (eg StingRay, McGill/IRICoR), Inaphaea retains the data and can still monetise should a 3rd party take the asset forward. Multiple monetisation routes now sit across the pipeline, supported by a commercially-savvy CEO who now owns 7% of the company. Valirx \u2013 a microcap with midcap potential.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.355",
          "thread_title": "Why invest? \u2013 FINANCIAL",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=8931CA86-EC8C-43F3-AA7F-54C7D7FD717E"
        },
        "ingested_at": "2026-02-11T17:21:05.912853+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261145-Marty130-54296798",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.274986",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Be good to see the directors buying some of the stock..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "0.355",
          "thread_title": "Directors deals",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=DC2D2A2F-B451-4EEF-B7C8-9C80695D4033"
        },
        "ingested_at": "2026-02-11T17:21:05.912871+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261107-ratcliff--7009489",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.275854",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "UXM - cutting and pasting the same post repeatedly is not convincing, but to humour you I had a listen to the link you have monotonously posted. It's not persuasive or convincing - Starts off about the 'objectives we have set' and 'milestones we're looking to achieve.' Then there's a bit about the group structure - this is rearranging the deck chairs on the Titanic isn't it? They've had more rearrangements over the decades, it's just a distraction now - meetings are the practical alternative to work. The we hear 'The objective is...' and 'If suitable...'  So nothing at all certain. Then he says BC201 and Val301 have 'not been spun out yet, but would benefit from all of the development work undertaken on Val201.' So BC201 and Val301 still of no interest (except maybe on Antiques Roadshow) and if Val201 had even a glimmer of potential it would have done something since it was quietly shelved - was that 6 years ago or 8? It's been stagnant for so long, the rest of the industry has moved on. The he says 'There is strong interest in endometriosis treatments.' True. There's strong interest in a lot of things, but stating a fact doesn't tie it to VAL. 'We have two new evaluations under consideration.' And...? I\u2019ve got a lot of things under consideration, but whether they get any further is often very uncertain. 'The vision is...' - A lot of people have visions, but a vision isn't even a plan. It's a nice idea at best. 'Our strategy is to do this based on identifying the highest quality assets we can find and afford.' That's like saying 'come round to my place for a meal' and when you get there you say 'There\u2019s a tin of Pedigree Chum between the four of us - it was the highest quality I could find on the available budget.' The he's going to have a system which 'allows us to prioritise selection of assets.' How early stage is all this? And no money to do it with.. Next we see \u2018The Team\u2019 but no mention of their salaries. Then a review of last year - no mention of the placings. Talk of last year's cost savings and redundancies - but if you are cutting 200k a year and laying people off, what were you wasting the money on in the first place? Or have you sold your food to pay the heating bill? Then he says 'Our runway through 2026' - sorry - that 'runway' stops in a couple of months without a placing. The 2026 Xmas do is potentially in the Job Centre unless money comes in very soon. Time is money. They seem dangerously short of both. Again.",
          "sentiment": 0.0,
          "engagement": "11,402",
          "price_at_post": "0.355",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-11T17:21:05.912889+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260954-uxm484-72132524",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.276634",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Plenty of news to come at a tiny valuation and likely this month. Cash until at least July that without warrants, revenue, deals, grants. Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-11T17:21:05.912907+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260919-Porky9-51948262",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.277452",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@Notpotalot Nick is a VERY experienced prolific investor. Frankly, i doff my cap to him as he called the trade perfectly in at .25 and out at .40. Beautiful. The Muppets are the traders in on the back of the Zac Mir pump without any research in blind on the dead cat bounce they will get burnt if still holding. As for Stephen and Jaspal at u3% they now dont have to declare BUT IMO they have about 8 weeks to slowly work the sells in to ensure they are out (just holding warrants options) before that next raise drops as they will be diluted to oblivion as sure as night is day. They can only drip sells in slowly to avoid the brokers hammering them at discount. You try selling big volumes of this close to the raise, or at anytime for that matter, you need to do it on a bounce really, sell whilst traders are buying. This is NOT an investment, its a short term punt. The reason its not an investment is because it can't generate revenue (well none in the last 15 yrs anyhow)  and is reliant on raise after raise after raise to maintain lifestyles. As I say, tick tock. Tick tock countdown already started imo.",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-11T17:21:05.912925+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261952-Notpotal--8678818",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.278260",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Porky, unlike some holders, I still keep you around for the entertainment value.  Calling Nick and other traders \u2018muppets\u2019 is certainly \u2026.\u201dcreative\u201d. \ud83d\ude00 Jaspal S and Stephen W dipping just under the 3% is nothing more than freeing up a couple of million to trade. There\u2019s no great sell-off and no drama. Most of us aren\u2019t brave enough to risk missing an RNS for the sake of a few hundred quid. Get your 40 winks while you can. Many sleepless nights await over the next few months.   \ud83e\udd71 Pleasant dreams.",
          "sentiment": 0.5,
          "engagement": "80",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-11T17:21:05.912944+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261804-uxm484-72132524",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.279044",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Plenty of news to come at a tiny valuation and likely this month. Cash until at least July that without warrants, revenue, deals, grants. Here is the recent presentation explaining the cash runway including catalysts. Facts not fiction. https://valirx.com/activity-updates/rk5VLy-update-19-12-2025",
          "sentiment": 0.0,
          "engagement": "1,011",
          "price_at_post": "0.345",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-11T17:21:05.912962+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261539-Porky9-14107441",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.279866",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "Err nope Only thing that will bring hard cash into the company of any meaningful amount in the next 8 weeks will be new placing money - sorry Regarding your continual pumps and fluffy updates, jam tommorrow dream fantasy posts, NONE of it can pay the bills now, end of. Anyone with any brains will be working the sells into any mupets trading this that are oblivious to the dire need for cash to keep the lights on and the pending essential discounted placing that has to happen to support the lifestyles here to keep the gravy train going. Tick Tock, Tick Tock",
          "sentiment": 0.0,
          "engagement": "7,469",
          "price_at_post": "0.35",
          "thread_title": "RE: Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-11T17:21:05.912980+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261042-paternos-72056249",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.280667",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "As standard, when Mark did the Dec webinar he emphasised nothing new, \u201cjust meat on the bones\u201d. However, often that meat can be pretty tasty. Blue Ribbon/VAL201 \u2013 \u201csynthesis almost complete\u201d (10m.30s). Then, \u201ca small amount (only \u00a350k) set aside for pre-clinical development of 201, the balance WILL then come from external investment into the asset\u201d (11m.55s). No \u201cMIGHT\u201d in that statement. The minimal outlay confirms that the VAL201 drug package is essentially finalised, and the entire development programme (preclinical \u2192 IND \u2192 partnering) is about to move forward. Mark has already confirmed Val will be diluting the asset, not Val PLC. With patents imminent, it\u2019s a clear signal that Blue Ribbon is not just a corporate shell \u2014 it\u2019s actively progressing VAL201 toward monetisation. Given Val\u2019s recent multi facet RNS style, the imminent update could well bundle new patent status with partnership confirmation. The last significant VAL201 update in 2021 saw the Val SP exceed 50p.",
          "sentiment": 0.5,
          "engagement": "360",
          "price_at_post": "0.365",
          "thread_title": "Monetisation Begins Here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=B12E5E46-FE1B-42FC-BCEC-5BFC370A090E"
        },
        "ingested_at": "2026-02-11T17:21:05.912997+00:00"
      },
      {
        "event_id": "SOCIAL-10Jan20261920-Kaeren--8024584",
        "event_type": "social_post",
        "date": "2026-01-29T09:48:15.281449",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kaeren",
          "content": "All great thx.",
          "sentiment": 0.0,
          "engagement": "10,948",
          "price_at_post": "0.39",
          "thread_title": "RE: McGill University/ IRICoR",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&share=VAL&thread=C94998FF-5728-4ADB-B876-A8B2F6FA23D8"
        },
        "ingested_at": "2026-02-11T17:21:05.913015+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262133-paternos-78747531",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.646223",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Seven consecutive \u201cblocked\u201d posts on a blue day tells me everything I need to know. LOL The desperation of the naysayers knows no bounds \u2013 and the newsflow hasn\u2019t even started yet. I fear for the sanity of Porky and his parrots over the coming months. With an absolute minimum cash runway into July already confirmed and multiple RNS imminent, Porky could well self-check in to the local abattoir. The lorry reversing toward the sty, isn\u2019t delivering feed. \ud83d\udc37 \ud83e\udee8 \u26a1 \ud83c\udf2d Anyone for a bacon butty or sausage cob?",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.385",
          "thread_title": "The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=A448B7A8-3AD1-4874-B3E6-DCD5CE726C52"
        },
        "ingested_at": "2026-02-11T17:21:05.913033+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261807-Porky9-64762246",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.646670",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@Nick I totally agree with you. If anyone can trade this you can. But I have to hand it to mark, the money just keeps on coming, I mean its shocking really, there is absolutely nothing here to invest in, it really is the emporers new clothes, but he keeps getting the cash and with over 20 raises, what's another one? I still think .15 or .20 but ultimately you would think the brokers would say, hang on a minute you never deliver on anything you say, our clients are losing money off our broker notes to buy, enough is enough but I guess as long as they get their fees they couldn't care less.",
          "sentiment": 0.0,
          "engagement": "7,466",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-11T17:21:05.913051+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261719-RayPoint-91860734",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.647089",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "It does explain all the voices in my head \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-11T17:21:05.913069+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261714-ratcliff--5454174",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.647517",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Viera - are you RayPointer and me as well?",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-11T17:21:05.913088+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261704-viera-65537950",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.647968",
        "source": "LSE_CHAT",
        "data": {
          "author": "viera",
          "content": "But why would anyone give this lot any money Porky  ? They earn 100k whilst having other part time jobs. Been 20 years of promises but zero revenue . There will be zero revenue in before April when the next begging bowl comes out . I was at 5pct with Theoremx and that failed . I\u2019m at zero pct with Ambrose ! Anyone holding this as we enter Feb/March needs to see a dr. Any monies raised goes to directors as not enough to make any investments. I will NOT be buying at any price . It\u2019s a shambles . Sorry",
          "sentiment": 0.0,
          "engagement": "1,550",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-11T17:21:05.913127+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261454-Porky9--4003758",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.648402",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "They dont have a pot to pee in, its a phoenix business and frankly if they raise cash it will be for themselves, not to give away to VAL - BE REAL. Would imagine meetings being scheduled by VAL with placing brokers shortly, can't be far off now - my call this time is another \u00a31m at .15 to .20 tops - give them another 5/6 months more gravy train assuming brokers can find more mugs to support the lifestyles.",
          "sentiment": 0.0,
          "engagement": "7,466",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-11T17:21:05.913146+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261440-ratcliff-51004482",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.648817",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "I was asking myouryourself the same question. But I knew that, as did Iyou.",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-11T17:21:05.913165+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261415-RayPoint-53169176",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.649253",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Are these people actually employed by Ambrose? Last time Ambrose received capital investments (as I recall, in the region of 900,000) they trumpeted the fact on their website. Yet, at March last year, they only had 25k in the bank. Subsequent to March last year,  there have been no announcements of further investments. I ask myself (i.e. Rats) how this all adds up.",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-11T17:21:05.913183+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261403-Notpotal--1065893",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.649678",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Nice to see momentum at Ambrose. They certainly are building a very strong team. However, this highlights another positive for Valirx. VAL401 is the result of a reformulation of the anti-psychotic drug, Risperidone into an oncology drug. One solitary repositioned drug has resulted in a potential multi-million deal. No wonder in the webinar Mark said he was excited regarding the Val/Dominion repurposing project. This collaboration has identified approx 200 FDA approved non oncology drugs which are showing anti-cancer against various Inaphaea PDCs. Ten of these candidates are now being fast tracked for deeper evaluation. Mark even mentioned looking to partner the prime repurposing asset this year. Because these compounds are clinically validated and safety de-risked, the probability of progressing to meaningful clinical proof of concept is far higher than in creating oncology drugs from scratch - positioning the Val/Dom alliance for multiple rapid, low cost shots on goal.",
          "sentiment": 0.5,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-11T17:21:05.913202+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261359-ratcliff-75649301",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.650086",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "True O alter ego. He even knows where my investments are. (Or should that be 'our' investments)",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-11T17:21:05.913220+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261356-RayPoint--7227857",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.650503",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "You can't fool uxm, he's so sharp \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-11T17:21:05.913238+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261348-uxm484--5767538",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.650918",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Ratcliffe are you Raypointer? Both invested in Scancell. Both are not invested in Valirx.",
          "sentiment": 0.0,
          "engagement": "1,009",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-11T17:21:05.913256+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261333-ratcliff--8762207",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.651345",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "The number of employees and the financial state is a bit concerning isn't it? They weren't flush in 2024's accounts, and they're worse in the 2025 ones. So back to the question - what are 500,000 odd shares in Ambrose actually worth? Potentially even less than 500,000 Val shares...? https://find-and-update.company-information.service.gov.uk/company/14409383/filing-history",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-11T17:21:05.913274+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261310-RayPoint--7931494",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.651773",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "The reason I ask is that if I look at Ambrose Healthcare on Companies House, I find the same name with the same month of birth: Tobias Adam WILSON WATERWORTH - born October 1964 Spookily, this person only has 1 director appointment - Ambrose Healthcare, the other 21 are missing! https://find-and-update.company-information.service.gov.uk/officers/SAWjapGOj9HbCMsLuSFBZeqVYiU/appointments Does anyone else find this rather strange?",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-11T17:21:05.913292+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261254-RayPoint--9092277",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.652198",
        "source": "LSE_CHAT",
        "data": {
          "author": "RayPointer",
          "content": "Could this be the CEO of Ambrose Healthcare? https://find-and-update.company-information.service.gov.uk/officers/JzAELIfnpaXPIZjjnhqdRjwB9KM/appointments",
          "sentiment": 0.0,
          "engagement": "5,065",
          "price_at_post": "0.385",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-11T17:21:05.913310+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260857-Rebster4-87004317",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.652606",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rebster408",
          "content": "Probably cos Ambrose only have about \u00a325k in capital and assets in 2025... not a pot to p155 in...",
          "sentiment": 0.0,
          "engagement": "1,174",
          "price_at_post": "0.375",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-11T17:21:05.913328+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260757-uxm484--5259567",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.653034",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "I understand they get a share of Ambrose  not just Val401. News on other clinical compounds increases the value of the shares therefore more valuable than just getting cash for Val401. Valirx will have options to sell some shares initially to get some cash.",
          "sentiment": 0.0,
          "engagement": "1,009",
          "price_at_post": "0.375",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-11T17:21:05.913346+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262226-ratcliff--2713375",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.653624",
        "source": "LSE_CHAT",
        "data": {
          "author": "ratcliffewriter",
          "content": "Why were Val given shares not cash by Ambrose? What are 576,000 Ambrose shares worth? Can they be sold to raise much-needed cash? How much cash had been raised for Val in the 7 months since that announcement? If it was a deal of any real worth, why did Val have to do a placing a few months later, and how come it's heading towards another one in a matter of weeks on current estimations?",
          "sentiment": 0.0,
          "engagement": "11,397",
          "price_at_post": "0.375",
          "thread_title": "RE: The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-11T17:21:05.913364+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262019-paternos-48042228",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.654069",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "A lucrative VAL401 licensing deal was announced on 20/6/25: \u201c ValiRx will receive 576,000 ordinary shares in Ambrose with clinical and commercial milestone payments to be made to Valiseek totalling a value of up to \u00a316 million plus royalties.\u201d Valirx owns 54% of Valiseek. Ambrose has a pipeline consisting of just TWO products: VAL401 (pancreatic cancer) and Renzapride (cystic fibrosis), both currently at phase 2 clinical. Today, Ambrose announced two further additions to their already impressive team: Dr. Janette Thomas joins as Director of Manufacturing Operations and Wendy Richings-Barrow as Director of Regulatory Affairs. \u201cThese appointments reflect our continued focus on building a world class team to deliver solutions for patients with rare conditions with no approved treatments.\u201d The Ambrose team already had a strong backbone: Chairman, Toby Waterworth has been part of leadership teams in multiple life science companies that have generated close to $1 billion in shareholder value. CEO Dr Hazel Jones was formerly Chief of Staff for AstraZeneca\u2019s Oncology R&D Leadership Team. Chief of Staff Virag Stephens an ex PMO Director at AZN and has strong fundraising expertise while Mike Webb led departments of up to 150 scientists in a 30-year career at GSK. Dr. Nick Meyers has 30 years\u2019 experience as a Program Director. In 2024, Ambrose was acknowledged by its peers when it won the Best Startup Biotech Company Award at the prestigious OBN Awards in London. Since then, it has grown significantly and confirmed it is exploring potential Middle-East listings. One of the partners on their webpage is SEHA (Abu Dhabi Health Services), a subsidiary of Pure-Health the largest integrated healthcare network in the UAE. (total assets $13B). Another partner is listed as Aparito, part of the Eli Lilly group. As Ambrose strengthens its leadership and global partnerships, Valirx is strategically placed to benefit from every milestone achieved on the VAL401 journey.",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.375",
          "thread_title": "The Ambrose Dream Team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=853C7C1D-556A-4963-A64B-CB20DD291DCB"
        },
        "ingested_at": "2026-02-11T17:21:05.913382+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261513-paternos-84165548",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.654610",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "\u201cValix is in discussions with several potential partners to progress CytoLytix, including a major pharma\u201d. So, why is Mark, currently in California, continuing to promote the compound so actively both in the UK and overseas? While it\u2019s plausible a major pharma might seek exclusivity, the most realistic outcome is exclusive rights carved by territory, formulation, indication, or even species (human/veterinary)\u2014leaving room for multiple, parallel deals outside that scope. Indication splits are historically used when partners specialise in different therapeutic areas (eg ovarian only). Geographic exclusivity is even more common. The TrX/201 deal eventually failed when Mark attempted to remove Taiwan from the original LOI. The veterinary angle highlighted in recent webinars reinforces that CLX spans markets no single pharma can cover, making a multi partner licensing model far more realistic than a single global licence. There are numerous real world examples of multi partner licensing structures in biopharma: TERRITORY - Immunex (Enbrel) / initially Amgen \u2192 US & Canada rights, then Wyeth (later Pfizer) \u2192 Europe + Rest of World rights FORMULATION - Gilead (Tamiflu) / initially Roche \u2192 Oral formulation rights, then Hetero & Teva, \u2192 sublicenses for additional formulations INDICATION - AstraZeneca (Lynparza) / Merck \u2192 initially Ovarian cancer rights, then subsequently obtained licenses for breast and pancreatic cancers. Each example above shows one originator, no single-party lock in and multiple partners or deals to acquire different rights. With so many variables in play, it is increasingly clear that Valirx is preserving the same optionality for CytoLytix. Mark is still promoting CytoLytix because he is targeting several partners \u2013 not just one. Everything suggests CLX is being shaped as a multi deal platform, with the first handshake simply opening the monetisation cycle -",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.385",
          "thread_title": "CLX - multi deal structure",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D1488F3A-09F4-41C4-B45B-AF908B85E267"
        },
        "ingested_at": "2026-02-11T17:21:05.913400+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261459-Notpotal--6903108",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.655026",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Some clever trading going on here \u2013 those selling at 0.37p will soon be able to buy back at 0.39p. \ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "RE: Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-02-11T17:21:05.913418+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261329-Porky9-84927247",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.655478",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porky9",
          "content": "@PP Yes, and as long as the rain holds off should be able to get some golf in on expenses. Who needs Zoom and Teams when you can have a nice all expenses trip to the US. Lovely. Keep pumping it, only a few weeks now to go before next placing @notpotatlot Only Update you will get shortly that isn't fluff, will be the placing news or the next 125:1 consolidation event which has to be well over due now. Keep ramping it though, the gravy train needs to stay on the tracks, there are lifestyles here that need to be maintained.",
          "sentiment": 0.0,
          "engagement": "7,466",
          "price_at_post": "0.385",
          "thread_title": "RE: Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-02-11T17:21:05.913436+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260943-paternos--6694942",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.655913",
        "source": "LSE_CHAT",
        "data": {
          "author": "paternostpauper",
          "content": "Mark re JPM in San Fran -  \u201cI have meetings lined up with our partner Omios Biologics so looking forward to catching up with Aldo Pourchet (CEO).\u201d In the Omios RNS (3/6/25), the evaluation was \u201cexpected to run up to 12 months, after which Omios can exercise its license option to continue using Cytolytix technology.\u201d Across both the June and Dec webinars, Mark emphasised CLX synergy with the Omios virus for potential to treat canine HSA, a clear signal that Omios sits firmly in the frame for a CLX licence. Valirx\u2019s revamped Advisory Board reinforces this direction, now with a notable weighting toward veterinary oncology and commercial expertise. The composition reflects a deliberate strategy to position CLX across both human and animal oncology. When your advisory structure is rebuilt around people who understand canine cancers, comparative oncology, and veterinary commercial pathways, it becomes clear Valirx is preparing for licensing routes across both human and veterinary markets. As a co-founder of VolitionRx, Mark transformed a human cancer test into a canine diagnostic test (Nu.Q) before negotiating a licencing deal with Heska for $26m. What price a cure? Human and veterinary oncology operate in separate regulatory and commercial channels. Most major pharmas, inc. AZN, Roche, GSK, AbbVie do NOT have any vet divisions. Even those historically involved have spun off their animal health units (Pfizer \u2192 Zoetis, Eli Lilly \u2192 Elanco). By envisaging veterinary opportunities for CLX, Mark is implicitly confirming the compound won\u2019t be a one partner asset; the split infrastructures required make multiple CytoLytix deals the only realistic outcome. GLA, DYOR, AIMO",
          "sentiment": 0.5,
          "engagement": "358",
          "price_at_post": "0.385",
          "thread_title": "Omios \u2013 the first CLX license?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=4266BD43-1BC8-418A-970F-A2B98425AF36"
        },
        "ingested_at": "2026-02-11T17:21:05.913454+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261543-Notpotal--3330738",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.656343",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "I notice a 71430 buy at 15.14 and a similar sell 4 mins later for a \u00a321 loss. Great to see Porky has started trading again!  \ud83e\udd23\ud83e\udd23\ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "Welcome back, Porky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=FE350133-0204-48E9-9785-7F80407B3421"
        },
        "ingested_at": "2026-02-11T17:21:05.913472+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261534-Notpotal--5578663",
        "event_type": "social_post",
        "date": "2026-01-24T01:33:18.656760",
        "source": "LSE_CHAT",
        "data": {
          "author": "Notpotalot",
          "content": "Val is obliged to RNS as it a change to No. shares in issue. Hardly the company\u2019s fault if a holder sees such value that he wants to buy above the current SP. Mind you, I\u2019m expecting a TR1 tomorrow to confirm Mark\u2019s holding has increased by 80,000 shares. \ud83e\udd23 If this is the reaction to \u00a3400 of warrants, heaven help Porky\u2019s groupies when the next material RNS arrives.  \ud83e\udee8 \ud83d\ude28 \ud83d\ude22\ud83d\ude2d",
          "sentiment": 0.5,
          "engagement": "77",
          "price_at_post": "0.385",
          "thread_title": "RE: Warrants",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VAL&thread=D06F3D2A-C667-476B-8588-5D72E778CEA6"
        },
        "ingested_at": "2026-02-11T17:21:05.913489+00:00"
      }
    ],
    "catalyst_dates": {
      "proxy_date": "2025-12-17"
    }
  },
  "ai_insights": {
    "key_insights": [],
    "hidden_patterns": [],
    "contrarian_signals": [],
    "risk_warnings": [],
    "opportunity_flags": [],
    "narrative_summary": "VAL.L presents a standard crash recovery setup without unusual patterns detected. Monitor for catalyst developments and trend shifts.",
    "_is_real": false
  },
  "crashdash": {
    "industry_intelligence": {
      "category": "BIOTECH_PHARMA",
      "name": "Biotech & Pharma",
      "icon": "\ud83e\uddec",
      "color": "#10b981",
      "crash_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "FDA/EMA rejection or delay",
        "Safety concerns or adverse events",
        "Patent expiry or IP challenges",
        "Funding gaps (cash runway concerns)"
      ],
      "recovery_paths": [
        "Positive trial data (efficacy endpoints met)",
        "Regulatory approvals (FDA/EMA)",
        "Partnership deals (big pharma licensing)",
        "Orphan drug designation or fast track",
        "New trial initiations (pipeline expansion)"
      ],
      "active_patterns": [
        "FDA/EMA rejection or delay"
      ],
      "relevant_rns_count": 0,
      "key_metrics": [
        "Clinical stage (preclinical, Phase 1/2/3, commercialized)",
        "Cash runway (months until next funding)",
        "Addressable market size (indication)",
        "Trial enrollment progress",
        "Intellectual property strength"
      ]
    },
    "panic_analysis": {
      "panic_score": 55.7,
      "signal": "MODERATE_FEAR",
      "interpretation": "\ud83d\udfe1 Cautious sentiment - assess risk/reward",
      "breakdown": {
        "price_destruction": 25.7,
        "volume_death": 14,
        "social_silence": 6,
        "news_sentiment": 10
      },
      "is_opportunity": false,
      "opportunity_reason": "\ud83d\udcca Moderate fear detected - monitor for escalation"
    },
    "fear_vs_facts": {
      "fear_points": [
        "\ud83d\udc94 Price destruction: 26/40 points"
      ],
      "facts_points": [],
      "verdict": "\u2696\ufe0f Mixed signals - Fear and facts balanced, wait for clarity"
    },
    "crashhunter_signals": [
      {
        "type": "CONFIRMED",
        "icon": "\u2705",
        "text": "Confirmed",
        "color": "#10b981"
      }
    ],
    "catalyst_pipeline": [
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Exercise of Warrants",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Replacement: Evaluation and Transfer Agreement",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "New Evaluation and Material Transfer Agreement",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Holding(s) in Company",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Holding(s) in Company",
        "status": "published",
        "icon": "\ud83d\udce2"
      }
    ],
    "decision_matrix": {
      "decision": "AVOID",
      "reason": "\u274c HOLD/WATCH - timing CONFIRMED",
      "checklist": [
        {
          "criterion": "Panic Score",
          "value": "56/100",
          "pass": false,
          "icon": "\ud83d\udfe2"
        },
        {
          "criterion": "Timing Regime",
          "value": "CONFIRMED",
          "pass": true,
          "icon": "\u2705"
        },
        {
          "criterion": "APEX Quality",
          "value": "40/100",
          "pass": false,
          "icon": "\u26a0\ufe0f"
        },
        {
          "criterion": "Data Confidence",
          "value": "40/100",
          "pass": true,
          "icon": "\ud83c\udfaf"
        },
        {
          "criterion": "Industry Pattern",
          "value": "1 active",
          "pass": true,
          "icon": "\ud83e\uddec"
        }
      ],
      "pass_rate": "3/5"
    },
    "contrarian_panic": {
      "total_score": 30,
      "band": "\ud83d\udfe2 MILD COMPRESSION (Top 50% - WATCHLIST)",
      "components": {
        "compression": {
          "score": 16,
          "max": 40,
          "signals_30d": 5,
          "signals_60d": 5,
          "signals_90d": 5,
          "signals_per_week": 0.38,
          "total_signals": 37,
          "rsi_extreme_count": 5,
          "rsi_ultra_count": 5,
          "escalation_count": 0,
          "density_score": 3,
          "rsi_score": 10,
          "escalation_score": 0,
          "description": "0.4 signals/week | 5 RSI<20 | \ud83d\udcca MODERATE COMPRESSION"
        },
        "intensification": {
          "score": 5,
          "max": 20,
          "recent_types": [
            "DEEP CRASH BOTTOM",
            "DEEP CRASH BOTTOM",
            "DEEP CRASH BOTTOM"
          ],
          "escalating": false,
          "sustained": false,
          "current_intensity": 2,
          "pattern": "NORMAL CRASH LEVEL"
        },
        "volume_death": {
          "score": 5,
          "max": 15,
          "relative_volume": 2.19,
          "description": "Elevated volume - Some activity"
        },
        "pop_potential": {
          "score": 4,
          "max": 15,
          "best_historical_rally": 110.5,
          "avg_rally": 48.1,
          "signal_count": 37,
          "description": "Baseline mover (111%)"
        },
        "accumulation": {
          "score": 0,
          "max": 10,
          "has_accumulation": false,
          "bars_since_accum": 0,
          "description": "No accumulation detected"
        }
      },
      "ticker": "VAL.L",
      "signal_date": "2025-11-21",
      "total_signals_history": 37
    }
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +15 (AI_Technical_Score=12.0/20)",
      "Drawdown reversion potential: +17 (Drawdown_Pct=87.1%)",
      "Volume confirmation: +10 (Relative_Volume=2.2)",
      "Pattern reliability: +5 (Rally_Count=1.0)",
      "Upside history: +8 (best_rally_pct=87%)",
      "Split risk penalty: -15 (HIGH, age_factor=1.00)"
    ],
    "technical_score": {
      "points": 15,
      "ai_score": 12.0,
      "reason": "AI Technical Score 12.0/20 translates to 15/25 points"
    },
    "drawdown_score": {
      "points": 17,
      "drawdown_pct": 87.14,
      "reason": "Drawdown of 87.1% gives 17/20 points"
    },
    "volume_score": {
      "points": 10,
      "rel_volume": 2.19,
      "reason": "Relative volume 2.19x gives 10 points"
    },
    "pattern_score": {
      "points": 5,
      "rally_count": 1.0,
      "reason": "1.0 historical rallies gives 5/15 points"
    },
    "upside_score": {
      "points": 8,
      "best_rally_pct": 86.67,
      "reason": "Best rally of 87% gives 8/20 points"
    },
    "penalties": {
      "total": -15,
      "items": [
        "Split risk penalty: -15 (HIGH, age_factor=1.00)"
      ]
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Proven winner - previously hit lock-in target",
        "tag": "MED",
        "evidence": [
          "lock_in_reached=True"
        ]
      }
    ],
    "reasons_to_sell": [
      {
        "reason": "Stale signal - not for active trading",
        "tag": "HIGH",
        "evidence": [
          "status=historical",
          "signal_date=2025-11-21"
        ]
      }
    ]
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Active trade",
      "action": "HOLD/WATCH",
      "sizing": "1-3% position based on conviction",
      "risk": "Stop below recent support / invalidation level",
      "profit_taking": "Scale out into strength: 25% @ +15%, 50% @ +50%, trail runner"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "CONFIRMED",
    "run_multiple": 0.77,
    "current_run_pct": 66.67,
    "avg_historical_run_pct": 86.67
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows CONFIRMED timing with 40/100 APEX score. Historical data shows 1 rallies averaging 87% upside. Current position: +66.7%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.",
    "bull_case": [
      "Limited upside case without catalysts"
    ],
    "bear_case": [
      "Monitor for breakdown signals"
    ],
    "timing_translation": "Momentum confirmed. This is the trade zone if thesis holds.",
    "confidence_explained": "Confidence 40/100 reflects full data quality with triangulation loaded."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": true,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": true
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  }
}